AR226-1342

TRADE SECRET

Study Title

8-2 Telomer B Alcohol: Subchronic Toxicity
90-Day Oral Gavage Study in Rats

Volume 1 of 3

Laboratory Project ID: DuPont-9478

TEST GUIDELINES: U.S. EPA Health Effects Test Guidelines
OPPTS 870.3100 (1998)

AUTHOR: Gregory S. Ladics, Ph.D

STUDY COMPLETED ON: April 1, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER: 13690

SERVICE CODE NUMBER: 1022

RECEIVED
OPPT NCIC
2003 JUL-7 10:59AM

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study was conducted in compliance with U.S. EPA TSCA (40 CFR part 792) Good Laboratory Practice Standards except for the item documented below. None of the items listed impact the validity of the study.

Test substance characterization was performed at Regional Analytical Services (RAS), Deepwater, NJ. None of the aforementioned analyses were performed under Good Laboratory Practice Standards; however, the analyses were conducted in compliance with ISO9002 regulations. All of the analyses are considered valid and sufficient for the purposes of this study.

Study Director: _____ 1-Apr-2003
Gregory S. Ladics, Ph.D. Date
Senior Research Scientist

QUALITY ASSURANCE STATEMENT

Haskell Sample Number(s):

24691

Dates of Inspections:

Protocol:	February 1,7, 2002
Conduct:	February 12, 2002; March 26, 2002; April 1,2,25, 2002; May 14,23, 2002
Records, Reports:	October 1-4,7-9,14-15,22-23,25,28, 2002; November 11-13,24-27 2002; December 16-19,22, 2002; January 12-15, 2003

Dates Findings Reported to:

Study Director:	October 9,15,28, 2002; November 13,27; January 14,15, 2003
Management:	October 9,18, 2002; November 5,27, 2002; December 10, 2002; January 14,29, 2003

Reported by: Kimberly B. Brebner 01-APR-2003
Kimberly B. Brebner Date
Staff Quality Assurance Auditor

CERTIFICATION

We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

Analytical Evaluations by: Janet C. Maslanka — 28-March-2003
Janet C. Maslanka, B.S.
Senior Staff Chemist — Date

Neurobehavioral Toxicology Evaluations by: Linda A Malley — 28 - March - 2003
Linda A. Malley, Ph.D., D.A.B.T.
Senior Research Toxicologist — Date

Clinical Pathology Evaluations by: Nancy E Everds — 28-Mar-2003
Nancy E. Everds, D.V.M.
Diplomate A.C.V.P.
Principal Research Clinical Pathologist and Manager — Date

Anatomic Pathology Evaluations by: Steven R. Frame for — 28-March-2003
G. Tracy Makovec, D.V.M.
Diplomate A.C.V.P.
Senior Research Pathologist — Date

Anatomic Pathology Evaluations Peer Review by: Steven R. Frame for — 28-March-2003
John F. Hansen, D.V.M., Ph.D.
Diplomate A.C.V.P.
Principal Research Pathologist — Date

Biochemical Evaluations by: John C O'Connor — 31 - March - 2003
John C. O'Connor, M.S.
Research Toxicologist — Date

Approved by: Scott E Loveless — 31 - March - 2003
Scott E. Loveless, Ph.D.
Research Manager and Director — Date

Issued by Study Director: Gregory S. Ladics — 1 - Apr - 2003
Gregory S. Ladics, Ph.D., D.A.B.T
Senior Research Toxicologist — Date

TABLE OF CONTENTS

Page

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT 2
QUALITY ASSURANCE STATEMENT 3
CERTIFICATION 4
LIST OF TABLES 7
LIST OF FIGURES 7
LIST OF APPENDICES 9
STUDY INFORMATION 10
STUDY PERSONNEL 11
SUMMARY 12
INTRODUCTION 15
OBJECTIVE 15
MATERIALS AND METHODS 15
A. Test Guidelines 15
B. Test Substance 15
C. Test Species 16
D. Animal Husbandry 16
E. Quarantine and Pretest Period 17
F. Study Design 17
G. Assignment to Groups 18
H. Dose Suspension Preparation 18
I. Test Substance Administration 19
J. Test Substance Sampling 19
K. Analytical Methods 20
L. Body Weights 21
M. Food Consumption and Food Efficiency 21
N. Detailed Clinical Observations and Mortality 22
O. Ophthalmological Evaluations 22
P. Neurotoxicity Evaluations 22
Q. Clinical Pathology 23
R. Collection of Blood, Urine, Feces, and Tissue (Three-Month Recovery) 25
S. Biochemical Measurements 25
T. Anatomic Pathology 26
RESULTS AND DISCUSSION 29
ANALYTICAL EVALUATIONS 29
A. Test Substance Stability 29
B. Chromatography 30
C. Homogeneity and Stability Samples 30
D. Concentration Verification Samples 32

E. Discussion of Results 36
F. Analytical Conclusion 36
IN-LIFE TOXICOLOGY 37
A. Dosage Data 37
B. Mean Body Weights and Body Weight Gains 37
C. Food Consumption and Food Efficiency 38
D. Clinical Observations and Mortality 38
E. In-Life Toxicology Conclusions 39
NEUROBEHAVIORAL TOXICOLOGY 39
A. Sensory Function Evaluations 39
B. Motor Activity 39
C. Neurobehavioral Toxicity Conclusions 40
CLINICAL PATHOLOGY 40
A. Hematology/Coagulation 40
B. Clinical Chemistry 42
C. Urinalysis 44
D. Plasma and Urine Fluoride 45
E. Clinical Pathology Conclusions 45
BIOCHEMICAL MEASUREMENTS 46
A. Biochemical Measurements 46
B. Biochemical Measurements Conclusions 47
ANATOMICAL PATHOLOGY 47
A. Mortality 47
B. Organ Weight Data 47
C. Gross Observations 48
D. Microscopic Findings 48
E. Anatomical Pathology Conclusions 50
CONCLUSIONS 51
RECORDS AND SAMPLE STORAGE 52
REFERENCES 53
TABLES 56
FIGURES 268
APPENDICES 280

LIST OF TABLES

Page

TABLE 1 SUMMARY OF DOSING MIXING AND STABILITY ANALYSES....60
TABLE 2 MEAN DAILY DOSE VOLUMES FOR MALE RATS 64
TABLE 3 MEAN DAILY DOSE VOLUMES FOR FEMALE RATS 66
TABLE 4 MEAN BODY WEIGHTS OF MALE RATS 68
TABLE 5 MEAN BODY WEIGHTS OF FEMALE RATS 71
TABLE 6 MEAN BODY WEIGHT GAINS OF MALE RATS 74
TABLE 7 MEAN BODY WEIGHT GAINS OF FEMALE RATS 77
TABLE 8 MEAN DAILY FOOD CONSUMPTION BY MALE RATS 80
TABLE 9 MEAN DAILY FOOD CONSUMPTION BY FEMALE RATS 83
TABLE 10 MEAN DAILY FOOD EFFICIENCY OF MALE RATS....86
TABLE 11 MEAN DAILY FOOD EFFICIENCY OF FEMALE RATS....89
TABLE 12 SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS....92
TABLE 13 SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS....97
TABLE 14 SUMMARY OF OPHTHALMOLOGY OBSERVATIONS FOR MALE RATS....103
TABLE 15 SUMMARY OF OPHTHALMOLOGY OBSERVATIONS FOR FEMALE RATS....104
TABLE 16 PERCENT SURVIVAL OF MALE RATS....105
TABLE 17 PERCENT SURVIVAL OF FEMALE RATS....106
TABLE 18 MEAN FORELIMB AND HINDLIMB GRIP STRENGTH FOR MALE RATS (MEAN OF THREE TRIALS)....107
TABLE 19 MEAN FORELIMB AND HINDLIMB GRIP STRENGTH FOR FEMALE RATS (MEAN OF THREE TRIALS)....108
TABLE 20 SUMMARY OF FUNCTIONAL OBSERVATION BATTERY FINDINGS FOR MALE RATS....109
TABLE 21 SUMMARY OF FUNCTIONAL OBSERVATION BATTERY FINDINGS FOR FEMALE RATS ..110
TABLE 22 MOTOR ACTIVITY ASSESSEMENT: DURATION OF MOVEMENTS FOR MALE RATS 111
TABLE 23 MOTOR ACTIVITY ASSESSEMENT: DURATION OF MOVEMENTS FOR FEMALE RATS ...112
TABLE 24 MOTOR ACTIVITY ASSESSEMENT: NUMBER OF MOVEMENTS FOR MALE RATS 113
TABLE 25 MOTOR ACTIVITY ASSESSEMENT: NUMBER OF MOVEMENTS FOR FEMALE RATS....114
TABLE 26 SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS....115
TABLE 27 SUMMARY OF HEMATOLOGY VALUES FOR FEMALE RATS....119
TABLE 28 SUMMARY OF COAGULATION VALUES FOR MALE RATS....123
TABLE 29 SUMMARY OF COAGULATION VALUES FOR FEMALE RATS....123
TABLE 30 SUMMARY OF CLINICAL CHEMISTRY VALUES FOR MALE RATS....124
TABLE 31 SUMMARY OF CLINICAL CHEMISTRY VALUES FOR FEMALE RATS....128

LIST OF TABLES (CONTINUED)

Page

TABLE 32 SUMMARY OF URINALYSIS VALUES FOR MALE RATS 132
TABLE 33 SUMMARY OF URINALYSIS VALUES FOR FEMALE RATS....134
TABLE 34 SUMMARY OF PEROXISOMAL BETA-OXIDATION ACTIVITY IN MALE RATS....136
TABLE 35 SUMMARY OF PEROXISOMAL BETA-OXIDATION ACTIVITY IN FEMALE RATS 137
TABLE 36 MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS....138
TABLE 37 MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS 145
TABLE 38 INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS....154
TABLE 39 INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS 175
TABLE 40 INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS NEOPLASTIC AND NON-NEOPLASTIC LESIONS 197
TABLE 41 INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS NEOPLASTIC AND NON-NEOPLASTIC LESIONS 215
TABLE 42 INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS NON-NEOPLASTIC LESIONS....231
TABLE 43 INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS NON-NEOPLASTIC LESIONS....251

LIST OF FIGURES

Page

FIGURE 1 MEAN BODY WEIGHTS OF MALE RATS....270
FIGURE 2 MEAN BODY WEIGHTS OF FEMALE RATS 271
FIGURE 3 MEAN FORELIMB GRIP STRENGTH FOR MALE RATS....272
FIGURE 4 MEAN FORELIMB GRIP STRENGTH FOR FEMALE RATS....273
FIGURE 5 MEAN HINDLIMB GRIP STRENGTH FOR MALE RATS....274
FIGURE 6 MEAN HINDLIMB GRIP STRENGTH FOR FEMALE RATS 275
FIGURE 7 MEAN TOTAL DURATION OF MOVEMENT FOR MALE RATS....276
FIGURE 8 MEAN TOTAL DURATION OF MOVEMENT FOR FEMALE RATS 277
FIGURE 9 MEAN TOTAL NUMBER OF MOVEMENTS FOR MALE RATS 278
FIGURE 10 MEAN TOTAL NUMBER OF MOVEMENTS FOR FEMALE RATS....279

LIST OF APPENDICES

Page

APPENDIX A ANALYTICAL DATA 282

VOLUME 2 294
APPENDIX B INDIVIDUAL DOSE VOLUMES 295
APPENDIX C INDIVIDUAL BODY WEIGHTS 376
APPENDIX D INDIVIDUAL FOOD CONSUMPTION 411
APPENDIX E INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA 436
APPENDIX F INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS 478
APPENDIX G INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH 490
APPENDIX H INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT 511
APPENDIX I INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS 522
APPENDIX J INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS 535
APPENDIX K INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA 548

VOLUME 3 622
APPENDIX L INDIVIDUAL ANIMAL BIOCHEMICAL DATA 651
APPENDIX M INDIVIDUAL ANIMAL BODY AND ORGAN WEIGHTS 658
APPENDIX N INDIVIDUAL ANIMAL GROSS AND MICROSCOPIC OBSERVATIONS 695
APPENDIX O INDIVIDUAL ANIMAL MICROSCOPIC OBSERVATIONS LISTING INDIVIDUAL ANIMALS AFFECTED 881

STUDY INFORMATION

9th Collective Nomenclature: 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluoro-1-decanol

Synonyms/Codes:
- (Perfluorooctyl)ethanol
- .β.-(Heptadecafluorooctyl)ethanol
- 1,1,2,2-Tetrahydroheptadecafluorodecanol
- 1,1,2,2-Tetrahydroperfluorodecan-1-ol
- 1,1,2,2-Tetrahydroperfluorodecanol
- 1,1,2,2-Tetrahydroperfluorodecyl alcohol
- 1H,1H,2H,2H-Perfluorodecan-1-ol
- 1H,1H,2H,2H-Perfluorodecanol
- 2-(Heptadecafluorooctyl)ethanol
- 2-(Perfluorooctyl)ethanol
- 2-(Perfluorooctyl)ethyl alcohol
- C-8 Telomer B Alcohol
- 2-Perfluorooctyl ethanol
- 8-2 Telomer B Alcohol
- P.00/001 (Lot No.)

Haskell Number: 24691

CAS Registry Number: 678-39-7

Composition: C-8 Telomer B Alcohol

Purity: 99.2 Wt. %

Known Impurities: C7F15CF=CHCH2OH (0.8 Wt. %)

Physical Characteristics: White to yellow wax

Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed.

Sponsor: Telomer Research Program
1200 South Hayes Street
Arlington, Virginia 22202-5050
U.S.A.

Study Initiated/Completed: February 7, 2002 / (see report cover page)

In-Life Initiated/Completed: February 12, 2002 / August 22, 2002

STUDY PERSONNEL

Study Director:	Gregory S. Ladics, Ph.D.
Management:	Scott E. Loveless, Ph.D. Janice L. Connell, M.S., B.A., C.I.H.
Primary Technician:	Deborah A. Vick, B.S.
Analytical Chemist:	Janet C. Maslanka, B.S.
Management:	S. Mark Kennedy, Ph.D.
Clinical Pathologist:	Nancy E. Everds, D.V.M.
Management:	Steven R. Frame, D.V.M., Ph.D.
Neurobehavioral Toxicologist:	Linda A. Malley, Ph.D.
Management:	Robert M. Parker, Ph.D.
Biochemical Toxicologist:	John C. O'Connor, M.S.
Management:	Matthew S. Bogdanffy, Ph.D.
Pathologist:	G. Tracy Makovec, D.V.M.
Management:	Steven R. Frame, D.V.M., Ph.D.
Peer Review Pathologist:	Steven R. Frame, D.V.M., Ph.D.
Toxicology Report Preparation:	Cecilia R. Kee, B.S. Brenda Tiffin
Ophthalmologist:	Nancy M. Bromberg, V.M.D., M.S. 6119 Massachusetts Avenue Bethesda, Maryland 20816
Statistical Analysis:	John W. Green, Ph.D.
Management:	Janice L. Connell, M.S., B.A., C.I.H.
Laboratory Veterinarian:	Thomas W. Mayer, D.V.M., A.C.L.A.M.

SUMMARY

Five groups of young adult male and female Crl:CD®(SD)IGS BR rats were administered 8-2 Telomer B Alcohol daily by gavage at dosages of 0, 1, 5, 25, and 125 mg/kg/day for approximately 90 days. Body weights, food consumption, and clinical signs were evaluated weekly. Clinical pathology endpoints were evaluated on weeks 7, 13, and near the end of the three-month recovery period. Neurobehavioral assessments were also performed prior to dosing and during week 13. Biochemical evaluations (hepatic β-oxidation) were performed on animals after 10 and approximately 90 days of dosing and following the three-month recovery period. After approximately 90 days of dosing, 10 rats/sex/dose were sacrificed and given a gross and microscopic pathological examination. Approximately three months after the 90-day dosing period, 10 animals/sex in the control and high dose group were examined for recovery of toxic effects. A subgroup of 5 rats/sex/dose were designated as satellite bleed animals. An additional five animals/sex/dose were designated for hepatic biochemical analysis following a 10-day exposure to the test substance.

The range of mean daily dose volumes of 8-2 Telomer B Alcohol administered to male rats was 1.2 to 3.0 ml. The range administered to female rats was 0.9 to 1.6 ml.

In-Life Toxicology Parameters: No test substance-related mortality occurred in the study. A test substance-related, toxicologically significant increase in the incidence of striated teeth was observed in the 125 mg/kg/day male and female dose groups. On test day 77, all male and female high dose animals were placed on ground chow due to test substance-induced alterations to the teeth. There were no test substance-related, toxicologically significant alterations in body weight, body weight gain, food consumption, or food efficiency observed in any of the male or female dose groups.

Neurotoxicology Parameters: No adverse changes in neurobehavioral parameters were observed in male or female rats in any dose group.

Biochemical Toxicology: The rate of hepatic β-oxidation, a measure of peroxisome proliferation, was significantly increased in females administered 25 mg/kg/day 8-2 Telomer B Alcohol and in males and females administered 125 mg/kg/day 8-2 Telomer B Alcohol. Following a three-month recovery period, the rate of hepatic β-oxidation was lower but still significantly increased in males administered 125 mg/kg/day 8-2 Telomer B Alcohol, and had returned to control levels in female rats.

Clinical Pathology: Samples were collected at mid-study, at the end of treatment, and after three months of recovery for hematology, clinical chemistry, urinalysis, coagulation (end of study only), and plasma and urine fluoride (end of study and three-month recovery period).

There were no toxicologically significant changes in clinical pathology parameters observed in rats dosed with up to 125 mg/kg/day 8-2 Telomer B Alcohol. Other changes during treatment or after a three-month recovery were considered treatment-related but non-adverse because the magnitude of change was small, transient, and/or in a direction not associated with toxicity.

Treatment-related changes observed in rats administered ≥ 25 mg/kg/day included decreases in some red cell mass parameters along with reticulocytosis and increased serum cholesterol (females only). Test substance-related changes in clinical pathology of rats dosed with 125 mg/kg/day included transiently increased alkaline phosphatase (males only), increased phosphorus (males only), decreased triglycerides (males only), increased total protein and albumin, increased calcium (females only), increased urine volume (males only), and decreased urine ketone concentrations (males only). Plasma fluoride levels were significantly increased in males and females dosed with 125 mg/kg/day, but returned to control levels following three months of recovery. Urine fluoride excretion was increased in males and females dosed with ≥ 5 mg/kg/day. After three months of recovery, urine fluoride levels in females returned to control levels, while levels in males were significantly reduced compared to those at the end of the exposure period.

Anatomical Pathology: Test substance-related, toxicologically significant degeneration/disorganization of enamel organ ameloblast cells occurred in male rats administered 125 mg/kg/day 8-2 Telomer B Alcohol.

A test substance-related, adverse increase in the incidence and severity of focal hepatic necrosis was observed in males administered 25 and 125 mg/kg/day. An increased incidence and severity of chronic progressive nephropathy occurred in the 125 mg/kg/day female group and was considered adverse.

Test-substance related and statistically significant increases in liver weight parameters were present in males and females administered 25 or 125 mg/kg/day for approximately 90 days. The increased liver weights correlated with microscopic hepatocellular hypertrophy in the 125 mg/kg/day male dose group. Liver weight changes and microscopic hypertrophy were considered to be a physiological adaptive response to metabolism of the test substance and not adverse. Test-substance related and statistically significant increases in kidney weight parameters occurred in males and females administered 25 or 125 mg/kg/day. The increased kidney weights correlated with microscopic renal tubular hypertrophy in the 25 and 125 mg/kg/day male groups only. However, no correlative microscopic or clinical pathological evidence of renal toxicity were present. Therefore, kidney weight changes and microscopic tubular hypertrophy were not considered adverse findings. Altered colloid, a common spontaneous finding in rats, was increased in incidence and/or severity in treated male groups. This change was not associated with other findings in the thyroid gland and was also not considered an adverse finding.

After three months of recovery, rats dosed with 125 mg/kg/day showed reversibility of some effects. The ameloblastic degeneration/disorganization persisted with decreased incidence and severity in the 125 mg/kg/day male group. Alterations in thyroid colloid persisted in male rats. Increased liver weight parameters and hepatocellular hypertrophy (males only) were no longer observed in the 125 mg/kg/day male and female groups. However, the incidence of hepatocellular necrosis in the 125 mg/kg/day male group increased after three months of recovery. Increased kidney weight parameters and renal tubular hypertrophy (males only) were not observed in rats sacrificed after three months of recovery. In contrast, the incidence and

severity of chronic progressive nephropathy were increased in the 125 mg/kg/day female group following three months of recovery.

In conclusion, the no-observed-effect level (NOEL)[a] for males was 5 mg/kg/day 8-2 Telomer B Alcohol based on the increased incidence of hepatic necrosis observed in males administered ≥ 25 mg/kg/day. The NOEL for females was 25 mg/kg/day 8-2 Telomer B Alcohol based on the increased incidence and severity of chronic progressive nephropathy observed in females administered 125 mg/kg/day.

[a] The NOEL for this study is defined as the highest dose at which toxicologically important effects attributable to the test substance were not detected. Thus, for this study, the NOEL is equivalent to the NOEL as defined by the United States Environmental Protection Agency (1985) and to the no-observed-adverse-effect level (NOAEL) as defined by the European Union (1994).

INTRODUCTION

The test substance, 8-2 Telomer B Alcohol, is an organofluorine compound. The 1, 5, 25, and 125 mg/kg/day dose levels for this study were selected based on the toxicity observed in an 84-day range finding study with 5, 25, and 125 mg/kg/day 8-2 Telomer B Alcohol and subchronic studies with similar fluorotelomer-based alcohols and perfluorooctanoic acid (PFOA). In the 8-2 Telomer B Alcohol range finder study, significantly lower mean body weights compared to control were observed in male rats administered 125 mg/kg/day. Similarly, significantly lower mean body weights compared to control were also observed in rats administered 100 mg/kg/day or greater of similar fluorotelomer-based alcohols. Significantly increased liver weights occurred in males dosed with 125 mg/kg/day 8-2 Telomer B Alcohol. Liver weights were also significantly increased compared to control in rats administered dose levels of fluorotelomer-based alcohols as low as 100 mg/kg/day. Furthermore, data suggest that the PFOA metabolite may accumulate in animals dosed with the 8-2 Telomer B Alcohol. In repeat dose studies, PFOA at doses of 10 mg/kg/day or lower produced the following effects: increased liver weights, increased hepatic cell proliferation and beta oxidation, and altered serum hormone levels.[1,2,3,4] The high-dose level of 125 mg/kg/day for this study was selected based on the reductions in body weight and increased liver weights observed in males dosed with 125 mg/kg/day 8-2 Telomer B Alcohol, as well as the ability of rats to tolerate a 100 mg/kg/day dose level in subchronic studies with similar fluorotelomer-based alcohols. The 125 mg/kg/day dose was expected to produce toxicity without excessive mortality. The low dose of 1 mg/kg/day was expected to be the no-observed-effect level (NOEL), while the 5 and 25 mg/kg/day dose levels were expected to induce minimal to no toxicity.

OBJECTIVE

The objective of this study is to evaluate the potential subchronic toxicity and reversibility of 8-2 Telomer B Alcohol when administered by gavage to male and female rats. The oral route of administration was selected as the most efficient way to deliver an accurate dosage.

MATERIALS AND METHODS

A. Test Guidelines

The subchronic toxicity study design complies with the United States Environmental Protection Agency (EPA), Office of Prevention, Pesticides, and Toxic Substances (OPPTS) Health Effects Test Guidelines, OPPTS 870.3100 90-Day Oral Toxicity in Rodents (Aug-1998).

B. Test Substance

The test substance, 8-2 Telomer B Alcohol, was supplied by the sponsor as a waxy solid with known purity (99.2%) and composition. A reserve sample of the test substance was collected and retained by Haskell Laboratory.

C. Test Species

On 29-Jan-2002, Crl:CD®(SD)IGS BR rats with an assigned birth date of 31-Dec-2001 were received from Charles River Laboratories, Inc., Raleigh, North Carolina. One hundred five male and 105 female rats were received for the main study and 28 male and 28 female rats were received for the 10-day biochemical evaluation.

The rat was selected because it is the species recommended in the subchronic toxicity guidelines. The Crl:CD®(SD)IGS BR strain was chosen because extensive background information is available from the literature, the supplier, and previous studies at Haskell Laboratory. This species/strain is considered suitable relative to longevity and low incidence of spontaneous diseases.

D. Animal Husbandry

1. Housing

All rats were housed one per cage, sexes separate, in stainless steel, wire-mesh cages suspended above cage boards. Cage racks were relocated within the animal room and cages were repositioned on the racks every 2 weeks. Animal rooms were maintained on a 12-hour light/dark cycle (fluorescent light) and at a temperature of 22 ± 3°C and a relative humidity of 50% ± 20%. Occasional excursions outside the acceptable ranges were minor and did not affect the study.

2. Feed and Water

Tap water was provided *ad libitum*. All rats were fed pelleted PMI Nutrition International, Inc. Certified Rodent LabDiet® 5002 *ad libitum*. On test day 77, all rats in the male and female 125 mg/kg/day groups were placed on ground chow because of test substance-induced alterations to the teeth.

3. Identification

An individual identification number was tattooed on the tail of each rat. The information on the cage labels included the unique 6-digit Haskell animal number and the individual identification number assigned to each rat.

4. Health Monitoring Program

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to ensure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Feed samples are analyzed for total bacterial, spore and fungal counts.

- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. Evaluation of these data did not indicate any conditions that affected the validity of the study.

E. Quarantine and Pretest Period

Upon arrival at Haskell Laboratory, all rats were quarantined for 7 days, observed daily for any clinically apparent signs of disease or injury, and weighed 4 times.

Rats designated for the subchronic toxicity and three-month recovery evaluations, and satellite bleeds were also examined by a veterinary ophthalmologist to identify animals with preexisting ocular lesions. Rats designated for the subchronic toxicity and three-month recovery evaluations were given a baseline neurobehavioral evaluation.

On the basis of acceptable body weight gains and clinical observations, all surviving main study rats were released from quarantine by the laboratory animal veterinarian designee on test day –11; rats designated for the 10-day biochemical analysis were released on test day -4.

F. Study Design

Group		Number/Group		
Male	Female	Male	Female	Dosage[a]
I	II	30	30	0 mg/kg/day (Control)
III	IV	20	20	1 mg/kg/day
V	VI	20	20	5 mg/kg/day
VII	VIII	20	20	25 mg/kg/day
IX	X	30	30	125 mg/kg/day

a Weight/weight of test substance (adjusted for sponsor-supplied purity of active ingredient).

Each group of study animals, except those designated for the 10-day biochemical analysis, consisted of three subgroups: the first 10 rats/sex/dose were designated for evaluation of subchronic toxicity; the next 5 rats/sex/dose were designated as satellite bleed animals; and the last 10 rats/sex/dose (control and high-dose groups only) were designated as three-month recovery animals. An additional subgroup of 5 rats/sex/dose were designated for hepatic biochemical analysis following a 10-day exposure to the test substance.

Male and female rats designated for the subchronic toxicity evaluation were dosed through test days 92 (male) and 93 (female), and necropsied on test days 93 and 94, respectively. Male and female rats designated for the satellite bleeds were dosed through test day 90 and necropsied on test day 175 (85 days post dosing). Male and female rats designated for the three-month recovery evaluations were dosed through test day 90 and necropsied on test day 183 (93 days post dosing).

Neurobehavioral evaluations were conducted on male and female animals designated for the subchronic toxicity evaluation and three-month recovery evaluation (predose and week 13).

A clinical pathology evaluation was conducted on rats designated for the subchronic toxicity evaluation during week 7 and week 13 (prior to necropsy). Coagulation parameters and plasma and urine fluoride were not determined on week 7. Plasma and urine fluoride were determined for the three-month recovery animals on week 26.

Biochemical evaluations were conducted on selected animals designated for the subchronic toxicity evaluation, the three-month recovery evaluations, and the 10-day exposure evaluation. In-life data (body weight, food consumption, clinical observations) for rats designated for the 10-day biochemical analysis were collected from these animals and are in study records. However, these data are not included in this report.

G. Assignment to Groups

1. Rats Designated for the Subchronic Toxicity and Three-Month Recovery Evaluations, and Satellite Bleeds

Rats were selected for study use on the basis of adequate body weight gain, freedom from any ophthalmological abnormalities or clinical signs of disease or injury, and a body weight within ± 20% of the mean within a sex. The selected rats were distributed by computerized, stratified randomization so that there were no statistically significant differences among group body weight means within a sex.

On test day 0, prior to the start of test substance administration, 3 male rats and 3 female rats with out-of-range body weights, clinical signs, or neurobehavioral findings during pretest were replaced. Replacement rats were selected on the basis of freedom from any clinical signs of disease or injury and a body weight ± 20% of the mean within a sex. Due to technician error, one male control rat with an out-of-range body weight was used on study.

H. Dose Suspension Preparation

8-2 Telomer B Alcohol was suspended in 0.5% aqueous methylcellulose. Dosing suspensions of the test substance were prepared twice per week up to day 48, then prepared daily through the remainder of the dosing period.

I. Test Substance Administration

The test substance was administered daily to the study animals by oral gavage to achieve dosage levels of 1, 5, 25, or 125 mg/kg body weight/day, based on the most recently recorded body weight. Dose volumes for all groups were 5 mL/kg. Male and female control rats were similarly treated with 0.5% aqueous methylcellulose at the same dose volume as used in their respective high-dosage group.

Based on the results of analytical analysis of a 4-day dose preparation obtained on test day 45, rats at all dose levels may not have received a full dose of test substance on test days 45, 46, 47, and 48. Subsequent analytical analysis on additional dose preparations (not administered to rats) indicated that the test day 45 results were due to a sampling error.

1. Rats Designated for the Subchronic Toxicity and Three-Month Recovery Evaluations, and Satellite Bleeds

Oral administration of 8-2 Telomer B Alcohol began on test day 0, when the rats were approximately 50 days of age. Rats designated for the subchronic toxicity evaluation were dosed through test day 92 (males) or 93 (females). Rats designated for the three-month recovery evaluation and satellite bleeds were dosed through test day 90. Rats designated for recovery and satellite bleeds did not receive test substance during the recovery period.

2. Rats Designated for 10-Day Biochemical Analysis

Oral administration of 8-2 Telomer B Alcohol began 7 days prior to study start when the rats were approximately 42 days of age and ended on test day 2.

J. Test Substance Sampling

Dosing suspensions for this study were prepared at the beginning of the study as a large volume mix to be used either for 3 or 4 days of dosing. Subsequently, on day 49 of the study, the dosing suspension preparation was changed to a small volume mix to be used for 1 day of dosing.

Samples containing 8-2 Telomer B Alcohol at the concentrations of 0, 0.2, 1.0, 5.0, and 25.0 mg/mL were collected on test day –6 (large volume/3-4 day mix). These samples were analyzed to determine homogeneity/concentration verification and 5-hour room temperature stability. Samples from the same preparation at the 0.2 mg/mL level only, were collected on test day 0, after 7 days of refrigeration. These samples were analyzed to determine re-dispersion/concentration verification and refrigerated stability along with 5-hour room temperature stability. The refrigerated re-dispersion/concentration verification and stability for the other levels had been established during the mixing/stability study for a previous study.[5]

On test days 48, 52, 56, 58, 65, and 91 (small volume/1 day mix), concentration verification samples for all levels were collected. The test day 48 preparation was not dosed to animals. On test days 42, 45, 63, and 73 (3-4 day mix), concentration verification samples for all levels were collected. Test day 63 and 73 preparations were not used for dosing the animals but for evaluation of the large volume mix (3-4 day).

All dosing suspension samples were collected on the day the suspensions were dosed to the animals or at the established stability time for analysis. They were analyzed when received or frozen until analyzed.

K. Analytical Methods

1. Dosing Solution Treatment

Each dosing sample (10 mL for 0.2 mg/mL; 3 mL for other levels) was diluted to 100 mL with methanol and mixed to dissolve the 8-2 Telomer B Alcohol in the suspension. The dosing samples were analyzed without further dilution or were further diluted with the 0 mg/mL sample (initial dilution) to an expected concentration of approximately 0.03mg/mL (a.i.) prior to analysis. Before all final dilutions, the internal standard diluted solution (refer to Calibration and Quantitation Section) was added to each test sample to give a final concentration of approximately 0.04 mg/mL. Each sample (final dilution) had an equivalent amount matrix (3%) when analyzed, except the 0.2 mg/mL (10%).

Samples submitted for analysis were analyzed the day the suspensions were received by the testing group or frozen until analyzed.

2. Chromatographic Conditions

Instrument: Hewlett-Packard Model 6890 GC
Column: J & W, DB-1701, 30 m, 0.32 mm ID, 1 um film thickness
Injector: Split, 250°C
Detector: FID; 250°C
Carrier Gas: Helium (2.1 mL/min)
Split vent: 22.3 mL/min
Injection Volume: 2 microliter
Oven Program: Gradient
Initial Temperature: 100°C
Initial Time: 1.00 min.
Level 1 Rate: 20.0°C/min.
Level 1 Temperature: 260°C
Level 1 Time: 0.00 min.
Total run time: 9.00 min.

3. Calibration and Quantitation

A separate sample of 8-2 Telomer B Alcohol was obtained for use as the analytical reference standard. A stock solution was prepared in methanol. This stock solution was sonicated to assure that all material was in solution. Before analysis, appropriate aliquots of the stock were diluted with the 0 mg/mL sample (initial dilution) to make calibration standards, which bracketed the target concentration of the diluted dosing samples. A stock solution of internal standard (1H, 1H, 2H, 2H-perfluoro-9-methyldecan-1-ol, 98% pure) was prepared in methanol and added to each calibration standard and test sample to give a final concentration of approximately 0.04 mg/mL.

The ratio of the internal standard and 8-2 Telomer B Alcohol peak heights from replicate GC analysis of these solutions was used to construct a calibration curve by least squares regression (see Appendix A, Figure 1 for a representative curve). Measured concentrations for the dosing samples were determined by applying the peak height ratios from replicate injections of each sample to the calibration curve.

Test substance homogeneity/uniformity in the vehicle was evaluated by calculating the coefficient of variation (C.V. = standard deviation/mean x 100) of the measured concentrations in the top, middle, and bottom samples (homogeneity) or duplicate samples (concentration verification) for each dosing level. A coefficient of variation of less than or equal to 10% is the standard criterion at Haskell Laboratory for acceptable distribution of the test substance throughout the solution. However, if the test substance has been shown to be difficult to disperse in the vehicle or the analysis has shown variability, a coefficient greater than 10 may be acceptable.

The mean result of the homogeneity samples or concentration verification duplicate samples for each dosing level was used to determine the concentration of the test substance for the respective dosing levels.

Stability was evaluated by using the mean result of the homogeneity samples or the duplicate samples from the concentration verification as the baseline for comparing the corresponding stability results.

L. Body Weights

1. Rats Designated for the Subchronic Toxicity and Three-Month Recovery Evaluations, and Satellite Bleeds

Rats were weighed once per week during the approximately 90-day exposure phase of the study. In addition, the rats designated for neurobehavioral evaluations (functional observational battery and motor activity assessments) were weighed on the days of those observations.

2. Rats Designated for 10-Day Biochemical Analysis

Rats were weighed on the first, eighth, and tenth day of test substance administration.

M. Food Consumption and Food Efficiency

The amount of food consumed by each rat over each weighing interval was determined throughout the study. Each feeder was weighed at the beginning and end of the interval and the final weight of the feeder and the amount of spillage from the feeder during the interval was subtracted from the initial feeder weight. From these measurements mean daily food consumption over the interval was determined. From the food consumption and body weight data the mean daily food efficiency was calculated.

N. Detailed Clinical Observations and Mortality

During the test period cage-site examinations to detect moribund or dead rats and abnormal behavior and/or appearance among rats were conducted at least twice daily, except on test day 46 only one cage-site examination was conducted. Moribund rats were sacrificed. At every weighing each rat was individually handled and examined for abnormal behavior and appearance. Detailed clinical observations in a standardized arena were also evaluated on rats designated for the subchronic toxicity and three-month recovery periods. Detailed clinical observations were not evaluated on rats designated for satellite bleeds.

The detailed clinical observations included (but were not limited to) evaluation of fur, skin, eyes, mucous membranes, occurrence of secretions and excretions, autonomic nervous system activity (lacrimation, piloerection, and unusual respiratory pattern), changes in gait, posture, response to handling, presence of clonic, tonic, stereotypical, or unusual behavior.

O. Ophthalmological Evaluations

Two ophthalmological examinations were conducted by a veterinary ophthalmologist. Both eyes were examined by focal illumination and indirect ophthalmoscopy. The examinations were conducted under subdued lighting after mydriasis had been produced with a 1% tropicamide solution.

On test day –11, prior to selection and grouping, the initial examination was performed on all main study rats received for the study. On test day 87, all surviving rats designated for the subchronic toxicity and three-month recovery evaluations were examined again.

P. Neurotoxicity Evaluations

1. Sensory Motor Function Evaluation

Prior to test substance administration and during week 13 of test substance administration, assessments of responses to approach/touch, sharp auditory stimulus, and tail pinch were made while the animal was in a standard arena. These assessments were conducted on the 10 animals per group designated for recovery from the control and high-dose groups, and on the 10 animals per group designated for subchronic toxicity from the low-dose and mid-dose groups.

Fore- and hindlimb grip strength were measured by a strain gauge device (Chatillon® Digital Force gauge). Pupillary constriction was measured immediately prior to removing the rats from the motor activity chambers (Section 2. below) because the darkened room in which the apparatus was located facilitated observing the response. The presence or absence of pupillary constriction was assessed after a beam of light was directed into each eye. For all these assessments, the experimenter was unaware of the group designation of the animal.

2. Motor Activity

Following the evaluation of grip strength and sensory function, assessment of motor activity (MA) was conducted. Rats were individually tested in 1 of 30 nominally identical, automated

activity monitors (Coulbourn® Infrared Motor Activity System). Group and sex were counterbalanced across the monitors and time of day to the fullest extent possible. The infrared monitoring device enables measurement of 2 dependent variables: duration of movement and number of movements. A continuous movement was counted as 1 movement regardless of duration. Each test session was 60 minutes in duration, and the results were expressed for the total session as well as for 6 successive 10-minute blocks.

Presence of defecation and urination on the cageboards below the motor activity monitor were also recorded following each motor activity session.

3. Test Facility Positive Control Data

Data on the effects of acrylamide, carbaryl, d-amphetamine, and trimethyltin are described in four separate reports.[6,7,8,9] These positive control studies are the basis of training certification for the individuals making judgments in the neurobehavioral and neuropathology tests. The data also document that the equipment and procedures are capable of detecting effects that may be seen in neurotoxicity studies of this type.

Q. Clinical Pathology

A clinical pathology evaluation was conducted on all rats designated for subchronic toxicity on test days 48/49 and 93/94 in males and females, respectively. The day before collection of samples for the clinical pathology evaluation the animals were placed in metabolism cages. These animals were fasted overnight (approximately 15-17 hours) and urine was collected from each animal. Blood samples for hematology and clinical chemistry measurements were collected from the orbital sinus of each animal while the animal was under light carbon dioxide anesthesia. Blood samples for coagulation parameters and fluoride analysis were collected at sacrifice from the abdominal *vena cava* of each animal while the animal was under carbon dioxide anesthesia. Additional blood collected from the *vena cava* was placed in a serum tube, processed to serum, and frozen at -80°C. Serum was discarded without analysis, however, because further tests were not required to support experimental findings. Bone marrow smears were prepared at the final sacrifice from all surviving animals. Bone marrow smears were stained with Wright's stain and coverslipped, but analysis was not necessary to support experimental findings.

At the end of a 3-month recovery period, samples for hematology, clinical chemistry, urinalysis, and plasma and urine fluoride were collected and analyzed from rats designated for recovery.

1. Hematology and Coagulation

Blood samples were evaluated for quality by visual examination prior to analysis. Complete blood counts, including reticulocytes, were determined on a Bayer® Advia 120 hematology analyzer or determined from microscopic evaluation of the blood smear. Wright-stained blood smears from all animals were examined microscopically for confirmation of automated results and evaluation of cellular morphology. Blood smears, stained with new methylene blue, were prepared from each animal undergoing a hematology evaluation but were not needed for examination. Coagulation times were determined on a Sysmex® CA-1000 Coagulation Analyzer.

The following hematology and coagulation parameters were determined:

red blood cell count
hemoglobin
hematocrit
mean corpuscular volume
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
red cell distribution width
absolute reticulocyte count
platelet count
white blood cell count
differential white blood cell count
microscopic blood smear examination

prothrombin time
activated partial thromboplastin time

2. Clinical Chemistry

Serum clinical chemistry parameters were determined on a Roche Diagnostics (BMC)/Hitachi® 717 clinical chemistry analyzer. Plasma fluorides were determined using a phi12 pH meter and a fluoride-selective electrode.

The following clinical chemistry parameters were determined:

aspartate aminotransferase
alanine aminotransferase
sorbitol dehydrogenase
alkaline phosphatase
total bilirubin
urea nitrogen
creatinine
cholesterol
triglycerides
glucose
total protein
albumin
globulin
calcium
inorganic phosphorus
sodium
potassium
chloride
fluoride[a]

3. Urinalysis

Urine volume and appearance (quality, color, and clarity) were measured and evaluated visually, respectively. Urine constituents were semi-quantitatively measured on a Bayer Clinitek® Atlas™ Automated Urine Chemistry analyzer. Urine protein was measured on a Roche Diagnostics (BMC)/Hitachi® 717 clinical chemistry analyzer. Urine osmolality was determined using an Advanced Osmometer 3900. Urine fluorides were determined using a phi12 pH meter and a fluoride-selective electrode. Sediments from all urine specimens were evaluated microscopically.

[a] Fluoride determination was analyzed on EDTA plasma.

The following urinalysis parameters were determined:

quality	ketone
color	bilirubin
clarity	blood
volume	urobilinogen
osmolality	fluoride[a]
pH	protein
glucose	microscopic urine sediment examination

R. Collection of Blood and Tissue (Three-Month Recovery)

Blood was collected from animals (5 animals/sex/group) designated as satellite bleeds during the 90-day dosing period and recovery period and stored for possible analysis of parent compound and metabolites.

Blood collection time points were: prior to dosing (test day -7), and days 0, 4, 10, 21, 35, 56, 77, 90, 94, 98, 105, 119, 133, 154, and 175. Blood (approximately 0.6 mL) was collected from the orbital sinus of designated animals while under light carbon dioxide anesthesia. On the day of blood collection, blood was collected from the animals approximately 2 hours (± 30 minutes) after dosing. For each bleeding, blood was collected at approximately the same time of day. The blood was collected in plastic tubes containing EDTA while on ice. The blood from each animal was then separated into plasma and red blood cells. The separated plasma samples were stored frozen at -80°C and red blood cells were discarded. After the final bleeding (day 175), all animals were euthanatized by carbon dioxide asphyxiation and exsanguination and liver and fat were collected, weighed, and stored at -80°C. The pharmacokinetic profile of 8-2 Telomer B Alcohol may be evaluated in the future and resulting data reported separately.

S. Biochemical Measurements

Following 10, 93 (males) or 94 (females) days of test substance administration or after three-months (test day 183 for males and females) of recovery, five rats from each group designated for biochemical evaluation were weighed and then euthanized by CO_2 anesthesia and exsanguination. At each time point, the livers were removed, weighed, and then a portion was homogenized (1 gram tissue/4 mL buffer) in homogenization buffer (50 mM Tris-HCl, 50 mM Trizma-base, 0.25 M sucrose, and 5.4 mM EDTA, pH 7.4). Hepatic peroxisomes were prepared using differential centrifugation. The resulting peroxisomal pellets were resuspended in the homogenization buffer, aliquoted, and stored between -65 and -85ºC until analyzed for peroxisomal β-oxidation activity. The peroxisomal suspensions were diluted to a protein concentration of approximately 0.5 mg/mL. Peroxisomal β-oxidation activity was determined using [^{14}C]palmitoyl CoA as the substrate.(10) The protein content of the peroxisomes was determined before and after analysis by the Biorad method.(11) Final rate calculations were made using the post-assay protein concentrations.

[a] Fluoride determination was analyzed from urine with EDTA added.

T. Anatomic Pathology

After approximately 90 days of exposure to the test substance (test days 93 and 94 for males and females, respectively), groups of 10 male and 10 female rats from the 0, 1, 5, 25, and 125 mg/kg/day groups were sacrificed and necropsied. Additional groups of 10 male and 10 female rats from the 0 and 125 mg/kg/day groups were sacrificed and necropsied approximately three months after the last exposure (test day 183) to evaluate recovery of toxic effects. In addition, groups of 5 male and 5 female rats from all groups designated for hepatic biochemical analysis were sacrificed and necropsied approximately three months after the last exposure (test day 183).

Rats were euthanatized by carbon dioxide anesthesia and exsanguination. Gross examinations were performed on all male and female rats. The following tissues were collected from subchronic exposure and 3-month recovery group rats sacrificed by design, or rats that were accidentally killed.

Digestive System	Cardiovascular System	Musculoskeletal System
liver	heart	skeletal muscle
esophagus	aorta	femur/knee joint
stomach		sternum
duodenum	Hematopoietic System	
jejunum	spleen	Reproductive System
ileum	thymus	Male
cecum	mandibular lymph node	testes
colon	mesenteric lymph node	epididymides
rectum	bone marrow[a]	prostate
salivary glands		seminal vesicles
pancreas	Endocrine System	Female
	pituitary gland	ovaries
Urinary System	thyroid gland	uterus
kidneys	parathyroid glands	mammary gland
urinary bladder	adrenal glands	
		Miscellaneous
Respiratory System	Nervous System	skin
lungs	brain (including cerebrum,	eyes (including optic
trachea	cerebellum, medulla/pons)	nerve)
nose	spinal cord (3 levels: cervical,	gross observations
larynx	mid-thoracic, lumbar)	
pharynx	sciatic nerve	

a Bone marrow was collected with the femur and sternum.

The following tissues were weighed from rats sacrificed by design in the subchronic exposure group and the 3-month recovery groups: liver, kidneys, adrenal glands, thyroid (weighed after fixation), brain, spleen, thymus, heart, ovaries, uterus, epididymides, and testes. Organ weight/final body weight and organ weight/brain weight ratios were calculated.

Gross lesions which were diagnosed at necropsy and for which microscopic examination was not appropriate (e.g., fluid accumulation, ruffled fur, missing anatomic parts) were generally not collected. Gross lesions for which a microscopic diagnosis would not be additive

(e.g., osteoarthritis, pododermatitis, chronic dermatitis of the tail, urinary calculi, and deformity of the teeth, toe, tail, or pinna) were saved but were generally not processed for microscopic evaluation.

Testes, epididymides, and eyes were fixed in Bouin's solution. All other tissues were fixed in 10% neutral buffered formalin. Processed tissues were embedded in paraffin, cut at a nominal thickness of 5 micrometers, stained with hematoxylin and eosin (H&E), and examined microscopically.

All collected tissues from 90-day exposure group control and 125 mg/kg/day rats, and all accidentally killed rats were processed and received a full histopathological examination. Liver and kidneys were processed from 1, 5, and 25 mg/kg/day 90-day exposure group and from all 3-month recovery group male and female rats. In addition, thymus, thyroid gland, and nose from 1, 5, and 25 mg/kg/day subchronic exposure group and all 3-month recovery group male rats were processed and examined microscopically.

U. Statistical Analyses

Except for Bartlett's test ($p < 0.005$), significance was judged at $p < 0.05$. Separate analyses were performed on the data for each sex.

		Method of Statistical Analysis	
Parameter	Preliminary Test	If preliminary test is not significant	If preliminary test is significant
Body Weight Body Weight Gain Food Consumption Food Efficiency ß-Oxidation Organ Weight	Test for lack of trend[12]	Sequential application[13] of the Jonckheere-Terpstra trend test[14]	Preliminary tests for pairwise comparison
	OR[a]		
	Levene's test for homogeneity[15] and Shapiro-Wilk test[16] for normality[b]	One-way analysis of variance[17] followed with Dunnett's test[18]	Kruskal-Wallis test[19] followed with Dunn's test[20]
Motor Activity[c]	Levene's test for homogeneity[15] and Shapiro-Wilk test[16] for normality[b]	Repeated measures analysis of variance[21] followed by contrasts[22]	Sequential application[13] of the Jonckheere-Terpstra trend test[14]
Grip Strength Foot Splay	Bartlett's test[23] for homogeneity of variances	One-way analysis of variance[17] followed with Dunnett's test[18]	Kruskal-Wallis test[19] followed with Dunn's test[20]
Clinical Pathology[d]	Levene's test for homogeneity[15] and Shapiro-Wilk test[16] for normality[b]	One-way analysis of variance[17] followed with Dunnett's test[18]	Kruskal-Wallis test[19] followed with Dunn's test[20]
Survival Incidence of Clinical Observations Incidence of Ophthalmological Observations Incidence of FOB Descriptive Parameters	None	Cochran-Armitage test for trend[17][e]	
Incidences of Gross and Microscopic Lesions	None	None	

a Pairwise comparisons and associated preliminary tests were only conducted if the test for lack of trend was significant.

b If the Shapiro-Wilk test was not significant but Levene's test was significant, a robust version of Dunnett's test was used (Dunnett/Tamhane-Dunnett).

c Test day and block (10-minute EPOCH) was used as repeated-measure factors.

d When an individual observation was recorded as being less than a certain value, calculations were performed on half the recorded value. For example, if bilirubin was reported as <0.1, 0.05 was used for any calculations performed with that bilirubin data.

e If the incidence was not significant, but a significant lack of fit occurred, then Fisher's Exact test[24] with a Bonferroni correction was used.

RESULTS AND DISCUSSION

ANALYTICAL EVALUATIONS

Dosing suspensions for this study were prepared at the beginning of the study as large volume mixes to be used either for 3 or 4 days of dosing. Samples containing 8-2 Telomer B Alcohol at the concentrations of 0, 0.2, 1.0, 5.0, and 25.0 mg/mL were collected at the initiation of the 90-day study (test day –6 for large volume/3-4 day mix). These samples were analyzed to determine homogeneity/concentration verification and 5-hour room temperature stability. Samples from the same preparation at the 0.2 mg/mL level only were collected on test day 0, after 7 days of refrigeration. These samples were analyzed to determine re-dispersion/concentration verification and refrigerated stability along with 5-hour room temperature stability. The refrigerated re-dispersion/concentration verification and stability for the other levels had been established during the mixing/stability study for a previous study. These data indicated that the test substance was homogeneously mixed, could be re-dispersed after refrigeration to the expected concentration, and was stable in the vehicle for 5 hours after refrigeration.

On test days 42 and 45 (3-4 day mix), concentration verification samples for all levels were collected. Results from analysis of the dosing suspensions collected near the mid-point of the study (test day 42) for concentration verification indicated that test substance was marginally at the targeted concentration (± 20% of nominal). In order to investigate these results, a new large volume preparation of the dosing suspensions was made and sampled on test day 45. The results for these samples were lower than expected (range: -33.4% to –66.0% of nominal) indicating a sampling problem. Investigation of the study records showed that the correct amount of test material was contained in the preparations but that a possible technician error had occurred with the re-dispersing and sampling of the test material to the analytical group. Due to the length of time needed for evaluation of the samples, the preparations had already been dosed to the animals and further sampling could not be done to define the problem with the sampling of this mix. Therefore, due to the unexpected analytical results observed on test day 45, the following study changes were implemented: 1) on test day 49 of the study, the dosing suspension preparation was changed to small volume mix to be used for 1 day of dosing and concentration verification samples for all levels were collected on test days 48 (not dosed to animals), 52, 56, 58, 65, and 91 (small volume/1 day mix); and 2) on test day 63 and 73 large volume mixes (3-4 day) were prepared and samples were collected from all levels for evaluation of the mixing and sampling for the study before test day 45. These preparations were not used for dosing the animals.

A. Test Substance Stability

Samples of test substance were analyzed near the beginning and the end of the study. These analyses indicated that the test substance was stable over the course of the study. The average percent of active ingredient was 99.1% ± 0.81 and 101.8% ± 2.9 for the samples analyzed on February 15, 2002, and May 30, 2002, respectively.[25] 8-2 Telomer B Alcohol was reported by

the sponsor to have 99.2% active ingredient. The differences in values between the sponsor reported purity and the experimental data represent analytical variability.

B. Chromatography

8-2 Telomer B Alcohol eluted from the GC column as resolved peak with a retention time of approximately 3.5 minutes. The internal standard eluted from the GC column as a resolved peak with a retention time of approximately 3.9 minutes. Representative GC chromatograms are shown in Appendix A, Figures 2(a - c). Test substance was not detected in the 0 mg/mL control.

C. Homogeneity and Stability Samples

Analytical results from dosing suspensions collected on test day -6 and test day 0 and analyzed for homogeneity and/or concentration verification and stability are shown in Appendix A, Table I and Summary Table 1.

The following table summarizes the results for all homogeneity and/or concentration verification and stability analyses.

Test Day Sample Type	Nominal mg/mL	Measured T,M,B[a] mg/mL	Mean (T,M,B) % Nominal	C.V.[b] (%)	Stability[c] % Nominal
Test Day -6 Homogeneity	0	ND[d]	---	---	---
	0.2	0.163, 0.164, 0.161	81.5	1	83.5
	1.0	0.803, 0.857, 0.890	85.0	5	81.8
	5.0	4.55, 4.80, 4.61	93.0	3	82.8
	25	19.9[d], 21.9, 22.9	86.4	7	87.2
Test Day 0 Stability 7 Day Refrigerated	0	ND[d]	---	---	---
	0.2[f]	0.161, 0.173	83.5	5	79.0[e]

a. Mean results for the analysis of the top (T), middle (M), and bottom (B) samples.
b. C.V. = Coefficient of Variation
c. Samples held 5 hours at room temperature.
d. Denotes none detected.
e. Duplicate re-analysis of the original sample supports the original result and are not reported.
f. Mean results for the analysis of duplicate concentration verification samples.

The data for samples collected on test day -6 indicates that the test substance was homogeneously mixed in the vehicle at all levels (C.V.'s = 1, 5, 3 and 7, respectively). The test substance was at the targeted concentration in the samples (± 18.5% of nominal) and was stable in the vehicle when held 5 hours at room temperature.

The data for 0.2 mg/mL sample collected on test day 0 after 7 days of refrigeration indicates that the test substance was homogeneously re-suspended in the vehicle (C.V. = 5). The test substance was at the targeted concentration (± 16.5% of nominal) and stable in the vehicle when held refrigerated for 7 days followed by 5 hours at room temperature. The 5-hour sample analyzed at

79.0% of nominal appeared to be lower than expected but this can be attributed to sampling and analytical variability and not stability of the test material in the vehicle.

All other concentrations in the study had been shown to be homogeneously mixed and stable in the vehicle after 7 days of refrigeration followed by 5 hours at room temperature in the mixing/stability study.(5) The following table from this study is included.

Test Day Sample Type	Nominal mg/mL	Measured T,M,B[a] mg/mL	Mean (T,M,B) % Nominal	C.V. (%)	Stability[b] % Nominal
Test Day 4 Homogeneity	0	ND[c]	---	---	---
	1.0	0.944, 0.884, 0.836[d]	88.8	6	85.4[e]
	5.0	4.43, 4.37, 4.72[d]	90.2	4	95.0
	25	22.2, 22.7, 24.2	92.0	5	96.0
Test Day 11 Stability 7 Day Refrigerated[f]	0	ND[c]	---	---	---
	1.0	0.900, 0.864, 0.859	87.4	3	90.4[g]
	5.0	4.46, 4.44	89.0	0	84.2[g]
	25	24.2, 23.9	96.4	1	84.8[g]

a Mean results for the analysis of the top (T), middle (M) and bottom (B) samples.
b Samples held 5 hours at room temperature.
c Denotes none detected.
d Mean result of all analyses reported.
e Mean result of all analyses reported except for one duplicate repeat sample which was low due to aliquot error.
f Duplicate concentration verification samples analyzed except for the 1.0 mg/mL level (homogeneity).
g Mean result of duplicate re-sampling from the original diluted sample. Original analysis was lower than expected due to aliquot error and not reported.

D. Concentration Verification Samples

Analytical results from dosing suspensions prepared test days 42, 45, 48, 52, 56, 58, 65, and 91 and analyzed for concentration verification are shown in Appendix A, Table II and Summary Table 1.

The following table summarizes the results for concentration verification analyses of the 8-2 Telomer B Alcohol sample preparations for the above test days 42 and 45 (3/4-day mix), that were dosed to the animals.

Preparation Day	Nominal mg/mL	Measured[a] mg/mL	Average % Nominal	CV %
Test Day 42	0.2[b]	0.156, 0.169	81.5	6
	1.0[b]	0.749, 0.776	76.3	3
	5.0	3.87[b], 3.91[c]	77.8	1
	25.0[c]	19.4, 19.1	77.2	1
Test Day 45	0.2[b]	0.066, 0.083	37.5	13
	1.0[b]	0.676, 0.656	66.6	2
	5.0[b]	2.20, 2.32	45.2	4
	25.0[b]	8.34, 8.64	34.0	3

a Duplicate samples per level were analyzed. C.V. calculated to verify uniformity of mixture.
b Mean result of the original analysis and duplicate reanalysis of the original sample.
c Mean result of duplicate re-sampling from the original diluted sample. Original analysis was lower than expected due to aliquot error and not reported.

Results from analysis of the dosing suspensions collected on test day 42 for concentration verification indicated that test substance was marginally acceptable (-23.7% of nominal). Therefore, to investigate these results, a new large volume preparation (3/4-day mix) of the dosing suspensions was made and sampled on test day 45. The results for these samples were lower than expected (range: -33.4% to –66.0% of nominal) based on previously analyzed samples for the study.

Additional work was then done to investigate whether the results for test day 45 were unique to the sampling for the analytical group. This involved the preparation of two large volume dose suspensions (3-4 day mixes) on test days 63 and 73 to be used only for analysis to verify the mixing and sampling procedures of the large volume dose preparations. These suspensions were not dosed to the animals. On test day 49 the dose suspensions were prepared daily for the remainder of the study.

The following table summarizes the results for concentration verification analyses of the 8-2 Telomer B Alcohol sample preparations for the test days 48 (not dosed to animals), and 52, 56, 58, 65, and 91 (1-day mixes) that were dosed to the animals.

Preparation Day	Nominal mg/mL	Measured[a] mg/mL	Average % Nominal	CV %
Test Day 48[b]	0.2	0.197, 0.219	104.0	7
	1.0	0.865, 0.948	90.7	6
	5.0	3.93, 3.90	78.3	1
	25.0	21.9, 22.5	88.8	2
Test Day 52	0.2	0.174, 0.184	89.5	4
	1.0	0.845, 0.895	87.0	4
	5.0	4.22, 4.16	83.8	1
	25.0	23.5, 22.3	91.6	4
Test Day 56	0.2	0.167, 0.189	89.0	9
	1.0	0.964, 0.950	95.7	1
	5.0	4.41, 4.31	87.2	2
	25.0	22.8, 21.4	88.4	4
Test Day 58	0.2	0.174, 0.150	81.0	10
	1.0	0.945, 0.937	94.1	1
	5.0	4.48, 4.17	86.5	5
	25.0	22.5, 22.1	89.2	1
Test Day 65	0.2[c]	0.159, 0.150	77.5	4
	1.0	0.832, 0.898	86.5	5
	5.0	4.32, 4.40	87.2	1
	25.0	20.8, 20.5	82.6	1
Test Day 91	0.2	0.162, 0.165	82.0	1
	1.0	0.760[c], 0.863	81.2	9
	5.0[c]	3.96, 3.90	78.6	1
	25.0[c]	19.9, 18.7	77.2	4

a Duplicate samples per level were analyzed. C.V. calculated to verify uniformity of mixture.
b Suspensions not dosed to animals.
c Mean result of the original analysis and duplicate reanalysis of the original sample.

Because of the results from test day 45, samples were collected from the daily mixes to verify concentration on test day 48 (not dosed to animals), 52, 56, 58, 65, and 91. With the exception of four samples, results from these analyses indicated that the dosing suspensions were at the targeted concentrations (± 20% of nominal). On test day 48, the result for the 5.0 mg/mL level was marginally acceptable at 78.3% of nominal. On test day 65, the result for the 0.20 mg/mL level was marginally acceptable at 77.5% of nominal. On test day 91, the result for the 5.0 mg/mL and the 25.0 mg/mL levels were marginally acceptable at 78.6% and 77.2% of nominal, respectively.

Based on the statistics (mean % of nominal) for all samples analyzed for the daily mixing, it can be concluded that the dosing suspensions contained the targeted amount of 8-2 Telomer B Alcohol during the period from test day 48 (not dosed to animals) until the end for the study. The following table shows the mean % of nominal for all analyzed samples at each concentration for the daily preparations and the average of the mean % of nominal, with the SD, and the CV based on this average for all the levels analyzed.

Statistics for all Samples Analyzed for Small Volume Mix (1-day)

Nominal mg/mL		Mean % Nominal
0		---
0.20		87.2
1.0		89.2
5.0		83.6
25		86.3
	Mean:	**86.6**
	SD	**±2.3**
	CV	**3%**

On test day 63 and 73, dose preparations (3-4 day/large volume) were prepared but used only for verification of mixing and sampling procedures on the large volume dose preparation. These suspensions were not dosed to the animals.

The following table summarizes the results for concentration verification analysis for these preparations.

Preparation Day	Nominal mg/mL	Measured[a] mg/mL	Average % Nominal	CV %
Test Day 63	0.2	0.190, 0.192	95.5	1
	1.0	0.784, 0.792	78.8	1
	5.0	4.12, 4.08	82.0	1
	25.0	23.0, 21.4	88.8	5
Test Day 73	0.2	0.176, 0.155	82.8	9
	1.0	0.980, 1.03	101.0	4
	5.0	4.57, 4.60	91.8	0.4
	25.0	23.3, 24.4	95.6	3

a. Duplicate samples per level were analyzed. C.V. calculated to verify uniformity of mixture.

With the exception of one sample, results from these analyses indicated that the dosing suspensions were at the targeted concentrations (± 20% of nominal). On test day 63, the result for the 1.0 mg/mL level was marginally acceptable at 78.8% of nominal. Neither of these preparations were dosed to the animals but the results were used as statistical data along with the results from the previously dosed large volume preparations (test days –6, 42, and 45) to show that the dosing suspensions contained the targeted amount of test substance before test day 45

and that the results for that day were due to technician error while sampling for the Analytical group.

Based on the statistics (mean % of nominal) for all samples analyzed for a 3-4-day preparation (large volume), it can be concluded that the dosing suspensions contained the targeted amount of 8-2 Telomer B Alcohol during the period from the initial sampling (test day –6) for the study until test day 45. The following table shows the mean % of nominal for all analyzed samples at each concentration and the average of the mean % of nominal, with the SD, and the CV based on this average for all the levels analyzed. Included are the two preparations (test day 63 and 73) that were not dosed to animals but prepared only to evaluate the mixing and sampling process.

The table includes results (a) with test day 45 and (b) excluding test day 45.

Statistics for all Samples Analyzed for Large Volume Mix (3-4-day)

Nominal mg/mL		Mean % Nominal
(a)		
0		---
0.20		75.8
1.0		81.5
5.0		78.0
25		76.4
	Mean:	**77.9**
	SD	**±2.6**
	CV	**3%**
(b)		
0		---
0.20		85.3
1.0		85.3
5.0		86.2
25		87.0
	Mean:	**85.9**
	SD	**±0.8**
	CV	**1%**

The statistics for the large volume dose preparations with the exclusion of the test day 45 indicate that the samples were at the targeted concentrations having a mean % of nominal 85.9% ± 0.8, and a CV of 1%. Although the statistics based on all large volume preparations are marginally acceptable with the inclusion of test day 45 (77.9% of nominal), the test day 45 sample analysis should not be considered as part of the dose verification samples for the study and should be excluded from these statistics because: 1) previous analysis on large volume mixes indicated no problem; 2) the study notebook dose preparation sheet shows that the correct amount of test substance was present at each dosing level for the preparation, and 3) subsequently, that in sampling and analyzing the two large volume preparations after test day 45 (test days 63 and 73), the test material was dispersed properly and at the targeted concentrations.

Test substance was not found in the 0 mg/mL samples.

E. Discussion of Results

Based on the statistics (mean % of nominal) for all sample sets analyzed for the study and dosed to the animals, it can be concluded that the dosing suspensions contained marginally the targeted amount (± 20% of nominal) of 8-2 Telomer B Alcohol with test day 45 included and the targeted amount (± 20% of nominal) of 8-2 Telomer B Alcohol with test day 45 excluded. The following table shows the mean % of nominal for all analyzed samples at each concentration and the average of the mean % of nominal, with the SD, and the CV based on this average for all the levels analyzed **(a)** including test day 45 and (b) excluding test day 45.

Statistics for all Samples Analyzed and Dosed to Animals

Nominal mg/mL		Mean % Nominal
(a)		
0		---
0.20		77.4
1.0		84.1
5.0		79.9
25		78.3
	Mean:	**79.9**
	SD	**±2.9**
	CV	**4%**
(b)		
0		---
0.20		83.1
1.0		86.5
5.0		84.9
25		84.9
	Mean:	**84.8**
	SD	**±1.4**
	CV	**2%**

F. Analytical Conclusion

Results from the analysis of the 8-2 Telomer B Alcohol dosing suspensions prior to the study start, at the initiation of the study, for the daily dose preparations after test day 45, and including the additional large volume dose preparation on test days 63 and 73 (not dosed to the animals) indicated that the test substance was homogeneously mixed, at the targeted concentrations and stable in the vehicle under the conditions of the study. Furthermore, the study records indicate that the correct amount of test substance was contained in the test day 45 dosing suspensions. Taken together, these data point to a problem unique to the analytical samples that were collected on test day 45.

IN-LIFE TOXICOLOGY

A. Dosage Data
(Tables 2-3, Appendix B)

Rats were dosed with suspensions of 8-2 Telomer B Alcohol in 0.5% aqueous methylcellulose, prepared at concentrations of 0, 0.2, 1, 5, and 25 mg/mL, designed to deliver the targeted dose of test substance at a dosing volume of 5 ml/kg body weight. The quantity of 8-2 Telomer B Alcohol administered to each rat was calculated, based on the most recent body weight for each rat, and subsequently rounded by a computer program.

The range of mean daily dose volumes administered to male rats was 1.2-2.9 mL for the control group, 1.2-2.8 mL for the 1 mg/kg/day group, 1.2-3.0 mL for the 5 mg/kg/day group, 1.2-3.0 mL for the 25 mg/kg/day group, and 1.2-2.8 mL for the 125 mg/kg/day group. The range of mean daily dose volumes administered to female rats was 0.9-1.5 mL for the control group, 0.9-1.5 mL for the 1 mg/kg/day group, 0.9-1.5 mL for the 5 mg/kg/day group, 0.9-1.6 mL for the 25 mg/kg/day group, and 0.9-1.6 mL for the 125 mg/kg/day group.

B. Mean Body Weights and Body Weight Gains
(Tables 4-7, Figures 1-2, Appendix C)

There were no test substance-related, toxicologically significant alterations in mean body weight or body weight gain observed in any of the male or female dose groups. Significant decrements of 40 and 51%, respectively, occurred in the mean body weight gain of the 25 and 125 mg/kg/day male groups during the 63-70 test day interval, while a significant increase occurred for the 125 mg/kg/day male group during the 7-14 day interval. For the 49-56 day interval, significant increases in mean body weight gain were observed for the 5 and 25 mg/kg/day male groups. On test day 77, all animals in the high-dose male and female dose groups were placed on ground chow because of test substance-induced alterations to the teeth. Once placed on ground chow, males in the 125 mg/kg/day group had a significant increase in mean body weight gain for the 84-91 test day interval. The overall (0-91 day interval) mean body weight gain of male rats, however, was similar to control across all dose levels. Over the course of the three-month recovery period, statistically significant increases in mean body weight gain occurred for the 125 mg/kg/day male group. Overall mean body weight gain for the three-month recovery period for the 125 mg/kg/day male group was significantly increased 36% compared to control.

During the 77-84 test day interval, females in the 125 mg/kg/day dose group had a significant increase in mean body weight gain following their placement on ground chow. For the overall interval (0-91 days), the mean body weight gain for females was similar to control across all dose levels. A significant increase in mean body weight gain occurred for the 25 mg/kg/day female group during the 154-161 test day interval. Statistically significant increases and decreases in mean body weight gain also occasionally occurred over the three-month recovery period for the 125 mg/kg/day female group; however, the mean body weight gain for all female dose groups was similar to control for the overall recovery interval.

C. Food Consumption and Food Efficiency
(Tables 8-11, Appendix D)

There were no test substance-related, toxicologically significant alterations in food consumption observed in any of the male or female dose groups. For the 98-105 and 105-112 test day intervals, males in the 125 mg/kg/day three month recovery group had statistically significant and lower food consumption of 9 and 10%, respectively. Overall (91-182 day interval), however, food consumption for the 125 mg/kg/day male three-month recovery group was similar to control.

There were no test substance-related, toxicologically significant alterations in mean daily food efficiency observed in any of the male or female dose groups. Male rats in the 125 mg/kg/day group had several incidences of significantly higher mean daily food efficiency compared to control over the course of the study except during the 63-70 day interval in which significantly lower (59% compared to control) mean daily food efficiency was observed. Males in the 25 mg/kg/day dose group also had a significantly lower mean daily food efficiency of 42% during the 63-70 test day interval. Following the replacement of pelleted chow with ground chow on test day 77 for the 125 mg/kg/day male group, a significantly higher mean daily food efficiency was observed for the 84-91 day interval. For the 0-91 day study interval, however, mean daily food efficiency for male rats was similar to control, while for the overall three-month recovery interval, mean daily food efficiency was significantly increased 26% compared to control for the 125 mg/kg/day male group.

Female rats in the 125 mg/kg/day group had significantly lower (60%) mean daily food efficiency during the 63-70 day interval. Following the replacement of pelleted chow with ground chow on test day 77 for the 125 mg/kg/day female group, a significantly higher mean daily food efficiency was observed for the 77-84 day interval. Overall mean daily food efficiencies for test-substance treated female groups, however, were similar to control. During the three-month recovery (test days 154-161), females in the 125 mg/kg/day group had a significant increase in mean daily food efficiency; however, for the overall three month recovery interval, mean daily food efficiency was similar to control.

D. Clinical Observations and Mortality
(Tables 12-17, Appendix E-F)

A test substance-related, toxicologically significant increase in the incidence of striated teeth was observed in the 125 mg/kg/day male and female dose groups. In addition, there was an increase in tooth clipping required for both males and females in the 125 mg/kg/day dose group.

No test substance-related ophthalmological signs of toxicity or effects on survival were observed.

E. In-Life Toxicology Conclusions

Under the conditions of this study, the NOEL for in-life toxicology parameters (body weight, body weight gain, food consumption, food efficiency, and clinical signs of toxicity) was 25 mg/kg/day for both males and females based on the increased incidence of striated teeth observed in male and female rats administered 125 mg/kg/day.

NEUROBEHAVIORAL TOXICOLOGY

A. Sensory Function Evaluations

1. Forelimb Grip Strength
(Table 18-19, Figures 3-4, Appendix G)

There were no test substance-related effects on forelimb grip strength in males or females administered any dosage of 8-2 Telomer B Alcohol. During the baseline evaluation, females in the 5 mg/kg/day group had significantly increased forelimb grip strength. However, since administration of the test material had not been initiated, this statistical difference was not test substance related. There were no statistically significant differences for males administered any dosage of the test material.

2. Hindlimb Grip Strength
(Table 18-19, Figures 5-6, Appendix G)

There were no test substance-related effects or statistically significant differences in hindlimb grip strength for either males or females administered any dosage of 8-2 Telomer B Alcohol.

3. Sensory Function Observation
(Table 20-21, Appendix H)

There were no test substance-related changes or statistically significant differences in neurobehavioral parameters in males or females administered any dosage of 8-2 Telomer B Alcohol.

B. Motor Activity
(Tables 22-25, Figures 7-10, Appendices I-J)

There were no test substance-related effects on duration of movement or number of movements for males or females for any dosage of 8-2 Telomer B Alcohol. During the third 10-minute interval for the baseline evaluation, males in the 1 mg/kg/day group had significantly higher duration of movement compared to the control value. During the fourth 10-minute interval of the baseline evaluation, males in the 1, 5, 25, and 125 mg/kg/day groups had significantly higher duration of movement compared to the control value. During the fifth 10-minute interval of the baseline evaluation, males in the 5 mg/kg/day group had significantly higher duration of

movement compared to the control value. However, since administration of the test material had not been initiated, these statistical differences were not test substance related.

During the fifth 10-minute interval for the 13-week evaluation, duration of movement for 25 mg/kg/day males was significantly lower compared to the control value. However, since duration of movement was similar to control for 125 mg/kg/males, the statistically lower value for the 25 mg/kg/day males was not considered to be test substance-related.

During the fourth 10-minute interval for the baseline evaluation, number of movements for 1, 5, and 25 mg/kg/day males was significantly higher than the control value. In addition, during the fifth 10-minute interval for the baseline evaluation, number of movements for 5 mg/kg/day males was significantly higher than the control value. However, since administration of the test material had not been initiated, these statistical differences were not test substance related.

Total number of movements and the number of movements during the fifth 10-minute interval of the 13-week evaluation were significantly lower for 25 mg/kg/day males compared to the control value. However, since number of movements for 125 mg/kg/day males was similar to control, these statistical differences were not considered to be test substance related. Number of movements for 125 mg/kg/day males during the fourth 10-minute interval for the 13-week evaluation was significantly lower compared to the control value. However, since the total number of movements was similar to the control value, the statistically lower value for 125 mg/kg/day males was not considered to be test substance related.

There were no statistically significant differences for females administered any dosage of the test material.

C. Neurobehavioral Toxicity Conclusions

Under the conditions of the study, the NOEL for neurobehavioral parameters was 125 mg/kg/day of 8-2 Telomer B Alcohol in males and females, the highest concentration tested.

CLINICAL PATHOLOGY

A. Hematology/Coagulation
(Tables 26-29, Appendix K)

There were no adverse changes in hematologic parameters in male or female rats at either time point during treatment. The following statistically significant changes in mean hematologic parameters were considered to be non-adverse.

- Red cell mass (red cell count, hemoglobin, hematocrit) was minimally decreased in males and females dosed with 125 mg/kg/day (at both time points during treatment, variable statistical significance for males) (Clinical Pathology Text Table 1). Decreased red cell mass was associated with regeneration of red cells (increased reticulocytes) in males (statistically significant only at 125 mg/kg/day, test days 48 and 93) and females (statistically significant at

test day 94 only). Increased reticulocytes resulted in increased red cell distribution width and mean cell volume (variable statistical significance). However, histologically, there was no increase in extramedullary hematopoiesis.

Red cell counts (males) and hematocrits (females) were minimally but statistically decreased in rats dosed with 25 mg/kg/day. These changes were sometimes associated with minimal increases in red cell distribution width and mean cell volume (variable statistical significance).

In addition, minimally increased changes in red cell morphology (acanthocytes) were present in males dosed with 25 or 125 mg/kg/day at both time-points during treatment.

The above changes in red cell parameters were considered to be related to treatment, and indicate minimally increased red cell turnover. However, due to the minimal nature of the changes, they were considered to be non-adverse. After approximately 90 days of recovery, red cell mass parameters, reticulocytes, red cell distribution width, and mean cell volume were similar to control group values of rats previously dosed with 125 mg/kg/day.

- Minimally increased mean corpuscular hemoglobin in males dosed with 125 mg/kg/day at test day 93 was considered to be possibly related to treatment, but was considered to be non-adverse because minimal increases in mean corpuscular hemoglobin are not associated with adverse effects. After approximately 90 days of recovery, mean corpuscular hemoglobin concentrations were similar to control group values of rats previously dosed with 125 mg/kg/day.

The following statistically significant changes in mean clinical chemistry parameters were considered to be non-adverse because they were unrelated to dose and/or occurred only at three months post dosing:

- Minimally and transiently decreased reticulocytes in females dosed with 25 mg/kg/day at test day 49.

- Minimally increased basophils in females previously dosed with 125 mg/kg/day after approximately 90 days of recovery.

Clinical Pathology Text Table 1:
Red cell mass parameters and reticulocytes (expressed as a percent of control group mean)*

		Males				Females			
Dosage (mg/kg/day):		1	5	25	125	1	5	25	125
	Test Day								
RBC	48/49	99%	98%	***95%***	***93%***	98%	98%	97%	***91%***
	93/94	100%	97%	***95%***	***91%***	100%	102%	98%	***93%***
	183	--	--	--	96%	--	--	--	100%
HGB	48/49	101%	100%	98%	96%	99%	99%	96%	***91%***
	93/94	100%	98%	98%	***94%***	102%	102%	98%	***94%***
	183	--	--	--	98%	--	--	--	103%
HCT	48/49	100%	100%	97%	96%	98%	99%	***96%***	***91%***
	93/94	101%	99%	98%	***95%***	101%	102%	97%	***94%***
	183	--	--	--	97%	--	--	--	103%
ARET	48/49	97%	111%	113%	***123%***	88%	97%	***85%***	94%
	93/94	92%	108%	112%	***126%***	98%	110%	99%	***125%***
	183	--	--	--	105%	--	--	--	107%

* Statistical significance indicated by bold italicized type

B. Clinical Chemistry
(Tables 30-31, Appendix K)

There were no adverse changes in clinical chemistry parameters in male or female rats. The following statistically significant changes in mean clinical chemistry parameters were not toxicologically significant (i.e., not adverse) or not related to exposure to test substance:

- Alkaline phosphatase activity was minimally and transiently increased in males dosed with 125 mg/kg/day at test day 48. At the end of dosing (test day 93), alkaline phosphatase activity was more similar to controls, although it was still minimally increased (not statistically significant). Increased alkaline phosphatase can be due to induction by a xenobiotic compound or can be due to increased biliary pressure. In this study, males dosed with 125 mg/kg/day had both increased liver weights and histologic evidence of hypertrophy, but no evidence of cholestasis. Therefore, in this study, increased alkaline phosphatase activity was probably due to induction by the test substance. Increased alkaline phosphatase activity was considered to be non-adverse because minimally increased alkaline phosphatase is not associated with adverse effects. After approximately 90 days of recovery, alkaline phosphatase activities were similar to control group values in rats previously dosed with 125 mg/kg/day.

- Cholesterol was mildly increased in females dosed with 25 or 125 mg/kg/day (variable statistical significance) at test days 49 and 94 (group means were 136% to 139% of control group means). Although this change was likely due to treatment, mildly increased cholesterol does not result in adverse events. Therefore, this change was considered to be non-adverse. After approximately 90 days of recovery, cholesterol concentrations were similar to control group values in females previously dosed with 125 mg/kg/day.

- Triglycerides were mildly decreased in males dosed with 125 mg/kg/day at test days 48 and 93 (49 and 48% of control group means, respectively). Mildly decreased triglycerides were considered to be related to treatment; however, mildly decreased triglycerides are not associated with adverse effects, and therefore were considered non-adverse. After approximately 90 days of recovery, triglyceride concentrations were similar to control group values in males previously dosed with 125 mg/kg/day.

- Total protein was mildly increased due to increased albumin in males and females dosed with 125 mg/kg/day at days 48/49 and 93/94. Mildly increased total protein and albumin concentrations were likely due to treatment, but were considered to be non-adverse because mild increases in these parameters are not associated with adverse effects. After approximately 90 days of recovery, protein concentrations were similar to control group values in rats previously dosed with 125 mg/kg/day.

- Calcium was increased in females dosed with 125 mg/kg/day at test day 94. The increased calcium was considered to be secondary to increased albumin. Calcium exists in serum in two forms, either bound to albumin or unbound ("ionized" calcium). Ionized calcium is the physiologically active form and is tightly regulated. Increases in albumin are necessarily associated with physiologically appropriate increased bound calcium, with resultant increased total calcium. However, ionized calcium is unaffected. Therefore, this change was considered to be non-adverse. After approximately 90 days of recovery, calcium concentrations were similar to control group values in rats previously dosed with 125 mg/kg/day.

- Phosphorus was minimally increased in males dosed with 125 mg/kg/day at test day 48 and 93, and at the end of recovery (test day 183). Increased phosphorus was possibly due to treatment at test day 48 and 93, but was likely to be unrelated to treatment at test day 183 (after three months of recovery). Increased phosphorus is of toxicologic significance when it is associated with evidence of decreased glomerular filtration rate, but may also be affected by extrarenal factors. In this study, other indicators of glomerular filtration rate (urea nitrogen and creatinine) were unaffected by treatment. Anatomic pathology changes included increased kidney weights associated with renal tubular hypertrophy; these changes were not present after three months of recovery. However, these anatomic pathology changes are not expected to result in decreased glomerular filtration rates. Therefore, the minimally increased phosphorus was considered to be non-adverse.

The following statistically significant changes in mean clinical chemistry parameters were considered to be non-adverse because they were unrelated to dose and/or occurred only at three months post-dosing:

- Decreased bilirubin in males dosed with 1 mg/kg/day at test days 48 and 93
- Decreased cholesterol in males dosed with 25 mg/kg/day at test day 48
- Increased urea nitrogen in males dosed with 25 mg/kg/day at test day 93
- Decreased urea nitrogen and creatinine in males previously dosed with 125 mg/kg/day at recovery test day 183
- Decreased cholesterol in males dosed with 1 mg/kg/day at test day 93

C. Urinalysis
(Tables 32-33, Appendix K)

Microscopic urine evaluation had lower priority than other urine tests. After other tests were completed on day 94, some females had insufficient urine for microscopic observation. Although no treatment-related changes were present in the samples evaluated, there were too few specimens to make unequivocal determinations. For other time-points and for males at test day 93, there were no adverse changes in urinalysis parameters. The following statistically significant changes in mean or individual urinalysis parameters were considered to be non-adverse.

- Urine volume was increased in males dosed with 125 mg/kg/day at test day 93. Increased urine volume can be due to primary increased urine production, or can be secondary to increased water consumption. The cause of increased urine production in this study was not determined. These changes correlated with anatomic pathology findings of increased kidney weights and renal tubular hypertrophy which were considered to be non-adverse (see discussion under Microscopic Findings). Increased urine production in the absence of alterations in other renal parameters (serum urea nitrogen, serum creatinine, or adverse histologic changes in the kidney) is considered to be non-adverse. After approximately 90 days of recovery, urine volumes were similar to control group values in rats previously dosed with 125 mg/kg/day.

- Decreased urine ketone concentrations were present in males dosed with 125 mg/kg/day at test day 93. These decreases were likely secondary to increased urine volumes, and were considered to be non-adverse. After approximately 90 days of recovery, urine ketone concentrations were similar to control group values in rats previously dosed with 125 mg/kg/day.

D. Plasma and Urine Fluoride
(Tables 30-33, Appendix K)

Plasma fluoride was increased in males dosed with 125 mg/kg/day, and in females dosed with 25 or 125 mg/kg/day at test day 93/94 (not statistically significant in females dosed with 25 mg/kg/day). After approximately 90 days of recovery, plasma fluoride concentrations were similar to control concentrations for males and females previously dosed with 125 mg/kg/day.

Urine fluoride was increased in males and females dosed with 5, 25, and 125 mg/kg/day at test day 93/94 (not statistically significant in females dosed with 5 mg/kg/day). After approximately 90 days of recovery, total urine fluoride amounts were approximately 3 times greater than controls in males previously dosed with 125 mg/kg/day, but only minimally greater than controls in females.

Increased plasma and urine fluoride indicates exposure to and metabolism of a fluoride-containing compound. The presence of fluoride after 90 days of recovery indicates continued metabolism of the test substance.

Clinical Pathology Text Table 2:
Plasma fluoride (expressed as mean and as percent of control group mean)*

Parameter	Sex	Test Day	I/II	III/IV	V/VI	VII/VIII	IX/X
			0 mg/kg/day	1 mg/kg/day	5 mg/kg/day	25 mg/kg/day	125 mg/kg/day
PFLU (ug/mL)	Males	93	0.1	0.1	0.1	0.1	***0.4***
				100%	100%	100%	***400%***
		183	0.1	--	--	--	0.1
			--	--	--	--	***100%***
PFLU (ug/mL)	Females	94	0.1	0.1	0.1	0.2	***0.5***
			--	100%	100%	200%	***500%***
		183	0.1	--	--	--	0.1
			--	--	--	--	100%
UFLU (ug)	Males	93	10.7	13	***38.8***	***202.4***	***997.2***
			--	121%	***363%***	***1892%***	***9320%***
		183	9.9	--	--	--	***27.6***
			--	--	--	--	***279%***
UFLU (ug)	Females	94	6	5.7	14.1	***88***	***702.6***
			--	95%	235%	***1467%***	***11710%***
		183	11.9	--	--	--	15.7
			--	--	--	--	132%

* Statistical significance indicated by bold italicized type.

E. Clinical Pathology Conclusions

In conclusion, there were no adverse effects, measured by clinical pathology parameters, in rats dosed with 8-2 Telomer B Alcohol at doses up to 125 mg/kg/day. Treatment related changes in rats dosed with ≥ 25 mg/kg/day included decreases in some red cell mass parameters along with

regeneration (increased reticulocytes), increased serum cholesterol (females only) and increased serum phosphorus (males only). Additional treatment-related changes in clinical chemistry observed in rats dosed with 125 mg/kg/day included transiently increased alkaline phosphatase (males only), decreased triglycerides, increased total protein and albumin, and increased calcium (females only). For urinalysis parameters, males dosed with 125 mg/kg/day had increased urine volume and decreased urine ketone concentration.

Treatment-related changes in fluoride measurements included increased plasma fluoride in males dosed with 125 mg/kg/day, and in females dosed with ≥ 25 mg/kg/day (variable statistical significance). Urine fluoride excretion was increased in males and females dosed with ≥ 5 mg/kg/day (variable statistical significance).

None of the above changes are expected to be adverse. Therefore, under the conditions of this study and for the clinical pathology parameters measured, the NOEL was 125 mg/kg/day for males and females, based on the lack of adverse effects at any dose.

BIOCHEMICAL MEASUREMENTS

A. Biochemical Measurements
(Table 34-35, Appendix L)

The rate of hepatic β-oxidation, a measure of peroxisome proliferation, was determined in a subchronic oral toxicity study with 8-2 Telomer B Alcohol in male and female rats after approximately 10 or 90 days of test substance administration or following a three-month recovery period.

At the 10-day, 90-day, and 3-month recovery time points in male rats, the rate of hepatic β-oxidation was statistically significantly increased at 125 mg/kg/day (163, 166 and 133% of control, respectively). At the 10-day and 90-day time points, the increases in hepatic β-oxidation activity at 125 mg/kg/day in male rats were accompanied by increases in relative liver weights (133 and 152% of control, respectively). At the three-month recovery time point, the relative liver weights had returned to control levels.

At the 10-day time point in female rats, the rate of hepatic β-oxidation was statistically significantly increased at 125 mg/kg/day (131% of control). At the 90-day time point, the rate of hepatic β-oxidation was statistically significantly increased at 25 and 125 mg/kg/day (116 and 152% of control, respectively). Hepatic β-oxidation returned to control levels at the three-month recovery time point. At the 10-day time point, the increase in hepatic β-oxidation activity at 125 mg/kg/day was accompanied by an increase in relative liver weight (132% of control). At the 90-day time point, the increases in hepatic β-oxidation activity at 25 and 125 mg/kg/day were accompanied by increases in relative liver weights (112 and 145% of control, respectively). At the three-month recovery time point, the relative liver weights had returned to control levels.

B. Biochemical Measurements Conclusions

Under the conditions of this study, 8-2 Telomer B Alcohol is a mild inducer of hepatic peroxisomal β-oxidation in male and female rats. At concentrations of 125 mg/kg/day in males and 25 mg/kg/day in females, changes in the rate of hepatic peroxisome proliferation were considered to be test substance-related effects. At the three-month recovery time point, the rate of hepatic peroxisome proliferation was still slightly increased at 125 mg/kg/day in males, but had returned to control levels in female rats.

ANATOMICAL PATHOLOGY

A. Mortality
(Appendix N)

There were no test substance-related deaths. One male rat (animal number 654949) and one female rat (animal number 655071) from the control group were accidentally killed on study days 183 and 19, respectively.

B. Organ Weight Data
(Tables 36-37, Appendix M)

Test substance-related and/or statistically significant increases, compared to controls, in liver weight parameters were present in 25 and 125 mg/kg/day males and females sacrificed at the end of the exposure period. Liver weight parameters were not significantly increased in males or females in the 125 mg/kg/day three-month recovery group (there were no recovery groups in intermediate dosed groups). In 125 mg/kg/day exposure group male rats, increased liver weight correlated with microscopic hepatocellular hypertrophy (see discussion under Microscopic Findings).

Test substance-related and/or statistically significant increases, compared to controls, in one or more kidney weight parameters were present in 25 and 125 mg/kg/day males and females sacrificed at the end of the exposure period. Kidney weight parameters were not significantly increased in males or females in the 125 mg/kg/day three-month recovery group (there were no recovery groups in intermediate dosed groups). In male rats, increased kidney weights correlated with microscopic tubular hypertrophy in the 25 and 125 mg/kg/day groups sacrificed at the end of the exposure period (see discussion under Microscopic Findings).

There were no other test substance-related organ weight effects. All other statistically significant organ weight changes in exposure and recovery groups were considered spurious and not biologically significant. These changes included decreased adrenal gland weight relative to body weight in 1 mg/kg/day female rats sacrificed at the end of the exposure period and decreased heart weight relative to body weight in the 125 mg/kg/day three-month recovery group females. In 125 mg/kg/day three-month recovery males, absolute, relative to body weight, and relative to brain weight thymus weights were increased; however, no test substance-related microscopic changes were present.

C. Gross Observations
(Tables 38-39, Appendix N)

Gross observations noted were sporadic across groups and were not test substance related.

D. Microscopic Findings
(Tables 40-45, Appendix N)

Test substance-related microscopic findings were present in liver, kidneys, thyroid gland, and teeth from male rats and in kidneys from female rats.

Anatomical Pathology Text Table: Incidences and Average Lesion Grades of Test substance-Related Microscopic Findings In Male and Female Rats

Dose (mg/kg/day):	0	1	5	25	125
	Males: 90-Day Exposure				
Liver:					
Hypertrophy, hepatocellular	0/10[a] (0.0)[b]	0/10 (0.0)	0/10 (0.0)	0/10 (0.0)	10/10 (1.6)
Necrosis, focal	0/10 (0.0)	0/10 (0.0)	1/10 (1.0)	5/10 (1.0)	3/10 (1.0)
Kidneys:					
Hypertrophy, tubular	0/10 (0.0)	0/10 (0.0)	0/10 (0.0)	9/10 (1.0)	10/10 (1.0)
Thyroid gland:					
Alteration, colloid	3/10 (1.0)	8/10 (1.1)	9/10 (1.0)	10/10 (1.0)	8/10 (2.3)
Teeth:					
Degeneration, ameloblasts (nose)	0/10 (0.0)	0/10 (0.0)	0/10 (0.0)	0/10 (0.0)	5/10 (1.6)
	Males: Three-Month Recovery				
Liver:					
Necrosis, focal	3/10 (1.3)	NA	NA	NA	7/10 (1.1)
Thyroid gland:					
Alteration, colloid	7/10 (1.4)	NA	NA	NA	10/10 (1.6)
Teeth:					
Degeneration, ameloblasts (nose)	0/10 (0.0)	NA	NA	NA	2/10 (1.0)
	Females: 90-Day Exposure				
Kidneys:					
Chronic progressive nephropathy	2/11 (1.0)	2/10 (1.0)	3/10 (1.0)	3/10 (1.0)	7/10 (1.0)
	Females: Three-Month Recovery				
Kidneys:					
Chronic progressive nephropathy	5/9 (1.0)	NA	NA	NA	8/10 (1.4)

a. Numerator indicates incidence of rats with microscopic lesion. Denominator indicates number of rats in group.
b. Number in parentheses indicates average severity of lesion.

NA Tissue not available because there were no intermediate recovery groups.

Focal hepatocellular necrosis accompanied by a minimal inflammatory response was present in 25 and 125 mg/kg/day male 90-day exposure groups. In addition, the incidence of hepatocellular necrosis in 125 mg/kg/day three-month recovery males was increased when compared to the control group. The single occurrence of hepatocellular necrosis in males at 5 mg/kg/day was most likely not test substance-related since this lesion can occur spontaneously in control animals.[26] Focal liver necrosis was considered to be a test substance-related adverse finding in 25 and 125 mg/kg/day male rats.

Hepatocellular hypertrophy was present in 125 mg/kg/day males sacrificed at the end of the exposure period. In three-month recovery male rats previously dosed with 125 mg/kg/day, hepatocellular hypertrophy was not present and appears to be reversible. Microscopically, hepatocellular hypertrophy was characterized by an increased amount of finely granular eosinophilic cytoplasm within hepatocytes. Thus, hepatocellular hypertrophy (and the associated increase in liver weights) was considered a test substance-related physiologic response to metabolism of a xenobiotic and not biologically adverse.[27,28,29]

Test substance-related tooth lesions in 125 mg/kg/day exposure group male rats consisted of degeneration and/or disorganization of enamel organ ameloblast cells. This lesion was most evident in the upper incisors of the level 1 (anterior) nose section. Following a three-month recovery, ameloblastic degeneration/disorganization was still present in male rats previously dosed with 125 mg/kg/day. This tooth lesion is similar to lesions seen with fluoride toxicosis and is considered adverse.[30]

In the thyroid gland, the incidence and/or relative degree of altered colloid was increased in males in all dosed groups at the end of the 90-day exposure period. Following the three-month recovery period, severity and incidence of altered colloid were increased in males at 125 mg/kg/day when compared to controls. The diagnosis of “alteration, colloid” was used for colloid changes characterized by stippled, granular, clumped, and/or diffusely basophilic colloid. A 4-level grading scheme was applied based on an estimate of the percentage of follicles that contained altered colloid. A grade of 1 was applied when 1 follicle to about 25% of the follicles were involved, with grades 2, 3, and 4 applied for each 25% increase in follicular involvement. The size, density, or staining intensity of stipples, granules, clumps, or diffuse basophilia within individual follicles did not impact the grading.

Altered colloid described as clumped or granular has been reported to occur spontaneously in Sprague-Dawley rats with increasing incidence correlating to increasing age.[31] Because altered colloid occurs spontaneously in healthy Sprague-Dawley rats, and since there were no other microscopic alterations in the thyroid gland, altered colloid, although likely test substance-related, was not considered adverse.

The incidence of chronic progressive nephropathy was increased in 125 mg/kg/day 90-day exposure females when compared to controls. Incidence and severity of this lesion were increased in 125 mg/kg/day females at three months recovery when compared to controls. This lesion appears to progress after cessation of test material exposure and is considered adverse.

Renal tubular hypertrophy was present in 25 and 125 mg/kg/day male rats sacrificed at the end of the exposure period. This change was not observed in male rats sacrificed after the three-month recovery period and appears to be reversible. Microscopically, tubular hypertrophy was characterized by increased eosinophilic staining of cortical tubule epithelium and a slight increase in cell height. Cortical tubule epithelial cells appeared to contain more granular cytoplasmic material then cortical tubules of control rats. Tubular lumina of hypertrophied tubules were slightly smaller then those in control rat kidneys. Tubular hypertrophy was not associated with other histomorphologic evidence of renal damage, and renal clinical pathology parameters indicative of renal toxicity were not present (see clinical pathology section). Increased kidney weights occurring absent correlative evidence of renal toxicity commonly occur in toxicology studies and may represent a physiological response to high doses of a test material.[32] Thus, increased kidney weights and the associated renal tubular hypertrophy were likely test substance-related; however, these changes were not considered adverse but most likely represent a test substance-related physiologic response.

All other microscopic observations noted are known to occur spontaneously in rats of this strain and age and were not present in a dose response fashion in either incidence or severity.

E. Anatomical Pathology Conclusions

Exposure to 125 mg/kg/day of the test substance for approximately 90 days produced degeneration/disorganization of enamel organ ameloblast cells in male rats. Ameloblastic degeneration/disorganization was not reversible after three months recovery. Increased incidence and severity of chronic progressive nephropathy in 125 mg/kg/day female recovery rats was considered test substance related and biologically adverse. Focal hepatic necrosis was present in 90-day males at 25 and 125 mg/kg/day and in three-month recovery males at 125 mg/kg/day. This lesion was considered test substance related and adverse. The incidence and/or severity of altered colloid in thyroid glands of male rats increased beyond control level as the dose increased; however, since there were no other microscopic alterations present this finding was not considered adverse.

Increased liver weights were present in males and females at 25 and 125 mg/kg/day. The increased liver weights correlated with microscopic hepatocellular hypertrophy in males at 125 mg/kg/day. Hepatocellular hypertrophy was reversible in males following three-months recovery. These liver changes were considered to represent a physiologic response to metabolism of a xenobiotic and thus were not considered to be adverse. Increased kidney weights were present in 25 and 125 mg/kg/day males and females. In males, these kidney weight changes correlated with microscopic renal tubular hypertrophy. The increased kidney weights and renal tubular hypertrophy appeared to be reversible by three-months recovery. Increased kidney weights and microscopic tubular hypertrophy were not associated with correlative morphologic or clinical pathological changes and thus were not considered to be adverse findings.

Under the conditions of this study, the NOEL for pathology for male rats was 5 mg/kg/day based on hepatic necrosis at the 25 and 125 mg/kg/day dose levels and for female rats was 25 mg/kg/day based on an increased incidence and severity of nephropathy at 125 mg/kg/day.

CONCLUSIONS

No test substance-related mortality or alterations in neurobehavioral parameters were observed in male or female rats. No test substance-related decrements in mean body weight, body weight gain, food consumption, or food efficiency were observed in male or female rats administered up to 125 mg/kg/day 8-2 Telomer B Alcohol. Test substance-related, toxicologically significant increases in the incidence of striated teeth occurred in the 125 mg/kg/day male and female dose groups.

There were no toxicologically significant changes observed in clinical pathology parameters in rats dosed with up to 125 mg/kg/day 8-2 Telomer B Alcohol. A statistically significant increase in the rate of hepatic β-oxidation occurred in the 25 mg/kg/day female and 125 mg/kg/day male and female groups. After the recovery period, the increased rate of β-oxidation persisted, albeit at a reduced level compared to the 90-day time point, in the 125 mg/kg/day male group.

Test substance-related, toxicologically significant degeneration/disorganization of enamel organ ameloblasts cells occurred in male rats dosed with 125 mg/kg/day 8-2 Telomer B Alcohol. This tooth lesion, along with the increased incidence of striated teeth, is consistent with fluoride toxicosis.[30] After three months, the degeneration/disorganization of ameloblasts persisted, at a lower incidence and severity.

A test substance-related, adverse increase in the incidence and severity of focal hepatic necrosis was observed in males administered 25 and 125 mg/kg/day. An increased incidence and severity of chronic progressive nephropathy occurred in the 125 mg/kg/day female group that was considered adverse. After three months of recovery, both the incidence of hepatocellular necrosis in the 125 mg/kg/day male group and the incidence and severity of chronic progressive nephropathy in the 125 mg/kg/day female group were increased compared to control.

Test-substance related and statistically significant increases in liver weight parameters were present in males and females administered 25 or 125 mg/kg/day for approximately 90 days. The increased liver weights correlated with microscopic hepatocellular hypertrophy in the 125 mg/kg/day male dose group. Liver weight changes and microscopic hypertrophy were considered to be a physiological adaptive response to metabolism of the test substance and not adverse. Test-substance related and statistically significant increases in kidney weight parameters occurred in males and females administered 25 or 125 mg/kg/day. The increased kidney weights correlated with microscopic renal tubular hypertrophy in the 25 and 125 mg/kg/day male groups only. However, no correlative microscopic or clinical pathological evidence of renal toxicity were present. Therefore, kidney weight changes and microscopic tubular hypertrophy were not considered adverse findings. Altered colloid, a common spontaneous finding in rats, was increased in incidence and/or severity in treated male groups. This change was not associated with other findings in the thyroid gland and was also not considered an adverse finding. After the three-month recovery period, increased liver weight parameters and hepatocellular hypertrophy (males only) were no longer observed in the 125 mg/kg/day male and female groups. Similarly, increased kidney weight parameters and renal tubular hypertrophy (males only) were not observed in rats sacrificed after three months of recovery.

The no-observed-effect level (NOEL)[a] for 8-2 Telomer B Alcohol for the 90-day exposure period was 5 mg/kg/day 8-2 Telomer B Alcohol based on the increased incidence of hepatic necrosis observed in males administered ≥ 25 mg/kg/day. The NOEL for females was 25 mg/kg/day 8-2 Telomer B Alcohol based on the increased incidence and severity of chronic progressive nephropathy observed in females administered 125 mg/kg/day.

RECORDS AND SAMPLE STORAGE

Laboratory-specific or site-specific raw data, such as personnel files and equipment records will be retained by the facility where the work was done.

A sample of the test substance was collected for archive purposes and retained at Haskell Laboratory. Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware. Test Substance characterization data will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware.

.

[a] The NOEL for this study is defined as the highest dose at which toxicologically important effects attributable to the test substance were not detected. Thus, for this study, the NOEL is equivalent to the NOEL as defined by the United States Environmental Protection Agency [33] and to the no-observed-adverse-effect level (NOAEL) as defined by the European Union.[34]

REFERENCES

1. Covance study No. 6329-183 (1998). "104-week dietary carcinogenicity study with perfluorooctane sulfonic acid potassium salt (PFOS; T-6295) in rats."
2. Ikeda, T., Fukuda, K., Mori, I., Enomoto, M., Komai, T., Suga, T. (1987). Induction of cytochrome P-450 and peroxisome proliferation in rat liver by perfluorinated octanesulfonic acid. In: Fahimi HD, Sies H, eds. Peroxisomes in Biology and Medicine. Springer Verlag, New York, pp 304-308.
3. Sohlenius, A.K., Eriksson, A.M., Hogstrom, C., Kimland, M., Depierre, J.W. (1993). Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid beta-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver. *Pharmacol. Toxicol*., 72: 90-93.
4. Haughom, B., Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. *Biochem. Biophys. Acta.*, 1128: 65-72.
5. DuPont Haskell Laboratory Work Request 13690, Service Code 1583, Analytical Report HA-2001-037.
6. DuPont (1995). Neurotoxicity Evaluation of Trimethyltin in Rats (Positive Control Study). HLR 266-95. (MRID 44628701).
7. DuPont (1997). Neurotoxicity Evaluation of Amphetamine in Rats (Positive Control Study). HL-1997-00686. (MRID 44628703).
8. DuPont (1997). Neurotoxicity Evaluation of Carbaryl in Rats (Positive Control Study). HL-1997-00361. (MRID 44628702).
9. DuPont (1996). Neurotoxicity Evaluation of Acrylamide in Rats (Positive Control Study). HLR 293-95. (MRID 44660601).
10. Lazarow, P.B. (1981). Assay of Peroxisomal Beta-Oxidation of Fatty Acids. Methods in Enzymology **72**, 315-319.
11. Bradford, M.M. (1976). A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. *Anal. Biochem.* **72**, 248-254.
12. Draper, N.R. and Smith, H. (1981). Applied Regression Analysis, 2nd edition, pp 266-273. Wiley, New York.
13. Selwyn, M.R. (1995). The use of trend tests to determine a no-observable-effect level in animal safety studies. *Journal of the American College of Toxicology* **14(2)**, 158-168.
14. Jonckheere, A.R. (1954). A distribution-free K-sample test against ordered alternatives. *Biometrika* **41**, 133-145.
15. Levene, H. (1960). Robust test for equality of variances. *Contributions to Probability and Statistics* (J. Olkin, ed.), pp 278-292. Stanford University Press, Palo Alto.

16. Shapiro, S.S. and Wilk., M.B. (1965). An analysis of variance test for normality (complete samples). *Biometrika* **52**, 591-611.

17. Snedecor, G.W. and Cochran, W.G. (1967). Statistical Methods, 6th edition, pp 246-248 and 349-352. The Iowa State University Press, Ames.

18. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Amer. Statist. Assoc.* **50**, 1096-1121.

19. Kruskal, W.H. and Wallis, W.A. (1952). Use of ranks in one-criterion analysis of variance. J. Amer. Statist. Assoc. 47, 583-621.

20. Dunn, O.J. (1964). Multiple contrasts using rank sums. *Technometrics* **6**, 241-252.

21. Milliken, G.A. and Johnson, D.A. (1984). Analysis of Messy Data, Volume 1.: Designed Experiments. Lifetime Learning Publications, Belmont.

22. Hocking, R.A. (1985). The Analysis of Linear Models. Brooks/Cole, Monterey.

23. Bartlett, M.S. (1937). Some examples of statistical methods of research in agriculture and applied biology. *J. Royal. Statis. Soc. Suppl*. **4**, 137-170.

24. Fisher, R.A. (1985). Statistical Methods for Research Workers, 13th edition. Haffner, New York.

25. DuPont Haskell Laboratory Work Request 5672, Analytical Reports HA-2002-050 and HA-2002-055

26. Greaves, P. (2000). *In Histopathology of Preclinical Drug Safety Evaluation*, Elsvier, Amsterdam, pp 453.

27. Sipes, G. I., and Gandolfi, A. J. (1991). In Biotransformation of Toxicants. In Casarett and Doull's Toxicology: The Basic Science of Poisons (Amdur, M. O., Doull, J., and Klaassen, C. D., Ed.), Pergamon Press, New York, pp 88-126.

28. Paynter, O.E., Harris, J.E., Burin, G.J., and Jaeger, R.B. (1985). Guidance for Analysis of Evaluation of Subchronic Exposure Studies. United States Environmental Protection Agency, EPA-540/9-85-020.

29. Greaves, P. (1990). Digestive System 2. *In Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation* (P. Greaves, Ed.), Elsvier, Amsterdam, pp 393-496.

30. Reddy, C.S., and Hayes, A.W. (1989). Food Borne Toxicants. In *Principles and Methods of Toxicology* (A.W. Hayes, Ed.), Raven Press, New York, pp 67-110.

31. Rao-Rupanagudi, S., Heywood, R., and Gopinah, C. (1991). "Age-related Changes in Thyroid Structures and Function in Sprague-Dawley Rats," *Vet. Pathol.*, Vol. 29, No. 4, pp. 278-287.

32. Greaves, P. (1990). Urinary Tract. In Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation (P. Greaves, Ed.), Elsvier, Amsterdam, pp 497-583.

33. Hazard Evaluation Division, Standard Evaluation Procedure, Toxicity Potential: Guidance for Analysis and Evaluation of Subchronic and Chronic Exposure Studies Paynter, O. E. et al., United States Environmental Protection Agency, Office of Pesticide Programs, Washington, D.C., 20406. EPA-540/9-85-020. (June 1985).

34. Risk Assessment of Notified New Substances. Technical Guidance Document (XI/283/94-EN), Chapter I, Sections 2.24 and 2.25. 1994.

TABLES

TABLES

EXPLANATORY NOTES

Critical Dates

Day 91
- Last day of test substance administration for rats designated for satellite bleeds and 3-month recovery.
- Last day of non-fasted body weight and food consumption data collection for rats designated for the 90-day exposure period.
- Last day of food consumption data collection for rats designated for satellite bleeds in the 1, 5, and 25 mg/kg/day dose groups.

Day 92 Last day of test substance administration for male rats designated for the 90-day exposure period.

Day 93
- Last day of test substance administration for female rats designated for the 90-day exposure period.
- Male rats designated for the 90-day exposure period were sacrificed.

Day 94 Female rats designated for 90-day exposure period were sacrificed.

Day 175 Rats designated for satellite bleeds were sacrificed

Day 182 Last day of non-fasted body weight and food consumption data collection for rats designated for the 3-month recovery period.

Day 183 Male and female rats designated for the 3-month recovery period were sacrificed.

Note

mg/kg = mg/kg/day

Notes for Clinical Pathology data:

When an individual observation was recorded as being less than a certain value, calculations were performed on half the recorded value. For example, if bilirubin was reported as <0.1, 0.05 was used for any calculations performed with that bilirubin data.

TABLES

EXPLANATORY NOTES (CONTINUED)

ABBREVIATIONS:

Summary of Hematology Values

RBC	-	red blood cell count
HGB	-	hemoglobin
HCT	-	hematocrit
MCV	-	mean corpuscular volume
MCH	-	mean corpuscular hemoglobin
MCHC	-	mean corpuscular hemoglobin concentration
RDW	-	red cell distribution width
ARET	-	absolute reticulocyte count
PLT	-	platelet count
WBC	-	white blood cell count
ANEU	-	absolute neutrophil (all forms)
ALYM	-	absolute lymphocyte
AMON	-	absolute monocyte
AEOS	-	absolute eosinophil
ABAS	-	absolute basophil
ALUC	-	absolute large unstained cell
--	-	no data

Summary of Coagulation Values

PT	-	prothrombin time
APTT	-	activated partial thromboplastin time
--	-	no data

TABLES

EXPLANATORY NOTES (CONTINUED)

ABBREVIATIONS: (Continued)

Summary of Clinical Chemistry Values

AST	-	aspartate aminotransferase
ALT	-	alanine aminotransferase
SDH	-	sorbitol dehydrogenase
ALKP	-	alkaline phosphatase
BILI	-	total bilirubin
BUN	-	urea nitrogen
CREA	-	creatinine
CHOL	-	cholesterol
TRIG	-	triglycerides
GLUC	-	glucose
TP	-	total protein
ALB	-	albumin
GLOB	-	globulin
CALC	-	calcium
IPHS	-	inorganic phosphorous
NA	-	sodium
K	-	potassium
CL	-	chloride
PFLU	-	plasma fluoride
--	-	no data

Summary of Urinalysis Values

VOL	-	volume
UOSM	-	urine osmolality
pH	-	the logarithm of the reciprocal of the hydrogen ion concentration
URO	-	urobilinogen
UFLU	-	urine fluoride
UMTP	-	urine protein
--	-	no data

TABLE 1

SUMMARY OF DOSING MIXING AND STABILITY ANALYSES

	Dosing Concentration of 8-2 Telomer B Alcohol (mg/mL)			
Nominal:	**0.20**	**1.0**	**5.0**	**25.0**
Homogeneity Samples				
Test Day 1/-6				
Top	0.163	0.803	4.55	19.9 [a]
	(81.5) [b]	(80.3)	(91.0)	(79.6)
Middle	0.164	0.857	4.80	21.9
	(82.0)	(85.7)	(96.0)	(87.6)
Bottom	0.161	0.890	4.61	22.9
	(80.5)	(89.0)	(92.2)	(91.6)
Average Measured Conc. [c]	**0.163**	**0.850**	**4.65**	**21.6**
Average Percent Nominal	**(81.5)**	**(85.0)**	**(93.0)**	**(86.4)**
Standard Deviation [c]	**± 0.002**	**± 0.04**	**± 0.13**	**± 1.5**
Coefficient of Variation [c]	**1%**	**5%**	**3%**	**7%**
Stability Samples				
5 Hour Room Temperature	0.167	0.818	4.14	21.8
	(83.5)	(81.8)	(82.8)	(87.2)
Test Day 1/-6 and Test Day 4 [d]				
(baseline for stability)	**0.163**	**0.888**	**4.51**	**23.0**
	(81.5)	**(88.8)**	**(90.2)**	**(92.0)**
7-Day Refrigerated				
#1	0.161	0.900	4.46[e]	24.2[e]
	(80.5)	(90.0)	(89.2)	(96.8)
#2	0.173	0.864	4.44	23.9
	(86.5)	(86.4)	(88.8)	(95.6)
#3	---	0.859	---	---
		(85.9)		
Average Measured Conc.	**0.167[e]**	**0.874[c]**	**4.45 [e]**	**24.1[ee]**
Average Percent Nominal	**(83.5)**	**(87.4)**	**(89.0)**	**(96.4)**
Standard Deviation	**± 0.01[e]**	**± 0.02[c]**	**± 0.01[e]**	**± 0.21[e]**
Coefficient of Variation	**5%[e]**	**3%[c]**	**0.2%[e]**	**1%[e]**
5 Hour Room Temperature	0.158[a]	0.904 [f]	4.21 [f]	21.2 [f]
	(79.0)	(90.4)	(84.2)	(84.8)

[a] Result of the original aliquot. Duplicate reanalysis of original sample support original analysis and not reported.
[b] Numbers in parentheses are the respective percent of nominal values.
[c] Statistics based on the average measured concentration of the top, middle and bottom of each dosing level.
[d] Samples analyzed in previous study (HA-2001-037/MR 13690/SC1583).
[e] Statistics based on the average measured concentration of duplicate samples for the dosing level.
[f] Mean results of duplicate re-analysis of the original sample. Original results were low due to aliquot error

TABLE 1 (CONTINUED)

SUMMARY OF DOSING MIXING AND STABILITY ANALYSES

	Dosing Concentration of 8-2 Telomer B Alcohol (mg/mL)			
Nominal:	**0.20**	**1.0**	**5.0**	**25.0**
Concentration Verification				
Test Day 42				
#1	0.156 [c]	0.749 [c]	3.87 [c]	19.4 [f]
	(78.0) [b]	(74.9)	(77.3)	(77.6)
#2	0.169 [c]	0.776 [c]	3.91 [f]	19.1 [f]
	(84.5)	(77.6)	(78.2)	(76.2)
Average Measured Conc. [e]	**0.163**	**0.763**	**3.89**	**19.3**
Average Percent Nominal	**(81.5)**	**(76.3)**	**(77.8)**	**(77.2)**
Standard Deviation [e]	**± 0.01**	**± 0.02**	**± 0.03**	**± 0.21**
Coefficient of Variation [e]	**6%**	**3%**	**1%**	**1%**
Test Day 45				
#1	0.066 [c]	0.676 [c]	2.20 [c]	8.34 [f]
	(33.0)	(67.6)	(44.0)	(33.4)
#2	0.083 [c]	0.656 [c]	2.32 [c]	8.64 [f]
	(41.5)	(65.6)	(46.4)	(34.6)
Average Measured Conc. [e]	**0.075**	**0.666**	**2.26**	**8.49**
Average Percent Nominal	**(37.5)**	**(66.6)**	**(45.2)**	**(34.0)**
Standard Deviation [e]	**± 0.01**	**± 0.01**	**± 0.09**	**± 0.21**
Coefficient of Variation [e]	**13%**	**2%**	**4%**	**3%**
Test Day 48 [g]				
#1	0.197	0.865	3.93	21.9
	(98.5)	(86.5)	(78.6)	(87.6)
#2	0.219	0.948	3.90	22.5
	(109.5)	(94.8)	(78.0)	(90.0)
Average Measured Conc. [e]	**0.208**	**0.907**	**3.92**	**22.2**
Average Percent Nominal	**(104.0)**	**(90.7)**	**(78.3)**	**(88.8)**
Standard Deviation [e]	**± 0.02**	**± 0.06**	**± 0.02**	**± 0.42**
Coefficient of Variation [e]	**7%**	**6%**	**1%**	**3%**
Test Day 52				
#1	0.174	0.845	4.22	23.5
	(87.0)	(84.5)	(84.4)	(94.0)
#2	0.184	0.895	4.16	22.3
	(92.0)	(89.5)	(83.2)	(89.2)
Average Measured Conc. [e]	**0.179**	**0.870**	**4.19**	**22.9**
Average Percent Nominal	**(89.5)**	**(87.0)**	**(83.8)**	**(91.6)**
Standard Deviation [e]	**± 0.01**	**± 0.04**	**± 0.04**	**± 0.85**
Coefficient of Variation [e]	**4%**	**4%**	**1%**	**4%**

[b] Numbers in parentheses are the respective percent of nominal values.
[c] Mean result of the original analysis and duplicate reanalysis of the original sample reported.
[e] Statistics based on the average measured concentration of duplicate samples for the dosing level.
[f] Mean results of duplicate re-analysis of the original sample. Original results were low due to aliquot error
[g] Suspension not dosed to animals.

TABLE 1 (CONTINUED)

SUMMARY OF DOSING MIXING AND STABILITY ANALYSES

	Dosing Concentration of 8-2 Telomer B Alcohol (mg/mL)			
Nominal:	**0.20**	**1.0**	**5.0**	**25.0**
Concentration Verification				
Test Day 56				
#1	0.167	0.964	4.41	22.8
	(83.5) [b]	(96.4)	(88.2)	(91.2)
#2	0.189	0.950	4.31	21.4
	(94.5)	(95.0)	(86.2)	(85.6)
Average Measured Conc. [e]	**0.178**	**0.957**	**4.36**	**22.1**
Average Percent Nominal	**(89.0)**	**(95.7)**	**(87.2)**	**(88.4)**
Standard Deviation [e]	**± 0.02**	**± 0.01**	**± 0.07**	**± 0.99**
Coefficient of Variation [e]	**9%**	**1%**	**2%**	**4%**
Test Day 58				
#1	0.174	0.945	4.48	22.5
	(87.0)	(94.5)	(89.6)	(90.0)
#2	0.150	0.937	4.17	22.1
	(75.0)	(93.7)	(83.4)	(88.4)
Average Measured Conc. [e]	**0.162**	**0.941**	**4.33**	**22.3**
Average Percent Nominal	**(81.0)**	**(94.1)**	**(86.5)**	**(89.2)**
Standard Deviation [e]	**± 0.02**	**± 0.01**	**± 0.22**	**± 0.28**
Coefficient of Variation [e]	**10%**	**1%**	**5%**	**1%**
Test Day 65				
#1	0.159 [c]	0.832	4.32	20.8
	(79.5)	(83.2)	(86.4)	(83.2)
#2	0.150 [c]	0.898	4.40	20.5
	(75.0)	(89.8)	(88.0)	(82.0)
Average Measured Conc. [e]	**0.155**	**0.865**	**4.36**	**20.7**
Average Percent Nominal	**(77.5)**	**(86.5)**	**(87.2)**	**(82.6)**
Standard Deviation [e]	**± 0.01**	**± 0.05**	**± 0.06**	**± 0.21**
Coefficient of Variation [e]	**4%**	**5%**	**1%**	**1%**

[b] Numbers in parentheses are the respective percent of nominal values.
[c] Mean result of the original analysis and duplicate reanalysis of the original sample reported.
[e] Statistics based on the average measured concentration of duplicate samples for the dosing level.

TABLE 1 (CONTINUED)

SUMMARY OF DOSING MIXING AND STABILITY ANALYSES

	Dosing Concentration of 8-2 Telomer B Alcohol (mg/mL)			
Nominal:	**0.20**	**1.0**	**5.0**	**25.0**
Concentration Verification				
Test Day 91				
#1	0.162	0.760 [c]	3.96 [c]	19.9 [c]
	(81.0) [b]	(76.0)	(79.2)	(76.4)
#2	0.165	0.863	3.90 [c]	18.7 [c]
	(82.5)	(86.3)	(78.0)	(74.8)
Average Measured Conc. [e]	**0.164**	**0.812**	**3.93**	**19.3**
Average Percent Nominal	**(82.0)**	**(81.2)**	**(78.6)**	**(77.2)**
Standard Deviation [e]	**± 0.002**	**± 0.07**	**± 0.04**	**± 0.85**
Coefficient of Variation [e]	**1%** [c]	**9%**	**1%**	**4%**
Test Day 63				
#1	0.190	0.784	4.12	23.0
	(95.0) [a]	(78.4)	(82.4)	(92.0)
#2	0.192	0.792	4.08	21.4
	(96.0)	(79.2)	(81.8)	(85.6)
Average Measured Conc. [e]	**0.191**	**0.788**	**4.10**	**22.2**
Average Percent Nominal	**(95.5)**	**(78.8)**	**(82.0)**	**(88.8)**
Standard Deviation [e]	**± 0.001**	**± 0.01**	**± 0.03**	**± 1.1**
Coefficient of Variation [e]	**1%**	**1%**	**1%**	**5%**
Test Day 73				
#1	0.176	0.980	4.57	23.3
	(88.0)	(98.0)	(91.4)	(93.2)
#2	0.155	1.03	4.60	24.4
	(77.5)	(103.0)	(92.0)	(97.6)
Average Measured Conc. [e]	**0.166**	**1.01**	**4.59**	**23.9**
Average Percent Nominal	**(82.8)**	**(101.0)**	**(91.8)**	**(95.6)**
Standard Deviation [e]	**± 0.01**	**± 0.04**	**± 0.02**	**± 0.78**
Coefficient of Variation [e]	**9%**	**4%**	**0.4%**	**3%**

[b] Numbers in parentheses are the respective percent of nominal values.
[c] Mean result of the original analysis and duplicate reanalysis of the original sample reported.
[e] Statistics based on the average measured concentration of duplicate samples for the dosing level.

TABLE 2

MEAN DAILY DOSE VOLUMES FOR MALE RATS (mL)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
DAY0	-DAY7	1.2 0.2(25)	1.2 0.1(15)	1.2 0.1(15)	1.2 0.1(15)	1.2 0.1(25)
DAY7	-DAY14	1.4 0.2(25)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.1(25)
DAY14	-DAY21	1.7 0.2(25)	1.8 0.1(15)	1.7 0.2(15)	1.7 0.1(15)	1.7 0.1(25)
DAY21	-DAY28	1.9 0.2(25)	2.0 0.1(15)	2.0 0.2(15)	2.0 0.1(15)	1.9 0.2(25)
DAY28	-DAY35	2.1 0.2(25)	2.1 0.1(15)	2.2 0.2(15)	2.1 0.2(15)	2.1 0.2(25)
DAY35	-DAY42	2.2 0.2(25)	2.3 0.1(15)	2.3 0.2(15)	2.3 0.2(15)	2.2 0.2(25)
DAY42	-DAY49	2.3 0.3(25)	2.4 0.2(15)	2.4 0.3(15)	2.4 0.2(15)	2.4 0.2(25)
DAY49	-DAY56	2.4 0.3(25)	2.4 0.2(15)	2.5 0.2(15)	2.5 0.2(15)	2.4 0.2(25)
DAY56	-DAY63	2.5 0.3(25)	2.5 0.2(15)	2.6 0.3(15)	2.6 0.2(15)	2.5 0.2(25)
DAY63	-DAY70	2.7 0.3(25)	2.7 0.2(15)	2.8 0.3(15)	2.8 0.2(15)	2.6 0.2(25)
DAY70	-DAY77	2.7 0.3(25)	2.7 0.2(15)	2.9 0.3(15)	2.9 0.2(15)	2.6 0.3(25)

TABLE 2 (CONTINUED)

MEAN DAILY DOSE VOLUMES FOR MALE RATS (mL)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
DAY84 -DAY91	2.8 0.3(25)	2.7 0.2(15)	2.9 0.3(15)	2.9 0.2(15)	2.7 0.3(25)
DAY91	2.8 0.3(25)	2.8 0.2(15)	2.9 0.3(15)	3.0 0.2(15)	2.8 0.3(25)
DAY92	2.9 0.2(10)	2.8 0.2(10)	3.0 0.3(10)	2.9 0.2(10)	2.8 0.1(10)

TABLE 3

MEAN DAILY DOSE VOLUMES FOR FEMALE RATS (mL)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg/day)		0	1	5	25	125
DAY0	-DAY7	0.9 0.1(25)	0.9 0.1(15)	0.9 0.1(15)	0.9 0.1(15)	0.9 0.1(25)
DAY7	-DAY14	1.0 0.1(25)	1.0 0.1(15)	1.0 0.1(15)	1.0 0.1(15)	1.0 0.1(25)
DAY14	-DAY21	1.1 0.1(25)	1.1 0.1(15)	1.1 0.1(15)	1.1 0.1(15)	1.1 0.1(25)
DAY21	-DAY28	1.2 0.1(24)	1.2 0.1(15)	1.2 0.1(15)	1.2 0.1(15)	1.3 0.1(25)
DAY28	-DAY35	1.3 0.1(24)	1.2 0.1(15)	1.3 0.1(15)	1.2 0.1(15)	1.3 0.1(25)
DAY35	-DAY42	1.3 0.1(24)	1.3 0.1(15)	1.3 0.1(15)	1.3 0.1(15)	1.3 0.1(25)
DAY42	-DAY49	1.4 0.1(24)	1.4 0.1(15)	1.4 0.1(15)	1.4 0.1(15)	1.4 0.1(25)
DAY49	-DAY56	1.4 0.2(24)	1.3 0.1(15)	1.4 0.1(15)	1.4 0.1(15)	1.4 0.2(25)
DAY56	-DAY63	1.4 0.2(24)	1.4 0.1(15)	1.4 0.1(15)	1.5 0.1(15)	1.5 0.2(25)
DAY63	-DAY70	1.4 0.2(24)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.2(25)
DAY70	-DAY77	1.5 0.2(24)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.1(15)	1.5 0.1(25)

TABLE 3 (CONTINUED)

MEAN DAILY DOSE VOLUMES FOR FEMALE RATS (mL)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
DAY77 -DAY84	1.5 0.2(24)	1.5 0.1(15)	1.5 0.1(15)	1.6 0.1(15)	1.5 0.2(25)
DAY84 -DAY91	1.5 0.2(24)	1.5 0.1(15)	1.5 0.1(15)	1.6 0.1(15)	1.6 0.2(25)
DAY91	1.5 0.2(24)	1.5 0.1(15)	1.5 0.1(15)	1.6 0.1(15)	1.6 0.1(25)
DAY92 -DAY93	1.5 0.1(10)	1.5 0.1(10)	1.5 0.1(10)	1.6 0.1(10)	1.5 0.1(10)

TABLE 4

MEAN BODY WEIGHTS OF MALE RATS (g)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation					
DAY0	234.5 23.9(25)	245.6 19.7(15)	240.8 21.0(15)	239.4 16.0(15)	235.1 22.1(25)
DAY7	288.7 29.3(25)	299.2 24.9(15)	295.8 26.6(15)	294.9 18.3(15)	289.2 25.7(25)
DAY14	337.2 33.0(25)	352.6 20.2(15)	348.4 31.7(15)	345.6 22.7(15)	343.3 28.4(25)
DAY21	383.6 37.5(25)	394.9 23.2(15)	396.1 36.4(15)	393.1 27.4(15)	387.9 32.3(25)
DAY28	415.5 40.3(25)	426.0 24.9(15)	432.2 42.8(15)	427.1 32.0(15)	422.0 36.4(25)
DAY35	445.1 48.4(25)	455.1 27.2(15)	464.0 47.0(15)	460.8 36.5(15)	448.9 40.7(25)
DAY42	467.2 56.5(25)	475.8 30.0(15)	487.4 50.4(15)	489.2 37.8(15)	473.8 42.2(25)
DAY49	483.2 52.4(25)	485.0 30.8(15)	498.4 48.7(15)	501.1 39.8(15)	486.8 45.5(25)
DAY56	503.8 56.9(25)	508.4 32.1(15)	525.8 53.1(15)	528.5 43.0(15)	507.2 49.1(25)
DAY63	520.5 58.6(25)	523.2 34.3(15)	545.1 56.7(15)	548.0 44.2(15)	516.0 51.9(25)
DAY70	537.8 57.4(25)	539.2 39.7(15)	559.1 56.4(15)	558.4 45.5(15)	524.5 50.8(25)

TABLE 4 (CONTINUED)

MEAN BODY WEIGHTS OF MALE RATS (g)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)					
DAY77	547.7 57.5(25)	544.8 36.4(15)	571.1 55.9(15)	571.2 45.9(15)	518.5 61.7(25)
DAY84	554.6 58.2(25)	549.5 39.1(15)	582.5 58.0(15)	581.2 45.7(15)	531.5 53.6(25)
DAY91	562.0 54.0(25)	561.0 42.2(15)	589.1 60.9(15)	591.2 47.6(15)	551.9 53.9(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation					
DAY98	568.1 55.2(15)	567.9 58.8(5)	567.0 69.6(5)	606.8 59.8(5)	556.0 65.4(15)
DAY105	573.3 64.3(15)	582.8 59.0(5)	575.6 70.3(5)	614.6 59.8(5)	567.8 68.6(15)
DAY112	581.6 63.4(15)	584.4 60.6(5)	579.2 72.9(5)	619.3 67.0(5)	573.5 67.4(15)
DAY119	590.9 62.8(15)	595.0 58.6(5)	590.6 74.8(5)	630.7 69.4(5)	583.3 71.3(15)
DAY126	605.5 62.7(15)	604.5 65.8(5)	600.6 74.0(5)	646.4 70.5(5)	599.3 76.1(15)
DAY133	613.7 61.8(15)	615.2 62.5(5)	610.0 75.9(5)	654.8 74.0(5)	610.3 80.7(15)
DAY140	612.0 64.0(15)	615.8 65.5(5)	608.0 87.4(5)	656.8 76.7(5)	612.9 81.7(15)

TABLE 4 (CONTINUED)

MEAN BODY WEIGHTS OF MALE RATS (g)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY147	617.2 65.6(15)	626.4 68.2(5)	618.3 86.9(5)	665.6 79.9(5)	621.5 83.0(15)
DAY154	625.0 68.2(15)	635.2 65.9(5)	627.1 82.4(5)	681.5 82.6(5)	635.7 81.2(15)
DAY161	623.7 71.9(15)	637.2 68.2(5)	629.5 85.5(5)	678.9 83.7(5)	636.5 82.0(15)
DAY168	629.8 71.5(15)	642.3 65.9(5)	631.0 88.6(5)	690.7 85.1(5)	649.1 85.3(15)
DAY175	631.4 79.3(15)	646.3 66.8(5)	632.5 85.8(5)	693.8 81.8(5)	648.1 84.3(15)
DAY182	647.6 66.5(10)	. . (0)	. . (0)	. . (0)	634.7 86.3(10)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant differences at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 5

MEAN BODY WEIGHTS OF FEMALE RATS (g)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation					
DAY0	186.6 15.1(25)	183.8 17.0(15)	182.2 17.0(15)	182.6 14.7(15)	188.5 16.5(25)
DAY7	204.8 18.0(25)	205.7 15.0(15)	204.5 15.3(15)	202.8 18.6(15)	209.0 18.1(25)
DAY14	223.5 21.1(25)	224.8 15.4(15)	223.7 17.1(15)	225.7 16.7(15)	230.4 18.6(25)
DAY21	241.1 24.2(24)	238.7 15.9(15)	239.0 20.8(15)	239.9 17.8(15)	247.7 21.8(25)
DAY28	251.8 26.5(24)	250.1 15.9(15)	250.9 20.0(15)	252.7 21.9(15)	259.9 24.1(25)
DAY35	263.5 27.3(24)	264.3 17.3(15)	264.0 24.3(15)	266.3 20.9(15)	270.3 24.5(25)
DAY42	273.0 27.6(24)	274.1 17.2(15)	274.9 24.1(15)	278.5 22.0(15)	278.2 25.4(25)
DAY49	272.8 30.2(24)	267.2 16.9(15)	271.6 22.6(15)	272.0 25.6(15)	280.4 30.1(25)
DAY56	284.4 30.2(24)	286.4 18.9(15)	286.8 26.2(15)	292.1 27.0(15)	292.1 29.8(25)
DAY63	288.7 31.7(24)	291.4 21.0(15)	292.7 27.3(15)	294.4 25.0(15)	297.1 31.1(25)
DAY70	296.1 31.0(24)	298.5 23.2(15)	297.4 26.2(15)	305.1 27.4(15)	300.0 28.6(25)

TABLE 5 (CONTINUED)

MEAN BODY WEIGHTS OF FEMALE RATS (g)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)					
DAY77	299.7 31.5(24)	302.1 22.2(15)	301.7 27.1(15)	310.5 28.9(15)	303.0 29.5(25)
DAY84	302.5 31.9(24)	305.8 25.0(15)	300.8 26.8(15)	311.3 29.7(15)	311.3 30.8(25)
DAY91	303.7 31.5(24)	304.9 25.4(15)	302.5 26.5(15)	310.6 29.0(15)	310.2 29.3(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation					
DAY98	310.9 38.7(14)	306.6 26.3(5)	299.9 30.8(5)	322.9 26.3(5)	317.6 36.4(15)
DAY105	315.8 39.9(14)	311.0 24.4(5)	299.8 34.1(5)	326.9 30.0(5)	317.8 35.1(15)
DAY112	318.0 37.7(14)	312.5 25.8(5)	305.7 34.2(5)	329.6 32.7(5)	319.1 39.8(15)
DAY119	320.2 36.9(14)	313.7 26.9(5)	309.2 32.0(5)	340.5 32.2(5)	324.9 40.8(15)
DAY126	327.9 38.0(14)	319.1 27.7(5)	314.5 35.7(5)	346.2 39.0(5)	340.1 45.6(15)
DAY133	328.9 38.6(14)	324.4 28.7(5)	319.8 38.7(5)	351.3 37.4(5)	343.9 46.4(15)
DAY140	331.6 36.5(14)	325.6 29.6(5)	320.3 34.9(5)	351.6 39.7(5)	343.3 48.3(15)
DAY147	337.0 39.2(14)	327.6 32.0(5)	324.5 42.0(5)	354.8 39.5(5)	349.5 50.8(15)

TABLE 5 (CONTINUED)

MEAN BODY WEIGHTS OF FEMALE RATS (g)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY154	339.3 39.8(14)	331.3 32.0(5)	331.3 45.1(5)	359.1 42.6(5)	355.1 52.2(15)
DAY161	333.4 36.8(14)	330.4 28.7(5)	327.9 41.2(5)	361.6 47.5(5)	353.9 54.0(15)
DAY168	340.3 37.0(14)	336.0 28.3(5)	333.9 44.3(5)	368.3 48.0(5)	360.4 58.2(15)
DAY175	342.3 38.6(14)	336.2 29.3(5)	335.9 44.6(5)	366.8 53.8(5)	363.6 60.0(15)
DAY182	354.1 33.0(9)	. . (0)	. . (0)	. . (0)	368.7 67.8(10)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant differences at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 6

MEAN BODY WEIGHT GAINS OF MALE RATS (g)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	54.3 7.9(25)	53.6 12.0(15)	55.0 9.3(15)	55.5 6.4(15)	54.1 10.0(25)
DAY7	-DAY14	48.5 7.2(25)	53.5 8.7(15)	52.6 8.7(15)	50.7 7.8(15)	54.1# 6.5(25)
DAY14	-DAY21	46.4 7.8(25)	42.3 4.2(15)	47.8 7.8(15)	47.6 9.2(15)	44.6 8.1(25)
DAY21	-DAY28	31.9 8.8(25)	31.1 6.7(15)	36.0 8.2(15)	34.0 8.9(15)	34.1 6.4(25)
DAY28	-DAY35	29.5 19.4(25)	29.0 5.3(15)	31.8 6.0(15)	33.7 7.1(15)	26.9 6.6(25)
DAY35	-DAY42	22.2 12.4(25)	20.8 6.6(15)	23.4 8.8(15)	28.3 4.8(15)	24.9 6.9(25)
DAY42	-DAY49	16.0 13.0(25)	9.2 6.1(15)	11.0 8.8(15)	11.9 8.7(15)	13.0 8.5(25)
DAY49	-DAY56	20.5 9.2(25)	23.5 5.4(15)	27.4* 8.1(15)	27.4* 7.5(15)	20.5 6.9(25)
DAY56	-DAY63	16.8 6.8(25)	14.8 4.5(15)	19.3 7.1(15)	19.5 4.3(15)	8.7 15.5(25)
DAY63	-DAY70	17.2 7.8(25)	16.0 7.9(15)	14.0 6.6(15)	10.4# 5.3(15)	8.5# 16.7(25)
DAY70	-DAY77	9.9 5.7(25)	5.5 11.4(15)	12.0 8.2(15)	12.8 5.5(15)	-6.0 28.0(25)

TABLE 6 (CONTINUED)

MEAN BODY WEIGHT GAINS OF MALE RATS (g)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)						
DAY77	-DAY84	6.9	4.8	11.5	10.0	13.1
		6.6(25)	13.7(15)	5.6(15)	6.8(15)	22.4(25)
DAY84	-DAY91	7.5	11.5	6.6	10.1	20.3#
		11.0(25)	8.0(15)	9.9(15)	6.4(15)	14.2(25)
DAY0	-DAY91	327.6	315.4	348.2	351.9	316.8
		43.5(25)	35.9(15)	50.8(15)	47.2(15)	43.9(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation						
DAY91	-DAY98	13.3	9.1	12.2	9.3	11.9
		6.5(15)	3.9(5)	5.1(5)	3.8(5)	6.9(15)
DAY98	-DAY105	5.3	14.9	8.6	7.9	11.9
		19.1(15)	2.8(5)	5.1(5)	2.2(5)	6.9(15)
DAY105	-DAY112	8.3	1.5	3.6	4.6	5.6
		7.1(15)	4.2(5)	7.5(5)	8.6(5)	7.2(15)
DAY112	-DAY119	9.3	10.7	11.4	11.5	9.8
		6.9(15)	3.7(5)	5.9(5)	7.5(5)	6.4(15)
DAY119	-DAY126	14.6	9.4	10.0	15.7	16.0
		6.7(15)	8.6(5)	5.1(5)	5.3(5)	7.6(15)
DAY126	-DAY133	8.2	10.7	9.4	8.3	11.0
		5.7(15)	7.1(5)	5.4(5)	4.2(5)	6.7(15)

TABLE 6 (CONTINUED)

MEAN BODY WEIGHT GAINS OF MALE RATS (g)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)						
DAY133	-DAY140	-1.7 6.4(15)	0.6 6.7(5)	-1.9 16.5(5)	2.0 6.0(5)	2.6 7.4(15)
DAY140	-DAY147	5.2 6.3(15)	10.6 3.0(5)	10.3 8.0(5)	8.9 4.9(5)	8.6 4.9(15)
DAY147	-DAY154	7.8 8.6(15)	8.8 2.7(5)	8.8 6.0(5)	15.9 4.5(5)	14.2# 6.7(15)
DAY154	-DAY161	-1.3 11.9(15)	2.0 2.5(5)	2.4 4.5(5)	-2.6 5.6(5)	0.8 5.6(15)
DAY161	-DAY168	6.1 5.4(15)	5.1 2.8(5)	1.6 4.4(5)	11.8 8.8(5)	12.6# 8.5(15)
DAY168	-DAY175	1.5 12.3(15)	4.0 5.7(5)	1.4 6.8(5)	3.1 5.0(5)	-1.0 7.6(15)
DAY175	-DAY182	2.1 5.0(10)	. . (0)	. . (0)	. . (0)	11.4# 4.6(10)
DAY91	-DAY175	76.6 32.2(15)	87.5 26.9(5)	77.7 18.0(5)	96.4 24.1(5)	104.1# 28.8(15)
DAY91	-DAY182	89.2 21.4(10)	. . (0)	. . (0)	. . (0)	108.2 31.3(10)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at p < 0.05 by Jonckheere-Terpstra trend test.
* Statistically significant difference at p < 0.05 by Dunnett/Tamhane-Dunnett test.

TABLE 7

MEAN BODY WEIGHT GAINS OF FEMALE RATS (g)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	18.2 5.6(25)	21.9 10.0(15)	22.3 9.0(15)	20.2 6.9(15)	20.5 4.8(25)
DAY7	-DAY14	18.7 7.9(25)	19.1 4.1(15)	19.2 4.0(15)	22.9 7.5(15)	21.4 4.2(25)
DAY14	-DAY21	16.4 5.7(24)	13.9 3.3(15)	15.2 7.6(15)	14.1 7.4(15)	17.3 6.5(25)
DAY21	-DAY28	10.7 5.7(24)	11.4 5.4(15)	11.9 4.4(15)	12.8 6.9(15)	12.2 4.9(25)
DAY28	-DAY35	11.8 5.7(24)	14.2 4.2(15)	13.1 6.7(15)	13.6 5.9(15)	10.4 5.9(25)
DAY35	-DAY42	9.5 5.3(24)	9.8 5.6(15)	10.9 8.9(15)	12.3 7.7(15)	7.9 7.2(25)
DAY42	-DAY49	-0.2 6.2(24)	-6.9 7.1(15)	-3.3 7.2(15)	-6.5 9.6(15)	2.2 9.2(25)
DAY49	-DAY56	11.6 6.0(24)	19.3 7.1(15)	15.2 7.7(15)	20.0 8.2(15)	11.7 12.4(25)
DAY56	-DAY63	4.3 5.4(24)	4.9 6.9(15)	5.9 7.4(15)	2.3 6.4(15)	5.0 7.6(25)
DAY63	-DAY70	7.4 5.7(24)	7.2 4.3(15)	4.7 5.8(15)	10.6 6.2(15)	2.9 6.3(25)
DAY70	-DAY77	3.5 4.2(24)	3.6 5.0(15)	4.3 4.5(15)	5.5 4.8(15)	3.0 5.3(25)

TABLE 7 (CONTINUED)

MEAN BODY WEIGHT GAINS OF FEMALE RATS (g)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)						
DAY77	-DAY84	2.8	3.7	-0.8	0.7	8.3#
		5.4(24)	5.2(15)	3.3(15)	5.4(15)	6.2(25)
DAY84	-DAY91	1.3	-0.9	1.6	-0.7	-1.1
		6.5(24)	5.9(15)	6.3(15)	5.8(15)	6.7(25)
DAY0	-DAY91	116.9	121.1	120.2	128.0	121.7
		21.6(24)	24.6(15)	20.5(15)	18.2(15)	19.9(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation						
DAY91	-DAY98	4.5	8.0	8.8	9.7	5.0
		7.4(14)	3.4(5)	4.4(5)	7.5(5)	9.3(15)
DAY98	-DAY105	4.9	4.4	-0.1	3.9	0.2
		6.8(14)	5.6(5)	6.3(5)	6.3(5)	5.3(15)
DAY105	-DAY112	2.2	1.5	5.9	2.8	1.3
		5.3(14)	4.5(5)	1.3(5)	4.1(5)	11.7(15)
DAY112	-DAY119	2.2	1.1	3.5	10.9	5.8
		6.5(14)	2.3(5)	5.3(5)	3.3(5)	10.5(15)
DAY119	-DAY126	7.7	5.4	5.2	5.7	15.2#
		6.0(14)	1.4(5)	3.7(5)	7.2(5)	7.1(15)
DAY126	-DAY133	1.0	5.3	5.3	5.1	3.8
		6.3(14)	1.6(5)	6.3(5)	4.8(5)	6.4(15)
DAY133	-DAY140	2.7	1.1	0.6	0.3	-0.6#
		6.2(14)	6.1(5)	5.3(5)	5.1(5)	5.4(15)

TABLE 7 (CONTINUED)

MEAN BODY WEIGHT GAINS OF FEMALE RATS (g)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg)		0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)						
DAY140	-DAY147	5.4 5.9(14)	2.0 4.5(5)	4.2 7.1(5)	3.2 11.2(5)	6.1 6.8(15)
DAY147	-DAY154	2.4 6.2(14)	3.7 6.2(5)	6.8 7.5(5)	4.4 11.0(5)	5.6 8.6(15)
DAY154	-DAY161	-6.0 5.2(14)	-0.9 5.2(5)	-3.5 5.0(5)	2.5# 8.3(5)	-1.2# 4.6(15)
DAY161	-DAY168	7.0 5.7(14)	5.6 4.8(5)	6.1 4.0(5)	6.7 3.4(5)	6.5 6.9(15)
DAY168	-DAY175	2.0 3.9(14)	0.2 5.3(5)	2.0 4.2(5)	-1.5 7.5(5)	3.2 5.8(15)
DAY175	-DAY182	2.7 6.2(9)	. . (0)	. . (0)	. . (0)	2.9 7.6(10)
DAY91	-DAY175	36.0 13.8(14)	37.5 10.7(5)	44.9 20.1(5)	53.6 24.3(5)	51.0 33.1(15)
DAY91	-DAY182	42.1 15.5(9)	. . (0)	. . (0)	. . (0)	56.3 38.4(10)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 8

MEAN DAILY FOOD CONSUMPTION BY MALE RATS (g/day)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	27.0 3.0(25)	28.7 2.6(15)	27.2 3.3(15)	27.9 2.5(15)	26.6 2.5(25)
DAY7	-DAY14	28.3 4.1(25)	30.1 2.1(15)	29.6 3.6(15)	30.2 2.7(15)	29.0 2.3(25)
DAY14	-DAY21	29.8 3.3(25)	31.2 2.1(15)	30.7 4.0(15)	31.2 3.4(15)	30.0 3.0(25)
DAY21	-DAY28	30.5 3.3(25)	29.8 1.9(15)	31.3 3.9(15)	30.9 4.1(15)	29.1 2.9(25)
DAY28	-DAY35	30.4 5.9(25)	30.4 2.4(15)	31.8 4.1(15)	32.2 4.1(15)	30.4 3.2(25)
DAY35	-DAY42	29.5 5.2(25)	30.0 1.7(15)	30.9 4.2(15)	31.5 3.7(15)	29.8 3.2(25)
DAY42	-DAY49	28.8 3.6(25)	27.1 2.2(15)	28.6 3.3(15)	29.1 3.7(15)	28.6 3.4(25)
DAY49	-DAY56	29.4 3.2(25)	29.2 1.4(15)	30.2 3.4(15)	31.5 3.3(15)	29.1 3.3(25)
DAY56	-DAY63	28.3 3.9(25)	29.1 1.9(15)	30.1 3.8(15)	31.6 3.2(15)	27.2 4.5(25)
DAY63	-DAY70	29.2 3.3(25)	29.6 2.5(15)	30.2 2.8(15)	30.2 3.1(15)	26.6 4.3(25)
DAY70	-DAY77	28.8 3.1(25)	30.0 2.9(15)	30.1 2.8(15)	30.3 2.8(15)	25.3 6.2(25)

TABLE 8 (CONTINUED)

MEAN DAILY FOOD CONSUMPTION BY MALE RATS (g/day)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)						
DAY77	-DAY84	28.3 3.0(25)	28.0 1.5(15)	29.7 2.6(15)	29.2 2.2(15)	26.6 4.6(25)
DAY84	-DAY91	27.8 3.2(25)	28.9 1.9(15)	28.9 3.1(15)	30.3 3.0(15)	29.4 3.5(25)
DAY0	-DAY91	28.9 3.0(25)	29.4 1.5(15)	30.0 3.2(15)	30.5 2.9(15)	28.3 2.5(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation						
DAY91	-DAY98	27.2 1.9(10)	. . (0)	. . (0)	. . (0)	25.5 3.8(10)
DAY98	-DAY105	28.4 2.3(10)	. . (0)	. . (0)	. . (0)	25.9# 3.5(10)
DAY105	-DAY112	28.8 2.0(10)	. . (0)	. . (0)	. . (0)	26.0# 2.6(10)
DAY112	-DAY119	27.6 2.9(10)	. . (0)	. . (0)	. . (0)	26.6 3.3(10)
DAY119	-DAY126	27.7 2.3(10)	. . (0)	. . (0)	. . (0)	26.2 4.6(10)
DAY126	-DAY133	28.1 2.3(10)	. . (0)	. . (0)	. . (0)	27.1 3.4(10)
DAY133	-DAY140	28.1 2.8(10)	. . (0)	. . (0)	. . (0)	28.1 3.3(10)

TABLE 8 (CONTINUED)

MEAN DAILY FOOD CONSUMPTION BY MALE RATS (g/day)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY140 -DAY147	26.8 2.9(10)	. . (0)	. . (0)	. . (0)	26.4 3.9(10)
DAY147 -DAY154	27.5 2.4(10)	. . (0)	. . (0)	. . (0)	26.8 2.4(10)
DAY154 -DAY161	28.3 2.3(10)	. . (0)	. . (0)	. . (0)	26.1 2.9(10)
DAY161 -DAY168	28.5 2.4(10)	. . (0)	. . (0)	. . (0)	27.5 3.0(10)
DAY168 -DAY175	28.2 3.0(10)	. . (0)	. . (0)	. . (0)	26.4 3.1(10)
DAY175 -DAY182	27.9 2.2(10)	. . (0)	. . (0)	. . (0)	27.0 3.7(10)
DAY91 -DAY175	27.9 2.2(10)	. . (0)	. . (0)	. . (0)	26.6 3.1(10)
DAY91 -DAY182	27.9 2.2(10)	. . (0)	. . (0)	. . (0)	26.6 3.1(10)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 9

MEAN DAILY FOOD CONSUMPTION BY FEMALE RATS (g/day)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	19.4 1.9(25)	19.9 1.9(15)	19.8 1.8(15)	19.5 1.9(15)	19.1 1.8(25)
DAY7	-DAY14	19.5 2.2(25)	19.6 1.4(15)	19.6 2.0(15)	19.5 1.6(15)	20.2 1.8(25)
DAY14	-DAY21	21.1 2.2(24)	21.0 1.9(15)	21.2 2.1(15)	21.8 2.8(15)	21.5 2.1(25)
DAY21	-DAY28	20.3 2.1(24)	20.1 1.8(15)	21.0 1.7(15)	20.8 2.1(15)	21.0 2.0(25)
DAY28	-DAY35	21.0 2.3(24)	20.8 1.8(14)	21.5 2.2(15)	21.7 2.3(15)	21.4 2.2(25)
DAY35	-DAY42	21.3 2.1(24)	21.2 1.6(15)	21.2 2.3(15)	22.0 2.7(15)	20.7 2.2(24)
DAY42	-DAY49	19.7 2.6(24)	18.9 1.4(15)	20.2 2.0(15)	20.4 2.7(15)	20.7 3.4(25)
DAY49	-DAY56	21.2 2.2(24)	21.5 2.3(15)	22.1 2.0(15)	23.0 1.6(15)	21.7 2.6(25)
DAY56	-DAY63	20.9 2.3(24)	20.9 2.1(15)	21.6 2.2(15)	21.8 1.8(15)	20.7 2.4(25)
DAY63	-DAY70	20.5 2.0(24)	20.6 2.8(15)	20.8 1.6(15)	22.1 2.2(15)	20.5 2.2(25)
DAY70	-DAY77	20.7 2.2(24)	20.6 2.1(15)	20.9 2.0(15)	21.9 2.2(15)	20.2 2.4(25)

TABLE 9 (CONTINUED)

MEAN DAILY FOOD CONSUMPTION BY FEMALE RATS (g/day)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)					
DAY77 -DAY84	20.4 2.6(24)	20.2 2.0(15)	20.3 1.5(15)	21.3 1.9(15)	20.4 4.0(25)
DAY84 -DAY91	19.7 2.3(24)	19.7 1.5(15)	20.2 1.2(15)	20.3 1.9(15)	20.1 3.1(25)
DAY0 -DAY91	20.5 2.0(24)	20.4 1.7(14)	20.8 1.6(15)	21.2 1.7(15)	20.6 2.1(24)
Three-Month Recovery Period for Subchronic Toxicity Evaluation					
DAY91 -DAY98	19.6 2.5(9)	. . (0)	. . (0)	. . (0)	19.4 2.5(10)
DAY98 -DAY105	21.1 3.2(9)	. . (0)	. . (0)	. . (0)	20.2 2.9(10)
DAY105 -DAY112	21.9 2.2(9)	. . (0)	. . (0)	. . (0)	20.0 3.0(10)
DAY112 -DAY119	20.6 2.0(9)	. . (0)	. . (0)	. . (0)	21.1 3.8(10)
DAY119 -DAY126	22.0 2.4(9)	. . (0)	. . (0)	. . (0)	22.4 4.5(10)
DAY126 -DAY133	21.8 2.4(9)	. . (0)	. . (0)	. . (0)	22.4 4.6(10)
DAY133 -DAY140	22.5 2.0(9)	. . (0)	. . (0)	. . (0)	23.5 3.3(10)

TABLE 9 (CONTINUED)

MEAN DAILY FOOD CONSUMPTION BY FEMALE RATS (g/day)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY140 -DAY147	19.9 4.9(9)	. . (0)	. . (0)	. . (0)	21.9 3.9(10)
DAY147 -DAY154	20.8 2.8(9)	. . (0)	. . (0)	. . (0)	22.2 4.4(10)
DAY154 -DAY161	20.6 2.9(9)	. . (0)	. . (0)	. . (0)	21.7 4.2(10)
DAY161 -DAY168	22.2 2.3(9)	. . (0)	. . (0)	. . (0)	24.5 4.8(10)
DAY168 -DAY175	22.4 1.9(9)	. . (0)	. . (0)	. . (0)	21.1 3.8(10)
DAY175 -DAY182	22.4 2.4(9)	. . (0)	. . (0)	. . (0)	20.6 2.7(10)
DAY91 -DAY175	21.3 2.1(9)	. . (0)	. . (0)	. . (0)	21.7 3.5(10)
DAY91 -DAY182	21.4 2.0(9)	. . (0)	. . (0)	. . (0)	21.6 3.4(10)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant differences at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 10

MEAN DAILY FOOD EFFICIENCY OF MALE RATS
(g body weight gain/g food consumed)

Group:		I	III	V	VII	IX
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	0.288 0.026(25)	0.265 0.050(15)	0.288 0.027(15)	0.284 0.025(15)	0.290 0.041(25)
DAY7	-DAY14	0.248 0.040(25)	0.256 0.055(15)	0.253 0.028(15)	0.239 0.023(15)	0.266# 0.025(25)
DAY14	-DAY21	0.222 0.027(25)	0.193 0.016(15)	0.223 0.026(15)	0.217 0.024(15)	0.211 0.026(25)
DAY21	-DAY28	0.149 0.036(25)	0.149 0.027(15)	0.163 0.022(15)	0.156 0.027(15)	0.166# 0.022(25)
DAY28	-DAY35	0.104 0.235(25)	0.136 0.023(15)	0.142 0.018(15)	0.149 0.021(15)	0.125# 0.023(25)
DAY35	-DAY42	0.094 0.104(25)	0.099 0.030(15)	0.107 0.034(15)	0.129 0.022(15)	0.119 0.030(25)
DAY42	-DAY49	0.079 0.067(25)	0.047 0.031(15)	0.055 0.042(15)	0.056 0.035(15)	0.063 0.037(25)
DAY49	-DAY56	0.098 0.046(25)	0.114 0.024(15)	0.129 0.032(15)	0.124 0.027(15)	0.099 0.028(25)
DAY56	-DAY63	0.083 0.037(25)	0.072 0.019(15)	0.090 0.027(15)	0.088 0.020(15)	0.039 0.099(25)
DAY63	-DAY70	0.085 0.044(25)	0.075 0.034(15)	0.067 0.034(15)	0.049# 0.024(15)	0.035# 0.107(25)
DAY70	-DAY77	0.048 0.031(25)	0.029 0.048(15)	0.057 0.038(15)	0.061 0.026(15)	-0.106 0.339(25)

TABLE 10 (CONTINUED)

MEAN DAILY FOOD EFFICIENCY OF MALE RATS
(g body weight gain/g food consumed)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)					
DAY77 -DAY84	0.034	0.023	0.054	0.049	0.059
	0.034(25)	0.067(15)	0.025(15)	0.032(15)	0.133(25)
DAY84 -DAY91	0.034	0.055	0.029	0.046	0.096#
	0.073(25)	0.037(15)	0.046(15)	0.029(15)	0.060(25)
DAY0 -DAY91	0.124	0.118	0.128	0.127	0.123
	0.012(25)	0.010(15)	0.010(15)	0.010(15)	0.010(25)
Three-Month Recovery Period for Subchronic Toxicity Evaluation					
DAY91 -DAY98	0.074	.	.	.	0.064
	0.029(10)	. (0)	. (0)	. (0)	0.033(10)
DAY98 -DAY105	0.070	.	.	.	0.050
	0.024(10)	. (0)	. (0)	. (0)	0.027(10)
DAY105 -DAY112	0.030	.	.	.	0.026
	0.022(10)	. (0)	. (0)	. (0)	0.034(10)
DAY112 -DAY119	0.035	.	.	.	0.051
	0.019(10)	. (0)	. (0)	. (0)	0.028(10)
DAY119 -DAY126	0.068	.	.	.	0.079
	0.024(10)	. (0)	. (0)	. (0)	0.044(10)
DAY126 -DAY133	0.038	.	.	.	0.055
	0.028(10)	. (0)	. (0)	. (0)	0.034(10)
DAY133 -DAY140	-0.008	.	.	.	0.009
	0.020(10)	. (0)	. (0)	. (0)	0.036(10)

TABLE 10 (CONTINUED)

MEAN DAILY FOOD EFFICIENCY OF MALE RATS
(g body weight gain/g food consumed)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY140 -DAY147	0.037	.	.	.	0.044
	0.015(10)	. (0)	. (0)	. (0)	0.025(10)
DAY147 -DAY154	0.037	.	.	.	0.078
	0.024(10)	. (0)	. (0)	. (0)	0.036(10)
DAY154 -DAY161	0.007	.	.	.	-0.006
	0.030(10)	. (0)	. (0)	. (0)	0.029(10)
DAY161 -DAY168	0.027	.	.	.	0.049
	0.026(10)	. (0)	. (0)	. (0)	0.033(10)
DAY168 -DAY175	0.025	.	.	.	0.006
	0.027(10)	. (0)	. (0)	. (0)	0.025(10)
DAY175 -DAY182	0.012	.	.	.	0.060
	0.026(10)	. (0)	. (0)	. (0)	0.020(10)
DAY91 -DAY175	0.037	.	.	.	0.043
	0.007(10)	. (0)	. (0)	. (0)	0.009(10)
DAY91 -DAY182	0.035	.	.	.	0.044#
	0.007(10)	. (0)	. (0)	. (0)	0.009(10)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant differences at p < 0.05 by Jonckheere-Terpstra trend test.

TABLE 11

MEAN DAILY FOOD EFFICIENCY OF FEMALE RATS
(g body weight gain/g food consumed)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation						
DAY0	-DAY7	0.133 0.036(25)	0.157 0.071(15)	0.161 0.066(15)	0.146 0.044(15)	0.153 0.033(25)
DAY7	-DAY14	0.134 0.053(25)	0.138 0.025(15)	0.140 0.023(15)	0.168 0.056(15)	0.152 0.028(25)
DAY14	-DAY21	0.109 0.031(24)	0.095 0.023(15)	0.101 0.049(15)	0.092 0.047(15)	0.114 0.039(25)
DAY21	-DAY28	0.074 0.040(24)	0.081 0.038(15)	0.082 0.032(15)	0.086 0.043(15)	0.082 0.030(25)
DAY28	-DAY35	0.080 0.036(24)	0.100 0.022(14)	0.085 0.038(15)	0.089 0.040(15)	0.069 0.036(25)
DAY35	-DAY42	0.064 0.034(24)	0.065 0.034(15)	0.070 0.063(15)	0.078 0.044(15)	0.053 0.047(24)
DAY42	-DAY49	0.004 0.044(24)	-0.054 0.057(15)	-0.023 0.051(15)	-0.052 0.069(15)	0.008 0.062(25)
DAY49	-DAY56	0.078 0.040(24)	0.125 0.040(15)	0.097 0.045(15)	0.124 0.051(15)	0.077 0.074(25)
DAY56	-DAY63	0.028 0.034(24)	0.032 0.045(15)	0.037 0.044(15)	0.015 0.041(15)	0.032 0.045(25)
DAY63	-DAY70	0.052 0.040(24)	0.048 0.029(15)	0.033 0.039(15)	0.068 0.034(15)	0.021# 0.045(25)
DAY70	-DAY77	0.024 0.028(24)	0.025 0.037(15)	0.028 0.029(15)	0.035 0.030(15)	0.020 0.038(25)

TABLE 11 (CONTINUED)

MEAN DAILY FOOD EFFICIENCY OF FEMALE RATS
(g body weight gain/g food consumed)

Group:		II	IV	VI	VIII	X
Dosage(mg/kg/day)		0	1	5	25	125
Dosing Period for Subchronic Toxicity Evaluation (continued)						
DAY77	-DAY84	0.019	0.024	-0.006	0.004	0.056#
		0.038(24)	0.035(15)	0.023(15)	0.037(15)	0.041(25)
DAY84	-DAY91	0.008	-0.007	0.010	-0.006	-0.009
		0.045(24)	0.044(15)	0.043(15)	0.041(15)	0.047(25)
DAY0	-DAY91	0.062	0.066	0.063	0.066	0.065
		0.008(24)	0.010(14)	0.008(15)	0.006(15)	0.007(24)
Three-Month Recovery Period for Subchronic Toxicity Evaluation						
DAY91	-DAY98	0.031	.	.	.	0.024
		0.064(9)	. (0)	. (0)	. (0)	0.078(10)
DAY98	-DAY105	0.026	.	.	.	0.008
		0.042(9)	. (0)	. (0)	. (0)	0.032(10)
DAY105	-DAY112	0.019	.	.	.	-0.011
		0.041(9)	. (0)	. (0)	. (0)	0.097(10)
DAY112	-DAY119	0.013	.	.	.	0.046
		0.047(9)	. (0)	. (0)	. (0)	0.081(10)
DAY119	-DAY126	0.067	.	.	.	0.095
		0.029(9)	. (0)	. (0)	. (0)	0.039(10)
DAY126	-DAY133	0.008	.	.	.	0.032
		0.047(9)	. (0)	. (0)	. (0)	0.041(10)
DAY133	–DAY140	0.010	.	.	.	-0.013
		0.048(9)	. (0)	. (0)	. (0)	0.028(10)

TABLE 11 (CONTINUED)

MEAN DAILY FOOD EFFICIENCY OF FEMALE RATS
(g body weight gain/g food consumed)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
Three-Month Recovery Period for Subchronic Toxicity Evaluation (continued)					
DAY140 -DAY147	0.041	.	.	.	0.054
	0.043(9)	. (0)	. (0)	. (0)	0.036(10)
DAY147 -DAY154	0.007	.	.	.	0.032
	0.063(9)	. (0)	. (0)	. (0)	0.029(10)
DAY154 -DAY161	-0.044	.	.	.	-0.011#
	0.027(9)	. (0)	. (0)	. (0)	0.030(10)
DAY161 -DAY168	0.053	.	.	.	0.037
	0.034(9)	. (0)	. (0)	. (0)	0.039(10)
DAY168 -DAY175	0.013	.	.	.	0.026
	0.023(9)	. (0)	. (0)	. (0)	0.035(10)
DAY175 -DAY182	0.015	.	.	.	0.024
	0.039(9)	. (0)	. (0)	. (0)	0.054(10)
DAY91 -DAY175	0.022	.	.	.	0.028
	0.008(9)	. (0)	. (0)	. (0)	0.018(10)
DAY91 -DAY182	0.021	.	.	.	0.028
	0.007(9)	. (0)	. (0)	. (0)	0.016(10)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 12

SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Absent					
Toe					
Forepaw Right					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)
Mean onset (Days)				35	
Eye Observation					
Corneal Opacity					
Right					
Incidence	1 (4%)	2 (13%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)	91	14			63
Exophthalmus					
Right					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					56
Exophthalmus					
Bilateral					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		21			
Enophthalmus					
Right					
Incidence	2 (8%)	2 (13%)	1 (7%)	0 (0%)	1 (4%)
Mean onset (Days)	88	77	35		63

TABLE 12 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Wet Fur					
Ventral body					
Ventral					
Incidence	0 (0%)	0 (0%)	1 (7%)	0 (0%)	0 (0%)
Mean onset (Days)			70		
General Teeth Observations					
Striated					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	24 (96%) #
Mean onset (Days)					58
Clipped					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	16 (64%) #
Mean onset (Days)				86	84
Absent					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					91

TABLE 12 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Discharge					
Eye right					
Black					
Incidence	4 (16%)	0 (0%)	1 (7%)	0 (0%)	2 (8%)
Mean onset (Days)	98		91		63
Nose					
Incidence	1 (4%)	0 (0%)	1 (7%)	0 (0%)	3 (12%)
Mean onset (Days)	98		42		98
Hair Loss					
Incidence	4 (16%)	5 (33%)	1 (7%)	1 (7%)	4 (16%)
Mean onset (Days)	65	83	25	18	62
Wound					
Superficial					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
Mean onset (Days)	112				42
Hyperreactive					
Incidence	2 (8%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
Mean onset (Days)	98				116

TABLE 12 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Hyperactive					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					42
Aggressive Behavior					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
Mean onset (Days)					77
Vocalization					
No Abnormality Detected					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)
Mean onset (Days)				21	
Protrusion					
Umbilical Hernia					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	21				
Stain Fur/Skin					
Incidence	5 (20%)	2 (13%)	2 (13%)	1 (7%)	6 (24%)
Mean onset (Days)	130	131	112	154	150

TABLE 12 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR MALE RATS

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Swollen Observations					
Face					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	91				
Forepaw					
Right					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)
Mean onset (Days)				35	

Incidence – The number of animals for which an observation was recorded.
Mean onset (Days) – The mean of the first test day an observation was recorded for that group.
Statistically significant difference at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 13

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Eye Observations					
Dark					
Right					
Incidence	1 (4%)	1 (7%)	1 (7%)	1 (7%)	0 (0%)
Mean onset (Days)	49	91	105	91	
Dark					
Left					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		49			
Corneal Opacity					
Right					
Incidence	1 (4%)	1 (7%)	1 (7%)	0 (0%)	0 (0%)
Mean onset (Days)	7	140	119		
Corneal Opacity					
Bilateral					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	35				
Exophthalmus					
Right					
Incidence	1 (4%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	7	147			

TABLE 13 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Exophthalmus					
Left					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	28				
Enophthalmus					
Right					
Incidence	1 (4%)	0 (0%)	1 (7%)	0 (0%)	0 (0%)
Mean onset (Days)	21		112		
Enophthalmus					
Bilateral					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	42				
Closed					
Bilateral					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	119				
Wet Fur					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		14			

TABLE 13 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Scab					
Face					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)	21				
General Teeth Observations					
Striated					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	24 (96%) #
Mean onset (Days)					53
Clipped					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	9 (36%) #
Mean onset (Days)					108
Breathing Observations					
Noise					
Incidence	0 (0%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)
Mean onset (Days)				63	
Discharge					
Eye					
Incidence	2 (8%)	1 (7%)	1 (7%)	0 (0%)	2 (8%)
Mean onset (Days)	74	91	91		137

TABLE 13 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Nose					
Black					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					112
Mouth					
Clear					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		14			
Hair Loss					
Incidence	5 (20%)	3 (20%)	1 (7%)	4 (27%)	2 (8%)
Mean onset (Days)	32	53	21	64	35
Wound					
Deep					
Mouth					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					112
Superficial					
Incidence	2 (8%)	0 (0%)	0 (0%)	1 (7%)	1 (4%)
Mean onset (Days)	11			42	119

TABLE 13 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Arches back during handling					
Incidence	2 (8%)	2 (13%)	4 (27%)	3 (20%)	6 (24%)
Mean onset (Days)	35	25	32	49	42
Ear twitch					
Incidence	3 (12%)	2 (13%)	3 (20%)	3 (20%)	4 (16%)
Mean onset (Days)	39	25	33	54	39
Hyperreactive					
Incidence	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)	42				63
Hyperactive					
Incidence	1 (4%)	1 (7%)	1 (7%)	3 (20%)	2 (8%)
Mean onset (Days)	77	35	28	49	74
Vocalization					
No Abnormality Detected					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		35			
Comments					
Excessive Salivation					
Incidence	0 (0%)	0 (0%)	1 (7%)	0 (0%)	0 (0%)
Mean onset (Days)			40		

TABLE 13 (CONTINUED)

SUMMARY OF CLINICAL OBSERVATIONS FOR FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Animal Count	25	15	15	15	25
Comments					
Teeth Stuck in Cage					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
Mean onset (Days)					108
Misshapen Observations					
Ear					
Incidence	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)
Mean onset (Days)		21			
Stain Fur/Skin					
Incidence	2 (8%)	0 (0%)	1 (7%)	1 (7%)	2 (8%)
Mean onset (Days)	147		42	154	110
Swollen Observations					
Nose					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)
Mean onset (Days)					105
Face					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)
Mean onset (Days)					109

Incidence – The number of animals for which an observation was recorded.
Mean onset (Days) – The mean of the first test day an observation was recorded for that group.
Statistically significant difference at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 14

SUMMARY OF OPHTHALMOLOGY OBSERVATIONS FOR MALE RATS

(Test Day 87)

Treatment Group	I	III	V	VII	IX
Dosage (mg/kg/day)	0	1	5	25	125
Number Examined	20	10	10	10	20
Retina					
Retinal Degeneration Focal					
Incidence	1 (5%)	1 (10%)	1 (10%)	0 (0%)	0 (0%)
Globe					
Phthisis bulbi					
Right					
Incidence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)

Incidence – The number of animals (percent of animals examined) for which an observation was recorded.
There were no statistically significant differences at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 15

SUMMARY OF OPHTHALMOLOGY OBSERVATIONS FOR FEMALE RATS

(Test Day 87)

Treatment Group	II	IV	VI	VIII	X
Dosage (mg/kg/day)	0	1	5	25	125
Number Examined	20	10	10	10	20
Retina					
Retinal Degeneration Focal					
Right					
Incidence	1 (5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Incidence – The number of animals (percent of animals examined) for which an observation was recorded.
There were no statistically significant differences at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 16

PERCENT SURVIVAL OF MALE RATS

Treatment Group	I	III	V	VII	IX
Dose (mg/kg/day)	0	1	5	25	125
DAYS ON TEST					
0	100	100	100	100	100
7	100	100	100	100	100
14	100	100	100	100	100
21	100	100	100	100	100
28	100	100	100	100	100
35	100	100	100	100	100
42	100	100	100	100	100
49	100	100	100	100	100
56	100	100	100	100	100
63	100	100	100	100	100
70	100	100	100	100	100
77	100	100	100	100	100
84	100	100	100	100	100
91	100	100	100	100	100
98 [a,b]	100	100	100	100	100
105	100	100	100	100	100
112	100	100	100	100	100
119	100	100	100	100	100
126	100	100	100	100	100
133	100	100	100	100	100
140	100	100	100	100	100
147	100	100	100	100	100
154	100	100	100	100	100
161	100	100	100	100	100
168	100	100	100	100	100
175	100	100	100	100	100
182	100	-	-	-	100
Number at study start	25	15	15	15	25
Sacrificed by design [b,c]	15	15	15	15	15
Alive on test day 182	10	0	0	0	10

Percent Survival = (Number of rats alive/Number of rats at risk)*100
Number of rats at risk = Number at study start – number sacrificed by design.

a. Rats designated for the 90-day recovery period and satellite bleeds began recovery on test day 92.
b. Rats designated for the 90-day exposure period were sacrificed on test day 93.
c. Rats designated for satellite bleeds were sacrificed on test day 175.

There were no statistically significant decreases in survival at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 17

PERCENT SURVIVAL OF FEMALE RATS

Treatment Group	II	IV	VI	VIII	X
Dose (mg/kg/day)	0	1	5	25	125
DAYS ON TEST					
0	100	100	100	100	100
7	100	100	100	100	100
14	100	100	100	100	100
21	100	100	100	100	100
28	100	100	100	100	100
35	100	100	100	100	100
42	100	100	100	100	100
49	100	100	100	100	100
56	100	100	100	100	100
63	100	100	100	100	100
70	100	100	100	100	100
77	100	100	100	100	100
84	100	100	100	100	100
91	100	100	100	100	100
98 [a,b]	100	100	100	100	100
105	100	100	100	100	100
112	100	100	100	100	100
119	100	100	100	100	100
126	100	100	100	100	100
133	100	100	100	100	100
140	100	100	100	100	100
147	100	100	100	100	100
154	100	100	100	100	100
161	100	100	100	100	100
168	100	100	100	100	100
175	100	100	100	100	100
182	100	-	-	-	100
Number at study start	25	15	15	15	25
Accidentally killed [a]	1	0	0	0	0
Sacrificed by design [b,c]	15	15	15	15	15
Alive on test day 182	9	0	0	0	10

Percent Survival = (Number of rats alive/Number of rats at risk)*100
Number of rats at risk = Number at study start – number accidentally killed - number sacrificed by design.

a. Rats designated for the 90-day recovery period and satellite bleeds began recovery on test days 92.
b. Rats designated for the 90-day exposure period were sacrificed on test day 94.
c. Rats designated for satellite bleeds were sacrificed on test day 175.

There were no statistically significant decreases in survival at $p < 0.05$ by Cochran-Armitage trend test.

TABLE 18

MEAN FORELIMB AND HINDLIMB GRIP STRENGTH FOR MALE RATS
(MEAN OF THREE TRIALS)

Assessment Period	Group	Dosage (mg/kg/day)	Forelimb Grip Strength (kg)	Hindlimb Grip Strength (kg)
Baseline				
	I	0	0.53 (0.08)	0.30 (0.06)
	III	1	0.58 (0.11)	0.31 (0.06)
	V	5	0.57 (0.11)	0.28 (0.05)
	VII	25	0.60 (0.11)	0.29 (0.06)
	IX	125	0.58 (0.11)	0.27 (0.07)
Week 13				
	I	0	1.13 (0.31)	0.53 (0.15)
	III	1	1.17 (0.17)	0.58 (0.12)
	V	5	1.22 (0.21)	0.53 (0.10)
	VII	25	1.27 (0.18)	0.58 (0.16)
	IX	125	1.14 (0.29)	0.49 (0.14)

Data arranged as : Mean (Standard Deviation)

Statistical Methods: Bartlett's test for homogeneity followed by analysis of variance and Dunnett's test.

There were no statistically significant differences from control at $p<0.05$.

TABLE 19

MEAN FORELIMB AND HINDLIMB GRIP STRENGTH FOR FEMALE RATS
(MEAN OF THREE TRIALS)

Assessment Period	Group	Dosage (mg/kg/day)	Forelimb Grip Strength (kg)	Hindlimb Grip Strength (kg)
Baseline				
	II	0	0.56 (0.08)	0.37 (0.07)
	IV	1	0.63 (0.09)	0.35 (0.05)
	VI	5	0.65 (0.09) *	0.36 (0.03)
	VIII	25	0.60 (0.09)	0.35 (0.09)
	X	125	0.60 (0.10)	0.33 (0.06)
Week 13				
	II [a]	0	0.88 (0.21)	0.50 (0.10)
	IV	1	1.03 (0.19)	0.40 (0.09)
	VI	5	1.05 (0.15)	0.49 (0.09)
	VIII	25	0.99 (0.19)	0.47 (0.13)
	X	125	0.97 (0.13)	0.46 (0.07)

Data arranged as : Mean (Standard Deviation)

[a] n=9 due to unscheduled death.

Statistical Methods: Bartlett's test for homogeneity followed by analysis of variance and Dunnett's test.

* Statistically significant difference from control at $p<0.05$ by Dunnett's test.

TABLE 20

SUMMARY OF FUNCTIONAL OBSERVATION BATTERY FINDINGS
FOR MALE RATS

	BASELINE					13-WEEK				
Group	I	III	V	VII	IX	I	III	V	VII	IX
Dosage (:mg/kg/day)	0	1	5	25	125	0	1	5	25	125
Number examined:	10	10	10	10	10	10	10	10	10	10
MANUPULATIONS:										
APPROACH & TOUCH:										
no reaction	0	0	0	0	0	0	0	0	0	0
normal	10	9	10	10	10	10	10	10	10	10
increased reaction (jumps away or attacks)	0	1	0	0	0	0	0	0	0	0
AUDITORY STIMULUS:										
no reaction	0	0	0	0	0	0	0	0	0	0
normal reaction (rat flinches or flicks ear)	10	10	10	10	10	10	10	10	10	10
exaggerated reaction (rat jumps, flips)	0	0	0	0	0	0	0	0	0	0
TAIL PINCH:										
no response	0	0	0	0	0	0	0	0	0	0
normal (turns toward site)	9	9	10	10	10	10	10	10	10	10
exaggerated response	1	1	0	0	0	0	0	0	0	0
IN MOTOR ACTIVITY MONITOR:										
PUPILLARY RESPONSE										
present	10	10	10	10	10	10	10	10	10	10
absent	0	0	0	0	0	0	0	0	0	0
DEFECATION										
present	6	3	8	3	4	4	7	3	3	4
absent	4	7	2	7	6	6	3	7	7	6
diarrhea	0	0	0	0	0	0	0	0	0	0
URINATION:										
present	10	9	10	10	9	8	9	9	7	9
absent	0	1	0	0	1	2	1	1	3	1

There were no statistically significant differences by Cochran-Armitage test for trend at $p < 0.05$.

TABLE 21

SUMMARY OF FUNCTIONAL OBSERVATION BATTERY FINDINGS
FOR FEMALE RATS

	BASELINE					13-WEEK				
Group	II	IV	VI	VIII	X	II [a]	IV	VI	VIII	X
Dosage (:mg/kg/day)	0	1	5	25	125	0	1	5	25	125
Number examined:	10	10	10	10	10	10	10	10	10	10
MANUPULATIONS:										
APPROACH & TOUCH:										
no reaction	0	0	0	0	0	0	0	0	0	0
normal	10	10	10	10	10	9	10	10	10	10
increased reaction (jumps away or attacks)	0	0	0	0	0	0	0	0	0	0
AUDITORY STIMULUS:										
no reaction	0	0	0	0	0	0	0	0	0	0
normal reaction (rat flinches or flicks ear)	10	10	10	10	10	9	10	10	10	10
exaggerated reaction (rat jumps, flips)	0	0	0	0	0	0	0	0	0	0
TAIL PINCH:										
no response	0	0	0	0	0	0	0	0	0	0
normal (turns toward site)	10	10	10	10	10	9	10	10	10	10
exaggerated response	0	0	0	0	0	0	0	0	0	0
IN MOTOR ACTIVITY MONITOR:										
PUPILLARY RESPONSE										
present	10	10	10	10	10	9	10	10	10	10
absent	0	0	0	0	0	0	0	0	0	0
DEFECATION										
present	4	3	7	6	8	3	7	7	5	5
absent	6	7	3	4	2	6	3	3	5	5
diarrhea	0	0	0	0	0	0	0	0	0	0
URINATION:										
present	7	9	10	10	9	7	10	9	9	10
absent	3	1	0	0	1	2	0	1	1	0

[a] n=9 due to unscheduled death.

There were no statistically significant differences by Cochran-Armitage test for trend at $p < 0.05$.

TABLE 22

MOTOR ACTIVITY ASSESSEMENT:
DURATION OF MOVEMENTS FOR MALE RATS (sec)

ASSESSMENT PERIOD	GROUP	DOSAGE (mg/kg/day)	SUCCESSIVE 10-MINUTE INTERVALS						
			1	**2**	**3**	**4**	**5**	**6**	**TOTAL**
BASELINE									
	I	0	383(34)	318(50)	216(90)	60(67)	35(87)	27(67)	1039(202)
	III	1	402(60)	344(56)	312(78) *	163(120) *	83(138)	34(52)	1338(354)
	V	5	401(39)	334(44)	254(74)	172(130) *	112(139) *	72(113)	1346(466)
	VII	25	398(33)	292(71)	200(108)	146(135) *	68(99)	60(105)	1163(430)
	IX	125	402(49)	343(74)	281(121)	164(149) *	90(123)	51(75)	1331(488)
13-WEEK									
	I	0	383(42)	327(36)	288(52)	270(55)	226(64)	158(96)	1652(280)
	III [a]	1	395(39)	345(27)	295(46)	277(54)	205(108)	127(98)	1645(310)
	V	5	390(42)	333(40)	244(46)	209(91)	163(96)	105(111)	1443(253)
	VII	25	413(27)	308(64)	228(107)	210(93)	129(85) *	158(77)	1446(364)
	IX	125	405(69)	327(69)	275(115)	220(133)	202(128)	168(108)	1596(556)

Data arranged as: Mean (Standard Deviation).

[a] n=9 due to sensor malfunction.

Statistical Methods: Shapiro-Wilk's and Levene's tests were performed. Repeated measures analysis of variance with linear contrasts was used to identify which dosage groups, if any, were significantly different from the control group. These tests were applied to bin data and total data.

* Statistically significant difference from control at $p < 0.05$.

TABLE 23

MOTOR ACTIVITY ASSESSEMENT:
DURATION OF MOVEMENTS FOR FEMALE RATS (sec)

ASSESSMENT PERIOD	GROUP	DOSAGE (mg/kg/day)	SUCCESSIVE 10-MINUTE INTERVALS						
			1	**2**	**3**	**4**	**5**	**6**	**TOTAL**
BASELINE									
	II	0	370(53)	265(101)	243(120)	241(83)	189(118)	112(92)	1419(381)
	IV	1	389(61)	302(75)	244(90)	207(135)	183(163)	145(158)	1471(599)
	VI	5	364(29)	283(94)	234(80)	256(107)	154(121)	140(124)	1430(372)
	VIII	25	373(45)	259(96)	234(75)	200(69)	153(128)	73(64)	1292(322)
	X	125	367(68)	321(64)	272(88)	236(112)	181(113)	145(116)	1522(442)
13-WEEK									
	II [a]	0	383(47)	289(44)	237(46)	226(59)	203(39)	202(85)	1540(215)
	IV	1	408(48)	294(69)	246(65)	249(70)	182(61)	150(114)	1529(288)
	VI	5	408(40)	311(58)	211(78)	166(88)	151(77)	170(88)	1418(230)
	VIII	25	407(64)	298(72)	234(58)	193(95)	142(78)	176(66)	1451(321)
	X [b]	125	403(47)	302(62)	241(71)	226(71)	206(89)	153(114)	1531(335)

Data arranged as: Mean (Standard Deviation).

[a] n=9 due to unscheduled death.
[b] n=9 due to sensor malfunction.

Statistical Methods: Shapiro-Wilk's and Levene's tests were performed. Jonckheere's trend test was used to identify which dosage groups, if any, were significantly different from the control group. These tests were applied to bin data and total data.

There were no statistically significant differences from control at $p < 0.05$.

TABLE 24

MOTOR ACTIVITY ASSESSEMENT:
NUMBER OF MOVEMENTS FOR MALE RATS

ASSESSMENT PERIOD	GROUP	DOSAGE (mg/kg/day)	SUCCESSIVE 10-MINUTE INTERVALS						
			1	**2**	**3**	**4**	**5**	**6**	**TOTAL**
BASELINE									
	I	0	135(19)	139(13)	124(36)	51(50)	21(47)	21(41)	491(141)
	III	1	129(26)	129(26)	128(25)	91(65) *	39(51)	23(36)	539(160)
	V	5	132(14)	140(17)	131(17)	100(50) *	61(61) *	44(57)	609(156)
	VII	25	138(13)	137(7)	108(47)	87(68) *	46(59)	40(53)	556(201)
	IX	125	127(26)	136(27)	126(34)	73(50)	44(56)	28(40)	534(162)
13-WEEK									
	I	0	141(16)	144(10)	134(13)	137(17)	123(22)	95(50)	773(79)
	III [a]	1	142(10)	148(10)	138(16)	133(16)	108(47)	76(54)	745(112)
	V	5	139(12)	138(17)	124(19)	109(32)	89(43)	66(60)	665(78)
	VII	25	130(16)	129(14)	108(45)	109(43)	73(44) *	87(47)	637(179) *
	IX	125	133(22)	134(16)	116(33)	96(45) *	101(57)	88(55)	668(168)

Data arranged as: Mean (Standard Deviation).

[a] n=9 due to sensor malfunction.

Statistical Methods: Shapiro-Wilk's and Levene's tests were performed. Repeated measures analysis of variance with linear contrasts was used to identify which dosage groups, if any, were significantly different from the control group. These tests were applied to bin data and total data.

* Statistically significant difference from control at $p < 0.05$.

TABLE 25

MOTOR ACTIVITY ASSESSEMENT:
NUMBER OF MOVEMENTS FOR FEMALE RATS

ASSESSMENT PERIOD	GROUP	DOSAGE (mg/kg/day)	SUCCESSIVE 10-MINUTE INTERVALS						
			1	**2**	**3**	**4**	**5**	**6**	**TOTAL**
BASELINE									
	II	0	138(17)	132(32)	120(48)	130(20)	115(54)	82(58)	717(146)
	IV	1	131(28)	127(27)	124(27)	97(48)	85(58)	71(55)	635(162)
	VI	5	137(13)	125(27)	130(32)	122(43)	95(60)	84(67)	692(160)
	VIII	25	138(17)	127(24)	132(20)	127(30)	86(66)	62(52)	673(148)
	X	125	131(26)	138(32)	131(29)	124(49)	94(56)	83(68)	702(195)
13-WEEK									
	II [a]	0	132(25)	133(14)	128(21)	126(27)	127(21)	121(35)	767(101)
	IV	1	135(24)	136(12)	128(24)	130(20)	117(22)	86(50)	732(82)
	VI	5	125(16)	138(15)	115(29)	100(36)	96(38)	101(41)	675(104)
	VIII	25	135(17)	133(16)	132(20)	108(37)	96(46)	111(29)	716(78)
	X [b]	125	136(11)	134(19)	130(27)	126(27)	111(35)	87(55)	725(103)

Data arranged as: Mean (Standard Deviation).

[a] n=9 due to unscheduled death.
[b] n=9 due to sensor malfunction.

Statistical Methods: Shapiro-Wilk's and Levene's tests were performed. Jonckheere's trend test was used to identify which dosage groups, if any, were significantly different from the control group. These tests were applied to bin data and total data.

There were no statistically significant differences from control at $p < 0.05$.

TABLE 26

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
RBC ($x10^6/\mu L$)					
DAY 48	8.33	8.26	8.18	7.90*	7.78*
	0.38(10)	0.35(10)	0.13(9)	0.20(10)	0.42(10)
DAY 93	8.57	8.55	8.32	8.12*	7.76*
	0.32(10)	0.37(10)	0.22(10)	0.22(10)	0.44(10)
DAY 183	8.71	--	--	--	8.39
	0.42(10)				0.47(7)
HGB (g/dL)					
DAY 48	15.1	15.2	15.1	14.8	14.5
	0.6(10)	0.7(10)	0.4(9)	0.5(10)	0.7(10)
DAY 93	15.9	15.9	15.6	15.6	15.0*
	0.6(10)	0.6(10)	0.5(10)	0.7(10)	0.7(10)
DAY 183	15.4	--	--	--	15.1
	0.6(10)				0.3(7)
HCT (%)					
DAY 48	48.3	48.3	48.4	47.0	46.4
	1.7(10)	2.2(10)	1.2(9)	1.4(10)	2.4(10)
DAY 93	47.7	48.0	47.0	46.8	45.5*
	1.7(10)	1.6(10)	1.5(10)	1.9(10)	2.5(10)
DAY 183	47.8	--	--	--	46.6
	1.8(10)				1.6(7)
MCV (fl)					
DAY 48	58.0	58.5	59.1	59.5	59.7
	1.4(10)	1.8(10)	1.2(9)	1.7(10)	2.0(10)
DAY 93	55.7	56.2	56.5	57.5*	58.7*
	0.9(10)	1.8(10)	1.0(10)	1.4(10)	2.4(10)
DAY 183	54.9	--	--	--	55.6
	1.6(10)				1.4(7)
MCH (pg)					
DAY 48	18.2	18.4	18.5	18.7	18.7
	0.5(10)	0.7(10)	0.4(9)	0.6(10)	0.5(10)
DAY 93	18.6	18.6	18.7	19.1	19.4*
	0.5(10)	0.7(10)	0.5(10)	0.5(10)	0.6(10)
DAY 183	17.7	--	--	--	18.1
	0.7(10)				0.8(7)

TABLE 26 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
MCHC (g/dL)					
DAY 48	31.3 0.5(10)	31.5 0.5(10)	31.3 0.4(9)	31.5 0.7(10)	31.3 0.5(10)
DAY 93	33.3 0.6(10)	33.1 0.5(10)	33.1 0.8(10)	33.3 0.6(10)	33.0 0.7(10)
DAY 183	32.3 0.7(10)	--	--	--	32.5 0.6(7)
RDW (%)					
DAY 48	11.9 0.4(10)	11.5 0.5(10)	11.9 0.6(9)	12.2 0.8(10)	12.9* 0.9(10)
DAY 93	12.8 0.6(10)	12.2 0.5(10)	12.6 0.7(10)	12.7 0.5(10)	13.6 1.8(10)
DAY 183	13.5 0.5(10)	--	--	--	13.3 0.6(7)
ARET ($x10^3/\mu L$)					
DAY 48	212.6 16.7(10)	206.0 25.6(10)	235.8 44.5(9)	239.6 43.2(10)	262.0* 26.0(10)
DAY 93	172.4 22.7(10)	159.2 21.2(10)	187.0 30.8(10)	192.6 31.2(10)	216.8* 53.6(10)
DAY 183	179.0 24.2(10)	--	--	--	188.4 22.9(7)
PLT ($x10^3/\mu L$)					
DAY 48	1010 151(6)	1098 20(4)	1054 104(7)	1012 48(5)	950 178(5)
DAY 93	1221 132(9)	1227 109(7)	1199 128(8)	1252 126(8)	1275 209(9)
DAY 183	1145 188(6)	--	--	--	1074 165(7)
WBC ($x10^3/\mu L$)					
DAY 48	14.18 2.18(10)	15.67 3.75(10)	15.12 3.70(9)	15.46 3.13(10)	16.29 4.01(10)
DAY 93	12.19 3.55(10)	12.45 1.99(10)	11.77 2.58(10)	13.36 3.59(10)	13.89 3.97(10)
DAY 183	13.47 3.28(10)	--	--	--	13.97 2.30(7)

TABLE 26 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
ANEU ($x10^3/\mu L$)					
DAY 48	1.63	1.61	1.96	2.00	2.04
	0.55(10)	0.79(10)	0.66(9)	0.68(10)	0.90(10)
DAY 93	1.86	1.45	1.81	2.48	2.17
	0.68(10)	0.33(10)	1.04(10)	1.13(10)	0.79(10)
DAY 183	2.75	--	--	--	2.49
	1.37(10)				0.56(7)
ALYM ($x10^3/\mu L$)					
DAY 48	11.97	13.50	12.50	12.84	13.69
	1.60(10)	3.21(10)	3.11(9)	2.95(10)	3.35(10)
DAY 93	9.89	10.55	9.49	10.34	11.26
	3.01(10)	1.99(10)	1.45(10)	2.79(10)	3.21(10)
DAY 183	9.99	--	--	--	10.67
	2.56(10)				1.74(7)
AMON ($x10^3/\mu L$)					
DAY 48	0.30	0.24	0.38	0.29	0.27
	0.13(10)	0.10(10)	0.15(9)	0.10(10)	0.11(10)
DAY 93	0.21	0.24	0.24	0.26	0.21
	0.06(10)	0.14(10)	0.12(10)	0.10(10)	0.06(10)
DAY 183	0.40	--	--	--	0.43
	0.14(10)				0.13(7)
AEOS ($x10^3/\mu L$)					
DAY 48	0.12	0.11	0.10	0.11	0.12
	0.08(10)	0.05(10)	0.05(9)	0.04(10)	0.04(10)
DAY 93	0.14	0.13	0.14	0.17	0.14
	0.07(10)	0.06(10)	0.12(10)	0.14(10)	0.04(10)
DAY 183	0.17	--	--	--	0.18
	0.06(10)				0.05(7)
ABAS ($x10^3/\mu L$)					
DAY 48	0.09	0.14	0.10	0.14	0.11
	0.05(10)	0.09(10)	0.05(9)	0.05(10)	0.07(10)
DAY 93	0.04	0.04	0.04	0.04	0.04
	0.03(10)	0.03(10)	0.01(10)	0.02(10)	0.01(10)
DAY 183	0.11	--	--	--	0.14
	0.05(10)				0.08(7)

TABLE 26 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
ALUC ($x10^3/\mu L$)					
DAY 48	0.08	0.07	0.08	0.09	0.07
	0.03(10)	0.04(10)	0.02(9)	0.02(10)	0.04(10)
DAY 93	0.06	0.05	0.05	0.06	0.06
	0.03(10)	0.04(10)	0.01(10)	0.03(10)	0.02(10)
DAY 183	0.05	--	--	--	0.07
	0.02(10)				0.02(7)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by Dunnett/Tamhane-Dunnett test.

TABLE 27

SUMMARY OF HEMATOLOGY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
RBC ($x10^6/\mu L$)					
DAY 49	8.28	8.09	8.14	8.00	7.50*
	0.29(10)	0.29(9)	0.36(10)	0.41(10)	0.43(10)
DAY 94	8.24	8.28	8.38	8.07	7.66*
	0.26(10)	0.25(10)	0.31(10)	0.46(10)	0.34(10)
DAY 183	7.76	--	--	--	7.75
	0.36(9)				0.30(10)
HGB (g/dL)					
DAY 49	15.6	15.4	15.5	14.9	14.2*
	0.5(10)	0.5(9)	0.6(10)	0.6(10)	0.7(10)
DAY 94	16.1	16.4	16.5	15.7	15.1*
	0.5(10)	0.4(10)	0.4(10)	0.7(10)	0.7(10)
DAY 183	14.7	--	--	--	15.1
	0.6(9)				0.5(10)
HCT (%)					
DAY 49	49.0	48.1	48.3	46.8*	44.5*
	1.7(10)	1.7(9)	1.7(10)	2.2(10)	2.5(10)
DAY 94	47.2	47.9	48.3	45.8	44.6*
	1.5(10)	1.4(10)	1.8(10)	2.4(10)	2.1(10)
DAY 183	44.0	--	--	--	45.1
	1.7(9)				1.9(10)
MCV (fl)					
DAY 49	59.2	59.5	59.4	58.5	59.4
	0.9(10)	1.1(9)	1.6(10)	1.2(10)	1.4(10)
DAY 94	57.2	57.8	57.7	56.8	58.3
	0.9(10)	0.9(10)	1.3(10)	0.8(10)	1.6(10)
DAY 183	56.8	--	--	--	58.2
	1.8(9)				1.1(10)
MCH (pg)					
DAY 49	18.8	19.1	19.0	18.7	19.0
	0.4(10)	0.3(9)	0.4(10)	0.4(10)	0.6(10)
DAY 94	19.6	19.8	19.7	19.5	19.8
	0.3(10)	0.3(10)	0.5(10)	0.5(10)	0.6(10)
DAY 183	19.0	--	--	--	19.4
	0.7(9)				0.3(10)

TABLE 27 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
MCHC (g/dL)					
DAY 49	31.8 0.4(10)	32.1 0.3(9)	32.0 0.4(10)	32.0 0.5(10)	32.0 0.5(10)
DAY 94	34.3 0.4(10)	34.3 0.4(10)	34.2 0.5(10)	34.4 0.8(10)	34.0 0.3(10)
DAY 183	33.4 0.3(9)	--	--	--	33.4 0.6(10)
RDW (%)					
DAY 49	11.7 0.6(10)	11.6 0.4(9)	11.8 0.5(10)	11.8 0.4(10)	12.0 0.4(10)
DAY 94	10.9 0.5(10)	11.0 0.4(10)	11.0 0.4(10)	10.8 0.3(10)	11.6* 0.5(10)
DAY 183	11.8 0.5(9)	--	--	--	12.1 0.8(10)
ARET ($x10^3/\mu L$)					
DAY 49	256.6 44.7(10)	225.4 26.9(9)	249.0 51.4(10)	217.1@ 31.2(10)	240.6 18.0(10)
DAY 94	141.4 31.4(10)	139.0 16.0(10)	155.1 28.4(10)	140.6 19.8(10)	176.6* 39.0(10)
DAY 183	153.5 33.4(9)	--	--	--	164.4 27.0(10)
PLT ($x10^3/\mu L$)					
DAY 49	973 46(7)	835 175(7)	1095 185(8)	952 181(8)	978 160(5)
DAY 94	1083 130(10)	1025 174(9)	1158 88(7)	1026 190(7)	1068 88(9)
DAY 183	1059 194(7)	--	--	--	957 231(6)
WBC ($x10^3/\mu L$)					
DAY 49	13.02 4.11(10)	11.83 2.63(9)	13.25 3.38(10)	12.56 2.78(10)	11.10 3.04(10)
DAY 94	10.84 3.92(10)	9.59 2.57(10)	10.57 2.47(10)	9.86 2.61(10)	10.26 1.38(10)
DAY 183	7.29 1.97(9)	--	--	--	8.19 1.73(10)

TABLE 27 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
ANEU (x10³/µL)					
DAY 49	1.36	0.94	1.50	1.43	1.40
	0.66(10)	0.36(9)	0.56(10)	0.82(10)	0.56(10)
DAY 94	1.28	1.32	1.45	1.76	1.74
	0.47(10)	0.81(10)	0.51(10)	1.22(10)	0.68(10)
DAY 183	1.33	--	--	--	1.43
	0.49(9)				0.47(10)
ALYM (x10³/µL)					
DAY 49	11.18	10.50	11.23	10.60	9.25
	3.47(10)	2.40(9)	3.25(10)	2.79(10)	2.67(10)
DAY 94	9.07	7.85	8.70	7.61	8.01
	3.39(10)	2.27(10)	2.48(10)	2.12(10)	1.14(10)
DAY 183	5.55	--	--	--	6.27
	1.65(9)				1.67(10)
AMON (x10³/µL)					
DAY 49	0.22	0.20	0.23	0.25	0.22
	0.15(10)	0.07(9)	0.10(10)	0.13(10)	0.08(10)
DAY 94	0.18	0.18	0.15	0.23	0.26
	0.07(10)	0.09(10)	0.08(10)	0.21(10)	0.09(10)
DAY 183	0.25	--	--	--	0.29
	0.11(9)				0.13(10)
AEOS (x10³/µL)					
DAY 49	0.11	0.09	0.12	0.11	0.10
	0.06(10)	0.03(9)	0.04(10)	0.05(10)	0.05(10)
DAY 94	0.18	0.13	0.17	0.15	0.13
	0.07(10)	0.03(10)	0.06(10)	0.06(10)	0.05(10)
DAY 183	0.09	--	--	--	0.11
	0.03(9)				0.05(10)
ABAS (x10³/µL)					
DAY 49	0.09	0.05	0.10	0.08	0.06
	0.05(10)	0.02(9)	0.08(10)	0.05(10)	0.04(10)
DAY 94	0.06	0.06	0.05	0.06	0.06
	0.02(10)	0.03(10)	0.05(10)	0.04(10)	0.02(10)
DAY 183	0.04	--	--	--	0.06@
	0.04(9)				0.01(10)

TABLE 27 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
ALUC ($x10^3/\mu L$)					
DAY 49	0.07	0.05	0.07	0.08	0.07
	0.03(10)	0.02(9)	0.03(10)	0.03(10)	0.04(10)
DAY 94	0.06	0.05	0.04	0.05	0.05
	0.04(10)	0.03(10)	0.03(10)	0.04(10)	0.02(10)
DAY 183	0.03	--	--	--	0.03
	0.01(9)				0.01(10)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by Dunnett/Tamhane-Dunnett test.
@ Statistically significant difference from control at $p < 0.05$ by Dunn's test.

TABLE 28

SUMMARY OF COAGULATION VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
PT (seconds)					
DAY 93	15.9	16.1	15.9	15.5	15.9
	0.8(9)	0.6(10)	1.1(9)	0.5(10)	1.7(9)
APTT (seconds)					
DAY 93	18.2	20.2	19.1	17.7	19.3
	2.5(9)	2.1(10)	1.6(9)	1.7(10)	2.1(9)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

There were no statistically significant differences from control at $p < 0.05$.

TABLE 29

SUMMARY OF COAGULATION VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
PT (seconds)					
DAY 94	15.3	14.9	15.3	15.2	14.9
	0.5(10)	0.6(10)	0.6(10)	0.6(10)	1.0(10)
APTT (seconds)					
DAY 94	15.8	16.2	15.0	15.4	14.1
	1.8(10)	2.0(10)	1.6(10)	1.7(10)	2.0(10)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

There were no statistically significant differences from control at $p < 0.05$.

TABLE 30

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
AST (U/L)					
DAY 48	69 10(10)	69 5(10)	70 6(10)	72 9(10)	69 6(10)
DAY 93	85 12(10)	88 13(9)	114 69(10)	186 152(10)	81 17(10)
DAY 183	147 134(10)	--	--	--	134 51(10)
ALT (U/L)					
DAY 48	33 4(10)	33 5(10)	32 5(10)	33 5(10)	34 7(10)
DAY 93	36 5(10)	42 8(9)	49 44(10)	89 71(10)	44 16(10)
DAY 183	77 91(10)	--	--	--	67 26(10)
SDH (U/L)					
DAY 48	14.1 3.5(10)	13.2 2.8(10)	12.6 2.4(10)	13.2 3.0(10)	13.3 3.5(10)
DAY 93	18.7 3.1(10)	16.9 4.8(10)	17.5 16.3(10)	41.5 38.2(10)	18.4 6.6(10)
DAY 183	24.7 18.0(10)	--	--	--	21.0 6.8(10)
ALKP (U/L)					
DAY 48	131 18(9)	114 21(10)	126 17(9)	135 33(10)	165* 39(10)
DAY 93	109 25(10)	97 18(9)	91 18(10)	110 25(10)	136 35(10)
DAY 183	86 20(10)	--	--	--	86 23(10)
BILI (mg/dL)					
DAY 48	0.11 0.04(10)	0.07* 0.03(10)	0.10 0.03(10)	0.10 0.04(10)	0.07 0.03(10)
DAY 93	0.10 0.03(10)	0.06@ 0.02(9)	0.10 0.04(10)	0.09 0.05(10)	0.09 0.03(10)
DAY 183	0.14 0.05(10)	--	--	--	0.12 0.04(10)

TABLE 30 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
BUN (mg/dL)					
DAY 48	14 2(10)	14 1(10)	14 2(10)	14 1(10)	13 1(10)
DAY 93	13 2(10)	14 2(10)	13 2(10)	15* 2(10)	13 2(10)
DAY 183	18 2(10)	--	--	--	16* 2(10)
CREA (mg/dL)					
DAY 48	0.25 0.06(10)	0.27 0.04(10)	0.28 0.04(10)	0.26 0.02(10)	0.26 0.04(10)
DAY 93	0.42 0.06(10)	0.39 0.08(10)	0.36 0.04(10)	0.37 0.06(10)	0.37 0.04(10)
DAY 183	0.46 0.03(10)	--	--	--	0.41* 0.04(10)
CHOL (mg/dL)					
DAY 48	66 9(10)	53 11(10)	62 12(10)	52* 15(10)	57 11(10)
DAY 93	80 16(10)	57* 9(10)	74 19(10)	66 17(10)	65 15(10)
DAY 183	76 28(10)	--	--	--	79 17(10)
TRIG (mg/dL)					
DAY 48	87 24(10)	74 27(10)	95 50(10)	83 42(10)	43* 21(10)
DAY 93	77 32(10)	67 23(9)	77 28(10)	64 26(10)	37* 18(10)
DAY 183	81 33(10)	--	--	--	95 59(10)
GLUC (mg/dL)					
DAY 48	119 7(10)	115 9(10)	122 10(10)	118 9(10)	122 20(10)
DAY 93	109 28(10)	117 32(10)	114 24(10)	110 29(10)	105 22(10)
DAY 183	129 40(10)	--	--	--	127 31(10)

TABLE 30 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
TP (g/dL)					
DAY 48	6.5	6.6	6.6	6.5	7.0*
	0.3(10)	0.4(10)	0.4(10)	0.3(10)	0.4(10)
DAY 93	7.2	7.0	7.0	7.0	7.6*
	0.4(10)	0.3(9)	0.5(10)	0.4(10)	0.1(10)
DAY 183	6.9	--	--	--	6.8
	0.2(10)				0.1(10)
ALB (g/dL)					
DAY 48	4.2	4.1	4.2	4.2	4.7*
	0.2(10)	0.3(10)	0.2(10)	0.2(10)	0.2(10)
DAY 93	4.4	4.3	4.3	4.4	5.0@
	0.2(10)	0.2(9)	0.2(10)	0.3(10)	0.2(10)
DAY 183	4.2	--	--	--	4.2
	0.2(10)				0.1(10)
GLOB (g/dL)					
DAY 48	2.4	2.4	2.5	2.3	2.3
	0.3(10)	0.2(10)	0.3(10)	0.2(10)	0.3(10)
DAY 93	2.8	2.6	2.7	2.6	2.6
	0.3(10)	0.2(9)	0.3(10)	0.2(10)	0.2(10)
DAY 183	2.7	--	--	--	2.7
	0.2(10)				0.1(10)
CALC (mg/dL)					
DAY 48	10.8	10.8	10.8	10.5	10.8
	0.4(10)	0.2(10)	0.5(10)	0.4(10)	0.4(10)
DAY 93	11.3	11.3	11.2	11.1	11.4
	0.4(10)	0.6(10)	0.6(10)	0.2(10)	0.4(10)
DAY 183	11.4	--	--	--	11.5
	0.5(10)				0.3(10)
IPHS (mg/dL)					
DAY 48	8.3	7.9	8.4	8.4	9.2*
	0.6(10)	0.5(10)	0.7(10)	1.0(10)	0.9(10)
DAY 93	8.1	8.9	8.7	9.2	9.5*
	0.6(10)	1.4(9)	0.9(10)	1.3(10)	1.2(10)
DAY 183	8.5	--	--	--	9.2
	0.8(10)				1.0(10)

TABLE 30 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
NA (mmol/L)					
DAY 48	148.2	149.5	148.2	148.3	147.7
	1.3(10)	4.7(10)	2.3(10)	1.2(10)	1.6(10)
DAY 93	148.4	149.4	148.3	148.3	148.1
	1.3(10)	2.2(10)	3.0(10)	2.5(10)	2.4(10)
DAY 183	147.9	--	--	--	148.4
	1.4(10)				2.2(10)
K (mmol/L)					
DAY 48	5.87	5.68	5.76	5.52	5.74
	0.53(10)	0.47(10)	0.62(10)	0.43(10)	0.34(10)
DAY 93	6.15	6.16	6.31	6.32	6.31
	0.51(10)	0.47(9)	0.52(10)	0.71(10)	0.59(10)
DAY 183	6.17	--	--	--	6.29
	0.45(10)				0.54(10)
CL (mmol/L)					
DAY 48	102.2	103.2	101.5	101.0	101.1
	2.1(10)	3.7(10)	2.2(10)	2.1(10)	2.0(10)
DAY 93	100.7	101.8	101.1	101.2	100.1
	1.9(10)	1.8(10)	1.5(10)	1.7(10)	1.5(10)
DAY 183	102.3	--	--	--	104.1
	2.2(10)				1.9(10)
PFLU (µg/mL)					
DAY 93	0.1	0.1	0.1	0.1	0.4@
	0.0(10)	0.0(10)	0.0(10)	0.0(10)	0.0(10)
DAY 183	0.1	--	--	--	0.1
	0.1(9)				0.0(10)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by Dunnett/Tamhane-Dunnett test.
@ Statistically significant difference from control at $p < 0.05$ by Dunn's test.

TABLE 31

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
AST (U/L)					
DAY 49	72	77	65	91	61
	11(10)	15(10)	6(10)	89(10)	9(10)
DAY 94	85	119	82	176	93
	17(10)	51(10)	18(10)	285(10)	40(10)
DAY 183	177	--	--	--	103
	176(9)				54(10)
ALT (U/L)					
DAY 49	34	35	29	44	32
	8(10)	7(10)	4(10)	41(10)	5(10)
DAY 94	40	64	37	75	45
	17(10)	46(10)	10(10)	106(10)	16(10)
DAY 183	96	--	--	--	58
	90(9)				41(10)
SDH (U/L)					
DAY 49	10.5	10.5	7.9	21.8	10.0
	2.7(10)	4.0(10)	0.9(10)	41.2(10)	2.2(10)
DAY 94	16.7	21.5	13.6	44.4	19.0
	4.4(10)	8.2(10)	2.7(10)	84.1(10)	10.4(10)
DAY 183	29.2	--	--	--	17.5
	27.5(9)				10.4(10)
ALKP (U/L)					
DAY 49	83	79	79	73	75
	16(10)	19(10)	24(10)	28(10)	14(10)
DAY 94	51	52	54	49	53
	11(10)	13(10)	19(10)	19(10)	10(10)
DAY 183	34	--	--	--	38
	8(9)				10(10)
BILI (mg/dL)					
DAY 49	0.15	0.15	0.13	0.14	0.16
	0.04(10)	0.03(10)	0.03(10)	0.04(10)	0.03(10)
DAY 94	0.15	0.15	0.12	0.14	0.17
	0.01(10)	0.03(10)	0.03(10)	0.04(10)	0.04(10)
DAY 183	0.17	--	--	--	0.15
	0.07(9)				0.04(10)

TABLE 31 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
BUN (mg/dL)					
DAY 49	15 2(10)	16 2(10)	16 2(10)	15 2(10)	15 2(10)
DAY 94	17 2(10)	17 2(10)	17 1(10)	17 4(10)	17 2(10)
DAY 183	17 2(9)	--	--	--	16 3(10)
CREA (mg/dL)					
DAY 49	0.33 0.05(10)	0.35 0.06(10)	0.34 0.06(10)	0.33 0.07(10)	0.31 0.03(10)
DAY 94	0.47 0.06(10)	0.49 0.03(10)	0.44 0.06(10)	0.48 0.10(10)	0.46 0.06(10)
DAY 183	0.52 0.05(9)	--	--	--	0.48 0.06(10)
CHOL (mg/dL)					
DAY 49	77 19(10)	86 16(10)	73 14(10)	105 28(10)	107@ 21(10)
DAY 94	85 19(10)	97 15(10)	79 18(10)	125 45(10)	123 39(10)
DAY 183	134 26(9)	--	--	--	147 67(10)
TRIG (mg/dL)					
DAY 49	44 20(10)	50 20(10)	37 12(10)	43 22(10)	55 46(10)
DAY 94	51 26(10)	66 53(10)	39 11(10)	41 13(10)	42 47(10)
DAY 183	78 14(9)	--	--	--	89 63(10)
GLUC (mg/dL)					
DAY 49	115 10(10)	112 13(10)	116 13(10)	113 5(10)	111 5(10)
DAY 94	101 9(10)	104 12(10)	104 9(10)	106 16(10)	100 5(10)
DAY 183	121 32(9)	--	--	--	104 6(10)

TABLE 31 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
TP (g/dL)					
DAY 49	7.3	7.3	7.0	7.6	7.9*
	0.3(10)	0.3(10)	0.5(10)	0.5(10)	0.4(10)
DAY 94	7.8	8.0	7.6	8.3	8.6*
	0.3(10)	0.3(10)	0.5(10)	0.7(10)	0.6(10)
DAY 183	8.5	--	--	--	8.4
	0.3(9)				0.4(10)
ALB (g/dL)					
DAY 49	4.9	4.9	4.6	5.0	5.5@
	0.2(10)	0.2(10)	0.4(10)	0.4(10)	0.3(10)
DAY 94	5.2	5.4	5.0	5.5	5.8*
	0.3(10)	0.3(10)	0.3(10)	0.5(10)	0.3(10)
DAY 183	5.7	--	--	--	5.4
	0.3(9)				0.4(10)
GLOB (g/dL)					
DAY 49	2.4	2.4	2.5	2.6	2.4
	0.2(10)	0.2(10)	0.3(10)	0.3(10)	0.2(10)
DAY 94	2.6	2.6	2.7	2.7	2.8
	0.2(10)	0.1(10)	0.3(10)	0.4(10)	0.3(10)
DAY 183	2.8	--	--	--	2.9
	0.1(9)				0.4(10)
CALC (mg/dL)					
DAY 49	11.3	11.3	11.0	11.4	11.6
	0.2(10)	0.4(10)	0.3(10)	0.4(10)	0.5(10)
DAY 94	11.7	11.5	11.3	11.8	12.2*
	0.4(10)	0.2(10)	0.4(10)	0.5(10)	0.4(10)
DAY 183	12.4	--	--	--	12.2
	0.3(9)				0.3(10)
IPHS (mg/dL)					
DAY 49	7.0	7.4	6.8	6.9	7.6
	1.3(10)	1.2(10)	0.7(10)	0.5(10)	1.0(10)
DAY 94	6.8	5.9	6.8	6.7	7.3
	1.7(10)	0.8(10)	0.9(10)	0.9(10)	0.5(10)
DAY 183	7.1	--	--	--	7.4
	1.3(9)				1.0(10)

TABLE 31 (Continued)

SUMMARY OF CLINICAL CHEMISTRY VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
NA (mmol/L)					
DAY 49	145.2 1.4(10)	145.1 1.7(10)	145.1 1.6(10)	144.1 2.4(10)	144.5 1.8(10)
DAY 94	145.6 2.1(10)	145.7 1.3(10)	145.9 1.6(10)	145.5 1.2(10)	146.3 2.5(10)
DAY 183	148.7 1.5(9)	--	--	--	149.6 1.5(10)
K (mmol/L)					
DAY 49	5.74 0.70(10)	5.59 0.48(10)	5.50 0.38(10)	5.36 0.27(10)	5.55 0.38(10)
DAY 94	5.74 0.67(10)	5.54 0.39(10)	5.96 0.36(10)	5.40 0.31(10)	5.95 0.31(10)
DAY 183	5.80 0.55(9)	--	--	--	5.94 0.53(10)
CL (mmol/L)					
DAY 49	101.2 1.6(10)	101.6 1.3(10)	101.9 1.1(10)	100.7 2.0(10)	100.9 1.0(10)
DAY 94	101.1 3.0(10)	101.1 1.8(10)	102.4 1.5(10)	100.5 2.0(10)	100.5 1.9(10)
DAY 183	104.1 1.6(9)	--	--	--	103.9 2.3(10)
PFLU (µg/mL)					
DAY 94	0.1 0.0(10)	0.1 0.1(10)	0.1 0.0(10)	0.2 0.0(10)	0.5@ 0.1(10)
DAY 183	0.1 0.0(9)	--	--	--	0.1 0.0(9)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by Dunnett/Tamhane-Dunnett test.
@ Statistically significant difference from control at $p < 0.05$ by Dunn's test.

TABLE 32

SUMMARY OF URINALYSIS VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
VOL (mL)					
DAY 48	14.4	10.9	11.7	13.0	17.2
	10.5(10)	5.6(10)	6.0(10)	7.9(10)	5.6(10)
DAY 93	6.8	6.3	7.6	7.8	21.1@
	2.5(10)	1.8(10)	4.2(10)	5.6(10)	13.4(10)
DAY 183	7.5	--	--	--	7.7
	6.5(10)				4.1(10)
UOSM (mOsm)					
DAY 48	790	841	913	840	605
	429(10)	341(10)	313(10)	365(10)	162(10)
DAY 93	1321	1324	1293	1549	703
	457(10)	323(10)	593(10)	854(10)	452(10)
DAY 183	1400	--	--	--	1322
	808(9)				590(10)
pH					
DAY 48	7.3	7.1	7.1	7.1	7.4
	0.3(10)	0.2(10)	0.2(10)	0.4(10)	0.3(10)
DAY 93	6.8	6.8	6.8	6.8	7.0
	0.7(10)	0.4(10)	0.4(10)	0.3(10)	0.4(10)
DAY 183	6.6	--	--	--	6.6
	0.6(10)				0.4(10)
URO (EU/dL)					
DAY 48	0.2	0.2	0.2	0.2	0.2
	0.0(10)	0.0(10)	0.0(10)	0.0(10)	0.0(10)
DAY 93	0.2	0.2	0.2	0.3	0.2
	0.0(9)	0.0(10)	0.0(10)	0.3(10)	0.0(10)
DAY 183	0.4	--	--	--	0.3
	0.3(10)				0.3(10)
UFLU (µg)					
DAY 93	10.7	13.0	38.8@	202.4@	997.2@
	4.4(10)	1.9(10)	10.1(9)	57.9(9)	246.3(10)
DAY 183	9.9	--	--	--	27.6*
	3.1(9)				5.1(10)

TABLE 32 (Continued)

SUMMARY OF URINALYSIS VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/kg/day	Group III 1 mg/kg/day	Group V 5 mg/kg/day	Group VII 25 mg/kg/day	Group IX 125 mg/kg/day
UMTP (mg/dL)					
DAY 48	49	48	55	47	43
	34(10)	26(10)	34(10)	33(10)	34(10)
DAY 93	108	98	81	89	67
	87(10)	47(10)	49(10)	53(10)	91(10)
DAY 183	161	--	--	--	95
	164(10)				91(10)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by Dunnett/Tamhane-Dunnett test.
@ Statistically significant difference from control at $p < 0.05$ by Dunn's test.

TABLE 33

SUMMARY OF URINALYSIS VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
VOL (mL)					
DAY 49	7.2	7.5	8.2	14.4	8.2
	3.3(10)	5.8(10)	6.2(10)	13.3(10)	5.2(10)
DAY 94	5.0	2.8	4.2	4.8	7.7
	4.5(10)	1.8(9)	2.5(10)	3.1(10)	4.3(10)
DAY 183	8.2	--	--	--	4.9
	14.1(7)				4.4(10)
UOSM (mOsm)					
DAY 49	882	985	1050	623	954
	281(10)	499(10)	509(9)	257(10)	569(10)
DAY 94	1336	1519	1317	1231	1051
	615(10)	598(8)	528(10)	493(10)	714(10)
DAY 183	1477	--	--	--	1445
	1104(7)				868(10)
pH					
DAY 49	7.1	7.0	6.8	7.0	6.9
	0.2(10)	0.6(10)	0.3(10)	0.3(10)	0.4(10)
DAY 94	6.0	6.1	5.9	6.4	6.2
	0.3(10)	0.4(9)	0.4(10)	0.3(10)	0.3(10)
DAY 183	5.7	--	--	--	6.1
	0.5(7)				0.5(10)
URO (EU/dL)					
DAY 49	0.2	0.2	0.2	0.2	0.2
	0.0(10)	0.0(10)	0.0(10)	0.0(10)	0.0(10)
DAY 94	0.2	0.2	0.2	0.2	0.2
	0.0(10)	0.0(9)	0.0(10)	0.0(10)	0.0(10)
DAY 183	0.2	--	--	--	0.3
	0.0(7)				0.3(10)
UFLU (µg)					
DAY 94	6.0	5.7	14.1	88.0@	702.6@
	2.3(8)	1.4(6)	3.3(8)	29.0(8)	255.8(9)
DAY 183	11.9	--	--	--	15.7
	12.4(5)				3.2(7)

TABLE 33 (Continued)

SUMMARY OF URINALYSIS VALUES FOR FEMALE RATS

TEST/ PERIOD	Group II 0 mg/kg/day	Group IV 1 mg/kg/day	Group VI 5 mg/kg/day	Group VIII 25 mg/kg/day	Group X 125 mg/kg/day
UMTP (mg/dL)					
DAY 49	22	34	26	13	46
	7(10)	24(10)	18(10)	6(10)	35(10)
DAY 94	33	48	30	88	230
	23(10)	37(9)	15(10)	147(10)	313(10)
DAY 183	172	--	--	--	588
	278(7)				1031(10)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

@ Statistically significant difference from control at $p < 0.05$ by Dunn's test.

TABLE 34

SUMMARY OF PEROXISOMAL BETA-OXIDATION ACTIVITY IN MALE RATS

		Hepatic Peroxisomal Beta-Oxidation Activity (nmol/min/mg protein)		
Group	Dosage (mg/kg/day)	10-Day Time point	90-Day Time point	3-Month Recovery Time point
I	0	14.8 ± 1.0[a]	12.4 ± 1.2	11.2 ± 1.8
III[b]	1	14.0 ± 1.7	13.6 ± 1.5	-----
V[b]	5	15.9 ± 2.1	13.6 ± 3.0	-----
VII[b]	25	14.7 ± 1.1	13.4 ± 2.1	-----
IX	125	24.1 ± 3.7#	20.6 ± 2.8#	14.9 ± 2.0*

[a] Mean ± standard deviation. The n = 5 for each group.
[b] Samples were not prepared for analysis from groups III, V and VII at the 90-day recovery time points.

Statistically significant difference from control ($p < 0.05$) by Jonckheere's Tend test.
* Statistically significant difference from control ($p < 0.05$) by Dunnett's test.

TABLE 35

SUMMARY OF PEROXISOMAL BETA-OXIDATION ACTIVITY IN FEMALE RATS

		Hepatic Peroxisomal Beta-Oxidation Activity (nmol/min/mg protein)		
Group	Dosage (mg/kg/day)	10-Day Time point	90-Day Time point	3-Month Recovery Time point
II	0	22.5 ± 2.2[a]	25.6 ± 3.3	23.8 ± 1.3
IV[b]	1	22.2 ± 1.5	25.4 ± 1.4	-----
VI[b]	5	23.8 ± 4.5	27.3 ± 2.1	-----
VIII[b]	25	23.2 ± 2.2	29.7 ± 3.3#	-----
X	125	29.5 ± 4.4#	39.1 ± 4.7#	27.0 ± 5.6

[a] Mean ± standard deviation. The n = 5 for each group.
[b] Samples were not prepared for analysis from groups IV, VI and VIII at the 90-day recovery time point.

Statistically significant difference from control ($p < 0.05$) by Jonckheere's Tend test.

TABLE 36

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	14.876	14.109	15.575	17.219#	21.976#
	1.770(10)	1.254(10)	1.744(10)	1.693(10)	1.928(10)
KIDNEYS	3.924	3.804	4.087	4.351#	4.636#
	0.463(10)	0.263(10)	0.501(10)	0.417(10)	0.346(10)
HEART	1.761	1.832	1.797	1.866	1.916
	0.184(10)	0.095(10)	0.187(10)	0.133(10)	0.303(10)
SPLEEN	0.913	0.842	0.874	0.919	0.963
	0.137(10)	0.126(10)	0.171(10)	0.102(10)	0.186(10)
BRAIN	2.186	2.167	2.234	2.175	2.175
	0.084(10)	0.105(10)	0.089(10)	0.094(10)	0.069(10)
THYMUS	0.450	0.375	0.480	0.457	0.455
	0.134(10)	0.072(10)	0.117(10)	0.131(10)	0.138(10)
ADRENAL GLANDS	0.061	0.048	0.065	0.057	0.062
	0.009(10)	0.013(10)	0.011(10)	0.012(10)	0.014(10)
THYROID GLAND	0.024	0.023	0.026	0.026	0.023
	0.004(10)	0.004(10)	0.003(10)	0.003(10)	0.003(10)
TESTES	3.588	3.500	3.700	3.697	3.552
	0.228(10)	0.255(10)	0.442(10)	0.330(10)	0.552(10)
EPIDIDYMIDES	1.528	1.549	1.623	1.636	1.456
	0.289(10)	0.133(10)	0.160(10)	0.221(10)	0.248(10)
FINAL BODY WEIGHT	552.940	540.790	582.650	564.140	536.980
	49.145(10)	37.400(10)	46.186(10)	43.119(10)	31.734(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
LIVER/					
FINAL BODY * 100	2.690	2.609	2.669	3.050#	4.102#
	0.225(10)	0.140(10)	0.148(10)	0.124(10)	0.410(10)
KIDNEYS/					
FINAL BODY * 100	0.712	0.707	0.702	0.771	0.867#
	0.091(10)	0.076(10)	0.069(10)	0.035(10)	0.096(10)
HEART/					
FINAL BODY * 100	0.320	0.339	0.308	0.331	0.357
	0.035(10)	0.016(10)	0.020(10)	0.013(10)	0.059(10)
SPLEEN/					
FINAL BODY * 100	0.165	0.156	0.149	0.164	0.180
	0.021(10)	0.023(10)	0.022(10)	0.020(10)	0.037(10)
BRAIN/					
FINAL BODY * 100	0.398	0.402	0.385	0.387	0.406
	0.038(10)	0.031(10)	0.030(10)	0.030(10)	0.028(10)
THYMUS/					
FINAL BODY * 100	0.081	0.069	0.082	0.081	0.085
	0.021(10)	0.010(10)	0.018(10)	0.020(10)	0.025(10)
ADRENAL GLANDS/					
FINAL BODY * 100	0.011	0.009	0.011	0.010	0.012
	0.002(10)	0.002(10)	0.002(10)	0.002(10)	0.003(10)
THYROID GLAND/					
FINAL BODY * 100	0.004	0.004	0.004	0.005	0.004
	0.001(10)	0.001(10)	0.001(10)	0.001(10)	0.001(10)
TESTES/					
FINAL BODY * 100	0.651	0.649	0.635	0.657	0.664
	0.048(10)	0.057(10)	0.053(10)	0.054(10)	0.110(10)
EPIDIDYMIDES/					
FINAL BODY * 100	0.279	0.287	0.280	0.290	0.273
	0.060(10)	0.025(10)	0.032(10)	0.035(10)	0.054(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN RELATIVE ORGAN WEIGHT (% organ to brain weight ratio)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
LIVER/ BRAIN * 100	680.794	652.386	697.513	792.330#	1011.448#
	80.356(10)	64.449(10)	76.846(10)	78.215(10)	93.853(10)
KIDNEYS/ BRAIN * 100	179.350	175.802	182.593	200.137#	213.371#
	19.034(10)	13.117(10)	17.359(10)	18.909(10)	16.868(10)
HEART/ BRAIN * 100	80.545	84.719	80.415	85.888	88.139
	7.730(10)	5.813(10)	7.364(10)	6.289(10)	13.934(10)
SPLEEN/ BRAIN * 100	41.735	38.817	39.063	42.302	44.283
	5.680(10)	5.273(10)	7.279(10)	4.614(10)	8.168(10)
THYMUS/ BRAIN * 100	20.511	17.295	21.496	21.087	20.829
	5.854(10)	3.170(10)	5.303(10)	6.168(10)	5.858(10)
ADRENAL GLANDS/ BRAIN * 100	2.794	2.230	2.901	2.642	2.849
	0.360(10)	0.622(10)	0.456(10)	0.553(10)	0.585(10)
THYROID GLAND/ BRAIN * 100	1.092	1.065	1.163	1.188	1.071
	0.164(10)	0.168(10)	0.101(10)	0.161(10)	0.124(10)
TESTES/ BRAIN * 100	164.247	161.999	165.628	170.071	163.479
	10.716(10)	15.726(10)	18.827(10)	14.477(10)	26.042(10)
EPIDIDYMIDES/ BRAIN * 100	69.848	71.552	72.719	75.102	66.885
	12.791(10)	5.886(10)	7.299(10)	8.741(10)	10.870(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR RECOVERY

Group:	I	IX
Dosage(mg/kg/day)	0	125
LIVER	15.779	15.067
	2.481(9)	2.727(10)
KIDNEYS	3.911	3.940
	0.428(9)	0.520(10)
HEART	1.799	1.841
	0.161(9)	0.276(10)
SPLEEN	0.863	0.840
	0.115(9)	0.106(10)
BRAIN	2.161	2.111
	0.100(9)	0.067(10)
THYMUS	0.222	0.338#
	0.088(9)	0.056(10)
ADRENAL GLANDS	0.055	0.049
	0.009(9)	0.010(10)
THYROID GLAND	0.031	0.029
	0.005(9)	0.005(10)
TESTES	3.655	3.460
	0.270(9)	0.125(10)
EPIDIDYMIDES	1.513	1.480
	0.144(9)	0.114(10)
FINAL BODY WEIGHT		
	626.311	609.860
	67.783(9)	85.864(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	I	IX
Dosage(mg/kg/day)	0	125
LIVER/		
FINAL BODY * 100	2.510	2.462
	0.159(9)	0.184(10)
KIDNEYS/		
FINAL BODY * 100	0.625	0.648
	0.027(9)	0.046(10)
HEART/		
FINAL BODY * 100	0.289	0.302
	0.024(9)	0.014(10)
SPLEEN/		
FINAL BODY * 100	0.138	0.139
	0.018(9)	0.015(10)
BRAIN/		
FINAL BODY * 100	0.348	0.352
	0.030(9)	0.051(10)
THYMUS/		
FINAL BODY * 100	0.036	0.056#
	0.015(9)	0.007(10)
ADRENAL GLANDS/		
FINAL BODY * 100	0.009	0.008
	0.002(9)	0.001(10)
THYROID GLAND/		
FINAL BODY * 100	0.005	0.005
	0.001(9)	0.001(10)
TESTES/		
FINAL BODY * 100	0.589	0.577
	0.064(9)	0.080(10)
EPIDIDYMIDES/		
FINAL BODY * 100	0.244	0.248
	0.032(9)	0.045(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)

Group:	I	IX
Dosage(mg/kg/day)	0	125
LIVER/ BRAIN * 100	728.243	714.942
	94.614(9)	133.730(10)
KIDNEYS/ BRAIN * 100	180.855	186.766
	17.182(9)	24.848(10)
HEART/ BRAIN * 100	83.180	87.334
	5.450(9)	13.549(10)
SPLEEN/ BRAIN * 100	39.852	39.856
	4.379(9)	5.478(10)
THYMUS/ BRAIN * 100	10.361	16.044#
	4.280(9)	2.650(10)
ADRENAL GLANDS/ BRAIN * 100	2.554	2.306
	0.421(9)	0.468(10)
THYROID GLAND/ BRAIN * 100	1.428	1.371
	0.267(9)	0.260(10)
TESTES/ BRAIN * 100	169.421	163.936
	14.492(9)	4.527(10)
EPIDIDYMIDES/ BRAIN * 100	70.022	70.171
	6.365(9)	5.982(10)

TABLE 36 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS (10-DAY SACRIFICE)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	10.419	10.216	10.419	10.703	14.182
	0.940(5)	0.733(5)	1.444(5)	1.004(5)	1.684(5)
FINAL BODY WEIGHT	248.38	244.66	245.66	241.36	252.94
	16.953(5)	11.964(5)	23.023(5)	17.085(5)	17.819(5)
LIVER/ FINAL BODY * 100	4.193	4.174	4.232	4.433	5.593
	0.206(5)	0.164(5)	0.290(5)	0.242(5)	0.297(5)

RATS DESIGNATED FOR SATELLITE EVALUATIONS (FINAL SACRIFICE)

Group:	I	III	V	VII	IX
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	19.628	20.521	19.963	22.601	22.559
	4.405(5)	3.768(5)	3.833(5)	3.976(5)	3.686(5)
FINAL BODY WEIGHT	603.040	646.340	632.480	693.840	697.940#
	98.436(5)	66.814(5)	85.838(5)	81.778(5)	65.719(5)
LIVER/ FINAL BODY * 100	3.232	3.157	3.139	3.241	3.220
	0.356(5)	0.296(5)	0.236(5)	0.203(5)	0.267(5)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at $p < 0.05$ by Jonckheere-Terpstra trend test.

TABLE 37

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	7.904	8.224	8.185	9.230#	11.513#
	0.849(10)	0.982(10)	0.845(10)	1.076(10)	0.972(10)
KIDNEYS	2.239	2.147	2.155	2.453	2.462#
	0.188(10)	0.239(10)	0.173(10)	0.267(10)	0.265(10)
HEART	1.223	1.108	1.130	1.161	1.150
	0.294(10)	0.067(10)	0.120(10)	0.125(10)	0.075(10)
SPLEEN	0.579	0.549	0.622	0.574	0.609
	0.090(10)	0.095(10)	0.105(10)	0.073(10)	0.065(10)
BRAIN	1.967	1.978	1.931	2.003	2.009
	0.068(10)	0.077(10)	0.085(10)	0.085(10)	0.126(10)
THYMUS	0.351	0.267	0.324	0.328	0.323
	0.074(10)	0.068(10)	0.082(10)	0.060(10)	0.074(10)
ADRENAL GLANDS	0.076	0.063	0.070	0.065	0.073
	0.012(10)	0.019(10)	0.010(10)	0.006(10)	0.013(10)
THYROID GLAND	0.020	0.020	0.020	0.021	0.022
	0.003(10)	0.006(10)	0.003(10)	0.004(10)	0.004(10)
OVARIES	0.141	0.132	0.141	0.134	0.140
	0.018(10)	0.025(10)	0.033(10)	0.024(10)	0.025(10)
UTERUS	0.704	0.779	0.738	0.780	0.808
	0.168(10)	0.170(10)	0.300(10)	0.166(10)	0.354(10)
FINAL BODY WEIGHT					
	286.830	294.600	294.090	297.520	288.960
	25.304(10)	25.107(10)	25.820(10)	26.045(10)	17.911(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
LIVER/ FINAL BODY * 100	2.755 0.158(10)	2.790 0.212(10)	2.784 0.161(10)	3.098# 0.171(10)	3.988# 0.287(10)
KIDNEYS/ FINAL BODY * 100	0.782 0.043(10)	0.732 0.087(10)	0.734 0.043(10)	0.825 0.056(10)	0.852# 0.064(10)
HEART/ FINAL BODY * 100	0.426 0.094(10)	0.378 0.032(10)	0.385 0.034(10)	0.390 0.020(10)	0.398 0.018(10)
SPLEEN/ FINAL BODY * 100	0.201 0.023(10)	0.186 0.025(10)	0.212 0.030(10)	0.194 0.028(10)	0.212 0.028(10)
BRAIN/ FINAL BODY * 100	0.689 0.049(10)	0.676 0.066(10)	0.660 0.050(10)	0.678 0.064(10)	0.696 0.039(10)
THYMUS/ FINAL BODY * 100	0.122 0.022(10)	0.091 0.022(10)	0.110 0.025(10)	0.111 0.023(10)	0.112 0.026(10)
ADRENAL GLANDS/ FINAL BODY * 100	0.027 0.004(10)	0.022* 0.007(10)	0.024 0.003(10)	0.022 0.003(10)	0.025 0.004(10)
THYROID GLAND/ FINAL BODY * 100	0.007 0.001(10)	0.007 0.002(10)	0.007 0.001(10)	0.007 0.001(10)	0.008 0.002(10)
OVARIES/ FINAL BODY * 100	0.049 0.005(10)	0.045 0.009(10)	0.048 0.012(10)	0.045 0.008(10)	0.049 0.010(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
UTERUS/					
FINAL BODY * 100	0.248	0.269	0.255	0.262	0.277
	0.064(10)	0.079(10)	0.123(10)	0.049(10)	0.111(10)

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
LIVER/					
BRAIN * 100	401.348	417.043	423.342	461.618#	573.617#
	34.727(10)	58.824(10)	33.481(10)	57.204(10)	41.766(10)
KIDNEYS/					
BRAIN * 100	113.798	108.831	111.492	122.547	122.384#
	8.306(10)	13.790(10)	5.931(10)	12.670(10)	7.831(10)
HEART/					
BRAIN * 100	62.105	56.163	58.463	58.037	57.377
	14.598(10)	4.703(10)	5.074(10)	6.592(10)	4.208(10)
SPLEEN/					
BRAIN * 100	29.353	27.759	32.243	28.670	30.410
	3.943(10)	4.468(10)	5.280(10)	3.645(10)	3.442(10)
THYMUS/					
BRAIN * 100	17.870	13.466	16.822	16.521	16.006
	3.645(10)	3.267(10)	4.325(10)	3.699(10)	3.187(10)
ADRENAL GLANDS/					
BRAIN * 100	3.862	3.188	3.631	3.260	3.613
	0.548(10)	0.905(10)	0.453(10)	0.278(10)	0.522(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)				
Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
THYROID GLAND/ BRAIN * 100	1.018	1.019	1.045	1.068	1.081
	0.159(10)	0.290(10)	0.144(10)	0.235(10)	0.211(10)
OVARIES/ BRAIN * 100	7.176	6.672	7.274	6.658	6.994
	0.857(10)	1.162(10)	1.569(10)	1.112(10)	1.301(10)
UTERUS/ BRAIN * 100	35.839	39.442	38.003	39.144	39.878
	8.615(10)	8.477(10)	14.926(10)	9.115(10)	16.348(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)

Group:	II	X
Dosage(mg/kg/day)	0	125
LIVER	10.309	10.339
	1.040(9)	1.961(10)
KIDNEYS	2.605	2.738
	0.277(9)	0.541(10)
HEART	1.332	1.234
	0.158(9)	0.175(10)
SPLEEN	0.637	0.592
	0.101(9)	0.090(10)
BRAIN	2.055	1.936
	0.102(9)	0.086(10)
THYMUS	0.239	0.269
	0.072(9)	0.102(10)
ADRENAL GLANDS	0.085	0.075
	0.020(9)	0.013(10)
THYROID GLAND	0.026	0.026
	0.007(9)	0.004(10)
OVARIES	0.131	0.123
	0.040(9)	0.035(10)
UTERUS	0.886	0.914
	0.364(9)	0.305(10)
FINAL BODY WEIGHT		
	334.033	348.920
	32.847(9)	65.818(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	II	X
Dosage(mg/kg/day)	0	125
LIVER/		
FINAL BODY * 100	3.094	2.977
	0.248(9)	0.340(10)
KIDNEYS/		
FINAL BODY * 100	0.783	0.793
	0.079(9)	0.137(10)
HEART/		
FINAL BODY * 100	0.399	0.357#
	0.040(9)	0.031(10)
SPLEEN/		
FINAL BODY * 100	0.192	0.174
	0.031(9)	0.037(10)
BRAIN/		
FINAL BODY * 100	0.619	0.570
	0.052(9)	0.096(10)
THYMUS/		
FINAL BODY * 100	0.072	0.076
	0.023(9)	0.018(10)
ADRENAL GLANDS/		
FINAL BODY * 100	0.026	0.022
	0.006(9)	0.005(10)
THYROID GLAND/		
FINAL BODY * 100	0.008	0.008
	0.002(9)	0.002(10)
OVARIES/		
FINAL BODY * 100	0.039	0.037
	0.010(9)	0.013(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	II	X
Dosage(mg/kg/day)	0	125
UTERUS/ FINAL BODY * 100	0.268	0.278
	0.107(9)	0.130(10)

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)

Group:	II	X
Dosage(mg/kg/day)	0	125
LIVER/ BRAIN * 100	501.311	533.737
	39.253(9)	96.914(10)
KIDNEYS/ BRAIN * 100	126.765	141.591
	11.614(9)	28.381(10)
HEART/ BRAIN * 100	64.848	63.675
	7.420(9)	8.079(10)
SPLEEN/ BRAIN * 100	30.944	30.642
	4.184(9)	4.777(10)
THYMUS/ BRAIN * 100	11.549	13.835
	3.111(9)	4.955(10)
ADRENAL GLANDS/ BRAIN * 100	4.118	3.882
	0.862(9)	0.689(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR RECOVERY

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)

Group:	II	X
Dosage(mg/kg/day)	0	125
THYROID GLAND/ BRAIN * 100	1.261	1.345
	0.297(9)	0.220(10)
OVARIES/ BRAIN * 100	6.330	6.355
	1.813(9)	1.650(10)
UTERUS/ BRAIN * 100	42.819	47.502
	15.794(9)	16.378(10)

TABLE 37 (CONTINUED)

MEAN FINAL BODY AND ORGAN WEIGHTS FOR FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS (10-DAY SACRIFICE)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	7.185	7.174	7.814	8.364	10.134
	0.785(5)	0.923(5)	0.582(5)	1.243(5)	1.129(5)
FINAL BODY WEIGHT	170.54	160.44	170.74	175.58	182.52
	17.825(5)	15.709(5)	16.129(5)	14.315(5)	18.060(5)
LIVER/ FINAL BODY * 100	4.213	4.473	4.589	4.748	5.557
	0.118(5)	0.355(5)	0.282(5)	0.424(5)	0.344(5)

RATS DESIGNATED FOR SATELLITE EVALUATIONS (FINAL SACRIFICE)

Group:	II	IV	VI	VIII	X
Dosage(mg/kg/day)	0	1	5	25	125
LIVER	12.444	11.897	12.711	13.527	12.729
	2.922(5)	1.637(5)	0.553(5)	3.301(5)	1.305(5)
FINAL BODY WEIGHT	325.900	336.160	335.920	366.840	359.320
	46.602(5)	29.278(5)	44.576(5)	53.771(5)	44.287(5)
LIVER/ FINAL BODY * 100	3.784	3.537	3.828	3.651	3.567
	0.445(5)	0.340(5)	0.449(5)	0.434(5)	0.402(5)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference at p < 0.05 by Jonckheere-Terpstra trend test.

TABLE 38

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (Numeric) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LIVER	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
KIDNEYS	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	9
DILATATION, RIGHT.					1
LUNGS	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
HEART	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
SKELETAL MUSCLE	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
SPLEEN	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
AORTA		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
BRAIN		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
SPINAL CORD		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
STOMACH		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
DUODENUM		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
JEJUNUM		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ILEUM		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
PANCREAS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
CECUM		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
COLON		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
RECTUM		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
MESENTERIC LYMPH NODE		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SALIVARY GLANDS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
MANDIBULAR LYMPH NODE		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
THYMUS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
ADRENAL GLANDS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
SCIATIC NERVE		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
PITUITARY GLAND		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
THYROID GLAND		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
PARATHYROID GLANDS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
TRACHEA		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
ESOPHAGUS		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
PHARYNX/LARYNX		(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
EYE(S) WITH OPTIC NERVE		(10)	(10)	(10)	(10)	(9)
NO ABNORMALITY DETECTED		10	10	10	10	9

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SKIN	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	9	10	10	10
ALOPECIA, RIGHT.		1			
PROSTATE	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
SEMINAL VESICLES	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
URINARY BLADDER	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	9	10	10
DILATATION.			1		
TESTES	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	9	10	9	10	9
SMALL, UNILATERAL.			1		1
DISCOLORATION, OPAQUE.	1				

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
EPIDIDYMIDES	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	9
SMALL, UNILATERAL.					1
FEMUR/KNEE JOINT	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
STERNUM	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
NOSE	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	TREATMENT	LESION INCIDE: Males 0 mg/kg I	125 mg/kg IX
LIVER		(10)	(10)
NO ABNORMALITY DETECTED		10	10
KIDNEYS		(10)	(10)
NO ABNORMALITY DETECTED		10	9
CALCULUS\CALCULI, RIGHT.			1
LUNGS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
HEART		(10)	(10)
NO ABNORMALITY DETECTED		10	10
SKELETAL MUSCLE		(10)	(10)
NO ABNORMALITY DETECTED		10	10
SPLEEN		(10)	(10)
NO ABNORMALITY DETECTED		10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Males — TREATMENT: 0 mg/kg I	125 mg/kg IX
AORTA	(10)	(10)
NO ABNORMALITY DETECTED	10	10
BRAIN	(10)	(10)
NO ABNORMALITY DETECTED	10	10
SPINAL CORD	(10)	(10)
NO ABNORMALITY DETECTED	10	10
STOMACH	(10)	(10)
NO ABNORMALITY DETECTED	10	10
DUODENUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10
JEJUNUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Males — TREATMENT: 0 mg/kg I	125 mg/kg IX
ILEUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10
PANCREAS	(10)	(10)
NO ABNORMALITY DETECTED	10	10
CECUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10
COLON	(10)	(10)
NO ABNORMALITY DETECTED	10	10
RECTUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10
MESENTERIC LYMPH NODE	(10)	(10)
NO ABNORMALITY DETECTED	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	TREATMENT	LESION INCIDE: Males 0 mg/kg I	125 mg/kg IX
SALIVARY GLANDS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
MANDIBULAR LYMPH NODE		(10)	(10)
NO ABNORMALITY DETECTED		10	10
THYMUS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
ADRENAL GLANDS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
SCIATIC NERVE		(10)	(10)
NO ABNORMALITY DETECTED		10	10
PITUITARY GLAND		(10)	(10)
NO ABNORMALITY DETECTED		10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Males TREATMENT	0 mg/kg I	125 mg/kg IX
THYROID GLAND		(10)	(10)
NO ABNORMALITY DETECTED		10	10
PARATHYROID GLANDS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
TRACHEA		(10)	(10)
NO ABNORMALITY DETECTED		10	10
ESOPHAGUS		(10)	(10)
NO ABNORMALITY DETECTED		10	10
PHARYNX/LARYNX		(10)	(10)
NO ABNORMALITY DETECTED		10	10
EYE(S) WITH OPTIC NERVE		(10)	(10)
NO ABNORMALITY DETECTED		10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Males — TREATMENT: 0 mg/kg I	125 mg/kg IX
SKIN	(10)	(10)
NO ABNORMALITY DETECTED	10	10
PROSTATE	(10)	(10)
NO ABNORMALITY DETECTED	10	10
SEMINAL VESICLES	(10)	(10)
NO ABNORMALITY DETECTED	10	10
URINARY BLADDER	(10)	(10)
NO ABNORMALITY DETECTED	10	10
TESTES	(10)	(10)
NO ABNORMALITY DETECTED	10	10
EPIDIDYMIDES	(10)	(10)
NO ABNORMALITY DETECTED	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Males — TREATMENT: 0 mg/kg I	125 mg/kg IX
FEMUR/KNEE JOINT	(10)	(10)
NO ABNORMALITY DETECTED	10	10
STERNUM	(10)	(10)
NO ABNORMALITY DETECTED	10	10
NOSE	(10)	(10)
NO ABNORMALITY DETECTED	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LIVER		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
KIDNEYS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
LUNGS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
HEART		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
SKELETAL MUSCLE		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
SPLEEN		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	LESION INCIDENCE (Numeric) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
AORTA	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
BRAIN	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SPINAL CORD	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
STOMACH	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
DUODENUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
JEJUNUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ILEUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PANCREAS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
CECUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
COLON	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
RECTUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
MESENTERIC LYMPH NODE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SALIVARY GLANDS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
MANDIBULAR LYMPH NODE		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
THYMUS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
ADRENAL GLANDS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
SCIATIC NERVE		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
PITUITARY GLAND		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
THYROID GLAND	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PARATHYROID GLANDS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
TRACHEA	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
ESOPHAGUS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PHARYNX/LARYNX	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
EYE(S) WITH OPTIC NERVE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SKIN	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PROSTATE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SEMINAL VESICLES	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
URINARY BLADDER	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
TESTES	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
EPIDIDYMIDES	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 38 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
FEMUR/KNEE JOINT	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
STERNUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
NOSE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LIVER		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
KIDNEYS		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
LUNGS		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
HEART		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
LARGE.		1				
SKELETAL MUSCLE		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

		LESION INCIDENCE (Numeric)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SPLEEN		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
AORTA		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
BRAIN		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
SPINAL CORD		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
STOMACH		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		10	10	10	10	10
FLUID, RED.		1				

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DUODENUM		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
JEJUNUM		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
ILEUM		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
PANCREAS		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
CECUM		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10
COLON		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
RECTUM	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
MESENTERIC LYMPH NODE	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
SALIVARY GLANDS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
MANDIBULAR LYMPH NODE	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
THYMUS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
ADRENAL GLANDS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SCIATIC NERVE	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
PITUITARY GLAND	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
THYROID GLAND	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
PARATHYROID GLANDS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
TRACHEA	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
ESOPHAGUS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ESOPHAGUS	(11)	(10)	(10)	(10)	(10)
PERFORATION.	1				
PHARYNX/LARYNX	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
EYE(S) WITH OPTIC NERVE	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
SKIN	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	10
STAIN, RED, NOSE.	1				
MAMMARY GLAND (FEMALE)	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
OVARIES	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
UTERUS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
VAGINA	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
URINARY BLADDER	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
FEMUR/KNEE JOINT	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10
STERNUM	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

		LESION INCIDENCE (Numeric)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
NOSE		(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		11	10	10	10	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=11 in Group II reflects 1 early death 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
LIVER	(9)	(10)
NO ABNORMALITY DETECTED	9	10
KIDNEYS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
LUNGS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
HEART	(9)	(10)
NO ABNORMALITY DETECTED	9	10
SKELETAL MUSCLE	(9)	(10)
NO ABNORMALITY DETECTED	9	10
SPLEEN	(9)	(10)
NO ABNORMALITY DETECTED	9	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
AORTA	(9)	(10)
NO ABNORMALITY DETECTED	9	10
BRAIN	(9)	(10)
NO ABNORMALITY DETECTED	9	10
SPINAL CORD	(9)	(10)
NO ABNORMALITY DETECTED	9	10
STOMACH	(9)	(10)
NO ABNORMALITY DETECTED	9	10
DUODENUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10
JEJUNUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
ILEUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10
PANCREAS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
CECUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10
COLON	(9)	(10)
NO ABNORMALITY DETECTED	9	10
RECTUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10
MESENTERIC LYMPH NODE	(9)	(10)
NO ABNORMALITY DETECTED	9	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
SALIVARY GLANDS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
MANDIBULAR LYMPH NODE	(9)	(10)
NO ABNORMALITY DETECTED	9	10
THYMUS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
ADRENAL GLANDS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
SCIATIC NERVE	(9)	(10)
NO ABNORMALITY DETECTED	9	10
PITUITARY GLAND	(9)	(10)
NO ABNORMALITY DETECTED	8	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
PITUITARY GLAND	(9)	(10)
LARGE.	1	
THYROID GLAND	(9)	(10)
NO ABNORMALITY DETECTED	9	10
PARATHYROID GLANDS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
TRACHEA	(9)	(10)
NO ABNORMALITY DETECTED	9	10
ESOPHAGUS	(9)	(10)
NO ABNORMALITY DETECTED	9	10
PHARYNX/LARYNX	(9)	(10)
NO ABNORMALITY DETECTED	9	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

	LESION INCIDE	
	Females	
LESIONS / TREATMENT	0 mg/kg II	125 mg/kg X
EYE(S) WITH OPTIC NERVE	(9)	(10)
NO ABNORMALITY DETECTED	9	10
SKIN	(9)	(10)
NO ABNORMALITY DETECTED	9	10
MAMMARY GLAND (FEMALE)	(9)	(10)
NO ABNORMALITY DETECTED	9	10
OVARIES	(9)	(10)
NO ABNORMALITY DETECTED	9	10
UTERUS	(9)	(10)
NO ABNORMALITY DETECTED	8	10
DILATATION.	1	

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDE: Females — TREATMENT: 0 mg/kg II	125 mg/kg X
VAGINA	(9)	(10)
NO ABNORMALITY DETECTED	9	10
URINARY BLADDER	(9)	(10)
NO ABNORMALITY DETECTED	9	10
FEMUR/KNEE JOINT	(9)	(10)
NO ABNORMALITY DETECTED	9	10
STERNUM	(9)	(10)
NO ABNORMALITY DETECTED	9	10
NOSE	(9)	(10)
NO ABNORMALITY DETECTED	9	10

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified
N=9 in Group II reflects 1 early death in 90 day time period

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LIVER	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
KIDNEYS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
LUNGS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
HEART	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SKELETAL MUSCLE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SPLEEN	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
AORTA	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
BRAIN	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SPINAL CORD	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
STOMACH	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
DUODENUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
JEJUNUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	LESION INCIDENCE (Numeric) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ILEUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PANCREAS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
CECUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
COLON	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
RECTUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
MESENTERIC LYMPH NODE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

	LESION INCIDENCE (Numeric)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SALIVARY GLANDS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
MANDIBULAR LYMPH NODE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
THYMUS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
ADRENAL GLANDS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
SCIATIC NERVE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
PITUITARY GLAND	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	TREATMENT	LESION INCIDENCE (Numeric) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
THYROID GLAND		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
PARATHYROID GLANDS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
TRACHEA		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
ESOPHAGUS		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
PHARYNX/LARYNX		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5
EYE(S) WITH OPTIC NERVE		(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	LESION INCIDENCE (Numeric) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SKIN	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
MAMMARY GLAND (FEMALE)	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
OVARIES	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
UTERUS	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
VAGINA	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
URINARY BLADDER	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 39 (CONTINUED)

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS

RATS DESIGNATED FOR SATELLITE EVALUATIONS

LESIONS	LESION INCIDENCE (Numeric) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
FEMUR/KNEE JOINT	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
STERNUM	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5
NOSE	(5)	(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED	5	5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 40

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
LIVER	(10)	(10)	(10)	(10)	(10)
NECROSIS, FOCAL.			1	5	3
INFLAMMATION, SUBACUTE/CHRONIC.	10	9	10	9	8
HYPERTROPHY, HEPATOCELLULAR.					10
FATTY CHANGE, MEDIAN CLEFT.	2	2	2	1	1
FATTY CHANGE, CENTRILOBULAR.					1
PANCREAS	(10)				(10)
NO ABNORMALITY DETECTED	8				8
ATROPHY.	2				2
ESOPHAGUS	(10)				(10)
NO ABNORMALITY DETECTED	10				10
STOMACH	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
DUODENUM	(10)				(10)
NO ABNORMALITY DETECTED	10				10
JEJUNUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
ILEUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
CECUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
COLON	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
RECTUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
SALIVARY GLANDS	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
URINARY SYSTEM					
KIDNEYS	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	5	4	3	1	
CHRONIC PROGRESSIVE NEPHROPATHY.	5	6	7	4	8
PIGMENT, TUBULAR.					1
HYPERTROPHY, TUBULAR.				9	10
HYDRONEPHROSIS, UNILATERAL.					1
CYST.				1	
URINARY BLADDER	(10)		(1)		(10)
NO ABNORMALITY DETECTED	10		1		10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM					
LUNGS	(10)				(10)
NO ABNORMALITY DETECTED	9				9
INFLAMMATION, SUBACUTE/CHRONIC.	1				1
TRACHEA	(10)				(10)
NO ABNORMALITY DETECTED	10				10
PHARYNX/LARYNX	(10)				(10)
NO ABNORMALITY DETECTED	10				10
NOSE	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	5
DEGENERATION, AMELOBLASTS.					5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CARDIOVASCULAR SYSTEM					
HEART	(10)				(10)
NO ABNORMALITY DETECTED	5				5
CARDIOMYOPATHY.	5				5
AORTA	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN	(10)				(10)
NO ABNORMALITY DETECTED	10				10
THYMUS	(10)				(10)
NO ABNORMALITY DETECTED	10				10
MANDIBULAR LYMPH NODE	(10)				(10)
NO ABNORMALITY DETECTED	10				10
MESENTERIC LYMPH NODE	(10)				(9)
NO ABNORMALITY DETECTED	10				9
BONE MARROW	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM					
PITUITARY GLAND	(9)				(10)
NO ABNORMALITY DETECTED	8				10
CYST.	1				
THYROID GLAND	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	7	2	1		2
ALTERATION, COLLOID.	3	8	9	10	8
PARATHYROID GLANDS	(9)				(9)
NO ABNORMALITY DETECTED	9				9
ADRENAL GLANDS	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
NERVOUS SYSTEM					
BRAIN	(10)				(10)
NO ABNORMALITY DETECTED	10				10
SPINAL CORD	(10)				(10)
NO ABNORMALITY DETECTED	10				10
SCIATIC NERVE	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
MUSCULAR AND SKELETAL SYSTEM					
SKELETAL MUSCLE	(10)				(10)
NO ABNORMALITY DETECTED	10				10
FEMUR/KNEE JOINT	(10)				(10)
NO ABNORMALITY DETECTED	10				10
STERNUM	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM					
TESTES	(10)		(1)		(10)
NO ABNORMALITY DETECTED	8				9
DILATATION, SEMINIFEROUS TUBULES, UNILATERAL.			1		
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL.			1		1
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL.	2				
EPIDIDYMIDES	(10)				(10)
NO ABNORMALITY DETECTED	9				9
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL.					1
OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL.	1				
PROSTATE	(10)				(10)
NO ABNORMALITY DETECTED	7				10
INFLAMMATION, SUBACUTE/CHRONIC.	3				
SEMINAL VESICLES	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CUTANEOUS SYSTEM					
SKIN	(10)	(1)			(10)
NO ABNORMALITY DETECTED	10	1			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SPECIAL SENSES SYSTEM					
EYE(S) WITH OPTIC NERVE	(10)				(10)
NO ABNORMALITY DETECTED	8				10
OPTIC NERVE NOT PRESENT.	3				1
FOLD/ROSETTE, RETINAL.	1				
ADHESION, RETINAL.	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE	
	Males	
TREATMENT	0 mg/kg I	125 mg/kg IX
DIGESTIVE SYSTEM		
LIVER	(10)	(10)
NECROSIS, FOCAL.	3	7
INFLAMMATION, SUBACUTE/CHRONIC.	9	9
HYPERPLASIA, BILE DUCT.	5	6
FATTY CHANGE, MEDIAN CLEFT.	2	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE	
	Males	
TREATMENT	0 mg/kg I	125 mg/kg IX
URINARY SYSTEM		
KIDNEYS	(10)	(10)
NO ABNORMALITY DETECTED	4	3
CHRONIC PROGRESSIVE NEPHROPATHY.	6	5
HYPERPLASIA, TRANSITIONAL CELL.		1
HYDRONEPHROSIS, UNILATERAL.		1
HYDRONEPHROSIS, BILATERAL.		1
CYST.		1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

	LESION INCIDENCE	
	Males	
LESIONS / TREATMENT	0 mg/kg I	125 mg/kg IX
RESPIRATORY SYSTEM		
NOSE	(10)	(10)
NO ABNORMALITY DETECTED	10	7
ODONTODYSPLASIA.		1
INFLAMMATION, SUBACUTE/CHRONIC.		1
DEGENERATION, AMELOBLASTS.		2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM			
THYMUS		(10)	(10)
NO ABNORMALITY DETECTED		10	10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 40 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

	LESION INCIDENCE	
	Males	
LESIONS / TREATMENT	0 mg/kg I	125 mg/kg IX
ENDOCRINE SYSTEM		
THYROID GLAND	(10)	(10)
NO ABNORMALITY DETECTED	3	
ALTERATION, COLLOID.	7	10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 41

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DIGESTIVE SYSTEM					
LIVER	(11)				(10)
NO ABNORMALITY DETECTED	1				1
INFLAMMATION, SUBACUTE/CHRONIC.	10				6
HYPERPLASIA, BILE DUCT.	2				3
FATTY CHANGE, MEDIAN CLEFT.	2				1
PANCREAS	(11)				(10)
NO ABNORMALITY DETECTED	11				9
INFLAMMATION, SUBACUTE/CHRONIC.					1
ESOPHAGUS	(11)				(10)
NO ABNORMALITY DETECTED	10				10
INFLAMMATION, SUBACUTE/CHRONIC.	1				
LACERATION.	1				
STOMACH	(11)				(10)
NO ABNORMALITY DETECTED	11				10
DUODENUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DIGESTIVE SYSTEM					
JEJUNUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
ILEUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
CECUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
COLON	(11)				(10)
NO ABNORMALITY DETECTED	11				10
RECTUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SALIVARY GLANDS	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
URINARY SYSTEM					
KIDNEYS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	7	8	7	7	1
CHRONIC PROGRESSIVE NEPHROPATHY.	2	2	3	3	7
INFLAMMATION, SUBACUTE/CHRONIC.	2	1			1
HYDRONEPHROSIS, UNILATERAL.					1
HYDRONEPHROSIS, BILATERAL.	1				
URINARY BLADDER	(11)				(10)
NO ABNORMALITY DETECTED	10				10
INFLAMMATION, SUBACUTE/CHRONIC.	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
RESPIRATORY SYSTEM					
LUNGS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
TRACHEA	(11)				(10)
NO ABNORMALITY DETECTED	11				10
PHARYNX/LARYNX	(11)				(10)
NO ABNORMALITY DETECTED	11				10
NOSE	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
CARDIOVASCULAR SYSTEM					
HEART	(11)				(10)
NO ABNORMALITY DETECTED	6				8
CARDIOMYOPATHY.	5				2
AORTA	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN	(11)				(10)
NO ABNORMALITY DETECTED	11				10
THYMUS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MANDIBULAR LYMPH NODE	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MESENTERIC LYMPH NODE	(11)				(10)
NO ABNORMALITY DETECTED	11				10
BONE MARROW	(11)				(10)
NO ABNORMALITY DETECTED	10				10
HYPERPLASIA, GRANULOCYTIC.	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ENDOCRINE SYSTEM					
PITUITARY GLAND	(11)				(10)
NO ABNORMALITY DETECTED	11				10
THYROID GLAND	(11)				(10)
NO ABNORMALITY DETECTED	11				10
PARATHYROID GLANDS	(9)				(9)
NO ABNORMALITY DETECTED	9				9
ADRENAL GLANDS	(11)				(10)
NO ABNORMALITY DETECTED	11				9
MINERALIZATION.					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
NERVOUS SYSTEM					
BRAIN	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SPINAL CORD	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SCIATIC NERVE	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
MUSCULAR AND SKELETAL SYSTEM					
SKELETAL MUSCLE	(11)				(10)
NO ABNORMALITY DETECTED	11				9
INFLAMMATION, SUBACUTE/CHRONIC.					1
FEMUR/KNEE JOINT	(11)				(10)
NO ABNORMALITY DETECTED	11				10
STERNUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
REPRODUCTIVE SYSTEM					
OVARIES	(11)				(10)
NO ABNORMALITY DETECTED	11				10
UTERUS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MAMMARY GLAND (FEMALE)	(11)				(8)
NO ABNORMALITY DETECTED	11				8

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
CUTANEOUS SYSTEM					
SKIN	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SPECIAL SENSES SYSTEM					
EYE(S) WITH OPTIC NERVE	(11)				(10)
NO ABNORMALITY DETECTED	11				9
OPTIC NERVE NOT PRESENT.					1
FOLD/ROSETTE, RETINAL.					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Females TREATMENT	0 mg/kg II	125 mg/kg X
DIGESTIVE SYSTEM			
LIVER		(9)	(10)
NO ABNORMALITY DETECTED		3	2
NECROSIS, FOCAL.		1	
INFLAMMATION, SUBACUTE/CHRONIC.		3	6
HYPERPLASIA, BILE DUCT.		1	1
FATTY CHANGE, MEDIAN CLEFT.		2	1
ANGIECTASIS.			2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

	LESION INCIDENCE	
	Females	
LESIONS / TREATMENT	0 mg/kg II	125 mg/kg X
URINARY SYSTEM		
KIDNEYS	(9)	(10)
NO ABNORMALITY DETECTED	4	2
CHRONIC PROGRESSIVE NEPHROPATHY.	5	8
HYDRONEPHROSIS, BILATERAL.		1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Females TREATMENT	0 mg/kg II	125 mg/kg X
ENDOCRINE SYSTEM			
PITUITARY GLAND		(1)	
NO ABNORMALITY DETECTED		1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 41 (CONTINUED)

INCIDENCES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NEOPLASTIC AND NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Females TREATMENT	0 mg/kg II	125 mg/kg X
REPRODUCTIVE SYSTEM			
UTERUS		(1)	
DILATATION.		1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 42

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
LIVER	(10)	(10)	(10)	(10)	(10)
NECROSIS, FOCAL.					
minimal			1	5	3
total observations per lesion			1	5	3
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	10	9	10	9	8
total observations per lesion	10	9	10	9	8
HYPERTROPHY, HEPATOCELLULAR.					
minimal					4
mild					6
total observations per lesion					10
FATTY CHANGE, MEDIAN CLEFT.					
minimal	2	2	1	1	1
mild			1		
total observations per lesion	2	2	2	1	1
FATTY CHANGE, CENTRILOBULAR.					
minimal					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
PANCREAS	(10)				(10)
NO ABNORMALITY DETECTED	8				8
ATROPHY.					
minimal	2				2
total observations per lesion	2				2
ESOPHAGUS	(10)				(10)
NO ABNORMALITY DETECTED	10				10
STOMACH	(10)				(10)
NO ABNORMALITY DETECTED	10				10
DUODENUM	(10)				(10)
NO ABNORMALITY DETECTED	10				10
JEJUNUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM					
ILEUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
CECUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
COLON	(10)				(10)
NO ABNORMALITY DETECTED	10				10
RECTUM	(10)				(9)
NO ABNORMALITY DETECTED	10				9
SALIVARY GLANDS	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
URINARY SYSTEM					
KIDNEYS	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	5	4	3	1	
CHRONIC PROGRESSIVE NEPHROPATHY.					
minimal	5	6	7	4	8
total observations per lesion	5	6	7	4	8
PIGMENT, TUBULAR.					
minimal					1
total observations per lesion					1
HYPERTROPHY, TUBULAR.					
minimal				9	10
total observations per lesion				9	10
HYDRONEPHROSIS, UNILATERAL.					
minimal					1
total observations per lesion					1
CYST.					
minimal				1	
total observations per lesion				1	
URINARY BLADDER	(10)		(1)		(10)
NO ABNORMALITY DETECTED	10		1		10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM					
LUNGS	(10)				(10)
NO ABNORMALITY DETECTED	9				9
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	1				1
total observations per lesion	1				1
TRACHEA	(10)				(10)
NO ABNORMALITY DETECTED	10				10
PHARYNX/LARYNX	(10)				(10)
NO ABNORMALITY DETECTED	10				10
NOSE	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	10	5
DEGENERATION, AMELOBLASTS.					
minimal					2
mild					3
total observations per lesion					5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CARDIOVASCULAR SYSTEM					
HEART	(10)				(10)
NO ABNORMALITY DETECTED	5				5
CARDIOMYOPATHY.					
minimal	5				5
total observations per lesion	5				5
AORTA	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN	(10)				(10)
NO ABNORMALITY DETECTED	10				10
THYMUS	(10)				(10)
NO ABNORMALITY DETECTED	10				10
MANDIBULAR LYMPH NODE	(10)				(10)
NO ABNORMALITY DETECTED	10				10
MESENTERIC LYMPH NODE	(10)				(9)
NO ABNORMALITY DETECTED	10				9
BONE MARROW	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM					
PITUITARY GLAND	(9)				(10)
NO ABNORMALITY DETECTED	8				10
CYST.					
minimal	1				
total observations per lesion	1				
THYROID GLAND	(10)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	7	2	1		2
ALTERATION, COLLOID.					
minimal	3	7	9	10	3
mild		1			2
moderate					1
severe					2
total observations per lesion	3	8	9	10	8

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM					
PARATHYROID GLANDS	(9)				(9)
NO ABNORMALITY DETECTED	9				9
ADRENAL GLANDS	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
NERVOUS SYSTEM					
BRAIN	(10)				(10)
NO ABNORMALITY DETECTED	10				10
SPINAL CORD	(10)				(10)
NO ABNORMALITY DETECTED	10				10
SCIATIC NERVE	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
MUSCULAR AND SKELETAL SYSTEM					
SKELETAL MUSCLE	(10)				(10)
NO ABNORMALITY DETECTED	10				10
FEMUR/KNEE JOINT	(10)				(10)
NO ABNORMALITY DETECTED	10				10
STERNUM	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM					
TESTES	(10)		(1)		(10)
NO ABNORMALITY DETECTED	8				9
DILATATION, SEMINIFEROUS TUBULES, UNILATERAL.					
moderate			1		
total observations per lesion			1		
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL.					
mild			1		
moderate					1
total observations per lesion			1		1
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL.					
minimal	1				
severe	1				
total observations per lesion	2				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Males				
TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM					
EPIDIDYMIDES	(10)				(10)
NO ABNORMALITY DETECTED	9				9
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL.					
severe					1
total observations per lesion					1
OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL.					
severe	1				
total observations per lesion	1				
PROSTATE	(10)				(10)
NO ABNORMALITY DETECTED	7				10
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	3				
total observations per lesion	3				
SEMINAL VESICLES	(10)				(10)
NO ABNORMALITY DETECTED	10				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CUTANEOUS SYSTEM					
SKIN	(10)	(1)			(10)
NO ABNORMALITY DETECTED	10	1			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SPECIAL SENSES SYSTEM					
EYE(S) WITH OPTIC NERVE	(10)				(10)
NO ABNORMALITY DETECTED	8				10
OPTIC NERVE NOT PRESENT.	3				1
FOLD/ROSETTE, RETINAL.					
minimal	1				
total observations per lesion	1				
ADHESION, RETINAL.					
minimal	1				
total observations per lesion	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
DIGESTIVE SYSTEM			
LIVER		(10)	(10)
NECROSIS, FOCAL.			
minimal		2	6
mild		1	1
total observations per lesion		3	7
INFLAMMATION, SUBACUTE/CHRONIC.			
minimal		8	9
mild		1	
total observations per lesion		9	9
HYPERPLASIA, BILE DUCT.			
minimal		5	6
total observations per lesion		5	6
FATTY CHANGE, MEDIAN CLEFT.			
minimal		2	
total observations per lesion		2	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
URINARY SYSTEM			
KIDNEYS		(10)	(10)
NO ABNORMALITY DETECTED		4	3
CHRONIC PROGRESSIVE NEPHROPATHY.			
minimal		6	5
total observations per lesion		6	5
HYPERPLASIA, TRANSITIONAL CELL.			
minimal			1
total observations per lesion			1
HYDRONEPHROSIS, UNILATERAL.			
minimal			1
total observations per lesion			1
HYDRONEPHROSIS, BILATERAL.			
minimal			1
total observations per lesion			1
CYST.			
minimal			1
total observations per lesion			1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
RESPIRATORY SYSTEM			
NOSE		(10)	(10)
NO ABNORMALITY DETECTED		10	7
ODONTODYSPLASIA.			
moderate			1
total observations per lesion			1
INFLAMMATION, SUBACUTE/CHRONIC.			
mild			1
total observations per lesion			1
DEGENERATION, AMELOBLASTS.			
minimal			2
total observations per lesion			2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM			
THYMUS		(10)	(10)
NO ABNORMALITY DETECTED		10	10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 42 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Males TREATMENT	0 mg/kg I	125 mg/kg IX
ENDOCRINE SYSTEM			
THYROID GLAND		(10)	(10)
NO ABNORMALITY DETECTED		3	
ALTERATION, COLLOID.			
minimal		5	6
mild		1	2
moderate		1	2
total observations per lesion		7	10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 43

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DIGESTIVE SYSTEM					
LIVER	(11)				(10)
NO ABNORMALITY DETECTED	1				1
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	10				6
total observations per lesion	10				6
HYPERPLASIA, BILE DUCT.					
minimal	2				3
total observations per lesion	2				3
FATTY CHANGE, MEDIAN CLEFT.					
minimal	2				1
total observations per lesion	2				1
PANCREAS	(11)				(10)
NO ABNORMALITY DETECTED	11				9
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DIGESTIVE SYSTEM					
ESOPHAGUS	(11)				(10)
NO ABNORMALITY DETECTED	10				10
INFLAMMATION, SUBACUTE/CHRONIC.					
severe	1				
total observations per lesion	1				
LACERATION.	1				
STOMACH	(11)				(10)
NO ABNORMALITY DETECTED	11				10
DUODENUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
JEJUNUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DIGESTIVE SYSTEM					
ILEUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
CECUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
COLON	(11)				(10)
NO ABNORMALITY DETECTED	11				10
RECTUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SALIVARY GLANDS	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
URINARY SYSTEM					
KIDNEYS	(11)	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	7	8	7	7	1
CHRONIC PROGRESSIVE NEPHROPATHY.					
minimal	2	2	3	3	7
total observations per lesion	2	2	3	3	7
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	2	1			1
total observations per lesion	2	1			1
HYDRONEPHROSIS, UNILATERAL.					
minimal					1
total observations per lesion					1
HYDRONEPHROSIS, BILATERAL.					
minimal	1				
total observations per lesion	1				
URINARY BLADDER	(11)				(10)
NO ABNORMALITY DETECTED	10				10
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal	1				
total observations per lesion	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
RESPIRATORY SYSTEM					
LUNGS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
TRACHEA	(11)				(10)
NO ABNORMALITY DETECTED	11				10
PHARYNX/LARYNX	(11)				(10)
NO ABNORMALITY DETECTED	11				10
NOSE	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
CARDIOVASCULAR SYSTEM					
HEART	(11)				(10)
NO ABNORMALITY DETECTED	6				8
CARDIOMYOPATHY.					
minimal	5				2
total observations per lesion	5				2
AORTA	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN	(11)				(10)
NO ABNORMALITY DETECTED	11				10
THYMUS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MANDIBULAR LYMPH NODE	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MESENTERIC LYMPH NODE	(11)				(10)
NO ABNORMALITY DETECTED	11				10
BONE MARROW	(11)				(10)
NO ABNORMALITY DETECTED	10				10
HYPERPLASIA, GRANULOCYTIC.					
mild	1				
total observations per lesion	1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ENDOCRINE SYSTEM					
PITUITARY GLAND	(11)				(10)
NO ABNORMALITY DETECTED	11				10
THYROID GLAND	(11)				(10)
NO ABNORMALITY DETECTED	11				10
PARATHYROID GLANDS	(9)				(9)
NO ABNORMALITY DETECTED	9				9
ADRENAL GLANDS	(11)				(10)
NO ABNORMALITY DETECTED	11				9
MINERALIZATION.					
minimal					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
NERVOUS SYSTEM					
BRAIN	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SPINAL CORD	(11)				(10)
NO ABNORMALITY DETECTED	11				10
SCIATIC NERVE	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
MUSCULAR AND SKELETAL SYSTEM					
SKELETAL MUSCLE	(11)				(10)
NO ABNORMALITY DETECTED	11				9
INFLAMMATION, SUBACUTE/CHRONIC.					
minimal					1
total observations per lesion					1
FEMUR/KNEE JOINT	(11)				(10)
NO ABNORMALITY DETECTED	11				10
STERNUM	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
REPRODUCTIVE SYSTEM					
OVARIES	(11)				(10)
NO ABNORMALITY DETECTED	11				10
UTERUS	(11)				(10)
NO ABNORMALITY DETECTED	11				10
MAMMARY GLAND (FEMALE)	(11)				(8)
NO ABNORMALITY DETECTED	11				8

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

LESIONS	LESION INCIDENCE (NUMERIC) Females				
TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
CUTANEOUS SYSTEM					
SKIN	(11)				(10)
NO ABNORMALITY DETECTED	11				10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR SUBCHRONIC TOXICITY

	LESION INCIDENCE (NUMERIC)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SPECIAL SENSES SYSTEM					
EYE(S) WITH OPTIC NERVE	(11)				(10)
NO ABNORMALITY DETECTED	11				9
OPTIC NERVE NOT PRESENT.					1
FOLD/ROSETTE, RETINAL.					
minimal					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=11 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Females TREATMENT	0 mg/kg II	125 mg/kg X
DIGESTIVE SYSTEM			
LIVER		(9)	(10)
NO ABNORMALITY DETECTED		3	2
NECROSIS, FOCAL.			
minimal		1	
total observations per lesion		1	
INFLAMMATION, SUBACUTE/CHRONIC.			
minimal		3	6
total observations per lesion		3	6
HYPERPLASIA, BILE DUCT.			
minimal		1	1
total observations per lesion		1	1
FATTY CHANGE, MEDIAN CLEFT.			
minimal		1	
mild		1	1
total observations per lesion		2	1
ANGIECTASIS.			
minimal			2
total observations per lesion			2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE Females TREATMENT	0 mg/kg II	125 mg/kg X
URINARY SYSTEM			
KIDNEYS		(9)	(10)
NO ABNORMALITY DETECTED		4	2
CHRONIC PROGRESSIVE NEPHROPATHY.			
minimal		5	5
mild			3
total observations per lesion		5	8
HYDRONEPHROSIS, BILATERAL.			
minimal			1
total observations per lesion			1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

LESIONS	LESION INCIDENCE	
	Females	
TREATMENT	0 mg/kg II	125 mg/kg X
ENDOCRINE SYSTEM		
PITUITARY GLAND	(1)	
NO ABNORMALITY DETECTED	1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

TABLE 43 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS

RATS DESIGNATED FOR RECOVERY

	LESION INCIDENCE	
	Females	
LESIONS	TREATMENT	0 mg/kg II	125 mg/kg X
REPRODUCTIVE SYSTEM		
UTERUS		(1)	
DILATATION.			
mild		1	
total observations per lesion		1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
N=9 IN GROUP II DUE TO EARLY DEATH

FIGURES

FIGURES

EXPLANATORY NOTES

Critical Dates

Day 91
- Last day of test substance administration for rats designated for satellite bleeds and 3-month recovery.
- Last day of non-fasted body weight and food consumption data collection for rats designated for the 90-day exposure period.
- Last day of food consumption data collection for rats designated for satellite bleeds in the 1, 5, and 25 mg/kg/day dose groups.

Day 92 Last day of test substance administration for male rats designated for the 90-day exposure period.

Day 93
- Last day of test substance administration for female rats designated for the 90-day exposure period.
- Male rats designated for the 90-day exposure period were sacrificed.

Day 94 Female rats designated for 90-day exposure period were sacrificed.

Day 175 Rats designated for satellite bleeds were sacrificed

Day 182 Last day of non-fasted body weight and food consumption data collection for rats designated for the 3-month recovery period.

Day 183 Male and female rats designated for the 3-month recovery period were sacrificed.

FIGURE 1

MEAN BODY WEIGHTS OF MALE RATS



FIGURE 2

MEAN BODY WEIGHTS OF FEMALE RATS



FIGURE 3

MEAN FORELIMB GRIP STRENGTH FOR MALE RATS



Error bars represent standard deviation

FIGURE 4

MEAN FORELIMB GRIP STRENGTH FOR FEMALE RATS



Error bars represent standard deviation
* Statistically significant difference from control at $p<0.05$.

FIGURE 5

MEAN HINDLIMB GRIP STRENGTH FOR MALE RATS



Error bars represent standard deviation

FIGURE 6

MEAN HINDLIMB GRIP STRENGTH FOR FEMALE RATS



Error bars represent standard deviation

FIGURE 7

MEAN TOTAL DURATION OF MOVEMENT FOR MALE RATS



Error bars represent standard deviation

FIGURE 8

MEAN TOTAL DURATION OF MOVEMENT FOR FEMALE RATS



Error bars represent standard deviation

FIGURE 9

MEAN TOTAL NUMBER OF MOVEMENTS FOR MALE RATS



Error bars represent standard deviation.
* Statistically significant difference from control at $p<0.05$.

FIGURE 10

MEAN TOTAL NUMBER OF MOVEMENTS FOR FEMALE RATS



Error bars represent standard deviation

APPENDICES

APPENDICES

EXPLANATORY NOTES

Critical Dates

Day 91
- Last day of test substance administration for rats designated for satellite bleeds and 3-month recovery.
- Last day of non-fasted body weight and food consumption data collection for rats designated for the 90-day exposure period.
- Last day of food consumption data collection for rats designated for satellite bleeds in the 1, 5, and 25 mg/kg/day dose groups.

Day 92 Last day of test substance administration for male rats designated for the 90-day exposure period.

Day 93
- Last day of test substance administration for female rats designated for the 90-day exposure period.
- Male rats designated for the 90-day exposure period were sacrificed.

Day 94 Female rats designated for 90-day exposure period were sacrificed.

Day 175 Rats designated for satellite bleeds were sacrificed

Day 182 Last day of non-fasted body weight and food consumption data collection for rats designated for the 3-month recovery period.

Day 183 Male and female rats designated for the 3-month recovery period were sacrificed.

Note

mg/kg = mg/kg/day

APPENDIX A

ANALYTICAL DATA

Table I. Homogeneity and Stability of 8-2 Telomer B Alcohol in Dosing Suspensions

Sample Type	mg/mL 8-2 Telomer B Alcohol		Percent
	Nominal	Measured	Nominal
Test Day 1/-6			
Homogeneity			
CONTROL	0.00	ND(A)	----
TOP	0.20	0.163	81.5
MIDDLE	0.20	0.164	82.0
BOTTOM	0.20	0.161	80.5
		Mean(B)***: 0.163±0.002***	***(81.5%)***
		C.V. 1%	
TOP	1.0	0.803	80.3
MIDDLE	1.0	0.857	85.7
BOTTOM	1.0	0.890	89.0
		Mean(B)***: 0.850±0.04***	***(85.0%)***
		C.V. 5%	
TOP	5.0	4.55	91.0
MIDDLE	5.0	4.80	96.0
BOTTOM	5.0	4.61	92.2
		Mean(B)***: 4.65±0.13***	***(93.0%)***
		C.V. 3%	
TOP	25.0	19.9(C)	79.6
MIDDLE	25.0	21.9	87.6
BOTTOM	25.0	22.9	91.6
		Mean(B)***: 21.6±1.5***	***(86.4%)***
		C.V. 7%	
Stability			
5 HOUR(D)	0.20	0.167	83.5
	1.0	0.818	81.8
	5.0	4.14	82.8
	25.0	21.8	87.2
7-DAY REFRIGERATED	0.2	0.161	80.5
	0.2	0.173	86.5
		Mean(E)***: 0.167±0.01***	***(83.5%)***
		C.V. 5%	
5 HOUR(D)	0.2	0.158(C)	79.0

(A) Denotes not detected.
(B) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation of top, middle, and bottom.
(C) Duplicate reanalysis of original sample support original analysis and are not reported.
(D) Stability samples held 5 hours a room temperature.
(E) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation of duplicate samples.

Table I. Homogeneity and Stability of 8-2 Telomer B Alcohol in Dosing Suspensions (continued)

Sample Type	mg/mL 8-2 Telomer B Alcohol Nominal	Measured	Percent Nominal
Test Day 4(F)			
Homogeneity			
CONTROL	0.00	ND(A)	----
TOP	1.0	0.944	94.4
MIDDLE	1.0	0.884	88.4
BOTTOM	1.0	0.836 (C)	83.6
		Mean*(B): *0.888+0.05	***(88.8%)***
		C.V. 6%	
TOP	5.0	4.43	88.6
MIDDLE	5.0	4.37	87.4
BOTTOM	5.0	4.72 (C)	94.4
		Mean*(B): *4.51±0.19	***(90.2%)***
		C.V. 4%	
TOP	25.0	22.2	88.8
MIDDLE	25.0	22.7	90.8
BOTTOM	25.0	24.2	96.8
		Mean*(B): *23.0±1.0	***(92.0%)***
		C.V. 5%	
Stability			
5 HOUR(D)	1.0	0.854(G)	85.4
	5.0	4.75	95.0
	25.0	24.0	96.0
7-DAY REFRIGERATED			
TOP	1.0	0.900	90.0
MIDDLE	1.0	0.864	86.4
BOTTOM	1.0	0.859	85.9
		Mean*(B): *0.874±0.02	***(87.4%)***
		C.V. 3%	
#1	5.0	4.46	89.2
#2	5.0	4.44	88.8
		Mean*(E): *4.45±0.01	***(89.0%)***
		C.V. 0.2%	
#1	25.0	24.2	96.8
#2	25.0	23.9	95.6
		Mean*(E): *24.1±0.21	***(96.4%)***
		C.V. 1%	
5 HOUR(D)	1.0	0.904(H)	90.4
	5.0	4.21(H)	84.2
	25.0	21.2(H)	84.8

(A) Denotes not detected.
(B) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation of top, middle, and bottom.
(C) Duplicate reanalysis of original sample support original analysis and are not reported..
(D) Stability samples held 5 hours a room temperature.
(E) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.
(F) Samples analyzed in a previous study (HA-2001- 037/MR 13690/SC1583).
(G) Mean result of all reported analyses except for one duplicate repeat sample. Aliquot error caused result to be low.
(H) Mean result of duplicate re-sampling from the original diluted sample. Original result was lower than expected due to aliquot error.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions

Preparation Day / Sample Type	mg/mL 8-2 Telomer B Alcohol Nominal	Measured	Percent Nominal
Test Day 42			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1(O)	0.153	76.5
	0.2-1(1)	0.158	79.0
	0.2-1(2)	0.158	79.0
	***mean*[C]:**	**0.156**	**78.0**
	0.2-2(O)	0.167	83.5
	0.2-2(1)	0.170	85.0
	0.2-2(2)	0.169	84.5
	***mean*[C]:**	**0.169**	**84.5**
	***Mean*[D]:**	***0.163 ± 0.01***	***(81.5)***
		C.V. 6%	
	1.0-1(O)	0.718	71.8
	1.0-1(1)	0.757	75.7
	1.0-1(2)	0.773	77.3
	***mean*[C]:**	**0.749**	**74.9**
	1.0-2(O)	0.764	76.4
	1.0-2(1)	0.779	77.9
	1.0-2(2)	0.784	78.4
	***mean*[C]:**	**0.776**	**77.6**
	***Mean*[D]:**	***0.763 ± 0.02***	***(76.3)***
		C.V. 3%	
	5.0-1(O)	3.89	77.8
	5.0-1(1)	3.82	76.4
	5.0-1(2)	3.89	77.8
	***mean*[C]:**	**3.87**	**77.3**
	5.0-2(1)	3.89	77.8
	5.0-2(2)	3.93	78.6
	***mean*[E]:**	**3.91**	**78.2**
	***Mean*[D]:**	***3.89 ± 0.03***	***(77.8)***
		C.V. 1%	
	25.0-1(1)	19.4	77.6
	25.0-1(2)	19.4	77.6
	***mean*[E]:**	**19.4**	**77.6**
	25.0-2(1)	19.3	77.2
	25.0-2(2)	18.8	75.2
	***mean*[E]:**	**19.1**	**76.2**
	***Mean*[D]:**	***19.3 ± 0.21***	***(77.2)***
		C.V. 1%	

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(C) Mean result of the original analysis [(O)], and duplicate reanalysis of the original sample [(1), (2)].
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples
(E) Mean result of duplicate reanalysis on the original submitted sample [(1), (2)]. Original analysis not reported due to aliquot error.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day	mg/mL 8-2 Telomer B Alcohol		Percent
Sample Type	Nominal	Measured	Nominal
Test Day 45			
Concentration Verification(A)			
Control	0.0	ND(B)	----
	0.2-1(O)	0.065	32.5
	0.2-1(1)	0.067	33.5
	0.2-1(2)	0.065	32.5
	mean(C)***:***	**0.066**	**33.0**
	0.2-2(O)	0.081	40.5
	0.2-2(1)	0.083	41.5
	0.2-2(2)	0.084	42.0
	mean(C)***:***	**0.083**	**41.5**
	Mean(D)***:***	***0.075 ± 0.01***	***(37.5)***
		C.V. 13%	
	1.0-1(O)	0.662	66.2
	1.0-1(1)	0.678	67.8
	1.0-1(2)	0.687	68.7
	mean(C)***:***	**0.676**	**67.6**
	1.0-2(O)	0.646	64.6
	1.0-2(1)	0.657	65.7
	1.0-2(2)	0.665	66.5
	mean(C)***:***	**0.656**	**65.6**
	Mean(D)***:***	***0.666 ± 0.01***	***(66.6)***
		C.V. 2%	
	5.0-1(O)	2.13	42.6
	5.0-1(1)	2.27	45.4
	5.0-1(2)	2.21	44.2
	mean(C)***:***	**2.20**	**44.0**
	5.0-2(O)	2.26	45.2
	5.0-2(1)	2.36	47.2
	5.0-2(2)	2.33	46.6
	mean(C)***:***	**2.32**	**46.4**
	Mean(D)***:***	***2.26 ± 0.09***	***(45.2)***
		C.V. 4%	
	25.0-1(1)	8.31	33.2
	25.0-1(2)	8.36	33.4
	mean(E)***:***	**8.34**	**33.4**
	25.0-2(1)	8.76	35.0
	25.0-2(2)	8.52	34.1
	mean(E)***:***	**8.64**	**34.6**
	Mean(D)***:***	***8.49 ± 0.21***	***(34.0)***
		C.V. 3%	

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(C) Mean result of the original analysis [(O)], and duplicate reanalysis of the original sample [(1), (2)].
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.
(E) Mean result of duplicate reanalysis on the original submitted sample [(1), (2)]. Original analysis not reported due to aliquot error.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day	mg/mL 8-2 Telomer B Alcohol		Percent
Sample Type	Nominal	Measured	Nominal
Test Day 48[F]			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.197	98.5
	0.2-2	0.219	109.5
	Mean[D]:	***0.208 ± 0.02 C.V. 7%***	***(104.0)***
	1.0-1	0.865	86.5
	1.0-2	0.948	94.8
	Mean[D]:	***0.907 ± 0.06 C.V. 6%***	***(90.7)***
	5.0-1	3.93	78.6
	5.0-2	3.90	78.0
	Mean[D]:	***3.92 ± 0.02 C.V. 1%***	***(78.3)***
	25.0-1	21.9	87.6
	25.0-2	22.5	90.0
	Mean[D]:	***22. 2± 0.42 C.V. 2%***	***(88.8)***
Test Day 52			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.174	87.0
	0.2-2	0.184	92.0
	Mean[D]:	***0.179 ± 0.01 C.V. 4%***	***(89.5)***
	1.0-1	0.845	84.5
	1.0-2	0.895	89.5
	Mean[D]:	***0.870 ± 0.04 C.V. 4%***	***(87.0)***
	5.0-1	4.22	84.4
	5.0-2	4.16	83.2
	Mean[D]:	***4.19 ± 0.04 C.V. 1%***	***(83.8)***
	25.0-1	23.5	94.0
	25.0-2	22.3	89.2
	Mean[D]:	***22.9± 0.85 C.V. 4%***	***(91.6)***

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.
(F) Suspension not dosed to animals.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day	mg/mL 8-2 Telomer B Alcohol		Percent
Sample Type	Nominal	Measured	Nominal
Test Day 56			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.167	83.5
	0.2-2	0.189	94.5
	Mean[D]:	***0.178 ± 0.02 C.V. 9%***	***(89.0)***
	1.0-1	0.964	96.4
	1.0-2	0.950	95.0
	Mean[D]:	***0.957 ± 0.01 C.V. 1%***	***(95.7)***
	5.0-1	4.41	88.2
	5.0-2	4.31	86.2
	Mean[D]:	***4.36 ± 0.07 C.V. 2%***	***(87.2)***
	25.0-1	22.8	91.2
	25.0-2	21.4	85.6
	Mean[D]:	***22. 1± 0.99 C.V. 4%***	***(88.4)***
Test Day 58			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.174	87.0
	0.2-2	0.150	75.0
	Mean[D]:	***0.162 ± 0.02 C.V. 10%***	***(81.0)***
	1.0-1	0.945	94.5
	1.0-2	0.937	93.7
	Mean[D]:	***0.941 ± 0.01 C.V. 1%***	***(94.1)***
	5.0-1	4.48	89.6
	5.0-2	4.17	83.4
	Mean[D]:	***4.33 ± 0.22 C.V. 5%***	***(86.5)***
	25.0-1	22.5	90.0
	25.0-2	22.1	88.4
	Mean[D]:	***22. 3± 0.28 C.V. 1%***	***(89.2)***

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day Sample Type	mg/mL 8-2 Telomer B Alcohol Nominal	 Measured	Percent Nominal
Test Day 65			
Concentration Verification(A)			
Control	0.0	ND(B)	----
	0.2-1(O)	0.158	79.0
	0.2-1(1)	0.158	79.0
	0.2-1(2)	0.162	81.0
	***mean*(C):**	**0.159**	**79.5**
	0.2-2(O)	0.148	74.0
	0.2-2(1)	0.149	74.5
	0.2-2(2)	0.153	76.5
	***mean*(C):**	**0.150**	**75.0**
	***Mean*(D):**	***0.155 ± 0.01***	***(77.5)***
		C.V. 4%	
	1.0-1	0.832	83.2
	1.0-2	0.898	89.8
	***Mean*(D):**	***0.865 ± 0.05***	***(86.5)***
		C.V. 5%	
	5.0-1	4.32	86.4
	5.0-2	4.40	88.0
	***Mean*(D):**	***4.36 ± 0.06***	***(87.2)***
		C.V. 1%	
	25.0-1	20.8	83.2
	25.0-2	20.5	82.0
	***Mean*(D):**	***20.7± 0.21***	***(82.6)***
		C.V. 1%	

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(C) Mean result of the original analysis [(O)], and duplicate reanalysis of the original sample [(1), (2)].
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day / Sample Type	mg/mL 8-2 Telomer B Alcohol Nominal	Measured	Percent Nominal
Test Day 91			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.162	81.0
	0.2-2	0.165	82.5
	Mean[D]:	***0.164 ± 0.002***	***(82.0)***
		C.V. 1%	
	1.0-1(O)	0.781	78.1
	1.0-1(1)	0.744	74.4
	1.0-1(2)	0.754	75.4
	mean[C]:	**0.760**	**76.0**
	1.0-2	0.863	86.3
	Mean[D]:	***0.812 ± 0.07***	***(81.2)***
		C.V. 9%	
	5.0-1(O)	3.90	78.0
	5.0-1(1)	4.07	81.4
	5.0-1(2)	3.91	78.2
	mean[C]:	**3.96**	**79.2**
	5.0-2(O)	3.81	76.2
	5.0-2(1)	3.98	79.6
	5.0-2(2)	3.90	78.0
	mean[C]:	**3.90**	**78.0**
	Mean[D]:	***3.93 ± 0.04***	***(78.6)***
		C.V. 1%	
	25.0-1(O)	19.1	76.4
	25.0-1(1)	20.3	81.2
	25.0-1(2)	20.2	80.8
	mean[C]:	**19.9**	**76.4**
	25.0-2(O)	18.8	75.2
	25.0-2(1)	18.9	75.6
	25.0-2(2)	18.4	73.6
	mean[C]:	**18.7**	**74.8**
	Mean[D]:	***19.3 ± 0.85***	***(77.2)***
		C.V. 4%	

(A) Duplicate samples (-1,-2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(C) Mean result of the original analysis [(O)], and duplicate reanalysis of the original sample [(1), (2)].
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.

Table II. Concentration Verification of 8-2 Telomer B Alcohol in Dosing Solutions (continued)

Preparation Day / Sample Type	mg/mL 8-2 Telomer B Alcohol Nominal	Measured	Percent Nominal
Test Day 63			
Concentration Verification[A]			
Control	0.0	ND[B]	----
	0.2-1	0.190	95.0
	0.2-2	0.192	96.0
	Mean[C]:	***0.191 ± 0.001***	***(95.5)***
		C.V. 1%	
	1.0-1	0.784	78.4
	1.0-2	0.792	79.2
	Mean[C]:	***0.788 ± 0.01***	***(78.8)***
		C.V. 1%	
	5.0-1	4.12	82.4
	5.0-2	4.08	81.8
	Mean[C]:	***4.10 ± 0.03***	***(82.0)***
		C.V. 1%	
	25.0-1	23.0	92.0
	25.0-2	21.4	85.6
	Mean[C]:	***22.2 ± 1.1***	***(88.8)***
		C.V. 5%	
Test Day 73			
Concentration Verification[B]			
Control	0.0	ND[C]	----
	0.2-1	0.176	88.0
	0.2-2	0.155	77.5
	Mean[C]:	***0.166 ± 0.01***	***(82.8)***
		C.V. 9%	
	1.0-1	0.980	98.0
	1.0-2	1.03	103.0
	Mean[C]:	***1.01 ± 0.04***	***(101.0)***
		C.V. 4%	
	5.0-1	4.57	91.4
	5.0-2	4.60	92.0
	Mean[D]:	***4.59 ± 0.02***	***(91.8)***
		C.V. 0.4%	
	25.0-1	23.3	93.2
	25.0-2	24.4	97.6
	Mean[C]:	***23.9 ± 0.78***	***(95.6)***
		C.V. 3%	

(A) Duplicate samples (-1, -2) per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(D) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation for duplicate samples.

Figure 1
Representative Analytical Calibration Curve



Figure 1: Calibration curve showing linear fit (line) to replicate peak height ratio measurements (squares) for calibration solutions of 8-2 Telomer B Alcohol diluted over a concentration range of 0.0050 to 0.0453 mg/mL with the 0 mg/mL control diluted sample was used as the zero.

Figure 2
Representative High Performance Liquid Chromatography Chromatograms



Figure 2a: Representative HPLC chromatogram of 0 mg/mL (control) sample with internal standard (1H,1H,2H,2H-perfluoro-9-methyldecan-1-ol) added. Retention time for 8-2 Telomer B Alcohol is approximately 3.5 minutes. Retention time for internal standard is approximately 3.9 minutes.



Figure 2b: Representative HPLC chromatogram of 5.0 mg/mL 8-2 Telomer B Alcohol dosing solution diluted to a nominalconcentration of 0.03 mg/mL. The measured concentration of the representative solution is 4.85 mg/mL



Figure 2c: Representative HPLC chromatogram of 0.0302 mg/mL 8-2 Telomer B Alcohol analytical reference solution.

TRADE SECRET

Study Title

8-2 Telomer B Alcohol: Subchronic Toxicity
90-Day Oral Gavage Study in Rats

Volume 2 of 3

Laboratory Project ID: DuPont-9478

TEST GUIDELINES: U.S. EPA Health Effects Test Guidelines
OPPTS 870.3100 (1998)

AUTHOR: Gregory S. Ladics, Ph.D

STUDY COMPLETED ON: April 1, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER: 13690

SERVICE CODE NUMBER: 1022

APPENDIX B

INDIVIDUAL DOSE VOLUMES

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, I 0 mg/kg/day												
654928	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654993	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.3	1.3	1.3
654929	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654972	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654950	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654953	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.9	1.9	1.9	1.9	1.9
654925	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654987	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654903	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654966	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654997	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654971	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
654939	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654919	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654994	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
654949	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654992	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654909	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654924	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654943	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654915	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654927	2.1	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6
654956	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.3	1.3	1.3
654910	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654936	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, I 0 mg/kg/day												
654928	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654993	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654929	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
654972	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654950	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654953	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.4	2.4	2.4
654925	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654987	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654903	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
654966	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654997	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654971	1.2	1.2	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.8	1.8	1.8
654939	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654919	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654994	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
654949	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654992	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654909	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654924	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
654943	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654915	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654927	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654956	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654910	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654936	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, I 0 mg/kg/day												
654928	1.7	1.7	1.7	1.7	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654993	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
654929	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654972	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654950	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654953	2.4	2.4	2.4	2.4	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.9
654925	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654987	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654903	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654966	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	1.7
654997	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654971	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654939	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654919	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
654994	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
654949	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
654992	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654909	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
654924	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654943	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654915	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654927	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654956	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
654910	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.5
654936	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, I 0 mg/kg/day												
654928	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3
654993	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
654929	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654972	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654950	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654953	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0
654925	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654987	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
654903	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654966	1.7	1.7	1.7	1.7	1.7	1.7	1.6	1.6	1.6	1.6	1.6	1.6
654997	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654971	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654939	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654919	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654994	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
654949	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
654992	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
654909	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654924	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
654943	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654915	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654927	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654956	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654910	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654936	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, I 0 mg/kg/day												
654928	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5
654993	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
654929	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4
654972	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654950	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654953	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.2	3.2	3.2	3.2
654925	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654987	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654903	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654966	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
654997	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654971	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654939	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654919	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654994	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.0	2.0	2.0	2.0
654949	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654992	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8
654909	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654924	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654943	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654915	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654927	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654956	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654910	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
654936	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, I 0 mg/kg/day												
654928	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654993	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
654929	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654972	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654950	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654953	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.4	3.4
654925	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654987	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654903	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654966	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1
654997	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654971	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654939	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654919	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654994	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3
654949	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
654992	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654909	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654924	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654943	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654915	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654927	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654956	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654910	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
654936	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, I 0 mg/kg/day												
654928	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654993	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654929	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654972	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654950	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654953	3.4	3.4	3.4	3.4	3.4	3.5	3.5	3.5	3.5	3.5	3.5	3.5
654925	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654987	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654903	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654966	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2
654997	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654971	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654939	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654919	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654994	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654949	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654992	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654909	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654924	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654943	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654915	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654927	3.0	3.0	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1
654956	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654910	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
654936	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Male, I 0 mg/kg/day									
654928	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654993	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654929	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654972	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
654950	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654953	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.3	3.3
654925	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654987	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654903	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654966	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	
654997	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	
654971	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
654939	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
654919	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
654994	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	
654949	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
654992	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
654909	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
654924	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	
654943	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
654915	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
654927	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
654956	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
654910	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	
654936	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, III 1 mg/kg/day												
654913	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654947	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654995	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654938	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654941	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654946	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.7	1.7	1.7	1.7	1.7
654960	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6
654908	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654984	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654932	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654948	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654904	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654954	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6
654945	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
654988	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, III 1 mg/kg/day												
654913	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654947	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654995	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654938	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654941	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654946	1.7	1.7	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2
654960	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654908	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654984	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654932	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654948	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654904	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654954	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654945	1.2	1.2	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654988	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, III 1 mg/kg/day												
654913	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654947	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654995	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654938	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654941	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654946	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654960	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654908	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654984	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654932	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654948	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
654904	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654954	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654945	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
654988	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, III 1 mg/kg/day												
654913	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654947	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654995	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654938	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
654941	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654946	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654960	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654908	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654984	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654932	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
654948	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654904	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654954	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654945	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654988	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, III 1 mg/kg/day												
654913	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654947	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654995	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654938	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654941	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654946	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654960	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654908	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654984	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
654932	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654948	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654904	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654954	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654945	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
654988	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, III 1 mg/kg/day												
654913	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	3.6	2.6	2.7	2.7
654947	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654995	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7
654938	2.6	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654941	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654946	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	3.0	3.0
654960	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
654908	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654984	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654932	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654948	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654904	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
654954	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654945	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654988	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, III 1 mg/kg/day												
654913	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654947	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654995	2.7	2.7	2.7	2.7	2.7	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654938	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654941	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654946	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654960	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654908	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654984	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654932	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654948	2.9	2.9	2.9	2.9	2.9	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654904	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654954	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654945	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654988	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Male, III 1 mg/kg/day									
654913	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654947	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654995	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654938	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654941	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654946	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654960	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654908	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654984	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
654932	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654948	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.1	
654904	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
654954	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	
654945	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	
654988	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, V 5 mg/kg/day												
655005	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654907	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654980	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654959	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654961	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.7	1.7	1.7	1.7	1.7
654916	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.7	1.7	1.7	1.7	1.7
654911	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654917	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654998	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6
654970	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
654926	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654918	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654981	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.3	1.3	1.3
654969	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654967	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, V 5 mg/kg/day												
655005	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
654907	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654980	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
654959	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654961	1.7	1.7	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.3	2.3	2.3
654916	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654911	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.2	2.2	2.2
654917	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654998	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654970	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
654926	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654918	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654981	1.3	1.3	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654969	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654967	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, V 5 mg/kg/day												
655005	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654907	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654980	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654959	2.1	2.1	2.1	2.1	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5
654961	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7
654916	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654911	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6
654917	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
654998	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
654970	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
654926	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654918	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654981	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654969	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
654967	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, V 5 mg/kg/day												
655005	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654907	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654980	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654959	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7
654961	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
654916	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654911	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7
654917	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
654998	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654970	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
654926	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654918	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654981	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654969	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654967	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, V 5 mg/kg/day												
655005	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
654907	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5
654980	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.9	2.9	2.9	2.9
654959	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.9	2.9	2.9	2.9
654961	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	3.0	3.0	3.0	3.0
654916	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654911	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654917	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
654998	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8
654970	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1
654926	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
654918	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654981	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654969	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654967	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, V 5 mg/kg/day												
655005	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654907	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654980	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654959	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
654961	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	3.2
654916	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654911	2.8	2.8	2.8	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654917	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654998	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654970	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3
654926	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654918	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	3.0	3.0
654981	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654969	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
654967	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, V 5 mg/kg/day												
655005	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654907	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654980	3.0	3.0	3.0	3.0	3.0	3.2	3.2	3.2	3.2	3.2	3.2	3.2
654959	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
654961	3.2	3.2	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.3
654916	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654911	3.0	3.0	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1
654917	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654998	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654970	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654926	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654918	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654981	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654969	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654967	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Male, V 5 mg/kg/day									
655005	3.0	3.0	3.0	3.0	3.0	3.0	3.0	2.9	2.9
654907	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654980	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3	3.3
654959	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
654961	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.4	3.4
654916	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654911	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
654917	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
654998	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.0	3.0
654970	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	
654926	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	
654918	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
654981	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
654969	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	
654967	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, VII 25 mg/kg/day												
655001	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654975	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654922	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654940	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654930	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654958	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654952	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.7	1.7	1.7	1.7	1.7
654923	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654989	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
655006	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654920	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654912	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654934	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654964	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654933	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, VII 25 mg/kg/day												
655001	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.1	2.1	2.1
654975	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
654922	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654940	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654930	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654958	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654952	1.7	1.7	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2
654923	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654989	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
655006	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654920	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
654912	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
654934	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654964	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654933	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, VII 25 mg/kg/day												
655001	2.1	2.1	2.1	2.1	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6
654975	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654922	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654940	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654930	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654958	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
654952	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654923	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654989	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
655006	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654920	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654912	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
654934	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
654964	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654933	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, VII 25 mg/kg/day												
655001	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7
654975	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654922	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654940	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654930	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7
654958	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2
654952	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654923	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654989	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
655006	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
654920	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
654912	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
654934	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654964	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
654933	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, VII 25 mg/kg/day												
655001	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
654975	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654922	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6
654940	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654930	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654958	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654952	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8
654923	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654989	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
655006	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654920	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654912	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
654934	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654964	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654933	2.7	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.1	3.1	3.1	3.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, VII 25 mg/kg/day												
655001	2.9	2.9	2.9	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	3.2
654975	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654922	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654940	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654930	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654958	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654952	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654923	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654989	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
655006	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654920	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654912	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654934	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654964	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654933	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3	3.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, VII 25 mg/kg/day												
655001	1.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
654975	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654922	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654940	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654930	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654958	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654952	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654923	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654989	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
655006	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654920	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654912	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654934	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654964	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
654933	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Male, VII 25 mg/kg/day									
655001	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3	3.3
654975	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654922	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654940	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654930	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
654958	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654952	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
654923	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654989	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
655006	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654920	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	
654912	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
654934	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	
654964	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
654933	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, IX 125 mg/kg/day												
654983	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654965	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654979	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654986	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
655003	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654921	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654996	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6
654951	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654955	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6
654914	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654937	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654962	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654982	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654931	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654906	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6
654985	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
654978	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
654974	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
654990	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
654976	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
654957	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
654973	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
654977	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
654942	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
654991	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, IX 125 mg/kg/day												
654983	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654965	1.3	1.3	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654979	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
654986	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
655003	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654921	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654996	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0
654951	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
654955	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
654914	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654937	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654962	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654982	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654931	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654906	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.2	2.2	2.2
654985	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
654978	1.2	1.2	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
654974	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654990	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654976	1.3	1.3	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
654957	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
654973	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
654977	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
654942	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
654991	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, IX 125 mg/kg/day												
654983	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654965	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654979	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654986	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
655003	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654921	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
654996	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
654951	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654955	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654914	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654937	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654962	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
654982	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
654931	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
654906	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6
654985	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8
654978	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
654974	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654990	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
654976	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654957	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
654973	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
654977	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8
654942	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
654991	2.1	2.1	2.1	2.1	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, IX 125 mg/kg/day												
654983	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654965	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654979	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654986	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
655003	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
654921	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654996	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654951	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654955	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654914	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
654937	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
654962	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654982	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654931	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
654906	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8
654985	1.8	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9
654978	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
654974	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
654990	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654976	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3
654957	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
654973	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
654977	1.8	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9
654942	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3
654991	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, IX 125 mg/kg/day												
654983	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654965	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
654979	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654986	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8
655003	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654921	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
654996	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654951	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654955	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654914	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654937	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
654962	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
654982	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654931	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
654906	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0
654985	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1
654978	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
654974	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654990	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
654976	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654957	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654973	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
654977	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1
654942	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
654991	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	3.0	3.0	3.0	3.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, IX 125 mg/kg/day												
654983	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654965	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
654979	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
654986	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.5	2.5
655003	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
654921	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654996	2.4	2.4	2.4	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
654951	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654955	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654914	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654937	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654962	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654982	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654931	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.7	2.7
654906	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	3.2
654985	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2
654978	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3
654974	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654990	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654976	2.4	2.4	2.4	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4
654957	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654973	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654977	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
654942	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654991	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, IX 125 mg/kg/day												
654983	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654965	2.4	2.4	2.4	2.4	2.4	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654979	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654986	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
655003	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654921	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654996	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
654951	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654955	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654914	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654937	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
654962	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
654982	2.7	2.7	2.7	2.7	2.7	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654931	2.7	2.7	2.7	2.7	2.7	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654906	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
654985	2.2	2.2	2.2	2.2	2.2	1.8	1.8	1.8	1.8	1.8	1.8	1.8
654978	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
654974	2.6	2.6	2.6	2.6	2.6	2.2	2.2	2.2	2.2	2.2	2.2	2.2
654990	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654976	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
654957	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654973	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
654977	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
654942	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
654991	3.0	3.0	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Male, IX 125 mg/kg/day									
654983	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654965	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6
654979	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654986	2.7	2.7	2.7	2.7	2.7	2.7	2.7	3.0	3.0
655003	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654921	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654996	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
654951	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
654955	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
654914	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
654937	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	
654962	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	
654982	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	
654931	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	
654906	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.4	
654985	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	
654978	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	
654974	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	
654990	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	
654976	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	
654957	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
654973	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
654977	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	
654942	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
654991	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, II 0 mg/kg/day												
655031	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
655107	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655098	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655016	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655079	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
655036	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
655025	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655099	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655032	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655083	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655093	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
655045	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655065	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655074	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655035	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655009	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655068	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655019	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655062	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655109	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655101	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
655072	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
655015	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655071	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655022	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, II 0 mg/kg/day												
655031	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655107	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655098	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655016	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655079	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655036	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655025	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655099	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655032	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655083	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655093	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
655045	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655065	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655074	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655035	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655009	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655068	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655019	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
655062	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655109	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655101	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655072	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
655015	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655071	1.0	1.0	1.0	1.0	1.0	1.0	1.0					
655022	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, II 0 mg/kg/day												
655031	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655107	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655098	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655016	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655079	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655036	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
655025	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655099	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655032	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655083	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655093	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655045	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655065	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655074	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655035	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655009	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655068	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655019	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655062	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655109	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655101	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6
655072	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655015	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1
655071												
655022	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, II 0 mg/kg/day												
655031	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655107	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655098	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655016	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655079	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655036	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655025	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655099	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655032	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655083	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655093	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655045	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655065	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655074	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655035	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655009	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655068	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655019	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655062	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655109	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655101	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655072	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655015	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
655071												
655022	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, II 0 mg/kg/day												
655031	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655107	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2
655098	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655016	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655079	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655036	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655025	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655099	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655032	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655083	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655093	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
655045	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655065	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655074	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655035	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655009	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655068	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655019	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655062	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655109	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655101	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655072	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655015	1.2	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2
655071												
655022	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, II 0 mg/kg/day												
655031	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655107	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655098	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655016	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655079	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655036	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655025	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655099	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655032	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655083	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655093	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655045	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655065	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
655074	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655035	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655009	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655068	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655019	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655062	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655109	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655101	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655072	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
655015	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655071												
655022	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, II 0 mg/kg/day												
655031	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655107	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655098	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655016	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655079	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655036	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655025	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655099	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655032	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655083	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655093	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655045	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655065	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655074	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655035	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655009	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655068	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655019	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655062	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655109	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655101	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655072	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655015	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655071												
655022	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92	Gavage ml Day 93
Female, II 0 mg/kg/day										
655031	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655107	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655098	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655016	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655079	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655036	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655025	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655099	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655032	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
655083	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655093	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1		
655045	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5		
655065	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8		
655074	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
655035	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655009	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6		
655068	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
655019	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655062	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655109	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
655101	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.8		
655072	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655015	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3		
655071										
655022	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, IV 1 mg/kg/day												
655086	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655041	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655108	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
655040	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655044	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655013	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
655089	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
655091	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655033	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655090	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
655051	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655018	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655096	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655057	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655028	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, IV 1 mg/kg/day												
655086	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655041	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655108	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655040	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655044	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655013	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655089	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655091	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655033	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655090	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655051	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655018	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655096	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655057	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655028	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, IV 1 mg/kg/day												
655086	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655041	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655108	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655040	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655044	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655013	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655089	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655091	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655033	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655090	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
655051	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655018	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655096	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655057	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655028	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, IV 1 mg/kg/day												
655086	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655041	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655108	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655040	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655044	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655013	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655089	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655091	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655033	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655090	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655051	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655018	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655096	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655057	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655028	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, IV 1 mg/kg/day												
655086	1.2	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2
655041	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5
655108	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655040	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655044	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655013	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655089	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655091	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655033	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655090	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655051	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655018	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655096	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655057	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655028	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, IV 1 mg/kg/day												
655086	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655041	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655108	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655040	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655044	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655013	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655089	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655091	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655033	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655090	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655051	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655018	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655096	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655057	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655028	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, IV 1 mg/kg/day												
655086	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655041	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655108	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655040	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655044	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655013	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655089	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655091	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655033	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655090	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655051	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655018	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655096	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655057	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655028	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92	Gavage ml Day 93
Female, IV 1 mg/kg/day										
655086	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655041	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655108	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655040	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655044	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655013	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655089	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655091	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655033	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655090	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655051	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
655018	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
655096	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6		
655057	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
655028	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, VI 5 mg/kg/day												
655054	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
655038	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655034	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655039	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655029	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655067	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655020	0.7	0.7	0.7	0.7	0.7	0.7	0.7	1.0	1.0	1.0	1.0	1.0
655087	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
655066	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655042	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
655059	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655064	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655050	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655021	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655017	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, VI 5 mg/kg/day												
655054	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655038	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655034	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655039	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655029	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655067	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655020	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655087	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655066	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655042	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655059	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655064	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
655050	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655021	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655017	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, VI 5 mg/kg/day												
655054	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655038	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655034	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655039	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655029	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655067	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655020	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655087	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655066	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655042	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6
655059	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655064	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655050	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655021	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655017	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, VI 5 mg/kg/day												
655054	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655038	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655034	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655039	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655029	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655067	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655020	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655087	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655066	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655042	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655059	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
655064	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655050	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655021	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655017	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, VI 5 mg/kg/day												
655054	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655038	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655034	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655039	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655029	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655067	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655020	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655087	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655066	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655042	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7	1.7
655059	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655064	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655050	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655021	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655017	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, VI 5 mg/kg/day												
655054	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655038	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655034	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
655039	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655029	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655067	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655020	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655087	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655066	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5
655042	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655059	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655064	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655050	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655021	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
655017	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, VI 5 mg/kg/day												
655054	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655038	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655034	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655039	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655029	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655067	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655020	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655087	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655066	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655042	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655059	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655064	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655050	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655021	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655017	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92	Gavage ml Day 93
Female, VI 5 mg/kg/day										
655054	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3
655038	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655034	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655039	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5
655029	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5
655067	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655020	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
655087	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655066	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655042	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655059	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3		
655064	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
655050	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
655021	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
655017	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, VIII 25 mg/kg/day												
655058	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655076	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655047	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655055	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655105	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655078	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2
655073	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655011	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655085	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655012	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655043	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655082	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655060	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655056	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
655081	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, VIII 25 mg/kg/day												
655058	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655076	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655047	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655055	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655105	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655078	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655073	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655011	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655085	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655012	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655043	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655082	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655060	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655056	0.8	0.8	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
655081	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, VIII 25 mg/kg/day												
655058	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655076	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655047	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655055	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655105	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655078	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
655073	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655011	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655085	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
655012	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655043	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655082	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655060	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655056	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
655081	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, VIII 25 mg/kg/day												
655058	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655076	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655047	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655055	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655105	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655078	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
655073	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655011	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655085	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655012	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655043	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655082	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655060	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655056	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655081	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, VIII 25 mg/kg/day												
655058	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655076	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655047	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655055	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655105	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4
655078	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8
655073	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655011	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5
655085	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655012	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655043	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655082	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655060	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655056	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
655081	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, VIII 25 mg/kg/day												
655058	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655076	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655047	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
655055	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655105	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655078	1.8	1.8	1.8	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8
655073	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655011	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655085	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
655012	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655043	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655082	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655060	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655056	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
655081	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, VIII 25 mg/kg/day												
655058	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655076	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655047	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655055	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655105	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655078	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9
655073	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655011	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655085	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655012	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655043	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655082	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655060	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655056	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655081	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92	Gavage ml Day 93
Female, VIII 25 mg/kg/day										
655058	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655076	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655047	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3
655055	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5
655105	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655078	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655073	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655011	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655085	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655012	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655043	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
655082	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655060	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
655056	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
655081	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, X 125 mg/kg/day												
655097	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655052	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655063	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655103	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
655026	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
655095	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655023	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655007	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655053	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655092	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655046	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655027	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655104	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
655106	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
655024	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655037	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
655088	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655010	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655077	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655030	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655075	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
655100	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2
655049	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
655084	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
655061	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, X 125 mg/kg/day												
655097	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655052	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655063	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655103	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655026	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655095	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655023	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655007	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655053	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655092	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655046	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655027	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655104	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655106	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
655024	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655037	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655088	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655010	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
655077	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
655030	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655075	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
655100	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655049	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
655084	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
655061	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, X 125 mg/kg/day												
655097	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655052	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655063	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655103	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655026	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655095	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655023	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655007	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
655053	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655092	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655046	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655027	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655104	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655106	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1
655024	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655037	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655088	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655010	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655077	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
655030	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655075	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
655100	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655049	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655084	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655061	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, X 125 mg/kg/day												
655097	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655052	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655063	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
655103	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655026	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655095	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655023	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
655007	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655053	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655092	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655046	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655027	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655104	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655106	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655024	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655037	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655088	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
655010	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655077	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655030	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655075	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
655100	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
655049	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655084	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
655061	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, X 125 mg/kg/day												
655097	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655052	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655063	1.2	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2
655103	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655026	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655095	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655023	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655007	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
655053	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6
655092	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655046	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655027	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655104	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655106	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655024	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655037	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
655088	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655010	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655077	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
655030	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
655075	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8
655100	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.4	1.4	1.4	1.4
655049	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
655084	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655061	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, X 125 mg/kg/day												
655097	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655052	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655063	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
655103	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655026	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655095	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655023	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
655007	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655053	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655092	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655046	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655027	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655104	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655106	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2
655024	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
655037	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655088	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655010	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655077	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4
655030	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.6	1.6
655075	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655100	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655049	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655084	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
655061	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, X 125 mg/kg/day												
655097	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655052	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655063	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
655103	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655026	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655095	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655023	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655007	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655053	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655092	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655046	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655027	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655104	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655106	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655024	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655037	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655088	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655010	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655077	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655030	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655075	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
655100	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655049	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
655084	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
655061	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92	Gavage ml Day 93
Female, X 125 mg/kg/day										
655097	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5
655052	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4	1.4
655063	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
655103	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655026	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655095	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.6	1.6	1.6
655023	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
655007	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
655053	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
655092	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
655046	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8		
655027	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655104	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655106	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3		
655024	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655037	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
655088	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
655010	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6		
655077	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
655030	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.7		
655075	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.8		
655100	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
655049	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2		
655084	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4		
655061	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4		

APPENDIX C

INDIVIDUAL BODY WEIGHTS

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, I 0 mg/kg/day									
654928	214.3	256.8	296.8	346.6	390.4	428.1	457.1	469.5	500.8
654993	208.4	260.0	298.1	337.2	362.3	391.9	407.2	417.1	448.9
654929	237.6	289.7	330.0	367.3	396.1	421.9	433.4	441.4	471.7
654972	242.9	288.4	329.9	369.6	393.9	415.9	434.4	441.6	457.5
654950	264.2	318.2	363.6	409.3	439.0	461.3	482.9	482.8	499.7
654953	299.7	371.8	423.6	483.6	536.8	575.9	607.2	607.1	638.8
654925	251.3	311.3	369.5	418.0	448.0	486.3	502.6	517.9	537.5
654987	237.7	292.6	344.3	387.3	395.9	447.2	474.3	483.9	505.4
654903	243.4	300.3	345.0	397.7	441.1	471.9	492.3	503.8	529.8
654966	223.6	277.5	318.5	360.3	397.0	341.5	313.3	374.6	384.8
654997	267.8	322.2	372.9	412.9	437.5	462.9	483.8	496.6	514.7
654971	202.9	247.4	294.7	351.2	391.9	434.8	460.9	482.4	497.2
654939	244.9	307.0	363.7	416.4	443.1	483.4	519.7	550.9	568.9
654919	235.7	277.0	317.6	358.5	384.9	407.4	425.5	438.6	461.3
654994	195.0	238.9	286.9	327.9	360.9	384.2	407.0	414.0	402.4
654949	213.4	261.1	307.6	349.8	379.3	410.4	428.7	450.7	475.9
654992	238.8	301.7	357.0	410.3	438.2	469.5	495.8	521.8	550.4
654909	213.7	261.7	307.7	344.3	376.1	403.6	429.8	451.6	467.0
654924	231.3	284.6	326.7	372.7	412.2	439.8	477.3	485.8	503.0
654943	229.2	283.3	329.5	362.2	390.6	419.6	441.8	457.7	467.7
654915	254.3	309.9	360.2	407.8	446.7	481.7	514.4	531.3	557.3
654927	249.5	317.7	374.1	426.9	460.2	495.5	517.6	543.9	568.1
654956	196.5	252.3	298.7	340.8	369.3	406.5	428.6	444.8	466.0
654910	239.4	295.6	358.6	421.7	446.5	492.5	521.4	550.1	576.8
654936	225.8	291.6	355.5	410.2	450.2	492.6	524.2	521.3	542.6

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 93	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Male, I 0 mg/kg/day									
654928	530.1	547.1	556.8	574.1	586.7	566.3			
654993	468.0	482.5	494.9	500.9	507.2	486.8			
654929	487.0	501.2	510.6	516.0	525.3	506.1			
654972	472.9	481.8	492.8	499.3	512.3	498.8			
654950	512.6	525.2	512.9	526.8	548.5	520.7			
654953	660.1	680.6	692.0	698.3	659.9	646.3			
654925	550.6	563.0	566.9	584.1	596.2	575.8			
654987	528.0	539.3	556.6	571.1	580.5	566.4			
654903	545.6	569.4	580.8	589.2	603.1	578.5			
654966	380.8	424.8	442.1	454.8	468.7		493.6	448.9	473.1
654997	525.5	545.8	557.7	562.0	572.4		578.2	586.1	606.2
654971	512.1	536.1	545.6	558.3	562.4		577.3	543.7	548.7
654939	575.1	591.0	606.1	617.0	629.9		634.9	647.2	660.2
654919	477.5	489.2	500.0	498.7	504.1		511.2	509.2	511.3
654994	423.2	450.4	458.3	460.1	466.3		484.7	497.1	503.0
654949	501.7	522.0	527.7	533.7	539.1		557.8	563.7	572.9
654992	563.4	575.8	586.2	596.6	601.6		609.5	626.5	636.3
654909	486.1	497.3	510.6	520.6	529.1		535.1	554.8	567.2
654924	522.5	539.2	544.7	532.7	556.8		576.1	592.2	597.0
654943	486.8	498.5	510.0	515.6	516.4		538.5	552.2	551.0
654915	574.5	589.8	603.9	611.7	619.4		630.0	652.6	653.6
654927	579.3	600.7	614.1	614.3	621.7		632.3	644.8	656.2
654956	481.9	485.2	495.9	494.7	498.9		509.8	519.9	523.1
654910	601.7	619.5	626.5	626.6	634.7		651.9	660.8	664.9
654936	566.6	588.9	597.8	606.8	609.6	583.7			

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Male, I 0 mg/kg/day									
654928									
654993									
654929									
654972									
654950									
654953									
654925									
654987									
654903									
654966	490.9	523.5	541.4	540.8	552.8	537.5	509.9	528.0	489.7
654997	610.7	628.5	632.0	619.5	624.7	635.0	643.9	649.3	655.1
654971	576.2	591.9	600.3	590.3	576.7	598.8	572.2	577.9	575.7
654939	676.0	687.7	697.7	712.4	715.1	728.6	738.8	741.9	743.6
654919	518.5	526.4	533.1	528.9	529.8	541.7	544.9	548.7	551.1
654994	508.7	520.9	527.8	520.0	526.3	530.6	529.5	536.6	535.8
654949	579.9	586.7	597.1	597.8	602.4	606.8	609.7	613.3	614.7
654992	644.3	662.5	661.3	656.4	659.4	669.6	667.7	674.5	683.7
654909	567.2	572.5	576.4	576.1	578.9	583.4	592.2	591.0	593.7
654924	605.2	619.4	627.6	623.0	629.5	628.6	637.3	647.6	658.7
654943	560.2	569.7	583.3	585.5	592.9	605.6	609.7	621.5	625.5
654915	666.4	680.4	697.0	694.1	705.6	721.5	723.0	732.9	751.4
654927	657.3	671.8	684.3	685.2	693.8	703.9	691.9	701.9	703.2
654956	529.0	547.3	553.9	555.6	562.9	572.1	574.0	570.5	569.6
654910	673.5	693.8	692.3	694.4	707.3	710.7	710.7	712.0	718.8
654936									

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 182	Body Weight g Day 183
Male, I 0 mg/kg/day		
654928		
654993		
654929		
654972		
654950		
654953		
654925		
654987		
654903		
654966		
654997		
654971		
654939		
654919		
654994	543.9	521.1
654949	623.7	601.2
654992	680.7	656.3
654909	598.6	578.3
654924	658.6	631.4
654943	631.2	605.8
654915	754.8	725.9
654927	697.7	674.6
654956	570.9	551.9
654910	715.8	691.5
654936		

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, III 1 mg/kg/day									
654913	224.8	280.3	334.3	376.2	410.8	436.6	464.0	473.1	499.7
654947	221.2	273.5	323.4	361.7	391.3	416.2	433.4	445.9	467.2
654995	230.5	287.2	342.4	381.4	411.4	446.8	469.3	472.3	495.0
654938	250.0	311.2	367.5	415.0	441.2	467.2	493.6	504.9	527.8
654941	241.2	305.9	358.2	404.4	437.0	468.2	472.2	476.9	498.0
654946	271.8	337.5	393.7	436.3	465.8	501.0	525.5	532.1	556.7
654960	283.0	325.6	361.3	401.6	417.9	440.7	457.6	455.4	484.5
654908	255.8	302.9	356.4	396.6	438.4	458.1	476.0	475.4	503.2
654984	236.4	302.8	352.7	396.1	437.7	471.7	491.5	501.5	535.5
654932	252.4	314.8	365.7	413.7	441.8	467.5	493.2	500.2	519.1
654948	255.3	315.7	372.2	417.5	454.2	489.5	512.0	524.8	542.7
654904	233.0	281.2	336.5	370.5	401.4	436.5	459.5	477.7	490.4
654954	272.2	319.0	363.6	411.7	448.5	481.4	511.7	530.1	557.7
654945	217.1	236.8	314.6	352.0	376.1	400.2	412.7	425.4	443.3
654988	239.2	292.9	347.1	388.8	416.7	444.2	465.0	478.9	505.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 93	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Male, III 1 mg/kg/day									
654913	515.5	537.1	546.9	537.9	557.6	534.1			
654947	479.9	491.3	502.3	503.4	509.0	489.6			
654995	508.9	532.7	529.8	526.5	528.2	514.1			
654938	552.8	570.4	576.3	574.6	600.7	579.4			
654941	514.0	533.4	543.9	524.3	540.3	515.8			
654946	568.8	596.3	598.8	599.0	595.3	577.7			
654960	498.9	512.7	522.9	529.5	540.5	513.2			
654908	510.6	513.9	529.7	532.0	541.0	516.1			
654984	556.7	584.5	594.0	607.4	623.1	601.8			
654932	533.5	554.7	561.5	570.6	584.8	566.1			
654948	561.4	574.7	543.2	587.4	610.0		625.3	640.9	649.3
654904	500.8	511.7	528.4	532.0	543.5		551.0	563.6	565.5
654954	574.5	590.1	593.5	600.9	611.1		618.2	636.0	635.0
654945	454.4	455.1	464.4	471.9	474.7		480.0	497.2	498.1
654988	517.3	529.9	535.8	545.4	554.9		565.1	576.4	573.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Male, III 1 mg/kg/day									
654913									
654947									
654995									
654938									
654941									
654946									
654960									
654908									
654984									
654932									
654948	661.4	674.0	689.4	699.6	713.9	721.2	727.0	729.2	738.3
654904	576.0	590.0	601.9	598.8	606.3	614.0	613.7	619.9	616.7
654954	642.5	661.2	661.0	661.2	674.3	680.2	683.1	687.6	690.9
654945	514.3	511.1	529.0	532.4	540.4	553.0	553.0	562.3	572.6
654988	580.9	586.0	594.5	586.9	597.1	607.6	609.3	612.5	613.2

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, V 5 mg/kg/day									
655005	235.1	288.9	345.7	400.1	439.5	470.0	498.9	509.4	538.2
654907	226.4	281.8	333.3	375.6	405.3	433.5	453.0	455.9	493.7
654980	227.0	289.9	348.4	405.5	448.1	487.2	522.5	535.6	576.4
654959	249.3	309.6	366.6	424.4	474.2	504.7	536.3	547.4	572.2
654961	268.1	330.2	396.3	452.5	497.7	537.0	552.1	558.7	600.3
654916	275.8	333.7	375.8	413.1	441.6	466.1	478.3	491.4	514.0
654911	260.6	327.3	388.8	439.2	486.0	517.7	546.5	539.7	566.6
654917	238.8	298.7	355.2	400.3	426.6	457.5	497.5	508.7	536.4
654998	248.3	311.9	368.1	415.5	453.5	489.3	519.9	518.5	550.2
654970	213.2	249.9	285.6	325.6	353.2	372.3	385.7	399.8	413.6
654926	269.8	320.4	369.1	423.4	467.2	509.6	529.6	554.3	574.7
654918	243.5	297.7	350.8	399.6	435.4	471.6	493.6	518.5	545.7
654981	208.9	260.2	316.9	368.8	394.6	424.1	435.9	453.2	469.9
654969	227.6	261.4	297.3	330.8	360.3	390.2	414.9	433.9	456.8
654967	220.2	275.8	327.9	367.7	399.2	428.5	446.3	451.7	478.5

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 93	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Male, V 5 mg/kg/day									
655005	565.3	576.2	589.4	596.5	587.6	567.8			
654907	510.3	520.3	530.4	544.2	553.5	532.9			
654980	597.7	607.4	630.1	645.1	661.6	626.5			
654959	600.2	613.6	623.7	633.9	649.1	621.1			
654961	621.6	642.9	653.1	666.1	672.7	643.3			
654916	519.9	516.2	522.9	544.1	550.2	526.3			
654911	591.9	606.7	622.8	638.2	638.0	619.9			
654917	568.1	580.2	597.8	600.9	613.3	587.8			
654998	565.0	575.8	598.2	617.8	608.2	587.6			
654970	429.4	451.8	474.4	481.7	477.3		496.9	508.6	513.4
654926	589.1	606.6	598.7	614.0	641.3		651.0	657.1	667.4
654918	569.9	590.0	596.8	610.1	619.2		632.2	646.2	648.6
654981	483.1	500.8	503.8	513.0	524.7		530.5	531.6	540.8
654969	468.4	489.6	505.5	508.3	511.5		524.5	534.4	525.8
654967	496.6	508.2	518.3	523.8	528.0	513.3			

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Male, V 5 mg/kg/day									
655005									
654907									
654980									
654959									
654961									
654916									
654911									
654917									
654998									
654970	517.6	529.2	535.6	532.9	540.7	550.4	545.6	546.2	542.4
654926	675.5	691.2	697.0	703.6	719.7	718.6	724.1	726.6	722.1
654918	667.3	669.2	686.6	699.5	704.8	713.5	719.0	727.2	726.8
654981	550.7	560.0	572.5	575.7	577.1	588.5	589.1	585.3	589.1
654969	542.0	553.3	558.1	528.4	549.4	564.5	569.6	569.9	582.0
654967									

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, VII 25 mg/kg/day									
655001	230.8	290.9	348.1	417.7	470.7	517.2	543.8	552.5	588.9
654975	219.2	275.1	327.6	378.0	410.7	433.2	467.4	473.0	502.7
654922	218.7	270.6	317.5	366.2	400.7	433.9	469.1	480.1	523.7
654940	238.9	296.2	340.6	387.5	414.2	442.2	467.8	474.4	496.5
654930	238.0	305.2	360.9	416.1	464.1	502.8	534.6	542.1	566.8
654958	248.9	290.8	325.6	358.7	382.3	409.2	432.1	439.1	454.9
654952	277.3	334.9	390.1	437.8	459.7	494.7	523.0	526.6	556.7
654923	251.5	308.3	363.6	412.8	447.4	477.5	498.3	503.8	519.7
654989	236.3	297.2	357.6	399.0	438.7	469.4	496.0	503.6	533.0
655006	251.9	310.4	363.7	409.5	440.2	467.9	495.4	500.1	522.7
654920	227.9	274.7	325.5	376.6	416.1	448.6	475.6	491.0	523.6
654912	217.7	264.6	305.4	339.8	364.9	395.6	423.6	441.8	466.6
654934	235.0	294.2	334.8	371.1	396.6	433.3	455.8	474.9	500.1
654964	252.8	307.4	357.6	405.7	443.2	480.6	510.9	534.2	558.2
654933	245.5	302.8	364.8	420.4	457.7	506.4	543.9	578.7	613.0

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 93	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Male, VII 25 mg/kg/day									
655001	612.3	630.5	641.2	646.1	661.8	641.7			
654975	530.6	542.1	553.4	558.9	580.6	554.9			
654922	543.4	555.8	572.5	580.3	583.5	555.6			
654940	516.2	529.8	543.7	542.2	554.6	534.8			
654930	584.3	597.7	598.8	602.4	619.4	596.1			
654958	471.2	480.7	486.6	496.9	506.6	483.1			
654952	576.2	575.4	592.7	617.2	620.7	598.4			
654923	533.3	533.8	548.5	560.9	566.3	539.3			
654989	557.2	565.1	582.9	600.2	612.7	580.5			
655006	542.3	549.1	556.4	573.2	575.2	557.0			
654920	540.6	549.9	560.1	576.8	588.0		591.8	602.8	607.2
654912	488.8	504.1	527.0	532.7	531.7		543.3	551.8	554.7
654934	510.8	520.1	531.3	544.2	554.7		566.6	571.7	563.4
654964	576.1	590.3	604.1	611.0	627.4		639.7	646.5	655.8
654933	636.1	651.0	668.5	674.3	685.4		692.4	700.4	715.2

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Male, VII 25 mg/kg/day									
655001									
654975									
654922									
654940									
654930									
654958									
654952									
654923									
654989									
655006									
654920	619.8	638.2	648.3	642.3	652.4	672.1	676.8	680.0	688.0
654912	555.9	576.0	581.7	580.2	590.0	606.0	595.3	617.5	622.5
654934	583.1	591.9	597.4	604.5	607.1	616.0	614.4	616.4	618.7
654964	662.7	674.0	679.4	681.3	687.5	702.3	701.3	717.7	723.2
654933	732.1	752.0	767.0	775.5	791.1	811.1	806.9	821.9	816.8

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, IX 125 mg/kg/day									
654983	236.6	298.9	351.7	396.7	437.1	470.5	504.4	510.9	530.4
654965	211.9	260.9	315.8	357.0	393.1	412.9	438.7	438.7	442.8
654979	218.3	273.2	329.8	363.5	391.5	423.4	446.2	459.9	484.1
654986	243.8	295.7	346.1	405.8	444.3	480.5	516.1	518.9	553.3
655003	231.8	278.0	334.5	374.5	401.3	421.6	449.2	456.5	473.7
654921	269.5	323.2	377.7	416.7	454.1	481.8	501.6	503.4	533.9
654996	275.4	325.6	371.5	400.9	426.4	454.4	460.2	457.6	485.6
654951	248.9	296.2	349.4	392.1	430.6	456.4	487.3	499.1	522.7
654955	238.8	310.9	376.9	428.6	462.1	490.2	513.9	522.5	544.3
654914	248.3	298.9	344.1	383.8	414.0	441.9	475.5	486.5	503.8
654937	234.6	298.6	358.5	409.9	446.6	476.5	500.0	518.8	538.8
654962	266.3	299.4	353.6	406.5	443.9	472.2	485.6	505.6	530.0
654982	222.9	280.1	338.7	386.1	419.8	456.2	477.5	500.1	527.8
654931	240.9	301.6	364.4	421.9	462.7	496.5	519.5	541.3	562.7
654906	248.1	316.0	379.6	438.7	476.0	516.8	550.3	581.1	607.8
654985	194.0	233.5	274.6	318.9	345.1	359.8	387.4	395.9	416.2
654978	201.7	248.2	291.0	329.7	357.4	378.7	398.2	410.4	430.3
654974	214.6	276.1	334.6	378.2	421.2	447.9	471.4	488.3	506.6
654990	234.9	290.2	336.2	373.7	415.0	440.9	462.8	481.6	495.4
654976	216.4	269.2	326.6	373.6	404.8	424.6	455.3	469.7	482.4
654957	253.6	308.8	360.2	400.5	431.4	449.4	469.0	493.1	505.7
654973	261.7	316.6	368.2	411.9	446.6	465.3	488.9	496.6	510.2
654977	194.1	232.0	285.7	321.6	344.5	367.9	388.8	404.3	414.4
654942	234.0	286.6	339.5	377.2	403.1	425.9	455.8	462.4	484.5
654991	236.1	311.4	374.3	429.1	476.6	509.2	540.8	566.0	593.6

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 93	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Male, IX 125 mg/kg/day									
654983	555.0	559.3	570.3	574.4	596.3	569.9			
654965	462.0	478.9	460.1	488.1	510.5	483.6			
654979	497.6	516.0	522.0	525.7	546.5	512.4			
654986	538.3	508.0	493.1	536.4	605.1	575.0			
655003	486.4	499.3	500.1	511.6	530.9	506.1			
654921	546.9	553.6	570.7	567.4	579.7	553.2			
654996	462.4	485.1	495.8	520.6	534.8	508.6			
654951	541.0	552.8	558.1	565.7	573.2	555.0			
654955	557.4	571.8	562.0	533.8	568.1	542.5			
654914	516.7	538.0	553.7	576.1	591.0	563.5			
654937	557.9	564.1	576.3	569.1	581.8		588.8	611.2	622.2
654962	536.4	561.4	561.9	545.9	550.5		570.6	580.8	579.7
654982	519.9	536.7	511.2	501.1	531.5		533.4	543.9	564.9
654931	569.0	537.5	464.6	541.0	559.7		580.1	600.7	608.1
654906	623.5	647.3	641.8	639.7	672.1		687.9	713.8	712.5
654985	427.9	435.0	369.9	388.5	421.4		430.8	441.1	446.5
654978	443.6	456.5	456.3	464.9	484.4		499.1	504.3	514.1
654974	528.9	520.9	438.2	497.8	533.0		560.5	566.6	579.6
654990	516.2	529.9	537.5	555.9	583.6		589.4	592.8	587.6
654976	438.9	486.5	484.2	506.1	531.0		539.0	549.0	542.4
654957	516.7	519.5	529.4	537.3	544.9		556.5	558.9	568.3
654973	523.6	527.8	548.4	557.3	560.7		566.6	579.8	587.2
654977	425.4	414.0	427.8	441.9	444.1		456.9	472.5	477.4
654942	500.3	503.6	512.1	513.0	522.3		528.5	536.8	542.3
654991	606.9	608.1	616.5	629.3	639.3		651.3	665.5	669.6

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Male, IX 125 mg/kg/day									
654983									
654965									
654979									
654986									
655003									
654921									
654996									
654951									
654955									
654914									
654937	633.6	657.6	665.9	670.1	684.6	704.4	703.1	725.9	704.7
654962	581.9	594.1	596.4	592.2	595.8	606.0	613.0	626.7	623.3
654982	575.0	584.2	595.4	613.8	627.8	636.5	646.3	678.3	667.9
654931	610.9	627.6	642.0	645.2	653.8	672.1	678.2	690.1	692.3
654906	734.9	758.8	777.3	773.5	778.0	785.7	786.0	796.4	801.5
654985	451.3	449.4	451.7	456.4	460.7	492.5	490.3	498.5	498.8
654978	513.6	535.0	540.1	539.3	545.5	556.7	562.6	566.6	565.4
654974	585.4	606.4	625.0	633.9	640.1	658.8	662.0	683.2	685.6
654990	603.0	621.5	639.3	631.2	648.9	668.4	678.0	690.1	682.1
654976	558.7	574.2	574.9	580.7	587.1	601.1	593.9	605.5	603.8
654957	581.2	588.9	604.5	612.3	619.2	623.5	619.8	617.9	622.2
654973	602.5	612.2	630.7	637.0	648.2	660.9	656.9	665.0	662.4
654977	482.1	496.5	501.9	492.8	494.6	504.0	499.0	502.2	508.4
654942	551.5	574.4	582.6	579.4	595.1	608.9	606.2	624.6	630.8
654991	683.4	708.6	726.6	735.7	742.9	756.1	752.7	766.2	772.8

INDIVIDUAL BODY WEIGHTS

Male, IX 125 mg/kg/day

	Body Weight g Day 182	Body Weight g Day 183
654983		
654965		
654979		
654986		
655003		
654921		
654996		
654951		
654955		
654914		
654937		
654962		
654982		
654931		
654906		
654985	505.5	475.3
654978	572.6	552.6
654974	702.9	673.0
654990	694.3	667.9
654976	613.5	597.1
654957	635.5	616.9
654973	669.1	642.7
654977	517.4	492.6
654942	651.0	620.8
654991	784.9	759.7

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, II 0 mg/kg/day									
655031	174.3	187.9	207.2	229.7	251.4	257.8	275.0	267.8	285.6
655107	174.0	190.1	199.3	206.5	214.1	219.5	226.9	220.2	234.4
655098	163.3	181.6	203.1	216.3	222.5	232.1	241.5	239.1	246.0
655016	181.5	199.3	212.7	218.3	233.8	239.1	255.6	251.6	269.8
655079	174.1	183.3	194.9	205.2	220.2	233.0	242.5	238.2	258.4
655036	214.7	232.8	252.5	266.2	285.0	299.1	301.2	294.8	315.7
655025	179.5	203.7	226.1	247.6	257.6	271.3	283.8	277.1	295.7
655099	195.9	212.1	242.5	256.9	267.1	276.4	287.8	276.3	292.3
655032	200.4	213.9	223.6	245.6	256.0	266.2	282.4	278.3	298.1
655083	203.8	220.3	234.0	250.7	259.0	275.1	280.2	278.2	295.8
655093	163.7	168.4	180.5	193.1	194.9	200.1	207.3	209.2	213.2
655045	183.9	202.2	226.7	241.9	244.2	261.1	269.7	271.6	274.5
655065	188.4	207.9	229.5	247.0	260.7	283.5	296.5	305.1	314.5
655074	193.6	219.9	236.5	259.4	262.8	278.2	286.9	284.7	284.1
655035	181.4	202.6	220.7	242.6	252.3	273.5	276.0	285.0	294.3
655009	177.0	195.3	219.0	241.5	252.2	261.2	265.4	274.4	286.6
655068	200.3	217.0	242.1	257.9	267.9	285.5	284.5	287.2	294.4
655019	200.2	218.6	247.3	270.2	276.3	289.9	299.1	301.6	311.8
655062	191.7	203.6	231.5	245.1	261.1	268.9	275.4	280.1	288.9
655109	191.6	210.7	235.9	247.7	256.6	267.9	278.6	279.1	288.1
655101	208.8	238.4	261.6	285.8	302.3	313.6	329.7	338.2	344.1
655072	204.6	233.3	248.9	271.7	286.4	286.7	305.4	312.0	320.4
655015	155.1	172.4	190.9	198.2	198.6	218.9	231.9	223.5	232.5
655071	179.2	202.6	196.4						
655022	183.5	201.9	224.1	240.6	259.0	265.9	269.6	274.9	286.4

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 94	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Female, II 0 mg/kg/day									
655031	287.2	301.3	306.4	309.2	300.2	292.6			
655107	234.3	245.5	245.3	251.9	250.1	238.5			
655098	250.9	265.5	264.8	266.3	268.3	261.1			
655016	282.6	282.6	289.4	301.1	296.1	286.5			
655079	259.3	267.0	272.3	276.4	282.0	266.8			
655036	320.5	325.7	329.4	337.3	338.7	322.5			
655025	299.9	317.2	319.9	315.7	320.7	301.7			
655099	289.8	299.5	302.1	302.9	302.1	284.9			
655032	300.1	302.4	312.1	300.8	317.3	302.9			
655083	297.3	308.8	314.7	324.0	326.0	310.8			
655093	213.3	224.2	231.1	229.4	229.3		236.7	234.5	234.7
655045	286.6	294.4	294.5	289.8	300.5		298.2	313.2	310.9
655065	326.0	340.7	339.3	340.2	352.2		356.0	362.6	365.0
655074	294.0	297.4	309.5	308.2	305.0		305.9	318.1	316.0
655035	297.8	298.4	305.0	311.2	311.1		309.7	321.4	324.8
655009	292.2	296.4	294.5	304.3	312.4		314.7	318.5	328.3
655068	294.0	301.7	298.5	306.0	298.6		304.6	317.5	324.2
655019	315.8	321.1	322.6	322.2	326.5		331.7	333.1	332.0
655062	289.7	299.9	310.2	315.2	312.1		319.9	332.4	330.9
655109	292.5	299.7	297.9	304.2	306.9		308.1	311.4	308.5
655101	362.5	358.6	366.5	374.1	366.5		381.8	381.9	377.8
655072	315.2	330.2	331.2	328.6	323.7		343.4	338.9	340.7
655015	239.8	240.4	241.0	243.8	250.5		240.0	238.1	251.4
655071									
655022	288.6	288.5	293.9	296.6	293.1		301.2	298.9	306.5

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Female, II 0 mg/kg/day									
655031									
655107									
655098									
655016									
655079									
655036									
655025									
655099									
655032									
655083									
655093	237.8	240.9	242.9	246.6	246.5	248.8	245.3	249.3	252.5
655045	306.1	307.3	305.7	308.7	321.1	325.4	321.9	330.4	336.3
655065	377.4	377.0	372.3	377.4	387.8	395.2	376.6	371.7	378.0
655074	316.1	325.7	326.9	336.3	341.1	341.4	338.8	348.9	345.8
655035	321.1	333.2	331.8	331.6	335.3	319.6	313.6	326.8	329.5
655009	324.2	328.7	327.4	334.2	338.5	339.4	331.8	337.9	338.1
655068	319.7	327.1	330.8	335.3	340.5	339.7	339.1	347.8	347.0
655019	337.2	340.5	343.9	353.9	352.2	362.1	352.3	362.7	365.3
655062	342.1	358.8	349.0	353.1	349.6	358.0	355.0	365.4	367.3
655109	313.5	320.8	314.9	321.0	324.8	328.8	321.5	322.9	326.1
655101	375.5	387.9	404.7	395.7	411.0	409.7	400.7	413.7	420.9
655072	338.6	356.0	357.5	345.5	360.6	366.4	354.9	354.0	360.7
655015	265.3	278.6	286.1	290.3	295.2	300.7	299.2	313.1	308.3
655071									
655022	308.3	308.3	310.5	312.4	313.4	315.4	316.4	320.1	316.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 182	Body Weight g Day 183
Female, II 0 mg/kg/day		
655031		
655107		
655098		
655016		
655079		
655036		
655025		
655099		
655032		
655083		
655093		
655045		
655065		
655074		
655035	343.5	322.8
655009	329.2	317.1
655068	352.1	329.8
655019	370.7	347.7
655062	371.5	344.4
655109	328.7	309.3
655101	420.5	405.9
655072	364.0	340.9
655015	306.9	288.4
655071		
655022		

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, IV 1 mg/kg/day									
655086	172.1	191.8	209.5	218.3	223.5	235.8	241.8	228.4	248.7
655041	186.9	192.1	209.7	229.6	238.3	246.0	267.6	260.9	292.3
655108	168.1	192.3	213.6	225.4	243.0	257.1	261.6	248.1	266.6
655040	182.6	205.2	229.5	243.5	247.5	267.5	275.8	264.5	286.7
655044	177.2	203.1	230.9	243.4	255.7	274.5	293.0	278.5	296.3
655013	201.2	231.3	254.4	269.5	269.4	283.7	289.3	274.7	287.2
655089	152.0	200.2	221.6	237.3	245.3	262.8	275.5	273.6	304.5
655091	181.2	207.8	221.3	239.5	255.9	274.9	282.6	274.9	292.8
655033	194.4	214.2	232.0	249.0	265.3	276.6	283.3	272.8	298.5
655090	211.0	235.2	250.7	267.0	281.1	297.9	301.5	291.6	315.2
655051	171.3	191.4	205.2	217.8	234.7	249.3	254.6	256.0	259.9
655018	203.4	220.4	239.6	247.2	264.6	281.6	294.0	287.1	307.2
655096	199.8	206.0	225.0	238.6	250.1	258.1	275.9	277.2	290.3
655057	161.4	183.4	203.6	217.2	226.8	241.7	250.8	245.0	262.4
655028	195.0	211.3	224.9	237.0	250.4	257.2	264.2	274.5	288.0

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 94	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Female, IV 1 mg/kg/day									
655086	254.2	256.6	257.5	258.6	254.3	243.3			
655041	287.3	293.9	298.3	299.9	290.0	276.1			
655108	281.7	284.7	289.9	284.7	284.7	269.3			
655040	283.5	295.5	299.9	301.5	305.6	293.1			
655044	307.4	318.7	324.4	324.6	329.3	317.2			
655013	295.3	303.8	306.1	302.6	309.3	299.4			
655089	318.6	325.7	327.4	338.3	340.1	317.9			
655091	300.7	310.7	305.5	318.6	315.0	302.6			
655033	292.5	306.5	309.0	317.0	310.2	303.6			
655090	326.6	329.3	333.4	343.5	342.6	323.5			
655051	263.5	262.0	274.8	277.0	283.8		290.6	300.6	299.0
655018	316.0	326.8	332.9	337.2	331.1		344.4	349.6	349.4
655096	294.8	305.0	297.7	303.0	310.2		319.3	314.3	320.6
655057	261.6	266.7	273.1	273.4	270.0		276.5	283.4	280.2
655028	286.6	292.2	301.7	307.2	298.0		302.4	307.3	313.5

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Female, IV 1 mg/kg/day									
655086									
655041									
655108									
655040									
655044									
655013									
655089									
655091									
655033									
655090									
655051	298.8	305.4	311.5	306.3	307.9	313.2	318.0	322.0	322.3
655018	353.8	361.1	367.0	364.0	373.5	370.2	368.6	367.9	364.3
655096	321.6	326.2	332.7	342.1	341.5	354.7	345.7	356.3	365.1
655057	282.2	286.7	289.2	288.3	290.1	290.1	292.6	296.4	296.2
655028	311.9	316.1	321.7	327.1	325.0	328.3	327.3	337.4	332.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, VI 5 mg/kg/day									
655054	169.6	193.7	209.4	214.5	231.6	237.2	239.9	236.1	260.6
655038	183.2	207.6	224.7	242.6	248.6	261.0	277.4	264.7	280.2
655034	170.3	192.7	211.7	223.0	231.7	243.3	257.6	248.5	258.6
655039	178.4	202.9	218.8	240.8	249.8	261.8	284.6	277.5	295.5
655029	185.3	206.4	222.8	246.5	255.9	263.9	251.3	262.6	279.5
655067	204.8	225.5	244.7	267.9	274.9	285.9	288.9	286.0	301.7
655020	148.6	197.9	222.6	221.8	237.4	254.5	277.7	274.5	282.3
655087	189.3	219.2	241.6	252.5	261.0	287.3	298.0	288.8	296.9
655066	196.1	212.6	241.7	260.3	274.3	289.1	298.1	286.9	309.6
655042	210.9	235.6	254.1	274.8	286.7	311.4	317.8	308.3	343.4
655059	162.7	182.2	197.0	206.4	218.4	226.5	240.5	239.3	246.8
655064	190.0	205.7	226.5	252.3	269.6	286.7	302.3	311.5	324.5
655050	193.3	209.3	231.5	241.9	258.5	269.6	280.1	275.9	289.9
655021	162.5	177.7	194.7	213.0	232.2	232.7	248.6	254.2	265.9
655017	188.6	198.8	214.1	226.3	232.7	249.6	261.3	259.9	266.6

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 94	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Female, VI 5 mg/kg/day									
655054	261.8	261.7	269.8	273.1	266.6	252.3			
655038	293.6	302.4	306.1	302.2	307.1	292.7			
655034	265.3	270.1	275.8	271.6	277.5	259.1			
655039	296.6	313.2	318.4	315.3	309.4	301.3			
655029	279.3	288.1	291.2	287.2	290.1	279.9			
655067	305.0	311.8	314.5	311.1	311.6	291.4			
655020	300.6	307.1	306.2	306.9	312.6	301.6			
655087	321.7	319.1	312.7	311.4	329.0	314.7			
655066	314.3	306.9	318.1	324.2	326.1	308.1			
655042	347.2	349.3	359.2	355.6	351.9	339.8			
655059	251.2	257.6	259.4	258.5	260.6		268.0	259.2	263.7
655064	324.0	329.6	339.4	338.2	333.6		346.7	351.8	356.7
655050	295.5	293.9	296.8	301.5	301.8		313.1	308.8	316.5
655021	264.4	271.6	276.1	277.2	273.7		284.3	290.2	296.4
655017	269.7	278.3	281.2	278.6	285.4		287.2	289.0	295.3

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Female, VI 5 mg/kg/day									
655054									
655038									
655034									
655039									
655029									
655067									
655020									
655087									
655066									
655042									
655059	272.6	273.2	277.4	278.1	274.3	284.8	283.3	287.0	286.6
655064	358.5	369.3	382.3	373.9	389.2	405.2	393.7	405.7	408.4
655050	317.0	322.6	318.4	323.8	329.2	325.3	327.5	328.9	328.5
655021	293.6	297.1	302.7	305.6	306.0	309.6	305.9	312.6	321.6
655017	304.5	310.2	318.0	320.2	324.0	331.8	328.9	335.4	334.5

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, VIII 25 mg/kg/day									
655058	172.7	197.1	220.3	233.6	245.9	265.0	272.3	251.8	272.1
655076	184.2	204.8	211.7	243.5	249.5	252.8	271.1	258.7	279.2
655047	161.2	177.4	207.8	210.3	224.3	233.1	255.5	242.3	269.2
655055	177.3	204.5	225.1	240.1	246.7	261.0	273.5	254.7	275.9
655105	177.2	192.8	212.1	225.6	227.4	248.1	251.2	243.7	272.7
655078	208.8	235.6	260.2	266.7	288.6	300.6	329.8	321.8	350.1
655073	171.7	199.8	226.4	236.2	251.7	260.7	276.1	266.6	287.2
655011	185.1	206.6	226.3	239.5	260.9	269.8	277.4	267.9	296.8
655085	200.2	223.6	248.5	267.3	288.3	303.0	308.7	296.7	321.6
655012	197.9	226.6	245.8	259.1	264.5	278.1	286.4	279.9	307.9
655043	173.4	190.0	214.5	223.6	232.9	248.4	257.5	249.7	259.7
655082	196.7	205.0	239.0	248.3	268.7	284.9	291.8	302.7	309.4
655060	187.1	203.3	220.7	243.2	261.8	266.5	289.7	297.7	316.8
655056	155.7	161.9	198.7	209.2	213.6	238.3	248.2	247.4	251.9
655081	189.4	213.2	228.8	251.6	265.5	283.6	288.8	298.9	310.7

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 94	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Female, VIII 25 mg/kg/day									
655058	281.5	289.4	294.3	290.1	293.1	278.2			
655076	277.7	290.4	298.5	303.8	303.3	297.0			
655047	264.1	273.3	278.6	274.0	264.8	264.9			
655055	281.4	293.8	294.1	287.4	292.5	279.5			
655105	275.6	283.4	278.8	283.6	279.2	268.8			
655078	340.3	368.1	370.5	364.9	361.4	351.3			
655073	291.4	309.2	317.3	318.0	313.9	305.3			
655011	301.6	304.4	311.6	319.9	319.5	306.7			
655085	324.2	331.3	340.0	347.3	339.3	317.9			
655012	299.9	312.3	317.8	320.6	326.1	305.6			
655043	261.0	264.8	273.1	277.9	273.4		293.8	295.9	292.0
655082	311.0	319.4	321.0	327.0	325.2		335.1	340.5	348.0
655060	320.5	329.5	339.1	337.5	342.6		349.5	349.9	353.1
655056	263.9	278.0	279.6	271.9	283.8		295.5	293.2	296.2
655081	322.1	328.5	343.8	345.3	341.0		340.8	354.9	358.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Female, VIII 25 mg/kg/day									
655058									
655076									
655047									
655055									
655105									
655078									
655073									
655011									
655085									
655012									
655043	303.1	300.0	304.7	300.4	315.8	306.2	302.9	313.1	305.6
655082	363.4	377.3	382.0	383.3	395.1	393.4	401.0	410.0	405.8
655060	363.6	373.3	370.8	379.2	369.5	388.7	383.6	387.4	393.7
655056	307.6	307.2	317.0	316.9	309.7	319.5	318.2	320.6	311.8
655081	364.9	373.2	381.9	378.2	383.8	387.9	402.3	410.5	417.3

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, X 125 mg/kg/day									
655097	179.5	195.9	216.7	233.9	239.1	252.7	267.5	264.0	283.3
655052	193.1	211.4	227.1	234.1	249.3	258.5	272.2	261.0	279.4
655063	165.6	185.0	204.1	211.0	219.7	229.9	233.8	223.3	245.3
655103	189.9	218.5	239.8	258.5	274.5	278.4	282.3	281.2	294.7
655026	181.1	211.1	231.4	253.0	260.5	281.7	277.6	273.8	288.7
655095	209.1	222.4	255.7	275.5	283.9	283.6	309.2	302.3	319.4
655023	180.1	201.6	227.4	236.2	250.9	263.8	271.9	270.4	277.5
655007	186.9	207.2	225.8	228.5	247.9	262.1	264.3	258.3	277.4
655053	203.7	218.3	236.6	258.6	277.3	288.1	286.6	273.8	310.6
655092	204.9	226.2	248.5	261.7	274.1	287.1	291.0	282.3	303.5
655046	183.8	203.3	218.6	247.4	263.5	280.9	284.1	300.0	313.0
655027	202.5	221.5	244.8	259.7	270.7	280.9	286.2	290.2	302.9
655104	183.9	205.6	228.5	246.2	255.3	277.2	280.1	289.7	299.9
655106	151.4	161.7	184.0	194.2	202.5	210.9	218.4	216.1	225.6
655024	192.9	213.5	230.9	254.3	267.2	274.2	284.1	295.2	307.4
655037	187.2	211.9	241.1	262.4	273.0	287.0	297.2	303.9	317.3
655088	204.4	223.2	244.6	261.9	284.1	285.8	294.2	310.9	311.6
655010	198.9	225.3	240.1	257.4	266.7	281.1	280.5	294.6	298.0
655077	195.4	210.5	229.9	250.0	265.9	272.5	271.8	284.3	290.6
655030	205.8	229.0	252.5	275.7	294.1	301.6	309.5	317.0	338.6
655075	207.0	228.1	248.1	275.3	287.2	306.2	326.2	340.3	355.4
655100	210.3	237.5	260.0	279.1	293.0	300.6	314.3	319.5	285.3
655049	160.3	177.9	198.9	210.3	212.7	222.1	229.1	223.4	229.5
655084	168.8	195.1	214.9	236.8	241.8	243.1	261.0	267.8	267.4
655061	165.4	182.8	209.5	230.7	242.5	247.1	262.3	266.3	279.0

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 94	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112
Female, X 125 mg/kg/day									
655097	290.0	294.2	301.8	315.9	309.7	294.8			
655052	280.3	288.4	278.6	293.4	289.8	277.8			
655063	246.8	250.7	251.7	265.8	272.2	251.5			
655103	302.5	303.6	305.8	314.5	310.1	294.3			
655026	294.7	307.5	296.8	300.9	298.8	283.1			
655095	334.2	332.3	336.6	336.1	324.6	317.1			
655023	285.6	292.3	292.1	298.1	304.2	282.7			
655007	288.3	286.2	290.3	307.2	310.1	283.0			
655053	315.0	313.8	317.9	332.0	333.9	305.9			
655092	304.4	296.5	308.0	315.6	310.7	299.4			
655046	324.0	324.2	332.4	343.5	350.9		357.2	354.4	371.1
655027	303.3	306.7	309.5	317.8	318.6		314.6	304.1	314.9
655104	301.6	310.4	314.0	329.6	326.3		335.7	332.4	340.0
655106	227.5	234.1	239.8	248.3	251.0		263.2	264.1	256.5
655024	304.1	314.7	323.3	323.8	319.5		333.0	340.7	340.4
655037	322.6	327.1	335.2	342.3	349.9		349.3	348.7	351.0
655088	315.2	310.3	311.1	315.0	314.7		322.2	328.0	294.0
655010	301.7	302.3	297.5	306.1	318.0		297.1	302.3	300.5
655077	292.4	285.1	291.2	291.8	299.2		304.4	305.3	311.1
655030	334.7	329.2	331.9	352.0	343.6		364.8	358.0	364.5
655075	363.5	359.2	359.8	371.3	360.3		366.4	361.9	374.6
655100	318.9	324.9	333.1	341.4	332.1		335.7	337.8	341.1
655049	235.0	240.4	242.0	241.0	241.5		246.8	244.2	245.6
655084	265.1	278.4	284.7	293.2	280.7		286.2	291.6	292.6
655061	275.7	288.3	290.5	285.5	283.8		288.1	294.2	288.9

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 119	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175
Female, X 125 mg/kg/day									
655097									
655052									
655063									
655103									
655026									
655095									
655023									
655007									
655053									
655092									
655046	375.6	389.0	388.9	397.5	398.5	400.2	405.5	415.1	418.3
655027	322.7	336.4	336.7	332.8	335.3	340.0	334.7	340.3	346.2
655104	334.0	354.6	347.7	356.8	348.1	380.4	384.9	381.0	372.1
655106	262.5	273.7	282.5	281.3	288.1	286.5	283.6	290.9	296.0
655024	342.9	355.2	355.1	351.8	357.5	357.7	353.2	365.2	364.0
655037	350.9	372.5	384.5	379.0	384.0	395.5	395.8	402.3	403.2
655088	332.5	358.3	373.6	368.1	382.1	381.9	386.5	395.3	404.3
655010	301.6	311.3	314.6	312.2	318.0	324.2	313.1	314.8	323.1
655077	323.7	332.0	324.8	319.2	332.9	338.2	333.9	331.2	339.1
655030	376.1	406.1	413.5	420.4	438.7	449.3	444.3	467.0	479.5
655075	384.1	402.6	410.2	409.1	422.3	427.5	429.5	445.4	449.4
655100	342.4	358.0	359.8	362.6	370.6	364.7	365.1	369.5	376.6
655049	246.5	252.7	253.9	253.0	259.1	263.2	258.5	261.1	262.2
655084	289.5	294.5	304.1	305.7	304.8	311.7	313.8	314.2	312.2
655061	289.1	304.9	308.6	300.5	302.1	305.7	306.0	313.3	308.4

INDIVIDUAL BODY WEIGHTS

	Body Weight g Day 182	Body Weight g Day 183
Female, X 125 mg/kg/day		
655097		
655052		
655063		
655103		
655026		
655095		
655023		
655007		
655053		
655092		
655046		
655027		
655104		
655106		
655024		
655037	416.9	394.4
655088	391.8	374.8
655010	327.7	306.3
655077	347.2	326.6
655030	480.0	455.3
655075	456.5	432.2
655100	370.6	358.5
655049	266.5	249.7
655084	320.3	302.1
655061	309.7	289.3

APPENDIX D

INDIVIDUAL FOOD CONSUMPTION

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Male, I 0 mg/kg/day										
654928	22.6	14.2	25.7	28.1	29.5	28.6	25.7	28.8	28.8	28.0
654993	23.2	24.5	25.8	26.8	27.4	26.1	22.9	26.5	25.8	24.5
654929	28.5	28.2	28.5	30.3	30.3	28.0	25.5	29.7	28.6	28.1
654972	25.7	25.6	26.9	26.9	26.4	26.1	23.6	26.1	25.0	25.0
654950	27.7	28.5	30.3	31.5	32.2	32.8	27.5	29.9	29.1	29.4
654953	34.9	35.8	35.9	38.6	40.7	38.5	33.2	36.2	36.3	37.8
654925	28.4	30.4	30.6	30.1	30.3	29.2	27.9	30.7	28.8	26.5
654987	30.0	29.7	30.4	26.4	29.0	29.6	26.9	28.9	28.8	28.2
654903	28.6	30.0	33.3	36.0	34.7	34.4	30.6	31.7	30.8	34.1
654966	27.6	28.7	28.6	31.8	7.8	10.4	25.8	26.2	16.3	24.6
654997	29.0	29.7	29.6	31.2	31.2	29.9	30.1	30.4	27.2	30.2
654971	22.9	25.4	30.0	31.7	33.6	31.5	32.0	30.9	29.1	32.2
654939	30.5	33.2	34.1	34.5	36.4	38.6	37.8	35.8	31.4	33.9
654919	25.3	26.2	28.0	29.0	28.1	29.3	29.8	28.9	28.1	29.0
654994	21.9	25.3	24.3	25.2	24.9	25.4	24.1	23.0	20.9	25.3
654949	25.1	25.5	26.6	27.8	28.2	27.2	28.7	29.5	30.2	29.5
654992	28.0	30.3	30.3	30.6	31.1	29.3	30.8	31.4	29.6	29.8
654909	23.8	27.5	27.5	26.9	27.7	27.9	26.0	25.0	26.3	27.0
654924	25.3	27.1	28.3	30.1	29.8	28.3	27.5	26.1	26.0	27.2
654943	26.0	28.3	28.2	29.9	30.6	28.9	29.9	27.1	28.1	28.6
654915	28.3	29.5	31.0	33.4	37.2	32.6	32.8	31.1	31.0	29.6
654927	30.3	31.9	37.5	34.5	34.6	31.6	31.6	32.0	30.2	32.7
654956	24.6	26.9	27.7	27.5	30.5	28.3	27.5	27.9	27.7	27.1
654910	28.9	31.4	34.0	30.8	34.2	32.5	34.9	33.9	33.9	32.1
654936	26.9	34.0	31.9	32.7	33.3	33.6	27.8	28.6	30.2	30.5

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91	Food Cons. g/anm/day Day 98	Food Cons. g/anm/day Day 105	Food Cons. g/anm/day Day 112	Food Cons. g/anm/day Day 119	Food Cons. g/anm/day Day 126	Food Cons. g/anm/day Day 133	Food Cons. g/anm/day Day 140
Male, I 0 mg/kg/day										
654928	27.5	28.0	28.1							
654993	24.8	23.7	23.6							
654929	28.7	28.6	28.2							
654972	26.0	24.7	26.5							
654950	22.8	31.8	30.6							
654953	36.1	34.8	18.9							
654925	28.5	28.0	28.1							
654987	29.8	28.2	28.0							
654903	31.9	33.1	32.3							
654966	27.1	28.7	28.2							
654997	30.8	28.7	30.1							
654971	30.6	29.3	30.7							
654939	34.3	33.7	34.5							
654919	29.2	25.7	27.4							
654994	23.3	23.1	24.2	25.1	23.7	24.9	23.2	24.7	25.5	22.4
654949	27.6	27.8	27.9	28.1	26.5	27.7	27.0	27.3	27.3	26.9
654992	30.5	29.0	29.5	27.0	29.6	30.8	29.9	31.0	30.0	29.2
654909	26.9	26.2	25.8	24.5	27.6	28.4	26.7	24.9	25.5	26.2
654924	26.8	24.4	25.8	26.2	27.9	28.6	28.5	26.6	26.7	25.9
654943	28.2	26.8	24.9	27.5	28.5	28.5	23.1	27.1	29.1	28.4
654915	30.3	29.1	29.2	29.0	31.4	30.8	30.4	29.7	31.6	29.9
654927	32.6	28.5	28.6	29.5	30.6	31.5	31.0	30.0	31.6	31.7
654956	26.9	25.5	24.6	25.1	27.4	26.8	26.1	25.8	26.2	28.5
654910	29.9	29.4	29.4	29.9	30.6	30.0	30.1	29.7	27.5	31.6
654936	29.5	30.4	30.6							

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 147	Food Cons. g/anm/day Day 154	Food Cons. g/anm/day Day 161	Food Cons. g/anm/day Day 168	Food Cons. g/anm/day Day 175	Food Cons. g/anm/day Day 182
Male, I 0 mg/kg/day						
654928						
654993						
654929						
654972						
654950						
654953						
654925						
654987						
654903						
654966						
654997						
654971						
654939						
654919						
654994	23.2	23.6	24.2	25.5	24.8	25.0
654949	26.8	26.8	26.9	28.3	26.6	26.6
654992	28.8	28.4	28.6	30.7	30.4	27.7
654909	21.8	24.9	26.3	25.6	24.5	26.3
654924	25.5	25.3	28.0	28.6	29.6	27.6
654943	25.3	28.5	28.3	30.4	26.5	26.8
654915	30.0	30.9	32.1	31.9	33.8	32.4
654927	30.6	30.4	30.3	29.1	29.9	29.9
654956	26.6	26.8	27.3	25.0	25.7	26.6
654910	29.5	29.3	30.6	29.7	30.4	29.9
654936						

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Male, III 1 mg/kg/day										
654913	26.4	30.2	30.2	29.2	30.8	29.8	25.3	29.4	29.2	29.8
654947	27.2	29.7	29.8	29.2	28.0	27.0	24.4	27.8	26.7	27.4
654995	27.2	29.5	30.5	27.1	29.1	28.9	25.2	26.9	27.9	29.6
654938	28.9	31.6	32.2	30.4	25.1	30.4	27.0	30.1	30.7	31.9
654941	30.8	32.0	34.2	32.6	34.2	30.4	25.6	28.9	28.9	30.9
654946	33.7	35.0	33.9	29.7	31.9	32.4	28.6	30.5	29.7	33.1
654960	30.0	29.4	29.3	26.7	28.3	27.7	24.1	29.9	29.0	27.0
654908	29.2	30.6	35.4	31.3	31.9	32.8	27.0	30.4	30.0	28.8
654984	30.8	30.9	29.7	30.8	31.6	31.5	25.3	30.3	32.2	33.4
654932	29.9	30.6	31.7	30.4	30.2	29.8	27.5	29.3	30.4	30.6
654948	30.6	31.0	32.1	32.3	32.7	30.4	30.2	29.2	30.2	30.3
654904	26.6	27.3	28.2	28.3	30.3	29.7	28.4	27.0	25.3	27.0
654954	28.2	29.0	31.7	31.4	33.1	32.0	31.1	32.0	31.0	31.6
654945	22.7	25.7	28.7	26.9	28.1	28.2	27.6	28.3	26.2	24.1
654988	28.0	29.3	31.0	30.2	30.6	29.3	29.8	28.7	28.5	28.9

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Male, III 1 mg/kg/day			
654913	29.2	27.1	30.0
654947	26.9	27.1	27.0
654995	27.1	26.2	28.1
654938	30.7	28.7	31.7
654941	31.3	26.8	27.3
654946	30.7	28.3	28.3
654960	28.2	27.2	28.1
654908	30.0	28.6	27.4
654984	32.4	30.3	29.2
654932	29.9	29.1	30.6
654948	37.7	29.9	31.4
654904	30.4	26.9	28.0
654954	31.8	28.8	31.7
654945	25.3	25.3	25.1
654988	28.5	29.6	30.0

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Male, V 5 mg/kg/day										
655005	26.5	28.9	30.6	31.7	30.7	30.9	28.5	31.2	32.3	31.0
654907	25.5	28.8	27.6	27.9	27.3	27.9	23.5	28.0	27.0	27.4
654980	28.4	30.6	32.4	33.2	35.0	34.8	30.2	33.9	32.4	31.1
654959	31.3	34.0	35.0	36.1	35.1	35.3	31.9	32.1	33.7	31.8
654961	29.5	33.7	36.9	36.6	38.3	34.4	30.4	33.2	34.0	35.3
654916	30.5	30.1	31.3	30.6	30.7	30.5	27.4	30.1	28.0	28.3
654911	30.7	35.4	36.7	37.7	36.9	37.5	31.2	34.7	34.0	32.3
654917	28.4	31.3	30.5	29.5	31.5	33.8	30.1	30.6	32.9	30.0
654998	29.6	31.1	31.8	32.9	33.6	32.1	30.1	31.5	32.1	32.4
654970	21.4	23.2	24.7	26.1	25.2	23.3	24.5	23.6	23.8	26.3
654926	27.3	28.7	32.1	33.4	35.8	32.3	33.8	32.2	32.2	33.8
654918	27.4	30.6	31.6	32.8	33.8	31.5	32.2	32.6	32.0	32.1
654981	22.7	25.6	27.4	28.1	27.9	25.9	25.8	24.6	24.5	27.1
654969	21.1	22.6	22.6	23.7	25.7	24.2	24.5	25.3	24.0	26.1
654967	27.4	29.9	29.3	29.6	30.3	29.0	25.2	29.2	28.6	28.6

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Male, V 5 mg/kg/day			
655005	32.0	30.3	27.4
654907	25.3	26.6	26.6
654980	33.4	31.3	32.9
654959	32.0	31.0	33.3
654961	33.5	32.0	30.2
654916	29.2	31.4	30.4
654911	32.7	34.2	32.0
654917	30.7	30.3	31.0
654998	32.7	32.1	25.4
654970	27.2	26.1	24.6
654926	30.5	28.9	33.6
654918	30.8	31.4	28.0
654981	25.9	26.4	27.2
654969	26.7	25.8	25.4
654967	28.4	27.4	26.0

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Male, VII 25 mg/kg/day										
655001	31.6	34.0	38.6	40.9	41.3	37.6	33.5	37.5	37.9	37.4
654975	26.2	29.5	30.8	28.4	28.3	28.4	26.0	28.8	30.5	27.6
654922	25.5	28.1	30.0	28.2	30.2	30.5	27.4	34.1	33.2	30.5
654940	28.7	30.3	31.2	29.7	32.2	30.9	27.5	28.8	30.6	31.1
654930	28.2	32.6	33.7	34.8	36.8	35.8	31.7	31.9	34.2	33.8
654958	26.4	27.7	28.0	27.6	30.0	28.2	25.6	27.6	27.5	27.5
654952	27.9	31.1	31.1	30.1	32.7	32.0	28.2	31.6	31.2	29.2
654923	26.9	31.9	32.4	32.9	31.4	30.5	26.5	29.7	28.8	26.5
654989	30.2	33.7	31.9	32.1	32.2	32.0	27.6	33.1	32.7	31.0
655006	31.7	31.3	31.2	30.6	31.5	32.1	26.9	31.1	29.9	29.7
654920	24.8	27.7	29.5	29.7	30.1	30.1	29.2	30.9	30.8	29.2
654912	23.4	24.4	24.1	24.5	24.8	24.8	24.8	26.3	26.7	26.1
654934	27.8	27.8	28.6	26.8	29.5	27.6	29.2	30.1	29.3	28.1
654964	29.7	29.8	30.6	30.9	33.4	34.0	33.6	32.8	34.3	30.8
654933	30.2	33.3	35.8	36.2	38.6	38.1	38.5	37.9	36.7	34.4

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Male, VII 25 mg/kg/day			
655001	36.4	32.7	35.3
654975	27.7	27.0	30.5
654922	32.1	29.7	30.2
654940	30.4	28.4	28.7
654930	32.2	28.3	30.5
654958	27.0	26.9	27.6
654952	32.4	31.0	30.3
654923	27.9	29.1	27.2
654989	31.3	30.9	32.3
655006	27.7	28.5	27.5
654920	29.2	28.9	29.7
654912	27.7	24.7	24.3
654934	27.8	29.1	31.5
654964	30.9	29.6	34.2
654933	34.3	33.3	34.5

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Male, IX 125 mg/kg/day										
654983	28.5	30.9	31.4	31.2	33.4	33.7	29.5	30.0	31.5	30.2
654965	23.7	26.9	28.1	27.5	27.7	27.5	24.6	23.6	27.4	25.7
654979	24.8	26.5	26.3	25.7	27.9	27.4	26.1	27.3	27.6	28.1
654986	28.5	29.3	31.8	31.9	33.5	33.4	28.5	32.9	24.7	17.4
655003	26.2	29.5	28.6	27.9	27.6	28.6	26.9	29.3	27.8	25.1
654921	29.5	31.7	31.7	31.6	34.1	28.7	28.1	32.7	31.9	29.8
654996	28.0	29.0	28.6	27.0	29.9	26.5	24.9	29.6	21.1	25.9
654951	27.7	28.8	30.2	30.8	31.6	31.3	28.5	29.6	29.3	27.4
654955	30.4	33.1	37.1	34.6	33.7	33.0	29.2	31.2	31.0	31.6
654914	27.4	29.1	27.9	28.3	30.5	29.4	27.1	27.9	28.8	27.2
654937	27.0	29.7	31.5	30.3	31.3	31.2	30.8	29.2	30.8	29.6
654962	26.4	30.4	33.7	32.2	33.6	32.0	31.7	32.2	29.8	31.2
654982	25.4	28.0	30.4	29.5	31.6	30.7	31.4	31.0	23.7	27.7
654931	26.5	29.8	32.6	31.3	32.0	32.6	32.2	30.3	28.1	17.7
654906	28.9	31.7	34.5	32.2	36.9	36.7	38.0	35.5	34.9	35.8
654985	22.3	24.1	26.2	25.0	23.9	26.9	26.1	25.3	25.6	22.5
654978	23.2	24.8	26.0	25.0	25.2	25.1	24.1	26.1	24.5	25.9
654974	25.7	29.0	29.1	29.2	29.8	29.4	28.6	27.5	28.4	24.8
654990	26.0	27.0	27.1	27.6	28.0	26.9	27.7	26.2	27.8	27.6
654976	23.6	28.9	29.6	26.7	27.7	27.0	26.8	26.3	19.3	26.8
654957	27.8	30.4	30.2	28.7	29.7	28.7	28.9	28.2	27.3	25.7
654973	28.5	28.8	28.3	28.0	29.9	27.6	25.7	26.3	13.9	26.7
654977	20.8	25.5	25.0	23.5	26.2	24.5	23.9	23.8	24.3	17.9
654942	27.9	30.1	30.4	28.2	29.2	29.9	29.5	28.5	32.1	27.9
654991	30.1	33.2	34.6	34.6	35.4	35.6	35.6	36.3	28.9	28.8

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91	Food Cons. g/anm/day Day 98	Food Cons. g/anm/day Day 105	Food Cons. g/anm/day Day 112	Food Cons. g/anm/day Day 119	Food Cons. g/anm/day Day 126	Food Cons. g/anm/day Day 133	Food Cons. g/anm/day Day 140
Male, IX 125 mg/kg/day										
654983	29.8	26.0	30.2							
654965	19.5	31.9	30.6							
654979	26.8	26.1	27.8							
654986	22.6	33.3	36.5							
655003	26.3	26.6	28.1							
654921	31.6	28.4	30.4							
654996	25.9	29.9	30.1							
654951	27.8	24.9	28.8							
654955	26.4	12.2	35.2							
654914	30.1	29.5	30.6							
654937	29.7	24.6	28.8							
654962	30.4	25.4	30.3							
654982	20.8	27.3	31.7							
654931	11.6	31.8	28.1							
654906	33.7	26.3	35.6							
654985	12.0	17.1	23.9	18.6	19.8	22.5	22.5	14.9	22.6	24.5
654978	25.6	25.4	25.9	25.1	25.2	26.3	24.3	25.7	25.0	25.7
654974	9.5	23.7	30.7	28.2	27.5	27.8	26.0	28.2	29.2	30.2
654990	27.4	29.8	29.7	25.6	26.2	27.4	29.0	29.0	30.3	29.2
654976	25.1	29.9	29.3	25.4	25.4	25.1	26.6	26.6	25.3	26.9
654957	27.4	27.3	26.2	25.5	26.2	26.7	27.4	27.2	28.3	31.3
654973	29.0	27.4	26.0	26.2	26.2	25.4	27.2	27.2	27.5	29.7
654977	24.2	23.5	21.5	22.0	23.4	23.1	22.8	23.4	22.9	23.0
654942	28.5	24.6	25.7	25.5	25.1	24.6	25.8	27.0	26.5	26.4
654991	29.6	32.0	32.7	33.3	33.9	31.6	33.8	32.6	33.7	33.8

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 147	Food Cons. g/anm/day Day 154	Food Cons. g/anm/day Day 161	Food Cons. g/anm/day Day 168	Food Cons. g/anm/day Day 175	Food Cons. g/anm/day Day 182
Male, IX 125 mg/kg/day						
654983						
654965						
654979						
654986						
655003						
654921						
654996						
654951						
654955						
654914						
654937						
654962						
654982						
654931						
654906						
654985	19.0	28.1	23.5	25.1	22.4	21.0
654978	24.1	24.8	24.5	24.5	23.5	24.8
654974	28.7	27.6	28.0	31.1	29.0	30.2
654990	30.0	29.5	30.1	30.5	27.5	28.1
654976	26.1	25.8	24.5	26.4	25.7	25.8
654957	28.9	26.4	25.9	26.6	26.5	28.2
654973	28.0	27.2	25.7	28.2	25.8	26.6
654977	21.8	21.7	21.8	23.0	23.3	22.8
654942	25.6	26.8	26.2	27.6	27.0	28.5
654991	31.7	30.4	31.1	32.2	33.0	33.8

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Female, II 0 mg/kg/day										
655031	16.7	19.3	21.5	20.8	21.4	22.8	19.1	22.4	22.2	22.0
655107	17.6	16.8	16.6	16.3	16.0	17.7	14.4	17.9	17.3	17.7
655098	18.2	18.0	19.1	18.7	17.9	18.6	15.3	18.8	17.3	17.8
655016	19.2	18.2	18.9	19.6	19.3	20.8	18.4	21.2	22.1	20.6
655079	16.1	15.0	17.1	16.8	16.9	17.6	16.6	18.3	17.5	17.4
655036	20.4	19.7	22.2	21.4	20.9	22.5	20.1	21.8	21.3	19.6
655025	19.5	20.0	21.9	21.1	21.4	22.5	19.8	21.4	22.0	22.3
655099	23.1	23.7	22.8	22.6	23.7	23.9	22.2	23.0	21.6	22.3
655032	20.1	19.8	22.1	21.4	21.7	23.5	21.2	23.5	21.5	21.8
655083	20.3	19.4	20.8	20.3	20.4	21.1	19.9	23.4	20.8	22.2
655093	14.9	15.2	17.2	15.7	16.9	17.4	15.7	17.9	17.2	17.5
655045	18.8	19.5	21.7	20.3	21.4	20.5	20.2	21.9	21.8	19.5
655065	20.5	20.8	22.4	22.8	24.6	23.8	23.1	27.0	26.2	24.0
655074	19.7	20.1	22.1	21.1	22.1	21.9	20.8	19.3	21.1	21.1
655035	19.6	21.0	22.5	20.2	21.3	22.3	21.6	19.9	21.7	21.5
655009	19.9	20.9	23.6	22.3	22.2	23.4	24.1	23.8	24.9	23.0
655068	20.7	22.2	23.0	20.5	22.5	20.2	19.7	21.6	20.0	20.4
655019	21.1	21.2	24.1	23.1	23.4	23.5	21.4	22.4	21.2	21.0
655062	20.8	20.1	21.8	19.8	22.8	22.5	20.9	21.8	22.0	22.2
655109	20.4	20.5	21.2	20.8	20.4	20.1	18.9	20.5	19.6	18.7
655101	22.0	21.6	23.0	23.5	25.1	24.0	23.9	23.1	23.0	22.9
655072	21.4	21.1	22.5	21.7	21.6	22.0	20.6	20.2	20.4	20.5
655015	18.2	18.4	17.7	17.6	19.8	18.7	15.8	18.6	18.9	17.1
655071	18.1	14.8								
655022	18.4	19.3	20.8	20.0	20.0	19.5	18.6	19.8	19.2	18.7

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91	Food Cons. g/anm/day Day 98	Food Cons. g/anm/day Day 105	Food Cons. g/anm/day Day 112	Food Cons. g/anm/day Day 119	Food Cons. g/anm/day Day 126	Food Cons. g/anm/day Day 133	Food Cons. g/anm/day Day 140
Female, II 0 mg/kg/day										
655031	21.5	20.2	18.1							
655107	16.6	16.5	16.4							
655098	17.0	17.3	15.9							
655016	19.8	20.9	19.7							
655079	18.1	17.0	16.9							
655036	21.4	22.3	20.5							
655025	22.0	21.2	21.7							
655099	21.8	22.0	17.9							
655032	22.3	18.0	21.7							
655083	22.1	22.1	21.4							
655093	18.0	17.4	16.9							
655045	20.3	20.7	20.1							
655065	23.8	25.9	25.0							
655074	21.7	20.1	21.7							
655035	23.3	21.5	19.8	18.3	22.6	20.6	20.4	21.9	21.2	20.9
655009	24.0	24.1	22.9	20.9	23.5	25.1	20.2	21.3	22.6	24.7
655068	19.7	20.0	17.5	19.0	21.0	23.3	19.2	21.2	21.8	22.4
655019	20.2	19.5	20.2	19.6	20.1	20.4	19.4	21.7	21.8	24.2
655062	24.0	24.3	21.6	22.0	26.1	25.1	25.6	27.3	24.1	24.9
655109	18.6	19.6	18.0	16.2	19.0	20.1	18.8	18.8	17.3	19.2
655101	21.9	24.8	22.3	22.3	22.6	22.3	20.8	23.0	26.0	23.3
655072	20.7	19.5	19.0	22.0	20.3	21.0	20.8	23.0	20.6	21.0
655015	18.0	17.3	18.4	15.6	14.8	19.2	20.2	20.2	21.3	21.4
655071										
655022	20.2	18.3	18.2							

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 147	Food Cons. g/anm/day Day 154	Food Cons. g/anm/day Day 161	Food Cons. g/anm/day Day 168	Food Cons. g/anm/day Day 175	Food Cons. g/anm/day Day 182
Female, II 0 mg/kg/day						
655031						
655107						
655098						
655016						
655079						
655036						
655025						
655099						
655032						
655083						
655093						
655045						
655065						
655074						
655035	7.3	15.1	16.2	22.0	21.4	24.3
655009	22.2	20.5	21.2	22.3	21.4	20.2
655068	21.6	19.7	21.4	22.1	23.0	21.6
655019	22.1	23.9	21.7	24.4	23.8	24.2
655062	23.8	23.9	25.8	26.1	25.0	25.0
655109	18.5	18.4	17.1	18.1	18.9	18.1
655101	22.4	22.4	22.3	22.6	24.4	23.9
655072	21.0	21.7	20.5	20.2	22.6	23.6
655015	20.5	21.3	18.8	21.5	21.1	20.6
655071						
655022						

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Female, IV 1 mg/kg/day										
655086	18.0	18.2	18.8	17.3	18.1	18.7	16.0	19.4	18.5	18.9
655041	18.1	18.9	20.9	19.0	- [a]	23.9	19.5	24.6	20.8	21.4
655108	18.8	19.2	20.5	20.4	19.3	19.1	16.9	20.5	20.3	19.5
655040	22.0	21.9	23.9	20.6	23.5	23.1	18.9	21.8	21.7	22.2
655044	20.3	21.1	22.9	21.7	21.4	22.1	18.8	20.6	22.1	21.3
655013	22.4	21.3	23.0	19.8	20.4	19.8	17.6	19.8	19.3	19.6
655089	19.8	20.2	22.4	20.7	22.2	22.3	21.0	24.4	24.2	23.7
655091	20.4	20.3	19.6	22.2	22.8	22.2	20.1	23.4	22.6	21.9
655033	19.1	19.1	20.6	20.1	20.5	21.8	18.5	21.2	20.3	21.2
655090	23.2	20.8	23.9	22.7	23.0	22.2	20.7	23.6	23.0	22.4
655051	18.1	16.5	17.9	17.6	18.7	19.3	18.0	17.5	17.4	13.2
655018	22.5	20.4	22.1	22.7	23.3	22.4	20.5	25.5	24.7	26.1
655096	18.9	19.1	20.0	18.6	19.1	20.8	19.1	20.5	20.9	20.1
655057	17.3	17.9	18.6	18.1	19.9	20.1	18.6	20.6	19.0	18.8
655028	19.1	19.3	19.9	19.5	19.6	20.8	18.8	19.5	19.3	19.5

[a] Inaccurate data; food consumption value not calculated.

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Female, IV 1 mg/kg/day			
655086	18.1	17.3	17.1
655041	20.2	19.0	17.0
655108	20.2	18.5	18.6
655040	22.0	21.8	22.5
655044	21.2	19.2	20.1
655013	19.9	20.1	19.0
655089	23.5	23.1	20.5
655091	20.6	21.3	21.0
655033	18.9	20.8	20.1
655090	23.9	22.5	20.2
655051	18.3	17.6	19.1
655018	24.3	24.3	22.2
655096	18.4	20.1	19.9
655057	18.7	18.4	19.0
655028	21.0	19.9	19.3

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Female, VI 5 mg/kg/day										
655054	19.6	19.5	20.0	20.5	19.8	18.9	18.7	20.8	20.0	20.8
655038	21.1	20.0	21.8	21.0	20.8	22.4	18.7	22.7	23.0	21.4
655034	19.5	18.0	20.2	19.8	20.6	20.9	18.5	20.4	20.8	20.1
655039	19.6	19.3	21.0	20.9	21.0	23.8	20.5	22.0	23.7	22.7
655029	20.3	19.5	22.5	20.6	21.1	16.0	18.9	20.8	18.5	20.6
655067	20.1	19.5	21.6	21.3	20.6	21.4	18.9	21.3	21.1	19.7
655020	19.1	20.1	18.4	20.2	22.8	22.9	21.7	25.1	24.7	21.9
655087	21.0	21.6	21.5	22.2	23.9	20.9	20.3	23.2	24.3	21.0
655066	22.6	23.7	25.5	24.3	26.0	24.1	21.4	23.3	21.8	21.2
655042	23.5	23.1	25.5	24.6	25.3	24.1	25.3	25.8	23.8	23.3
655059	17.3	18.0	18.8	19.1	19.3	19.2	17.9	19.2	18.7	19.1
655064	17.9	18.4	21.5	21.3	22.6	22.8	23.5	24.1	23.9	22.8
655050	19.7	19.4	21.3	21.0	20.9	21.2	20.1	22.1	21.4	20.4
655021	16.6	15.9	19.0	19.3	17.7	18.9	19.1	18.9	18.4	16.9
655017	19.0	18.2	19.6	18.7	20.6	20.4	19.4	21.8	20.1	19.5

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Female, VI 5 mg/kg/day			
655054	20.7	19.2	19.8
655038	21.6	21.8	20.8
655034	20.6	20.5	20.6
655039	22.2	20.2	19.4
655029	19.4	19.0	20.1
655067	18.6	18.5	19.7
655020	23.3	22.9	20.6
655087	20.0	21.2	22.1
655066	23.3	22.0	20.4
655042	24.1	22.2	21.4
655059	18.7	19.3	18.7
655064	22.9	21.1	21.4
655050	21.4	20.1	21.2
655021	17.0	17.3	17.1
655017	20.4	19.5	20.2

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Female, VIII 25 mg/kg/day										
655058	19.6	19.0	20.3	19.5	21.8	19.5	17.0	20.8	21.2	23.7
655076	19.4	18.7	22.3	19.9	20.2	21.4	18.6	21.3	21.3	22.8
655047	16.6	18.2	17.7	18.1	19.0	20.3	17.4	20.5	18.8	18.5
655055	19.6	18.8	28.3	20.0	20.7	20.4	19.0	22.4	20.0	20.4
655105	18.0	17.4	20.9	17.8	19.8	19.7	17.7	22.8	20.0	19.5
655078	23.1	22.8	25.4	25.1	27.4	30.7	25.1	26.4	25.4	26.5
655073	20.3	21.0	22.1	22.0	21.1	23.1	20.3	24.0	23.0	23.1
655011	19.3	19.8	21.3	21.8	21.2	20.9	19.1	24.3	23.1	20.9
655085	21.7	21.4	23.6	24.5	24.7	22.9	21.2	22.9	22.8	23.4
655012	22.0	20.9	22.2	21.5	21.6	21.5	19.9	24.2	21.6	21.8
655043	18.5	17.9	18.7	19.9	20.5	19.9	18.7	21.8	18.7	20.1
655082	21.2	20.8	21.4	22.1	23.9	22.1	25.3	22.8	23.2	20.6
655060	18.0	17.4	19.6	19.4	19.0	22.8	21.6	24.5	22.2	22.3
655056	16.5	18.3	18.3	19.3	21.3	20.7	20.2	22.6	22.5	22.9
655081	19.4	20.8	24.4	21.2	22.8	23.8	24.4	23.7	22.9	25.2

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91
Female, VIII 25 mg/kg/day			
655058	21.8	19.7	18.8
655076	22.3	21.6	23.1
655047	18.6	17.4	16.9
655055	20.4	19.9	19.4
655105	17.9	19.0	17.7
655078	26.2	23.5	18.5
655073	21.5	22.2	20.1
655011	22.1	21.9	21.9
655085	24.8	24.2	22.4
655012	21.8	21.8	21.5
655043	19.8	19.9	18.2
655082	21.8	22.6	22.0
655060	23.2	22.6	21.0
655056	22.2	20.4	21.4
655081	24.7	23.3	21.9

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 7	Food Cons. g/anm/day Day 14	Food Cons. g/anm/day Day 21	Food Cons. g/anm/day Day 28	Food Cons. g/anm/day Day 35	Food Cons. g/anm/day Day 42	Food Cons. g/anm/day Day 49	Food Cons. g/anm/day Day 56	Food Cons. g/anm/day Day 63	Food Cons. g/anm/day Day 70
Female, X 125 mg/kg/day										
655097	18.4	19.3	21.2	19.2	20.8	22.2	19.8	22.0	21.3	21.0
655052	18.6	18.9	19.4	20.4	19.1	19.6	18.0	21.1	20.2	19.9
655063	16.2	16.7	18.2	17.3	17.2	17.7	15.2	18.7	16.7	17.8
655103	19.9	21.3	22.3	20.6	20.4	19.9	18.6	21.4	21.3	19.5
655026	18.8	19.1	20.7	20.1	21.5	20.6	17.7	21.8	20.1	21.5
655095	20.2	23.1	23.5	23.6	22.8	24.5	21.7	25.8	25.9	24.4
655023	19.4	20.0	21.6	21.8	21.1	21.1	20.0	20.6	20.2	20.0
655007	18.4	19.2	19.5	20.9	22.9	19.8	18.9	21.7	21.5	19.1
655053	19.7	20.2	22.9	22.2	23.1	22.2	19.8	24.2	22.2	21.5
655092	19.6	20.1	21.5	21.3	20.7	19.6	19.1	21.4	19.6	19.3
655046	19.3	20.6	24.5	23.3	23.9	21.8	23.8	24.5	21.2	22.6
655027	19.3	20.5	20.3	20.2	20.2	19.6	20.8	20.7	19.0	18.4
655104	19.5	21.3	22.1	22.7	24.4	22.2	24.3	24.3	21.9	23.1
655106	14.7	16.7	16.9	16.4	16.9	15.7	15.8	16.6	16.5	16.5
655024	19.7	19.6	21.4	20.4	21.5	- [a]	22.1	21.2	19.7	21.5
655037	19.5	22.1	23.3	23.3	23.8	22.8	22.5	23.3	22.1	22.0
655088	22.0	22.8	26.4	24.0	23.8	22.5	28.0	21.2	23.3	21.5
655010	21.1	21.4	21.9	21.1	21.6	20.9	22.8	22.1	20.9	22.3
655077	18.6	20.1	20.9	20.7	20.2	19.2	20.4	19.7	18.8	19.2
655030	20.7	21.6	22.8	22.2	21.1	21.6	21.4	23.8	20.1	17.8
655075	20.7	22.2	23.8	23.2	25.9	24.7	28.2	25.9	23.9	22.7
655100	22.6	23.0	23.4	23.2	23.7	23.2	23.5	26.1	25.4	24.1
655049	16.0	18.2	18.6	17.9	18.8	17.2	15.1	16.6	16.9	16.4
655084	18.3	18.6	19.8	18.6	20.0	19.1	19.7	17.5	18.7	19.9
655061	17.3	18.7	20.1	19.7	20.5	20.0	19.1	21.2	20.1	20.5

[a] Inaccurate data; food consumption value not calculated.

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 77	Food Cons. g/anm/day Day 84	Food Cons. g/anm/day Day 91	Food Cons. g/anm/day Day 98	Food Cons. g/anm/day Day 105	Food Cons. g/anm/day Day 112	Food Cons. g/anm/day Day 119	Food Cons. g/anm/day Day 126	Food Cons. g/anm/day Day 133	Food Cons. g/anm/day Day 140
Female, X 125 mg/kg/day										
655097	22.0	23.7	20.5							
655052	18.4	18.5	19.0							
655063	17.2	20.4	20.7							
655103	19.3	20.8	19.3							
655026	19.0	6.1	18.6							
655095	26.2	18.6	23.5							
655023	19.3	20.7	21.0							
655007	20.3	23.8	23.5							
655053	22.6	21.8	21.4							
655092	20.1	20.3	18.4							
655046	23.5	24.4	24.0							
655027	18.3	19.7	12.7							
655104	22.9	25.3	25.2							
655106	15.7	17.5	16.8							
655024	19.9	20.1	20.1							
655037	21.4	22.6	22.3	20.5	19.0	19.7	21.3	23.4	23.5	22.6
655088	20.3	21.1	19.4	21.2	24.1	17.9	21.8	25.6	26.6	24.6
655010	19.1	20.7	23.2	17.2	19.4	21.6	20.0	22.4	23.5	25.9
655077	19.6	18.4	18.9	18.1	18.2	20.3	20.1	18.7	17.8	18.7
655030	20.2	23.4	24.4	22.6	22.4	20.6	24.3	28.1	27.5	26.9
655075	20.7	27.2	19.2	22.4	22.2	24.4	27.9	27.0	26.0	24.5
655100	23.7	22.1	20.8	21.5	23.3	24.6	24.8	26.6	27.4	28.8
655049	16.1	15.0	14.4	15.2	14.8	14.9	14.8	15.0	14.9	18.6
655084	18.7	19.8	16.2	17.0	20.5	18.9	18.2	17.7	18.4	21.7
655061	19.5	19.2	17.8	18.5	17.7	17.2	18.1	19.6	18.5	22.5

INDIVIDUAL FOOD CONSUMPTION

	Food Cons. g/anm/day Day 147	Food Cons. g/anm/day Day 154	Food Cons. g/anm/day Day 161	Food Cons. g/anm/day Day 168	Food Cons. g/anm/day Day 175	Food Cons. g/anm/day Day 182
Female, X 125 mg/kg/day						
655097						
655052						
655063						
655103						
655026						
655095						
655023						
655007						
655053						
655092						
655046						
655027						
655104						
655106						
655024						
655037	22.0	23.4	22.3	22.3	21.4	17.6
655088	22.5	24.9	22.4	26.3	23.2	21.8
655010	23.9	24.5	24.6	29.6	20.9	20.9
655077	19.4	18.8	18.3	18.6	18.8	18.9
655030	26.9	28.6	24.5	29.3	28.7	24.5
655075	25.2	24.9	26.5	27.5	23.2	22.9
655100	26.5	26.0	27.5	29.2	23.6	23.7
655049	15.4	15.7	15.3	16.3	15.4	17.5
655084	20.0	17.9	17.9	25.5	18.2	20.5
655061	17.1	17.4	17.6	20.5	17.6	17.4

APPENDIX E

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	I	654928	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	I	654993	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	I	654929	General observation, No Abnormality Detected	0-21,91-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Stain Fur/Skin, Shoulder, Bilateral, Brown	28-42,49-84
			Sacrificed by design	93
M	I	654972	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	I	654950	General observation, No Abnormality Detected	0-14
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Hyperreactive	70-93
			Hair Loss, Forepaw, Bilateral	28-42,49-93
			Protrusion, Umbilical Hernia	21-42,49-93
			Sacrificed by design	93
M	I	654953	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	I	654925	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	I	654987	General observation, No Abnormality Detected	0-21,35-42,49-93
			Eye Observations, Enophthalmus, Right	28
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Discharge, Eye right, Black	28
			Sacrificed by design	93
M	I	654903	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	I	654966	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	10,21
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175
M	I	654997	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Left	56
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,77,90,94-105,119,133,154,175
			Sacrificed by design	175
M	I	654971	General observation, No Abnormality Detected	0,7,14-84,91,98-133
			Eye Observations, Enophthalmus, Right	147-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	I	654971	Discharge, Eye right, Black	140-147
			Sacrificed by design	175
M	I	654939	General observation, No Abnormality Detected	0,7,14-21
			Eye Observations, Bled via Orbital for Clin Path, Left	94-105,119,133,154
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,175
			Eye Observations, Corneal Opacity, Right	91,98-175
			Discharge, Eye right, Black	91,98-105
			Hair Loss, Forelimb, Bilateral	42-84,91,98-175
			Hair Loss, Forelimb, Left	28-35
			Hair Loss, Forepaw, Bilateral	42-84,91,98-175
			Hair Loss, Forepaw, Left	28-35
			Swollen Observations, Face	91,98
			Sacrificed by design	175
M	I	654919	General observation, No Abnormality Detected	0,7,14-84,91,105,126-140,168-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	35
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,56,77,90,94-105,119,133,154, 175
			Discharge, Nose, Black	98
			Hair Loss, Nose	119
			Wound, Superficial, Nose	112,147-161
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	I	654994	General observation, No Abnormality Detected	0-140
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Stain Fur/Skin, Face, Red	147-183
			Stain Fur/Skin, Head, Red	147-183
			Sacrificed by design	183
M	I	654949	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Accidentally killed	183
M	I	654992	General observation, No Abnormality Detected	0-140
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Stain Fur/Skin, Face, Red	147-183
			Stain Fur/Skin, Head, Red	147-183
			Sacrificed by design	183
M	I	654909	General observation, No Abnormality Detected	0-119,133-140
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Hyperreactive	126
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Sacrificed by design	183
M	I	654924	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
M	I	654943	General observation, No Abnormality Detected	0-126

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	I	654943	Eye Observations, Bled via Orbital for Clin Path, Right	183
			Discharge, Eye right, Black	133-161,183
			Hair Loss, Face, Right	168-183
			Sacrificed by design	183
M	I	654915	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
M	I	654927	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
M	I	654956	General observation, No Abnormality Detected	0-119
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Face, Red	126-183
			Sacrificed by design	183
M	I	654910	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
M	I	654936	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	III	654913	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654947	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654995	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654938	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654941	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654946	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654960	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Hair Loss, Forelimb, Bilateral	49-93
			Hair Loss, Forepaw, Bilateral	42,49-93
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	III	654908	General observation, No Abnormality Detected	0-42,49-70
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Hair Loss, Side, Right	77-93
			Sacrificed by design	93
M	III	654984	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	93
			Eye Observations, Bled via Orbital for Clin Path, Right	48
			Sacrificed by design	93
M	III	654932	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	III	654948	General observation, No Abnormality Detected	0,7,14-56,98-126
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Hair Loss, Forepaw, Bilateral	161-175
			Hair Loss, Forepaw, Right	133-154
			Stain Fur/Skin, Forelimb, Left, Brown	63-84,91
			Stain Fur/Skin, Shoulder, Left, Red	154-175
			Stain Fur/Skin, Ventral body, Red	154-175
			Sacrificed by design	175
M	III	654904	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Left	10

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	III	654904	Eye Observations, Bled via Orbital for Clin Path, Right	0-4,21,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175
M	III	654954	General observation, No Abnormality Detected	0,7,28-84,91,98-105
			Eye Observations, Enophthalmus, Right	112-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Hair Loss, Forelimb, Bilateral	14-21
			Sacrificed by design	175
			General observation, No Abnormality Detected	0,7
			Eye Observations, Exophthalmus, Bilateral	21
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	35
			Eye Observations, Bled via Orbital for Clin Path, Left	10
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,21,56,77,90,94-105,119,133,154,175
			Eye Observations, Corneal Opacity, Right	14-84,91,98-175
			Stain Fur/Skin, Dorsal Body, Red	154-175
			Sacrificed by design	175
M	III	654988	General observation, No Abnormality Detected	0,7,49-77,91,98,133-175
			Eye Observations, Enophthalmus, Right	42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Eye Observations, Corneal Opacity, Right	14-42
			Hair Loss, Forepaw, Left	105-126
			Hair Loss, Forepaw, Right	84
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	V	655005	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654907	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654980	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654959	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654961	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654916	General observation, No Abnormality Detected	0-42,49-63,77-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Comments, animal out of cage	70
			Stain Fur/Skin, Ventral body, Brown	70
			Stain Fur/Skin, Face, Brown	70
			Wet Fur, Ventral body, Ventral	70
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	V	654911	General observation, No Abnormality Detected	0-7
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Hair Loss, Forelimb, Left	35-42,49-93
			Hair Loss, Forepaw, Bilateral	14-42,49-93
			Sacrificed by design	93
M	V	654917	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654998	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	V	654970	General observation, No Abnormality Detected	0,7,14-35,56-84,105-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Discharge, Nose, Black	42-49,98
			Discharge, Eye right, Black	91
			Sacrificed by design	175
M	V	654926	General observation, No Abnormality Detected	0,7,14-28,42-84,91,98-175
			Eye Observations, Enophthalmus, Right	35
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	V	654918	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
M	V	654981	General observation, No Abnormality Detected	0,7,14-84,91,98-147
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Stain Fur/Skin, Dorsal Body, Red	154-175
			Stain Fur/Skin, Face, Red	154-175
			Sacrificed by design	175
M	V	654969	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	105,154
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-98,119,133,175
			Eye Observations, excessive bleeding	133
			Sacrificed by design	175
M	V	654967	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	VII	655001	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Left	93
			Eye Observations, Bled via Orbital for Clin Path, Right	48
			Sacrificed by design	93
M	VII	654975	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	93
			Eye Observations, Bled via Orbital for Clin Path, Right	48
			Sacrificed by design	93
M	VII	654922	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	VII	654940	General observation, No Abnormality Detected	0
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Vocalization, No Abnormality Detected	21,28,35,42
			Hair Loss, Forelimb, Bilateral	28-42,49-93
			Hair Loss, Forepaw, Bilateral	7-42,49-93
			Sacrificed by design	93
M	VII	654930	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	VII	654958	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	VII	654952	General observation, No Abnormality Detected	0-28
			Absent, Toe, Forepaw Right	35-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Swollen Observations, Forepaw, Right	35-42,49-63
			Sacrificed by design	93
M	VII	654923	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	VII	654989	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	VII	655006	General observation, No Abnormality Detected	0-42,49-93
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			Sacrificed by design	93
M	VII	654920	General observation, No Abnormality Detected	0,7,14-84,91,98-147
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Stain Fur/Skin, Head, Red	154-175
			Sacrificed by design	175
M	VII	654912	General observation, No Abnormality Detected	0,7,14-84
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			General Teeth Observations, Clipped	86,91,98-175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	VII	654934	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	56
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,77,90,94-105,119,133,154, 175
			Sacrificed by design	175
M	VII	654964	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
M	VII	654933	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654983	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	49-93
			Hyperactive	42,49-84
			Sacrificed by design	93
M	IX	654965	General observation, No Abnormality Detected	0-42
			Eye Observations, Enophthalmus, Right	63-93
			Eye Observations, Exophthalmus, Right	56
			Eye Observations, Bled via Orbital for Clin Path, Left	93
			Eye Observations, Bled via Orbital for Clin Path, Right	48
			Eye Observations, Corneal Opacity, Right	63-93
			General Teeth Observations, Clipped	77-93
			General Teeth Observations, Striated	84-93
			Discharge, Eye right, Black	49-56
			Hair Loss, Face, Right	63-93
			Wound, Superficial, Head	70-77
			Sacrificed by design	93
M	IX	654979	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	49-93
			Sacrificed by design	93
M	IX	654986	General observation, No Abnormality Detected	0-42,49-70
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654986	General Teeth Observations, Clipped	75-93
			General Teeth Observations, Striated	75-93
			Sacrificed by design	93
M	IX	655003	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	49-93
			Sacrificed by design	93
M	IX	654921	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	49-93
			Sacrificed by design	93
M	IX	654996	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Clipped	75-93
			General Teeth Observations, Striated	49-93
			Sacrificed by design	93
M	IX	654951	General observation, No Abnormality Detected	0-42,49-56
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	63-93
			Sacrificed by design	93
M	IX	654955	General observation, No Abnormality Detected	0-42,49-70
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Clipped	77-93

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654955	General Teeth Observations, Striated	77-93
			Sacrificed by design	93
M	IX	654914	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	48,93
			General Teeth Observations, Striated	49-93
			Aggressive Behavior	42,84-93
			Hyperreactive	70-93
			Discharge, Nose, Red	42
			Sacrificed by design	93
M	IX	654937	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	77
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,90,94-105,119,133,154
			Eye Observations, Bled via Orbital for Clin Path	175
			General Teeth Observations, Clipped	126-175
			General Teeth Observations, Striated	49-84,91,98-175
			Sacrificed by design	175
M	IX	654962	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			General Teeth Observations, Clipped	77-84,91,98-175
			General Teeth Observations, Striated	49-84,91,98-175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654982	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			General Teeth Observations, Clipped	63-84,91,98-175
			General Teeth Observations, Striated	49-84,91,98-175
			Sacrificed by design	175
M	IX	654931	General observation, No Abnormality Detected	0,7,14-56
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			General Teeth Observations, Clipped	74-84,91,98-175
			General Teeth Observations, Striated	63-84,91,98-175
			Sacrificed by design	175
M	IX	654906	General observation, No Abnormality Detected	0,7,14-70
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	133,154
			Eye Observations, Bled via Orbital for Clin Path, Left	90
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,94-105,119,175
			General Teeth Observations, Clipped	75-84,91,98-175
			General Teeth Observations, Striated	84,91,98-175
			Sacrificed by design	175
M	IX	654985	General observation, No Abnormality Detected	0-7
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Absent	91-183
			General Teeth Observations, Clipped	77-183
			General Teeth Observations, Striated	49-183

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654985	Discharge, Nose, Black	77
			Discharge, Eye right, Black	77-98
			Hair Loss, Forelimb, Bilateral	35-147
			Hair Loss, Forepaw, Bilateral	14-147
			Sacrificed by design	183
M	IX	654978	General observation, No Abnormality Detected	0-42,183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	49-182
			Sacrificed by design	183
M	IX	654974	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	75-183
			General Teeth Observations, Striated	49-183
			Aggressive Behavior	112-119
			Hyperreactive	161-168
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Face, Red	175-183
			Sacrificed by design	183
M	IX	654990	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	112-183
			General Teeth Observations, Striated	49-183
			Hair Loss, Forelimb, Bilateral	56-175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654990	Hair Loss, Forelimb, Left	182-183
			Hair Loss, Forepaw, Bilateral	70-183
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Face, Red	147-183
			Sacrificed by design	183
M	IX	654976	General observation, No Abnormality Detected	0-14
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	77-183
			Discharge, Nose, Black	175-183
			Hair Loss, Forelimb, Right	56
			Hair Loss, Forepaw, Bilateral	21-56
			Hair Loss, Forepaw, Right	63-84
			Sacrificed by design	183
M	IX	654957	General observation, No Abnormality Detected	0-7
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	91-183
			General Teeth Observations, Striated	49-183
			Wound, Superficial, Shoulder, Right	14-56
			Sacrificed by design	183
M	IX	654973	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	126-183
			General Teeth Observations, Striated	49-182

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
M	IX	654973	Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Head, Red	147-183
			Sacrificed by design	183
M	IX	654977	General observation, No Abnormality Detected	0-140,175-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Stain Fur/Skin, Head, Red	147-168
			Sacrificed by design	183
M	IX	654942	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	84-183
			General Teeth Observations, Striated	49-183
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Head, Red	147-182
			Sacrificed by design	183
M	IX	654991	General observation, No Abnormality Detected	0-56
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	63-183
			General Teeth Observations, Striated	77-182
			Stain Fur/Skin, Dorsal Body, Red	147-183
			Stain Fur/Skin, Head, Red	147-183
			Sacrificed by design	183

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	II	655031	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	II	655107	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	II	655098	General observation, No Abnormality Detected	0,21-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Wound, Superficial, Shoulder, Left	7-14
			Sacrificed by design	94
F	II	655016	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	49
			Eye Observations, Bled via Orbital for Clin Path, Right	94
			Sacrificed by design	94
F	II	655079	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	II	655036	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	II	655025	General observation, No Abnormality Detected	0-42,56-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Eye Observations, Dark, Right	49

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	II	655025	Sacrificed by design	94
F	II	655099	General observation, No Abnormality Detected	0-7,21-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Wound, Superficial, Shoulder, Right	14
			Sacrificed by design	94
F	II	655032	General observation, No Abnormality Detected	0-35,49-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Arches back during handling	42
			Sacrificed by design	94
F	II	655083	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	II	655093	General observation, No Abnormality Detected	0
			Eye Observations, Closed, Bilateral	119-175
			Eye Observations, Enophthalmus, Bilateral	42-84,91,98-112
			Eye Observations, Enophthalmus, Right	21-35
			Eye Observations, Exophthalmus, Left	28-35
			Eye Observations, Exophthalmus, Right	7,14
			Eye Observations, Bled via Orbital for Clin Path, Left	10,21
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,35,56
			Eye Observations, Corneal Opacity, Bilateral	35-84,91,98-175
			Eye Observations, Corneal Opacity, Right	7,14-28
			Eye Observations, tail vein	77,90,94-105,119,133,154,175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	II	655093	Discharge, Eye left, Black	28-35
			Discharge, Eye right, Black	7,14
			Hair Loss, Face, Left	35-42
			Hair Loss, Face, Right	21-28
			Scab, Face	21-49
			Sacrificed by design	175
F	II	655045	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
F	II	655065	General observation, No Abnormality Detected	0,7,14-28,49-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Hair Loss, Inguen, Right	35-42
			Sacrificed by design	175
F	II	655074	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
F	II	655035	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Hair Loss, Forelimb, Bilateral	56-183
			Hair Loss, Forepaw, Bilateral	56-183
			Ear twitch, Bilateral	42-49

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	II	655035	Ear twitch	63-70
			Sacrificed by design	183
F	II	655009	General observation, No Abnormality Detected	0-14,28-35,56-70,154-182
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Hyperactive	77-140
			Hyperreactive	42-49
			Discharge, Eye bilateral, Black	98-105,183
			Discharge, Eye right, Black	112
			Discharge, Eye right, Red	126-147
			Ear twitch, Bilateral	21
			Sacrificed by design	183
F	II	655068	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
F	II	655019	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
F	II	655062	General observation, No Abnormality Detected	0-7
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Hair Loss, Forelimb, Bilateral	14-183
			Hair Loss, Forepaw, Bilateral	28-183
			Sacrificed by design	183

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	II	655109	General observation, No Abnormality Detected	0-21,35-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Ear twitch, Bilateral	28
			Arches back during handling	28
			Sacrificed by design	183
F	II	655101	General observation, No Abnormality Detected	0-7,70-77,154-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Hair Loss, Forelimb, Bilateral	14-63,84-147
			Hair Loss, Forepaw, Bilateral	28-63
			Sacrificed by design	183
F	II	655072	General observation, No Abnormality Detected	0-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Sacrificed by design	183
F	II	655015	General observation, No Abnormality Detected	0-147,182-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Stain Fur/Skin, Head, Red	154-175
			Sacrificed by design	183
F	II	655071	General observation, No Abnormality Detected	0-14
			Accidentally killed	19
F	II	655022	General observation, No Abnormality Detected	0,7,14-84,91,98-133
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Stain Fur/Skin, Head, Red	140-175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	IV	655086	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	IV	655041	General observation, No Abnormality Detected	0-14,70-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hair Loss, Forelimb, Left	21-63
			Hair Loss, Forepaw, Left	21-63
			Sacrificed by design	94
F	IV	655108	General observation, No Abnormality Detected	0-14,28,49-70,84,94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Vocalization, No Abnormality Detected	35,42
			Hyperactive	35-42
			Ear twitch, Bilateral	21,77
			Arches back during handling	21,77,91
			Sacrificed by design	94
F	IV	655040	General observation, No Abnormality Detected	0-21,35-70,84-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Ear twitch, Bilateral	28
			Arches back during handling	28,77
			Sacrificed by design	94
F	IV	655044	General observation, No Abnormality Detected	0
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Misshapen Observations, Ear, Bilateral	35-94

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	IV	655044	Misshapen Observations, Ear, Left	7-28
			Sacrificed by design	94
F	IV	655013	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	IV	655089	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	IV	655091	General observation, No Abnormality Detected	0-7,21-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Discharge, Mouth, Clear	14
			Wet Fur, Hindpaw, Bilateral	14
			Wet Fur, Thoracic, Ventral	14
			Wet Fur, Face, Right	14
			Sacrificed by design	94
F	IV	655033	General observation, No Abnormality Detected	0-42,56-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Eye Observations, Dark, Left	49
			Sacrificed by design	94
F	IV	655090	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	IV	655051	General observation, No Abnormality Detected	0,7,14-84,91,98-175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	IV	655051	Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175
F	IV	655018	General observation, No Abnormality Detected	0,7,14-84,98-105,133-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	90
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,94-105,119,133,154,175
			Eye Observations, Dark, Right	91,112-126
			Discharge, Eye right, Black	91
			Sacrificed by design	175
F	IV	655096	General observation, No Abnormality Detected	0,7,14-28,49-56,119-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Hair Loss, Forelimb, Right	35-42
			Hair Loss, Forepaw, Right	63-84,91,98-112
			Sacrificed by design	175
F	IV	655057	General observation, No Abnormality Detected	0,7,14-84,91,98-119,133
			Eye Observations, Exophthalmus, Right	147-175
			Eye Observations, Bled via Orbital for Clin Path, Left	154,175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133
			Eye Observations, Corneal Opacity, Right	140-175
			Hair Loss, Face, Right	126
			Sacrificed by design	175
F	IV	655028	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VI	655054	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VI	655038	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VI	655034	General observation, No Abnormality Detected	0-21,35-77,94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Ear twitch, Bilateral	28
			Arches back during handling	28,84-91
			Sacrificed by design	94
F	VI	655039	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VI	655029	General observation, No Abnormality Detected	0-35,49-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Comments, excessive salivation	40
			Stain Fur/Skin, Chin, Red	42
			Stain Fur/Skin, Face, Red	42
			Sacrificed by design	94
F	VI	655067	General observation, No Abnormality Detected	0-35,49-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Ear twitch, Bilateral	42

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VI	655067	Arches back during handling	42
			Sacrificed by design	94
F	VI	655020	General observation, No Abnormality Detected	0-21,35-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Ear twitch, Bilateral	28
			Arches back during handling	28
			Sacrificed by design	94
F	VI	655087	General observation, No Abnormality Detected	0-21,35-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hyperactive	28
			Arches back during handling	28
			Sacrificed by design	94
F	VI	655066	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VI	655042	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VI	655059	General observation, No Abnormality Detected	0,56-84,91,98
			Eye Observations, Enophthalmus, Right	112-175
			Eye Observations, Bled via Orbital for Clin Path, Left	133
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,154, 175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VI	655059	Eye Observations, Corneal Opacity, Right	119-175
			Eye Observations, Dark, Right	105-133
			Hair Loss, Forelimb, Bilateral	28-49
			Hair Loss, Forepaw, Bilateral	28-49
			Hair Loss, Forepaw, Left	7,14-21
			Sacrificed by design	175
F	VI	655064	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
F	VI	655050	General observation, No Abnormality Detected	0,7,14-84,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Discharge, Eye right, Black	91
			Sacrificed by design	175
F	VI	655021	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175
F	VI	655017	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VIII	655058	General observation, No Abnormality Detected	0-56,70-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Breathing Observations, Noise	63
			Sacrificed by design	94
F	VIII	655076	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hair Loss, Forelimb, Bilateral	49-94
			Hair Loss, Forepaw, Bilateral	42
			Sacrificed by design	94
F	VIII	655047	General observation, No Abnormality Detected	0-28,42-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Ear twitch, Bilateral	35
			Arches back during handling	35
			Sacrificed by design	94
F	VIII	655055	General observation, No Abnormality Detected	0-77,91-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hyperactive	84
			Ear twitch, Bilateral	84
			Arches back during handling	84
			Sacrificed by design	94
F	VIII	655105	General observation, No Abnormality Detected	0-21,35-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hyperactive	28

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VIII	655105	Arches back during handling	28
			Sacrificed by design	94
F	VIII	655078	General observation, No Abnormality Detected	0-28,42-56,70-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hyperactive	35,63
			Ear twitch, Bilateral	35
			Ear twitch	63
			Sacrificed by design	94
F	VIII	655073	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VIII	655011	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VIII	655085	General observation, No Abnormality Detected	0-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Sacrificed by design	94
F	VIII	655012	General observation, No Abnormality Detected	0-7,21-94
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			Hair Loss, Shoulder, Right	14
			Sacrificed by design	94
F	VIII	655043	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	VIII	655043	Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154
			Sacrificed by design	175
F	VIII	655082	General observation, No Abnormality Detected	0,7,14-84,91,98-147
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Hair Loss, Forelimb, Left	175
			Stain Fur/Skin, Head, Red	154-175
			Sacrificed by design	175
F	VIII	655060	General observation, No Abnormality Detected	0,7,14-84,105-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Eye Observations, Dark, Right	91,98
			Sacrificed by design	175
F	VIII	655056	General observation, No Abnormality Detected	0,7,14-35,56-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	35,56
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,77,90,94-105,119,133,154,175
			Hair Loss, Face, Right	42-49
			Wound, Superficial, Face	42
			Sacrificed by design	175
F	VIII	655081	General observation, No Abnormality Detected	0,7,14-84,91,98-175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			Sacrificed by design	175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655097	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655052	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655063	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655103	General observation, No Abnormality Detected	0-56
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Clipped	84-94
			General Teeth Observations, Striated	77-94
			Hyperreactive	63-94
			Sacrificed by design	94
F	X	655026	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655095	General observation, No Abnormality Detected	0-14

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655095	Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Hair Loss, Forelimb, Bilateral	21-42
			Ear twitch, Bilateral	35
			Arches back during handling	35
			Sacrificed by design	94
F	X	655023	General observation, No Abnormality Detected	0-21,35-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Arches back during handling	28,84
			Sacrificed by design	94
F	X	655007	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655053	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	49-94
			Sacrificed by design	94
F	X	655092	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	49,94
			General Teeth Observations, Striated	77-94
			Hyperactive	77-84

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655092	Hair Loss, Forepaw, Bilateral	49-94
			Arches back during handling	70
			Sacrificed by design	94
F	X	655046	General observation, No Abnormality Detected	0,7,14-70
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	133
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,154,175
			General Teeth Observations, Striated	77-84,91,98-175
			Sacrificed by design	175
F	X	655027	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	133,154,175
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-98,105,119
			General Teeth Observations, Clipped	104-175
			General Teeth Observations, Striated	49-84,91,98-140
			Discharge, Eye right, Black	161-175
			Wound, Deep, Mouth	112-119
			Comments, animal caught teeth on cage, nose was stuck	104
			Swollen Observations, Face	105-119
			Swollen Observations, Nose	105
			Sacrificed by design	175
F	X	655104	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133, 154,175
			General Teeth Observations, Clipped	126-175
			General Teeth Observations, Striated	49-84,91,98-175

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655104	Sacrificed by design	175
F	X	655106	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			General Teeth Observations, Striated	49-84,91,98-175
			Sacrificed by design	175
F	X	655024	General observation, No Abnormality Detected	0,7,14-42
			Eye Observations, Bled via Orbital for Clin Path, Right	0-4,10,21,35,56,77,90,94-105,119,133,154,175
			General Teeth Observations, Clipped	147-175
			General Teeth Observations, Striated	49-84,91,98-175
			Sacrificed by design	175
F	X	655037	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	49-183
			Sacrificed by design	183
F	X	655088	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	112-183
			General Teeth Observations, Striated	49-183
			Discharge, Eye bilateral, Black	112
			Discharge, Nose, Black	112
			Comments, teeth caught in cage	112
			Stain Fur/Skin, Forepaw, Bilateral, Red	112
			Stain Fur/Skin, Face, Red	112

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655088	Swollen Observations, Face	112
			Sacrificed by design	183
F	X	655010	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	77-183
			General Teeth Observations, Striated	49-183
			Wound, Superficial, Mouth	119-126
			Ear twitch, Bilateral	42
			Arches back during handling	42-49
			Sacrificed by design	183
F	X	655077	General observation, No Abnormality Detected	0-35
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	49-183
			Hyperactive	70-140
			Ear twitch, Bilateral	42,70
			Arches back during handling	42,70
			Sacrificed by design	183
F	X	655030	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	105-183
			General Teeth Observations, Striated	49-183
			Sacrificed by design	183
F	X	655075	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA

Sex	Group	Animal	Observation	Days
F	X	655075	General Teeth Observations, Clipped	112-183
			General Teeth Observations, Striated	49-183
			Sacrificed by design	183
F	X	655100	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Clipped	105-183
			General Teeth Observations, Striated	49-183
			Sacrificed by design	183
F	X	655049	General observation, No Abnormality Detected	0-49
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	56-182
			Stain Fur/Skin, Head, Red	91-183
			Stain Fur/Skin, Neck, Red	126-183
			Sacrificed by design	183
F	X	655084	General observation, No Abnormality Detected	0-42
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			General Teeth Observations, Striated	49-183
			Sacrificed by design	183
F	X	655061	General observation, No Abnormality Detected	0-28,42-84,98-183
			Eye Observations, Bled via Orbital for Clin Path, Right	183
			Ear twitch, Bilateral	35,91
			Arches back during handling	35,91
			Sacrificed by design	183

APPENDIX F

OPHTHALMOLOGY REPORT AND INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS

NANCY M. BROMBERG, V.M.D., M.S.
EYE CLINIC FOR ANIMALS
6119 MASSACHUSETTS AVE
BETHESDA, MD 20816

STUDY INFORMATION: **Study No. 13690 1022**
H#: 24691
Species: Rat
Study Director: Greg Ladics

OPHTHALMOLOGICAL EXAMINATION SUMMARY
Examination Date: May 17, 2002
Study Interval: Day 87

METHODS: Indirect Ophthalmoscopy following 1% Tropicamide mydriasis

Sex	Group#	Animal #	Observation
Male	I	654925	Focal retinal degeneration OD
	III	654932	Focal retinal degeneration OS
		654965	Focal retinal degeneration OS
Female	II	655072	Focal retinal degeneration OD

COMMENTS/DISCUSSION

Four (4) animals were identified with ophthalmoscopic lesions, three (3) males and one (1) female. In all three males, the retinal changes can be attributed to trauma to the globe and/or orbit during orbital sinus bleeding. In the female, it is considered to be an incidental finding.

No compound related ocular abnormalities were identified.

Nancy M. Bromberg, V.M.D., M.S. May 19, 2002
Nancy M. Bromberg, V.M.D., M.S. **Date**
Diplomate, A.C.V.O.

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
M	I	654928	No Ophthalmological Abnormalities Detected	87
M	I	654993	No Ophthalmological Abnormalities Detected	87
M	I	654929	No Ophthalmological Abnormalities Detected	87
M	I	654972	No Ophthalmological Abnormalities Detected	87
M	I	654950	No Ophthalmological Abnormalities Detected	87
M	I	654953	No Ophthalmological Abnormalities Detected	87
M	I	654925	Retina, Retinal Degeneration Focal, Right	87
M	I	654987	No Ophthalmological Abnormalities Detected	87
M	I	654903	No Ophthalmological Abnormalities Detected	87
M	I	654994	No Ophthalmological Abnormalities Detected	87
M	I	654949	No Ophthalmological Abnormalities Detected	87
M	I	654992	No Ophthalmological Abnormalities Detected	87
M	I	654909	No Ophthalmological Abnormalities Detected	87
M	I	654924	No Ophthalmological Abnormalities Detected	87
M	I	654943	No Ophthalmological Abnormalities Detected	87
M	I	654915	No Ophthalmological Abnormalities Detected	87
M	I	654927	No Ophthalmological Abnormalities Detected	87
M	I	654956	No Ophthalmological Abnormalities Detected	87
M	I	654910	No Ophthalmological Abnormalities Detected	87
M	I	654936	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
M	III	654913	No Ophthalmological Abnormalities Detected	87
M	III	654947	No Ophthalmological Abnormalities Detected	87
M	III	654995	No Ophthalmological Abnormalities Detected	87
M	III	654938	No Ophthalmological Abnormalities Detected	87
M	III	654941	No Ophthalmological Abnormalities Detected	87
M	III	654946	No Ophthalmological Abnormalities Detected	87
M	III	654960	No Ophthalmological Abnormalities Detected	87
M	III	654908	No Ophthalmological Abnormalities Detected	87
M	III	654984	No Ophthalmological Abnormalities Detected	87
M	III	654932	Retina, Retinal Degeneration Focal, Left	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
M	V	655005	No Ophthalmological Abnormalities Detected	87
M	V	654907	No Ophthalmological Abnormalities Detected	87
M	V	654980	No Ophthalmological Abnormalities Detected	87
M	V	654959	No Ophthalmological Abnormalities Detected	87
M	V	654961	No Ophthalmological Abnormalities Detected	87
M	V	654916	No Ophthalmological Abnormalities Detected	87
M	V	654911	Retina, Retinal Degeneration Focal, Left	87
M	V	654917	No Ophthalmological Abnormalities Detected	87
M	V	654998	No Ophthalmological Abnormalities Detected	87
M	V	654967	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
M	VII	655001	No Ophthalmological Abnormalities Detected	87
M	VII	654975	No Ophthalmological Abnormalities Detected	87
M	VII	654922	No Ophthalmological Abnormalities Detected	87
M	VII	654940	No Ophthalmological Abnormalities Detected	87
M	VII	654930	No Ophthalmological Abnormalities Detected	87
M	VII	654958	No Ophthalmological Abnormalities Detected	87
M	VII	654952	No Ophthalmological Abnormalities Detected	87
M	VII	654923	No Ophthalmological Abnormalities Detected	87
M	VII	654989	No Ophthalmological Abnormalities Detected	87
M	VII	655006	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
M	IX	654983	No Ophthalmological Abnormalities Detected	87
M	IX	654965	Globe, Phthisis bulbi, Right	87
M	IX	654979	No Ophthalmological Abnormalities Detected	87
M	IX	654986	No Ophthalmological Abnormalities Detected	87
M	IX	655003	No Ophthalmological Abnormalities Detected	87
M	IX	654921	No Ophthalmological Abnormalities Detected	87
M	IX	654996	No Ophthalmological Abnormalities Detected	87
M	IX	654951	No Ophthalmological Abnormalities Detected	87
M	IX	654955	No Ophthalmological Abnormalities Detected	87
M	IX	654914	No Ophthalmological Abnormalities Detected	87
M	IX	654985	No Ophthalmological Abnormalities Detected	87
M	IX	654978	No Ophthalmological Abnormalities Detected	87
M	IX	654974	No Ophthalmological Abnormalities Detected	87
M	IX	654990	No Ophthalmological Abnormalities Detected	87
M	IX	654976	No Ophthalmological Abnormalities Detected	87
M	IX	654957	No Ophthalmological Abnormalities Detected	87
M	IX	654973	No Ophthalmological Abnormalities Detected	87
M	IX	654977	No Ophthalmological Abnormalities Detected	87
M	IX	654942	No Ophthalmological Abnormalities Detected	87
M	IX	654991	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
F	II	655031	No Ophthalmological Abnormalities Detected	87
F	II	655107	No Ophthalmological Abnormalities Detected	87
F	II	655098	No Ophthalmological Abnormalities Detected	87
F	II	655016	No Ophthalmological Abnormalities Detected	87
F	II	655079	No Ophthalmological Abnormalities Detected	87
F	II	655036	No Ophthalmological Abnormalities Detected	87
F	II	655025	No Ophthalmological Abnormalities Detected	87
F	II	655099	No Ophthalmological Abnormalities Detected	87
F	II	655032	No Ophthalmological Abnormalities Detected	87
F	II	655083	No Ophthalmological Abnormalities Detected	87
F	II	655035	No Ophthalmological Abnormalities Detected	87
F	II	655009	No Ophthalmological Abnormalities Detected	87
F	II	655068	No Ophthalmological Abnormalities Detected	87
F	II	655019	No Ophthalmological Abnormalities Detected	87
F	II	655062	No Ophthalmological Abnormalities Detected	87
F	II	655109	No Ophthalmological Abnormalities Detected	87
F	II	655101	No Ophthalmological Abnormalities Detected	87
F	II	655072	Retina, Retinal Degeneration Focal, Right	87
F	II	655015	No Ophthalmological Abnormalities Detected	87
F	II	655071	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
F	IV	655086	No Ophthalmological Abnormalities Detected	87
F	IV	655041	No Ophthalmological Abnormalities Detected	87
F	IV	655108	No Ophthalmological Abnormalities Detected	87
F	IV	655040	No Ophthalmological Abnormalities Detected	87
F	IV	655044	No Ophthalmological Abnormalities Detected	87
F	IV	655013	No Ophthalmological Abnormalities Detected	87
F	IV	655089	No Ophthalmological Abnormalities Detected	87
F	IV	655091	No Ophthalmological Abnormalities Detected	87
F	IV	655033	No Ophthalmological Abnormalities Detected	87
F	IV	655090	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
F	VI	655054	No Ophthalmological Abnormalities Detected	87
F	VI	655038	No Ophthalmological Abnormalities Detected	87
F	VI	655034	No Ophthalmological Abnormalities Detected	87
F	VI	655039	No Ophthalmological Abnormalities Detected	87
F	VI	655029	No Ophthalmological Abnormalities Detected	87
F	VI	655067	No Ophthalmological Abnormalities Detected	87
F	VI	655020	No Ophthalmological Abnormalities Detected	87
F	VI	655087	No Ophthalmological Abnormalities Detected	87
F	VI	655066	No Ophthalmological Abnormalities Detected	87
F	VI	655042	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
F	VIII	655058	No Ophthalmological Abnormalities Detected	87
F	VIII	655076	No Ophthalmological Abnormalities Detected	87
F	VIII	655047	No Ophthalmological Abnormalities Detected	87
F	VIII	655055	No Ophthalmological Abnormalities Detected	87
F	VIII	655105	No Ophthalmological Abnormalities Detected	87
F	VIII	655078	No Ophthalmological Abnormalities Detected	87
F	VIII	655073	No Ophthalmological Abnormalities Detected	87
F	VIII	655011	No Ophthalmological Abnormalities Detected	87
F	VIII	655085	No Ophthalmological Abnormalities Detected	87
F	VIII	655012	No Ophthalmological Abnormalities Detected	87

INDIVIDUAL OPHTHALMOLOGICAL OBSERVATIONS (Test Day 87)

Sex	Group	Animal	Observation	Days
F	X	655097	No Ophthalmological Abnormalities Detected	87
F	X	655052	No Ophthalmological Abnormalities Detected	87
F	X	655063	No Ophthalmological Abnormalities Detected	87
F	X	655103	No Ophthalmological Abnormalities Detected	87
F	X	655026	No Ophthalmological Abnormalities Detected	87
F	X	655095	No Ophthalmological Abnormalities Detected	87
F	X	655023	No Ophthalmological Abnormalities Detected	87
F	X	655007	No Ophthalmological Abnormalities Detected	87
F	X	655053	No Ophthalmological Abnormalities Detected	87
F	X	655092	No Ophthalmological Abnormalities Detected	87
F	X	655037	No Ophthalmological Abnormalities Detected	87
F	X	655088	No Ophthalmological Abnormalities Detected	87
F	X	655010	No Ophthalmological Abnormalities Detected	87
F	X	655077	No Ophthalmological Abnormalities Detected	87
F	X	655030	No Ophthalmological Abnormalities Detected	87
F	X	655075	No Ophthalmological Abnormalities Detected	87
F	X	655100	No Ophthalmological Abnormalities Detected	87
F	X	655049	No Ophthalmological Abnormalities Detected	87
F	X	655084	No Ophthalmological Abnormalities Detected	87
F	X	655061	No Ophthalmological Abnormalities Detected	87

APPENDIX G

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Male Rats/Group I 0 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654909	0.63	0.53	0.46	0.54	0.26	0.38	0.41	0.35
654910	0.66	0.62	0.62	0.63	0.48	0.41	0.27	0.39
654915	0.46	0.65	0.65	0.59	0.24	0.27	0.29	0.27
654924	0.46	0.53	0.58	0.52	0.27	0.38	0.22	0.29
654927	0.56	0.52	0.40	0.49	0.23	0.22	0.23	0.23
654943	0.51	0.66	0.66	0.61	0.48	0.29	0.27	0.35
654949	0.41	0.41	0.32	0.38	0.31	0.40	0.35	0.35
654956	0.49	0.40	0.41	0.43	0.22	0.31	0.23	0.25
654992	0.72	0.61	0.52	0.62	0.39	0.26	0.38	0.34
654994	0.41	0.56	0.45	0.47	0.23	0.22	0.20	0.22

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Male Rats/Group III 1 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654908	0.77	0.46	0.56	0.60	0.28	0.27	0.36	0.30
654913	0.57	0.37	0.54	0.49	0.26	0.25	0.36	0.29
654932	0.47	0.58	0.69	0.58	0.32	0.20	0.21	0.24
654938	0.42	0.40	0.36	0.39	0.19	0.27	0.25	0.24
654941	0.70	0.46	0.45	0.54	0.46	0.36	0.23	0.35
654946	0.52	0.39	0.60	0.50	0.40	0.43	0.42	0.42
654947	0.62	0.74	0.64	0.67	0.31	0.38	0.28	0.32
654960	0.80	0.76	0.72	0.76	0.38	0.37	0.30	0.35
654984	0.64	0.72	0.82	0.73	0.28	0.18	0.26	0.24
654995	0.61	0.48	0.63	0.57	0.47	0.33	0.29	0.36

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Male Rats/Group V 5 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654911	0.68	0.85	0.71	0.75	0.23	0.27	0.32	0.27
654916	0.56	0.42	0.58	0.52	0.29	0.25	0.26	0.27
654917	0.61	0.59	0.56	0.59	0.36	0.24	0.22	0.27
654959	0.56	0.64	0.48	0.56	0.34	0.31	0.30	0.32
654961	0.76	0.85	0.69	0.77	0.35	0.27	0.30	0.31
654967	0.56	0.56	0.45	0.52	0.22	0.18	0.20	0.20
654998	0.45	0.53	0.52	0.50	0.23	0.22	0.22	0.22
654907	0.52	0.37	0.38	0.42	0.35	0.47	0.28	0.37
654980	0.61	0.44	0.42	0.49	0.23	0.25	0.28	0.25
655005	0.76	0.53	0.56	0.62	0.20	0.46	0.28	0.31

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Male Rats/Group VII 25 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654922	0.70	0.45	0.61	0.59	0.32	0.32	0.30	0.31
654923	0.53	0.64	0.76	0.64	0.19	0.20	0.23	0.21
654952	0.72	0.85	1.01	0.86	0.29	0.35	0.41	0.35
654958	0.61	0.56	0.48	0.55	0.45	0.25	0.31	0.34
654975	0.54	0.55	0.49	0.53	0.36	0.20	0.29	0.28
654989	0.45	0.66	0.51	0.54	0.31	0.25	0.21	0.26
655001	0.44	0.58	0.56	0.53	0.21	0.22	0.31	0.25
655006	0.47	0.49	0.56	0.51	0.26	0.20	0.24	0.23
654930	0.54	0.53	0.51	0.53	0.29	0.22	0.25	0.25
654940	0.69	0.71	0.65	0.68	0.34	0.49	0.33	0.39

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Male Rats/Group IX 125 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654942	0.67	0.48	0.59	0.58	0.19	0.18	0.19	0.19
654957	0.60	0.57	0.76	0.64	0.65	0.37	0.34	0.45
654973	0.91	0.72	0.75	0.79	0.34	0.26	0.22	0.27
654974	0.60	0.61	0.66	0.62	0.29	0.38	0.26	0.31
654976	0.35	0.28	0.63	0.42	0.26	0.20	0.30	0.25
654977	0.57	0.69	0.61	0.62	0.23	0.19	0.28	0.23
654978	0.41	0.36	0.47	0.41	0.33	0.18	0.20	0.24
654985	0.67	0.73	0.53	0.64	0.31	0.22	0.28	0.27
654990	0.40	0.60	0.50	0.50	0.30	0.35	0.25	0.30
654991	0.51	0.50	0.65	0.55	0.25	0.18	0.19	0.21

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Male Rats/Group I 0 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654909	1.85	1.55	1.19	1.53	0.46	0.47	0.61	0.51
654910	1.58	1.37	1.20	1.38	0.66	0.69	0.55	0.63
654915	1.46	0.75	0.84	1.02	0.34	0.38	0.44	0.39
654924	1.31	1.76	1.40	1.49	0.73	0.63	0.61	0.66
654927	0.97	1.16	1.11	1.08	0.67	0.74	0.58	0.66
654943	0.85	1.32	0.94	1.04	0.46	0.38	0.41	0.42
654949	1.52	1.31	1.19	1.34	0.30	0.53	0.51	0.45
654956	0.59	1.07	1.02	0.89	0.39	0.29	0.44	0.37
654992	1.08	1.06	1.00	1.05	0.79	0.95	0.65	0.80
654994	0.59	0.46	0.52	0.52	0.34	0.53	0.22	0.36

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Male Rats/Group III 1 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654908	1.47	1.01	1.19	1.22	0.66	0.54	0.75	0.65
654913	1.35	0.75	0.75	0.95	0.22	0.42	0.41	0.35
654932	0.77	1.34	1.45	1.19	0.61	0.76	0.66	0.68
654938	0.78	1.12	1.07	0.99	0.77	0.51	0.47	0.58
654941	0.97	1.00	0.97	0.98	0.63	0.58	0.55	0.59
654946	0.95	1.07	1.23	1.08	0.49	0.59	0.48	0.52
654947	0.95	1.28	1.05	1.09	0.52	0.36	0.37	0.42
654960	1.52	0.96	1.46	1.31	0.51	0.67	0.65	0.61
654984	1.52	1.09	1.58	1.40	0.58	0.71	0.65	0.65
654995	1.43	1.59	1.28	1.43	0.85	0.71	0.72	0.76

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Male Rats/Group V 5 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654911	1.06	1.59	1.22	1.29	0.62	0.67	0.56	0.62
654916	0.92	1.14	0.87	0.98	0.38	0.51	0.53	0.47
654917	1.52	1.03	1.48	1.34	0.54	0.39	0.49	0.47
654959	0.96	1.25	1.67	1.29	0.58	0.74	0.42	0.58
654961	1.56	1.80	1.03	1.46	0.66	0.62	0.71	0.66
654967	1.06	1.27	0.94	1.09	0.57	0.61	0.50	0.56
654998	1.07	1.09	0.95	1.04	0.33	0.31	0.42	0.35
654907	1.44	1.11	1.19	1.25	0.45	0.33	0.51	0.43
654980	1.15	0.72	0.81	0.89	0.55	0.53	0.41	0.50
655005	1.60	1.55	1.41	1.52	0.59	0.74	0.59	0.64

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Male Rats/Group VII 25 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654922	1.01	1.33	0.85	1.06	0.40	0.46	0.54	0.47
654923	1.27	1.09	1.64	1.33	0.63	0.71	0.68	0.67
654952	1.45	1.67	1.24	1.45	0.84	0.56	0.57	0.66
654958	0.95	1.20	0.71	0.95	0.60	0.51	0.46	0.52
654975	1.67	1.62	1.19	1.49	0.63	0.57	0.85	0.68
654989	0.99	1.38	1.18	1.18	0.51	0.65	0.69	0.62
655001	1.29	1.25	1.50	1.35	0.31	0.43	0.31	0.35
655006	0.96	0.95	1.56	1.16	0.35	0.31	0.41	0.36
654930	1.27	1.44	0.98	1.23	0.51	0.65	0.55	0.57
654940	1.51	1.38	1.49	1.46	0.81	0.90	0.85	0.85

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Male Rats/Group IX 125 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
654942	1.56	1.18	1.51	1.42	0.46	0.51	0.42	0.46
654957	1.24	1.32	1.33	1.30	0.95	0.61	0.64	0.73
654973	1.30	1.73	1.41	1.48	0.59	0.56	0.56	0.57
654974	1.16	1.32	1.04	1.17	0.42	0.40	0.42	0.41
654976	1.36	1.55	1.22	1.38	0.65	0.49	0.49	0.54
654977	0.66	1.03	0.66	0.78	0.31	0.25	0.31	0.29
654978	1.00	1.29	1.31	1.20	0.48	0.47	0.44	0.46
654985	0.57	0.46	0.72	0.58	0.35	0.19	0.27	0.27
654990	0.75	0.99	1.13	0.96	0.44	0.62	0.61	0.56
654991	1.23	1.31	0.88	1.14	0.40	0.65	0.82	0.62

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Female Rats/Group II 0 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655019	0.65	0.41	0.63	0.56	0.69	0.35	0.43	0.49
655071	0.73	0.76	0.67	0.72	0.45	0.36	0.36	0.39
655062	0.44	0.41	0.55	0.47	0.37	0.25	0.31	0.31
655068	0.45	0.54	0.48	0.49	0.29	0.29	0.37	0.32
655009	0.51	0.43	0.67	0.54	0.27	0.34	0.35	0.32
655015	0.72	0.57	0.50	0.60	0.33	0.27	0.27	0.29
655035	0.47	0.56	0.40	0.48	0.36	0.32	0.33	0.34
655072	0.60	0.67	0.51	0.59	0.39	0.38	0.20	0.32
655101	0.54	0.62	0.79	0.65	0.46	0.53	0.47	0.49
655109	0.54	0.50	0.59	0.54	0.42	0.42	0.40	0.41

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Female Rats/Group IV 1 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655013	0.74	0.66	0.76	0.72	0.39	0.46	0.31	0.39
655033	0.60	0.51	0.46	0.52	0.50	0.28	0.24	0.34
655040	0.71	0.57	0.45	0.58	0.31	0.28	0.26	0.28
655041	0.61	0.75	0.77	0.71	0.35	0.34	0.28	0.32
655044	0.59	0.56	0.50	0.55	0.32	0.34	0.31	0.32
655086	0.57	0.70	0.52	0.60	0.22	0.32	0.44	0.33
655089	0.73	0.69	0.57	0.66	0.45	0.42	0.35	0.41
655090	0.66	0.72	0.77	0.72	0.32	0.29	0.30	0.30
655091	0.73	0.73	0.72	0.73	0.34	0.49	0.51	0.45
655108	0.44	0.55	0.56	0.52	0.41	0.32	0.29	0.34

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Female Rats/Group VI 5 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655020	0.61	0.63	0.44	0.56	0.34	0.24	0.39	0.32
655029	0.43	0.64	0.43	0.50	0.43	0.44	0.31	0.39
655034	0.58	0.71	0.70	0.66	0.42	0.38	0.33	0.38
655039	0.66	0.75	0.85	0.75	0.34	0.44	0.28	0.35
655042	0.66	0.76	0.55	0.66	0.27	0.41	0.32	0.33
655066	0.70	0.51	0.62	0.61	0.42	0.28	0.26	0.32
655067	0.57	0.65	0.57	0.60	0.39	0.36	0.32	0.36
655087	0.61	0.91	0.73	0.75	0.31	0.36	0.36	0.34
655038	0.73	0.57	0.59	0.63	0.51	0.30	0.39	0.40
655054	0.78	0.93	0.68	0.80	0.33	0.49	0.26	0.36

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Female Rats/Group VIII 25 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655011	0.90	0.72	0.56	0.73	0.50	0.43	0.51	0.48
655012	0.80	0.62	0.66	0.69	0.44	0.40	0.41	0.42
655047	0.59	0.49	0.65	0.58	0.22	0.26	0.26	0.25
655055	0.66	0.57	0.48	0.57	0.36	0.37	0.26	0.33
655058	0.56	0.79	0.65	0.67	0.23	0.31	0.32	0.29
655073	0.45	0.38	0.58	0.47	0.36	0.31	0.34	0.34
655076	0.56	0.66	0.75	0.66	0.47	0.34	0.35	0.39
655078	0.62	0.61	0.53	0.59	0.58	0.41	0.42	0.47
655085	0.59	0.44	0.79	0.61	0.31	0.36	0.28	0.32
655105	0.44	0.49	0.44	0.46	0.28	0.20	0.22	0.23

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

BASELINE

Female Rats/Group X 125 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655010	0.42	0.50	0.51	0.48	0.23	0.29	0.25	0.26
655030	0.58	0.65	0.51	0.58	0.40	0.44	0.38	0.41
655037	0.61	0.41	0.46	0.49	0.31	0.29	0.28	0.29
655049	0.54	0.66	0.36	0.52	0.28	0.27	0.41	0.32
655061	0.67	0.46	0.48	0.54	0.35	0.44	0.41	0.40
655075	0.69	0.69	0.75	0.71	0.38	0.34	0.32	0.35
655077	0.80	0.68	0.72	0.73	0.20	0.22	0.41	0.28
655084	0.59	0.66	0.53	0.59	0.26	0.34	0.33	0.31
655088	0.71	0.58	0.45	0.58	0.27	0.31	0.21	0.26
655100	0.71	0.72	0.75	0.73	0.45	0.38	0.45	0.427

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Female Rats/Group II 0 mg/kg/day

Animal Number		Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
		Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655019		1.02	0.88	0.74	0.88	0.56	0.70	0.76	0.67
655071	[1]	…	…	…	…	…	…	…	…
655062		1.04	0.76	0.80	0.87	0.47	0.49	0.45	0.47
655068		0.85	0.53	0.58	0.65	0.38	0.28	0.36	0.34
655009		1.24	0.94	0.82	1.00	0.54	0.51	0.49	0.51
655015		0.99	0.70	0.76	0.82	0.41	0.69	0.45	0.52
655035		1.23	1.23	1.13	1.20	0.49	0.44	0.68	0.54
655072		1.21	1.34	0.96	1.17	0.33	0.57	0.52	0.47
655101		0.74	0.75	0.78	0.76	0.61	0.59	0.67	0.62
655109		0.62	0.53	0.66	0.60	0.38	0.45	0.36	0.40

[1] Rat accidentally killed on test day 19.

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Female Rats/Group IV 1 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655013	1.23	1.10	0.81	1.05	0.51	0.52	0.51	0.51
655033	0.57	1.10	1.09	0.92	0.34	0.45	0.29	0.36
655040	1.20	0.99	0.53	0.91	0.45	0.37	0.40	0.41
655041	0.84	1.36	0.96	1.05	0.35	0.60	0.31	0.42
655044	1.40	1.05	1.10	1.18	0.35	0.41	0.32	0.36
655086	0.71	0.61	0.50	0.61	0.31	0.22	0.29	0.27
655089	1.21	1.05	1.14	1.13	0.43	0.47	0.48	0.46
655090	1.22	1.10	0.97	1.10	0.26	0.27	0.39	0.31
655091	0.97	1.55	1.46	1.33	0.61	0.56	0.57	0.58
655108	1.16	0.83	1.01	1.00	0.24	0.38	0.46	0.36

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Female Rats/Group VI 5 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655020	1.29	0.64	1.07	1.00	0.55	0.60	0.54	0.56
655029	1.05	1.30	0.92	1.09	0.46	0.53	0.68	0.56
655034	1.05	0.84	0.80	0.90	0.44	0.48	0.48	0.47
655039	1.42	1.12	1.36	1.30	0.62	0.61	0.46	0.56
655042	0.95	0.89	1.20	1.01	0.70	0.45	0.44	0.53
655066	1.19	0.98	1.24	1.14	0.73	0.54	0.43	0.57
655067	1.12	0.88	0.84	0.95	0.29	0.48	0.41	0.39
655087	0.73	0.92	0.98	0.88	0.34	0.37	0.41	0.37
655038	1.27	1.18	1.42	1.29	0.47	0.62	0.56	0.55
655054	0.83	1.08	0.88	0.93	0.30	0.39	0.30	0.33

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Female Rats/Group VIII 25 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655011	1.18	1.23	1.34	1.25	0.75	0.84	0.73	0.77
655012	1.21	0.82	1.00	1.01	0.39	0.42	0.41	0.41
655047	1.19	1.13	0.96	1.09	0.28	0.30	0.37	0.32
655055	1.00	1.10	0.90	1.00	0.58	0.43	0.46	0.49
655058	0.99	1.26	1.52	1.26	0.34	0.33	0.35	0.34
655073	0.72	0.77	0.66	0.72	0.50	0.42	0.39	0.44
655076	0.71	0.92	0.78	0.80	0.59	0.45	0.56	0.53
655078	1.24	1.19	0.95	1.13	0.65	0.61	0.50	0.59
655085	0.88	0.63	0.90	0.80	0.28	0.41	0.54	0.41
655105	0.77	0.96	0.79	0.84	0.42	0.46	0.36	0.41

INDIVIDUAL FORELIMB GRIP STRENGTH AND HINDLIMB GRIP STRENGTH

WEEK 13

Female Rats/Group X 125 mg/kg/day

Animal Number	Forelimb Grip Strength (kg)				Hindlimb Grip Strength (kg)			
	Trial 1	Trial 2	Trial 3	Mean of Three Trials	Trial 1	Trial 2	Trial 3	Mean of Three Trials
655010	0.96	0.65	0.68	0.76	0.33	0.34	0.56	0.41
655030	1.08	1.06	0.81	0.98	0.59	0.51	0.49	0.53
655037	0.96	1.15	0.94	1.02	0.46	0.52	0.55	0.51
655049	1.03	1.19	1.13	1.12	0.44	0.55	0.38	0.46
655061	1.10	0.76	1.05	0.97	0.52	0.56	0.41	0.50
655075	0.95	0.81	0.80	0.85	0.61	0.46	0.47	0.51
655077	1.15	0.88	0.91	0.98	0.44	0.43	0.31	0.39
655084	1.01	0.94	1.46	1.14	0.57	0.45	0.41	0.48
655088	0.88	0.84	0.63	0.78	0.31	0.33	0.28	0.31
655100	0.85	1.24	1.11	1.07	0.65	0.45	0.46	0.52

APPENDIX H

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Male Rats/Group I: 0 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
654909	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654910	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654915	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654924	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654927	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654943	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	0
654949	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654956	Baseline	0	0	1	0	1	1
	Week 13	0	0	0	0	0	1
654992	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
654994	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Male Rats/Group III: 1 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
654908	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654913	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654932	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654938	Baseline	0	0	0	0	0	0
	Week 13	0	0	0	0	1	1
654941	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654946	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654947	Baseline	1	0	1	0	0	1
	Week 13	0	0	0	0	1	1
654960	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654984	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
654995	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Male Rats/Group V: 5 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
654911	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654916	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654917	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654959	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	0
654961	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654967	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654998	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654907	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654980	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655005	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Male Rats/Group VII: 25 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
654922	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654923	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
654952	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654958	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654975	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654989	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655001	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	0
655006	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
654930	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654940	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Male Rats/Group IX: 125 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
654942	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654957	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	0
654973	Baseline	0	0	0	0	1	0
	Week 13	0	0	0	0	1	1
654974	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
654976	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654977	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
654978	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654985	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
654990	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
654991	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Female Rats/Group II: 0 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
655019	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	0
655071	Baseline	0	0	0	0	0	1
	Week 13 [a]	…	…	…	…	…	…
655062	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655068	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655009	Baseline	0	0	0	0	1	0
	Week 13	0	0	0	0	1	1
655015	Baseline	0	0	0	0	0	0
	Week 13	0	0	0	0	0	1
655035	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
655072	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655101	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655109	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1

[a] Rat accidentally killed on test day 19.

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Female Rats/Group IV: 1 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
655013	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655033	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655040	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655041	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655044	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655086	Baseline	0	0	0	0	0	0
	Week 13	0	0	0	0	0	1
655089	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655090	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655091	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655108	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Female Rats/Group VI: 5 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
655020	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655029	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655034	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655039	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655042	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655066	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655067	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655087	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	0
655038	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655054	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Female Rats/Group VIII: 25 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
655011	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655012	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655047	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655055	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655058	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1
655073	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655076	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655078	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	0
655085	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655105	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	1	1

INDIVIDUAL FUNCTIONAL OBSERVATIONAL BATTERY ASSESSMENT

Female Rats/Group X: 125 mg/kg/day

		MANIPULATIONS			MOTOR ACTIVITY		
ANIMAL NUMBER	ASSESSMENT PERIOD	APPROACH & TOUCH	AUDITORY STIMULUS	TAIL PINCH	PUPILLARY RESPONSE	DEFECATION	URINATION
655010	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1
655030	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655037	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655049	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655061	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655075	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655077	Baseline	0	0	0	0	1	0
	Week 13	0	0	0	0	0	1
655084	Baseline	0	0	0	0	0	1
	Week 13	0	0	0	0	0	1
655088	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	1	1
655100	Baseline	0	0	0	0	1	1
	Week 13	0	0	0	0	0	1

APPENDIX I

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline

Male Rats/Group I: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654909	395	336	162	0	14	1	908
654910	398	273	151	1	3	10	836
654915	440	389	282	59	1	2	1173
654924	359	325	246	22	0	0	952
654927	383	364	35	1	36	12	831
654943	324	247	215	214	280	217	1497
654949	396	288	201	30	3	0	918
654956	419	375	260	66	0	12	1132
654992	363	259	373	99	17	6	1117
654994	350	321	230	112	0	11	1024

Baseline

Male Rats/Group III: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654908	345	270	249	236	4	145	1249
654913	442	366	384	213	19	12	1436
654932	423	307	262	40	3	3	1038
654938	420	397	254	202	6	0	1279
654941	322	311	195	0	2	0	830
654946	377	340	321	364	175	73	1650
654947	353	280	316	188	13	8	1158
654960	409	368	394	276	125	0	1572
654984	396	345	295	23	45	3	1107
654995	535	457	449	85	439	95	2060

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline
Male Rats/Group V: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654907	420	292	160	77	3	3	955
654911	370	323	211	40	19	0	963
654916	431	320	356	321	331	266	2025
654917	357	314	168	22	12	4	877
654959	324	271	243	96	9	4	947
654961	420	426	387	326	319	279	2157
654967	411	361	267	235	268	129	1671
654980	426	342	284	328	35	7	1422
654998	405	315	216	239	119	6	1300
655005	450	374	247	38	8	21	1138

Baseline
Male Rats/Group VII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654922	393	345	323	344	103	48	1556
654923	384	260	288	216	34	2	1184
654930	384	233	141	0	0	13	771
654940	328	196	31	3	0	0	558
654952	405	299	249	231	245	181	1610
654958	434	295	229	270	245	316	1789
654975	398	314	205	35	0	15	967
654989	399	197	2	2	0	5	605
655001	454	392	275	79	2	14	1216
655006	400	391	252	280	48	6	1377

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline

Male Rats/Group IX: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654942	413	328	72	67	3	0	883
654957	500	471	478	420	231	77	2177
654973	415	310	343	226	222	220	1736
654974	390	359	257	11	1	20	1038
654976	351	265	111	0	0	0	727
654977	337	320	331	334	120	40	1482
654978	451	390	317	315	316	142	1931
654985	355	233	304	51	4	4	951
654990	416	438	374	119	2	1	1350
654991	388	315	227	94	5	5	1034

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline

Female Rats/Group II: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655009	329	155	279	215	232	103	1313
655015	317	118	2	145	189	141	912
655019	324	262	261	234	126	4	1211
655035	425	377	283	336	31	7	1459
655062	351	247	172	101	2	1	874
655068	407	313	322	261	198	155	1656
655071	460	443	380	355	400	157	2195
655072	326	314	380	175	208	66	1469
655101	338	243	248	306	188	217	1540
655109	424	178	101	277	314	265	1559

Baseline

Female Rats/Group IV: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655013	446	365	305	361	338	339	2154
655033	363	288	160	187	310	157	1465
655040	388	312	229	20	8	3	960
655041	322	266	337	243	254	66	1488
655044	361	294	212	174	4	0	1045
655086	370	216	106	288	130	68	1178
655089	357	239	191	53	185	158	1183
655090	336	284	231	81	1	1	934
655091	525	482	419	444	484	481	2835
655108	424	278	254	222	116	176	1470

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline
Female Rats/Group VI: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655020	413	63	59	330	290	158	1313
655029	334	233	207	198	1	3	976
655034	341	322	181	5	6	10	865
655038	349	289	194	272	152	268	1524
655039	339	350	263	263	38	11	1264
655042	339	307	283	247	40	2	1218
655054	371	269	216	313	299	285	1753
655066	404	344	317	258	247	164	1734
655067	392	410	307	422	237	299	2067
655087	362	239	311	248	231	196	1587

Baseline
Female Rats/Group VIII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655011	301	123	178	111	7	66	786
655012	400	290	291	192	205	11	1389
655047	329	360	262	223	319	98	1591
655055	394	264	191	144	0	0	993
655058	306	198	97	160	190	107	1058
655073	385	243	196	198	288	175	1485
655076	384	331	307	265	231	47	1565
655078	391	91	192	312	34	56	1076
655085	433	334	290	116	2	1	1176
655105	410	359	340	275	252	168	1804

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Baseline

Female Rats/Group X: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655010	392	345	285	77	0	0	1099
655030	336	285	188	312	263	187	1571
655037	466	472	428	410	255	105	2136
655049	423	286	272	271	267	246	1765
655061	303	283	200	264	205	298	1553
655075	391	337	353	311	276	243	1911
655077	274	257	119	36	49	0	735
655084	294	285	300	192	43	1	1115
655088	337	286	266	225	148	120	1382
655100	453	369	313	266	308	246	1955

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13
Male Rats/Group I: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654909	405	324	313	227	249	3	1521
654910	317	276	191	215	96	27	1122
654915	417	371	259	280	170	185	1682
654924	371	315	245	169	196	77	1373
654927	394	384	368	318	287	263	2014
654943	411	341	283	254	258	254	1801
654949	415	333	277	350	213	217	1805
654956	431	349	341	321	331	255	2028
654992	358	284	268	289	231	128	1558
654994	312	295	335	276	229	173	1620

Week 13
Male Rats/Group III: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654908	386	368	294	273	299	200	1820
654913	390	365	258	282	274	238	1807
654932	388	350	343	237	100	42	1460
654938	428	365	261	302	334	180	1870
654941	320	281	206	164	24	15	1010
654946	415	358	344	296	252	250	1915
654947	381	346	312	283	130	50	1502
654960	463	346	331	363	291	162	1956
654984	385	329	307	295	140	10	1466
654995 [a]	518	529	469	441	516	459	2932

[a] Data inaccurate due to sensor malfunction; data excluded from summary table and statistical analysis

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13
Male Rats/Group V: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654911	309	301	200	248	104	9	1171
654916	446	360	338	226	130	278	1778
654917	414	328	290	273	147	9	1461
654959	363	278	210	38	55	157	1101
654961	375	332	264	206	203	281	1661
654967	455	353	220	131	265	144	1568
654998	385	375	252	166	206	131	1515
654907	370	264	262	163	3	7	1069
654980	379	373	191	265	195	5	1408
655005	401	362	211	371	324	26	1695

Week 13
Male Rats/Group VII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654922	395	320	229	244	188	236	1612
654923	455	361	138	256	20	65	1295
654952	399	321	208	114	70	172	1284
654958	459	381	318	236	232	186	1812
654975	387	224	162	194	90	202	1259
654989	398	180	0	2	0	1	581
655001	417	295	337	280	94	113	1536
655006	381	335	272	262	218	149	1617
654930	433	367	351	186	205	224	1766
654940	410	292	264	324	175	230	1695

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13

Male Rats/Group IX: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654942	290	236	61	21	0	119	727
654957	456	372	314	348	328	250	2068
654973	391	380	276	276	236	170	1729
654974	339	303	288	151	202	254	1537
654976	340	232	98	21	8	2	701
654977	476	423	385	379	336	317	2316
654978	472	317	369	378	239	261	2036
654985	360	252	228	243	109	2	1194
654990	460	393	388	232	206	119	1798
654991	466	358	340	155	357	182	1858

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13

Female Rats/Group II: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655019	368	267	237	233	206	157	1468
655071 [a]	…	…	…	…	…	…	…
655062	390	227	210	252	166	246	1491
655068	378	244	236	246	204	247	1555
655009	347	345	292	311	256	215	1766
655015	342	279	140	156	136	32	1085
655035	362	283	238	291	239	201	1614
655072	357	289	258	203	185	128	1420
655101	406	305	231	219	187	308	1656
655109	497	365	292	126	245	281	1806

Week 13

Female Rats/Group IV: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655013	385	272	256	211	174	243	1541
655033	358	278	139	227	74	56	1132
655040	375	298	317	293	274	319	1876
655041	431	306	206	250	185	182	1560
655044	387	356	282	180	142	184	1531
655086	367	141	195	270	135	34	1142
655089	471	259	221	310	226	0	1487
655090	463	340	364	279	172	26	1644
655091	477	402	261	358	265	281	2044
655108	364	289	215	114	173	179	1334

[a] Rat accidentally killed on test day 19.

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13
Female Rats/Group VI: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655020	451	307	263	49	10	229	1309
655029	380	349	287	227	223	119	1585
655034	398	233	142	67	200	5	1045
655039	419	259	102	118	38	191	1127
655042	356	265	157	322	187	181	1468
655066	393	381	243	204	180	114	1515
655067	460	332	135	102	216	284	1529
655087	348	261	172	118	218	181	1298
655038	413	315	318	205	110	107	1468
655054	458	412	293	251	127	292	1833

Week 13
Female Rats/Group VIII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655011	369	250	175	228	18	148	1188
655012	447	327	243	210	194	218	1639
655047	378	290	211	216	15	142	1252
655055	348	217	171	121	137	103	1097
655058	284	152	147	144	71	83	881
655073	464	352	313	288	201	260	1878
655076	457	318	321	197	178	198	1669
655078	415	370	250	103	206	239	1583
655085	415	332	243	377	191	113	1671
655105	496	376	266	47	212	251	1648

INDIVIDUAL MOTOR ACTIVITY: DURATION OF MOVEMENTS

Week 13

Female Rats/Group X: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655010	381	297	235	261	177	66	1417
655030	394	295	257	260	201	202	1609
655037 [a]	493	484	427	503	408	95	2410
655049	396	333	255	260	188	129	1561
655061	400	204	169	276	190	268	1507
655075	454	352	331	64	291	222	1714
655077	381	279	105	187	49	1	1002
655084	470	326	274	247	351	169	1837
655088	313	228	219	187	135	0	1082
655100	439	405	322	292	272	321	2051

[a] Data inaccurate due to sensor malfunction; data excluded from summary table and statistical analysis

APPENDIX J

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline

Male Rats/Group I: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654909	132	141	86	2	10	5	376
654910	146	165	133	2	5	10	461
654915	88	115	128	42	3	6	382
654924	146	132	143	19	1	2	443
654927	138	148	36	1	20	9	352
654943	129	138	145	144	153	136	845
654949	137	141	154	39	7	2	480
654956	139	133	150	58	0	16	496
654992	135	127	124	97	13	9	505
654994	159	146	142	103	2	17	569

Baseline

Male Rats/Group III: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654908	141	135	126	159	9	97	667
654913	119	139	139	140	15	17	569
654932	146	151	132	38	5	7	479
654938	145	145	131	97	8	0	526
654941	137	119	118	1	4	0	379
654946	150	133	143	177	158	84	845
654947	125	121	131	113	10	5	505
654960	130	139	134	143	96	0	642
654984	134	146	159	26	35	11	511
654995	59	62	64	15	54	8	262

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline
Male Rats/Group V: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654907	134	140	91	67	5	7	444
654911	138	162	141	53	17	3	514
654916	124	163	143	141	157	151	879
654917	149	138	128	30	14	15	474
654959	157	136	140	92	19	6	550
654961	122	116	126	128	126	131	749
654967	130	136	148	133	147	92	786
654980	128	161	146	159	31	8	633
654998	129	132	120	159	84	17	641
655005	109	120	129	38	9	14	419

Baseline
Male Rats/Group VII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654922	158	143	153	142	88	63	747
654923	120	123	130	152	30	3	558
654930	157	135	100	4	4	10	410
654940	141	136	40	5	2	1	325
654952	142	137	134	151	159	145	868
654958	128	138	136	161	130	124	817
654975	126	142	113	42	1	15	439
654989	141	130	9	3	3	10	296
655001	130	134	134	80	6	14	498
655006	133	150	135	131	37	13	599

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline

Male Rats/Group IX: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654942	133	137	67	52	5	1	395
654957	66	76	69	67	43	9	330
654973	110	121	141	137	121	124	754
654974	152	161	163	18	1	19	514
654976	144	157	110	1	4	2	418
654977	151	172	162	134	98	35	752
654978	121	143	131	142	145	72	754
654985	138	135	138	54	12	7	484
654990	117	120	123	47	4	2	413
654991	141	141	151	77	6	12	528

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline

Female Rats/Group II: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655009	174	97	150	127	147	101	796
655015	135	94	4	108	124	113	578
655019	135	158	163	142	103	7	708
655035	121	122	132	120	33	7	535
655062	144	144	108	95	4	9	504
655068	133	179	142	153	128	116	851
655071	118	126	128	137	144	108	761
655072	152	152	138	140	149	60	791
655101	148	162	160	159	163	172	964
655109	120	87	74	116	156	131	684

Baseline

Female Rats/Group IV: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655013	124	126	163	127	132	154	826
655033	153	139	105	134	133	98	762
655040	138	129	139	27	8	5	446
655041	105	126	125	139	122	62	679
655044	126	130	133	104	4	1	498
655086	149	128	104	136	130	85	732
655089	150	131	106	45	127	99	658
655090	150	165	151	43	3	5	517
655091	66	59	74	62	73	57	391
655108	151	139	143	155	116	141	845

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline
Female Rats/Group VI: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655020	148	57	54	163	157	111	690
655029	118	125	136	112	3	2	496
655034	128	126	127	8	10	16	415
655038	134	147	143	139	143	153	859
655039	134	136	138	141	43	11	603
655042	153	140	154	139	60	3	649
655054	129	101	106	134	117	121	708
655066	147	146	168	146	142	139	888
655067	123	128	123	108	126	111	719
655087	156	139	147	131	149	168	890

Baseline
Female Rats/Group VIII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655011	137	119	113	77	11	58	515
655012	130	130	132	111	131	13	647
655047	118	96	130	134	136	90	704
655055	134	131	135	108	4	1	513
655058	151	132	89	139	120	86	717
655073	172	146	143	146	150	144	901
655076	146	149	132	154	141	39	761
655078	150	79	156	146	26	53	610
655085	120	137	132	85	3	3	480
655105	124	154	159	166	141	137	881

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Baseline

Female Rats/Group X: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655010	146	139	143	72	0	2	502
655030	133	122	125	126	111	133	750
655037	64	61	67	60	38	13	303
655049	137	154	138	152	125	148	854
655061	129	152	124	144	163	151	863
655075	148	147	140	181	145	137	898
655077	155	184	107	42	42	0	530
655084	146	150	177	177	54	4	708
655088	133	137	141	143	120	110	784
655100	123	136	151	142	145	132	829

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13

Male Rats/Group I: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654909	120	133	125	101	143	7	629
654910	155	152	147	148	70	32	704
654915	140	131	119	126	109	100	725
654924	142	151	125	128	128	53	727
654927	120	132	114	126	121	127	740
654943	129	142	139	155	139	150	854
654949	158	148	131	141	114	122	814
654956	126	136	146	143	124	150	825
654992	166	155	139	141	145	88	834
654994	150	158	150	157	137	124	876

Week 13

Male Rats/Group III: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654908	151	156	148	151	150	138	894
654913	135	134	128	125	123	133	778
654932	144	151	138	125	73	22	653
654938	136	164	155	141	139	95	830
654941	152	149	101	102	23	30	557
654946	154	146	139	124	148	112	823
654947	132	132	137	146	78	26	651
654960	128	149	141	135	158	121	832
654984	146	152	151	151	78	7	685
654995 [a]	58	65	55	60	59	58	355

[a] Data inaccurate due to sensor malfunction; data excluded from summary table and statistical analysis

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13
Male Rats/Group V: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654911	144	124	118	142	53	11	592
654916	124	133	127	131	86	164	765
654917	134	157	134	135	104	13	677
654959	154	162	124	34	45	127	646
654961	131	132	135	108	116	124	746
654967	120	119	104	74	120	86	623
654998	150	151	149	113	138	97	798
654907	154	156	151	113	3	4	581
654980	142	137	99	110	100	19	607
655005	136	113	98	126	129	16	618

Week 13
Male Rats/Group VII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654922	145	147	130	134	108	128	792
654923	104	121	67	133	12	23	460
654952	133	124	100	82	53	123	615
654958	136	143	144	104	101	80	708
654975	150	124	93	117	60	124	668
654989	138	100	3	3	0	2	246
655001	103	119	121	99	58	43	543
655006	133	141	150	158	128	111	821
654930	123	135	132	116	108	115	729
654940	134	139	141	144	106	121	785

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13

Male Rats/Group IX: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
654942	148	129	63	19	1	86	446
654957	119	113	116	111	143	82	684
654973	136	149	151	133	161	131	861
654974	148	140	146	89	134	168	825
654976	172	138	66	31	10	3	420
654977	131	155	146	159	145	151	887
654978	111	153	137	130	139	108	778
654985	148	124	108	114	77	6	577
654990	117	136	132	105	86	68	644
654991	101	106	91	66	117	72	553

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13
Female Rats/Group II: 0 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655019	148	145	158	114	153	124	842
655071 [a]	…	…	…	…	…	…	…
655062	124	127	127	141	132	149	800
655068	134	123	146	163	134	158	858
655009	143	136	134	142	142	117	814
655015	147	149	118	137	114	37	702
655035	120	117	116	125	124	109	711
655072	161	150	152	136	149	140	888
655101	138	139	100	104	108	136	725
655109	74	110	100	71	89	121	565

Week 13
Female Rats/Group IV: 1 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655013	165	143	156	123	108	116	811
655033	168	146	135	144	81	79	753
655040	148	126	108	163	153	127	825
655041	100	135	118	111	107	120	691
655044	149	155	140	138	104	106	792
655086	144	117	140	138	146	22	707
655089	105	135	87	103	108	1	539
655090	129	145	159	152	136	28	749
655091	118	118	103	124	103	131	697
655108	125	140	138	105	121	129	758

[a] Rat accidentally killed on test day 19.

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13
Female Rats/Group VI: 5 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655020	108	139	129	44	15	132	567
655029	125	122	141	128	127	86	729
655034	124	123	89	34	107	6	483
655039	131	112	84	105	47	103	582
655042	131	152	112	137	116	106	754
655066	103	141	118	127	99	94	682
655067	107	151	61	88	128	122	657
655087	155	159	128	96	132	139	809
655038	142	143	132	118	93	74	702
655054	125	136	156	122	99	145	783

Week 13
Female Rats/Group VIII: 25 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655011	143	133	132	163	25	132	728
655012	123	117	141	123	110	145	759
655047	119	116	132	122	19	67	575
655055	153	141	109	80	105	92	680
655058	160	109	109	98	61	92	629
655073	121	154	133	144	141	129	822
655076	116	138	146	101	103	103	707
655078	149	156	161	77	135	145	823
655085	146	132	101	139	143	76	737
655105	120	137	155	37	120	131	700

INDIVIDUAL MOTOR ACTIVITY: NUMBER OF MOVEMENTS

Week 13

Female Rats/Group X: 125 mg/kg/day

Animal Number	Successive 10-Minute Intervals 1	2	3	4	5	6	Total
655010	135	123	122	157	109	52	698
655030	135	123	118	120	118	124	738
655037 [a]	57	56	66	56	45	11	291
655049	137	133	128	139	101	92	730
655061	156	103	118	135	127	139	778
655075	135	147	168	63	154	140	807
655077	136	128	74	119	36	5	498
655084	134	171	143	127	124	95	794
655088	145	137	143	128	88	2	643
655100	113	140	155	150	144	133	835

[a] Data inaccurate due to sensor malfunction; data excluded from summary table and statistical analysis

APPENDIX K

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES

ABBREVIATIONS:

General:

ADEQ	-	adequate
CLOT	-	sample clotted
DECR	-	decreased
INCR	-	increased
NSR	-	no sample received for testing
NT	-	not taken or not performed
NT-HEMOL	-	not taken due to hemolysis
OK	-	sample condition OK for testing
QNS	-	quantity not sufficient for testing
RNV	-	result not valid
UTD	-	unable to determine
>	-	greater than
<	-	less than

Individual Hematology Values:

COND	-	sample condition
RBC	-	red blood cell count
HGB	-	hemoglobin
HCT	-	hematocrit
MCV	-	mean corpuscular volume
MCH	-	mean corpuscular hemoglobin
MCHC	-	mean corpuscular hemoglobin concentration
RDW	-	red cell distribution width
ARET	-	absolute reticulocyte count
PLT	-	platelet count
WBC	-	white blood cell count
ANEU	-	absolute neutrophil (all forms)
ALYM	-	absolute lymphocyte
AMON	-	absolute monocyte
AEOS	-	absolute eosinophil
ABAS	-	absolute basophil
ALUC	-	absolute large unstained cell
SPEC	-	special observations

Individual Red Blood Cell Morphology Values:

NORM	-	Normal
ANIS	-	anisocytosis
MIC	-	microcytes
MAC	-	macrocytes
POLY	-	polychromasia
HYPO	-	hypochromasia
ECHI	-	echinocytes
ACAN	-	acanthocytes
TARG	-	Target cells
RX	-	rouleaux
HJB	-	Howell-Jolly body
-	-	not observed or not examined; see whole blood sample condition

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES (Continued)

ABBREVIATIONS: (Continued)

Individual White Blood Cell / Platelet Morphology Values:

NORM	-	Normal
SM	-	Smudge white blood cells
TOX	-	toxic neutrophils
DB	-	Döhle bodies
VC	-	vacuolated cytoplasm
BC	-	basophilic cytoplasm
PCE	-	platelet clumps / estimate
GP	-	giant platelets
BP	-	bizarre platelets
SPEC	-	special observations
-	-	not observed or not examined; see whole blood sample condition

Individual Coagulation Values:

PHEM	-	plasma hemolysis
PLIP	-	plasma lipemia
PICT	-	plasma icterus
PT	-	prothrombin time
APTT	-	activated partial thromboplastin time

Individual Clinical Chemistry Values:

SHEM	-	serum hemolysis
SLIP	-	serum lipemia
SICT	-	serum icterus
AST	-	aspartate aminotransferase
ALT	-	alanine aminotransferase
SDH	-	sorbitol dehydrogenase
ALKP	-	alkaline phosphatase
BILI	-	total bilirubin
BUN	-	urea nitrogen
CREA	-	creatinine
CHOL	-	cholesterol
TRIG	-	triglycerides
GLUC	-	glucose
TP	-	total protein
ALB	-	albumin
GLOB	-	globulin
CALC	-	calcium
IPHS	-	inorganic phosphorous
NA	-	sodium
K	-	potassium
CL	-	chloride
PHEM	-	plasma hemolysis from blood sample for fluoride determination
PLIP	-	plasma lipemia from blood sample for fluoride determination
PICT	-	plasma icterus from blood sample for fluoride determination
PFLU	-	plasma fluoride

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES (Continued)

ABBREVIATIONS: (Continued)

Individual Urinalysis Values:

QUAL - quality (modifies color)
COL - color
CLAR - clarity
VOL - volume
UOSM - urine osmolality
pH - the logarithm of the reciprocal of the hydrogen ion concentration
UGLU - urine glucose
KET - ketone
UBIL - urine bilirubin
BLD - blood
URO - urobilinogen
UFLU - urine fluoride
UMTP - urine protein
SPEC - special observations

Individual Urine Microscopic Examination Values:

EPIT - epithelial cells
UWBC - urine white blood cells
URBC - urine red blood cells
NCRY - normal crystals
MICR - microorganisms
SPER - sperm
SPEC - special observations

KEY:

Special Observations:

1 - trace
2 - few
3 - moderate
4 - many

Urine Microscopic Values:

EPIT/UWBC/URBC per high power field (40x)	NCRY/MICR per high power field (40x)	SPERM/MUCUS per low power field (10x)
1 - 1-10	1 - 1-25%/field	1 - 1-5
2 - 11-50	2 - 26-50%/field	2 - 6-20
3 - >50	3 - >50%/field	3 - >20

NOTES:

When individual animal data are not reported, it may be due to one of the following reasons or other reasons, all of which are explained in the study records:

the sample was clotted (CLOT)
there was insufficient sample for testing (QNS)
a valid result could not be obtained (RNV)
the sample was not suitable for testing
the animal died prior to sample collection
no sample was available for testing (NSR)

When an individual observation was recorded as being less than a certain value, calculations were performed on half the recorded value. For example, if bilirubin was reported as <0.1, 0.05 was used for any calculations performed with that bilirubin data.

Individual Hematology Values

Animal Number	COND	RBC $x10^6/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET $x10^9/L$	PLT $x10^3/\mu L$	WBC $x10^3/\mu L$
Male, Group I - 0 mg/kg/day - Day 48											
654903	OK	7.83	14.5	46.0	58.8	18.5	31.4	12.1	211.0	847	17.02
654925	OK	8.48	15.7	49.8	58.7	18.5	31.5	11.5	215.8	1106	15.00
654928	OK	7.98	15.1	47.3	59.3	18.9	31.8	12.2	191.6	1184	13.95
654929	OK	8.68	15.4	49.8	57.3	17.7	31.0	11.6	193.9	814	12.96
654936	OK	8.10	15.0	48.3	59.7	18.6	31.1	12.5	194.0	RNV	12.79
654950	OK	8.48	15.3	48.2	56.8	18.0	31.7	11.2	205.0	998	14.01
654953	OK	8.10	14.7	46.6	57.6	18.1	31.5	11.8	221.1	RNV	12.51
654972	OK	8.86	15.4	48.8	55.1	17.4	31.6	11.9	231.9	RNV	10.54
654987	OK	7.98	14.1	46.7	58.6	17.7	30.2	12.3	240.9	1110	17.84
654993	OK	8.82	16.2	51.3	58.2	18.3	31.5	12.1	220.5	RNV	15.17
Male, Group III - 1 mg/kg/day - Day 48											
654908	OK	8.61	15.3	49.5	57.5	17.8	30.9	11.4	207.7	RNV	9.81
654913	OK	7.91	14.9	46.2	58.4	18.9	32.3	11.2	174.9	1073	16.38
654932	OK	8.88	16.4	52.2	58.8	18.5	31.4	11.1	193.7	1094	17.29
654938	OK	8.15	14.6	45.9	56.3	17.9	31.8	11.2	196.3	RNV	17.48
654941	OK	8.04	14.1	45.3	56.3	17.5	31.0	11.9	247.6	RNV	18.44
654946	OK	8.03	14.6	47.5	59.1	18.2	30.9	12.1	210.1	RNV	13.28
654947	OK	8.56	16.2	51.2	59.8	18.9	31.6	11.6	250.3	RNV	22.51
654960	OK	8.40	15.1	48.4	57.6	17.9	31.1	12.1	185.2	RNV	13.97
654984	OK	8.21	15.3	48.2	58.7	18.6	31.7	12.0	183.7	1104	11.01
654995	OK	7.77	15.4	48.5	62.3	19.8	31.8	10.8	210.6	1122	16.52
Male, Group V - 5 mg/kg/day - Day 48											
654907	OK	8.24	15.5	50.1	60.7	18.8	30.9	11.4	213.4	961	16.45
654911	OK	8.29	15.1	47.6	57.4	18.2	31.7	10.8	172.4	RNV	17.07
654916	OK	8.26	14.9	48.2	58.4	18.0	30.9	12.5	280.9	RNV	10.00
654917	OK	8.05	15.3	49.2	61.1	19.0	31.1	12.4	310.7	1026	15.65
654959	OK	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654961	OK	8.08	14.7	47.8	59.1	18.2	30.7	11.9	250.3	1102	12.57
654967	OK	8.33	15.8	49.8	59.8	19.0	31.7	11.6	183.9	1008	12.82
654980	OK	8.32	15.2	48.6	58.4	18.2	31.2	12.6	248.0	1267	22.89
654998	OK	8.07	14.9	47.7	59.1	18.5	31.2	11.3	214.1	1029	12.92
655005	OK	8.01	14.8	46.4	58.0	18.5	31.9	12.5	248.2	983	15.71

Individual Hematology Values

Animal Number	COND	RBC $x10^6/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET $x10^9/L$	PLT $x10^3/\mu L$	WBC $x10^3/\mu L$
Male, Group VII - 25 mg/kg/day - Day 48											
654922	OK	8.03	14.4	46.4	57.8	17.9	31.0	12.5	256.4	987	13.14
654923	OK	7.99	15.1	46.6	58.4	18.9	32.4	12.3	237.1	997	17.40
654930	OK	8.01	15.1	47.4	59.1	18.9	31.9	11.7	265.4	RNV	18.46
654940	OK	7.83	14.4	45.2	57.6	18.4	32.0	12.8	291.8	RNV	17.96
654952	OK	7.87	14.8	47.3	60.0	18.8	31.3	11.9	207.7	RNV	11.37
654958	OK	8.04	14.4	48.1	59.9	17.9	29.9	13.9	309.1	RNV	15.08
654975	OK	7.88	14.6	46.3	58.8	18.6	31.6	11.6	249.9	954	16.02
654989	OK	8.14	15.9	50.0	61.5	19.5	31.8	11.1	212.6	RNV	20.45
655001	OK	7.73	14.4	45.4	58.7	18.6	31.7	12.6	188.1	1046	11.26
655006	OK	7.46	14.8	47.0	63.0	19.8	31.4	11.7	178.2	1074	13.48
Male, Group IX - 125 mg/kg/day - Day 48											
654914	OK	8.44	15.1	49.6	58.8	17.9	30.4	13.5	276.3	985	20.10
654921	OK	7.74	14.6	46.4	60.0	18.8	31.3	12.1	244.0	RNV	13.31
654951	OK	8.38	15.5	49.5	59.0	18.5	31.3	13.0	258.2	RNV	18.02
654955	OK	7.51	14.3	45.9	61.1	19.1	31.2	13.4	247.1	1207	22.06
654965	OK	7.48	14.0	44.8	59.9	18.7	31.2	13.6	237.7	RNV	18.80
654979	OK	7.04	13.3	42.7	60.7	18.9	31.1	13.2	309.0	RNV	11.74
654983	OK	7.93	15.3	48.6	61.3	19.3	31.4	11.4	244.1	718	16.60
654986	OK	7.61	14.8	47.9	63.0	19.4	30.9	11.6	231.1	880	11.31
654996	OK	7.76	14.2	43.8	56.4	18.3	32.5	14.4	291.0	959	19.49
655003	OK	7.88	14.2	44.9	56.9	18.0	31.6	13.1	281.9	RNV	11.49

Individual Hematology Values

Animal Number	ANEU $x10^3/\mu L$	ALYM $x10^3/\mu L$	AMON $x10^3/\mu L$	AEOS $x10^3/\mu L$	ABAS $x10^3/\mu L$	ALUC $x10^3/\mu L$
Male, Group I - 0 mg/kg/day - Day 48						
654903	1.60	14.54	0.40	0.29	0.08	0.10
654925	1.99	12.37	0.28	0.13	0.16	0.07
654928	1.23	12.12	0.33	0.11	0.09	0.07
654929	1.36	10.98	0.24	0.13	0.15	0.10
654936	1.28	11.09	0.27	0.05	0.04	0.07
654950	1.96	11.42	0.30	0.14	0.11	0.07
654953	1.42	10.59	0.30	0.06	0.06	0.08
654972	1.16	9.38	0.00	0.00	0.00	0.00
654987	2.98	14.04	0.49	0.12	0.10	0.11
654993	1.35	13.13	0.37	0.12	0.12	0.09
Male, Group III - 1 mg/kg/day - Day 48						
654908	1.51	7.93	0.13	0.09	0.09	0.06
654913	1.84	13.79	0.20	0.16	0.30	0.09
654932	0.77	16.12	0.12	0.09	0.09	0.10
654938	1.55	15.14	0.31	0.09	0.26	0.14
654941	1.83	15.96	0.32	0.09	0.15	0.09
654946	1.12	11.58	0.26	0.18	0.08	0.07
654947	3.60	18.46	0.45	0.00	0.00	0.00
654960	1.26	12.20	0.18	0.15	0.11	0.07
654984	0.97	9.56	0.24	0.10	0.09	0.05
654995	1.63	14.28	0.23	0.13	0.18	0.07
Male, Group V - 5 mg/kg/day - Day 48						
654907	1.42	14.36	0.31	0.13	0.11	0.11
654911	2.89	13.40	0.55	0.05	0.09	0.08
654916	0.93	8.81	0.14	0.06	0.03	0.05
654917	2.54	12.25	0.54	0.10	0.14	0.08
654959	NT	NT	NT	NT	NT	NT
654961	1.38	10.67	0.24	0.11	0.08	0.08
654967	1.55	10.59	0.44	0.07	0.10	0.07
654980	2.55	19.35	0.47	0.20	0.21	0.11
654998	2.06	10.17	0.49	0.07	0.07	0.06
655005	2.29	12.89	0.23	0.13	0.10	0.08

Individual Hematology Values

Animal Number	ANEU $x10^3/\mu L$	ALYM $x10^3/\mu L$	AMON $x10^3/\mu L$	AEOS $x10^3/\mu L$	ABAS $x10^3/\mu L$	ALUC $x10^3/\mu L$
Male, Group VII - 25 mg/kg/day - Day 48						
654922	0.89	11.75	0.17	0.08	0.16	0.10
654923	2.43	14.22	0.37	0.14	0.17	0.08
654930	2.19	15.43	0.40	0.14	0.16	0.13
654940	3.13	14.05	0.40	0.14	0.15	0.10
654952	1.76	9.01	0.20	0.12	0.21	0.07
654958	1.23	13.43	0.19	0.10	0.07	0.06
654975	1.49	14.02	0.19	0.06	0.18	0.08
654989	2.28	17.64	0.22	0.12	0.11	0.09
655001	2.62	7.94	0.38	0.14	0.11	0.07
655006	1.98	10.94	0.38	0.04	0.07	0.07
Male, Group IX - 125 mg/kg/day - Day 48						
654914	3.01	16.26	0.40	0.18	0.15	0.10
654921	1.75	11.08	0.28	0.12	0.04	0.06
654951	3.70	13.59	0.37	0.15	0.11	0.10
654955	2.98	18.25	0.44	0.15	0.12	0.11
654965	1.26	16.93	0.22	0.08	0.23	0.08
654979	0.99	10.45	0.12	0.05	0.07	0.06
654983	2.22	13.74	0.28	0.18	0.12	0.06
654986	1.53	9.41	0.19	0.09	0.05	0.04
654996	1.55	17.28	0.28	0.10	0.16	0.12
655003	1.39	9.88	0.11	0.11	0.00	0.00

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Male, Group I - 0 mg/kg/day - Day 93											
654903	OK	8.29	15.4	46.1	55.6	18.6	33.4	13.5	209.40	1142	18.08
654925	OK	8.66	16.5	48.7	56.2	19.1	34.0	12.1	184.00	1377	12.47
654928	OK	8.08	15.7	46.3	57.2	19.5	34.0	13.3	161.20	1390	15.58
654929	OK	8.93	16.3	48.8	54.6	18.2	33.3	11.9	131.40	1019	9.18
654936	OK	8.46	15.7	47.8	56.5	18.5	32.8	13.4	186.30	1187	12.86
654950	OK	8.28	15.0	44.8	54.1	18.1	33.5	13.2	179.70	1120	9.73
654953	OK	8.75	15.6	48.4	55.3	17.9	32.3	12.9	141.10	1233	10.40
654972	OK	9.04	16.4	50.1	55.4	18.2	32.8	12.4	177.50	RNV	6.75
654987	OK	8.37	15.4	46.4	55.5	18.4	33.1	12.8	172.50	1369	16.24
654993	OK	8.82	16.8	49.8	56.5	19.1	33.7	12.9	180.80	1149	10.61
Male, Group III - 1 mg/kg/day - Day 93											
654908	OK	8.69	15.7	47.0	54.1	18.0	33.3	12.3	170.10	1102	9.48
654913	OK	8.20	15.1	45.9	56.0	18.4	32.8	12.0	136.50	1245	12.48
654932	OK	8.99	16.9	50.4	56.1	18.8	33.6	11.8	149.10	1300	14.29
654938	OK	8.81	15.5	48.2	54.7	17.6	32.2	12.7	202.20	1411	15.40
654941	OK	8.70	15.5	47.0	54.0	17.8	33.0	12.9	161.20	1222	12.23
654946	OK	8.71	16.4	50.7	58.2	18.8	32.3	11.7	134.60	RNV	11.46
654947	OK	8.03	15.5	46.8	58.3	19.3	33.1	12.2	182.10	RNV	13.29
654960	OK	8.93	16.4	49.5	55.5	18.3	33.0	12.8	162.20	1103	11.01
654984	OK	8.44	16.1	47.5	56.3	19.1	34.0	12.2	143.70	RNV	10.09
654995	OK	7.96	15.6	47.1	59.2	19.6	33.2	11.4	150.60	1203	14.78
Male, Group V - 5 mg/kg/day - Day 93											
654907	OK	8.27	16.3	47.8	57.8	19.7	34.0	12.4	171.70	1165	10.27
654911	OK	8.38	15.1	46.8	55.8	18.0	32.3	12.0	146.20	1244	11.22
654916	OK	8.64	15.7	48.1	55.7	18.2	32.7	12.3	193.90	RNV	9.77
654917	OK	7.96	15.4	45.5	57.1	19.4	34.0	12.4	235.00	1315	15.92
654959	OK	8.18	15.6	44.9	54.9	19.1	34.7	12.3	186.00	1096	12.37
654961	OK	8.42	15.6	47.7	56.7	18.5	32.7	12.6	201.50	1379	10.57
654967	OK	8.54	16.2	49.0	57.4	19.0	33.1	12.2	141.80	966	11.44
654980	OK	8.44	15.5	47.6	56.3	18.4	32.7	14.1	219.20	1216	16.81
654998	OK	8.41	15.7	48.4	57.6	18.6	32.3	12.0	209.50	1211	9.67
655005	OK	7.98	14.6	44.6	55.9	18.4	32.8	13.8	165.30	RNV	9.62

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Male, Group VII - 25 mg/kg/day - Day 93											
654922	OK	7.99	15.2	44.7	56.0	19.0	34.0	12.8	172.20	1332	9.19
654923	OK	8.32	15.7	47.0	56.5	18.9	33.4	12.6	229.40	1398	17.36
654930	OK	8.02	14.8	45.3	56.4	18.5	32.8	12.5	197.60	1348	10.48
654940	OK	7.86	14.6	44.7	56.9	18.6	32.6	12.7	202.40	1376	9.14
654952	OK	7.97	15.4	46.6	58.4	19.3	33.1	12.5	160.70	1106	8.86
654958	OK	8.14	15.6	46.1	56.7	19.1	33.8	13.5	229.00	1094	16.48
654975	OK	8.05	15.5	47.8	59.4	19.2	32.3	13.2	224.00	RNV	15.11
654989	OK	8.63	17.1	51.1	59.2	19.8	33.5	12.0	195.10	RNV	17.91
655001	OK	8.19	15.4	46.4	56.6	18.8	33.3	13.2	181.50	1153	14.40
655006	OK	8.07	16.3	47.9	59.3	20.2	34.1	12.2	134.00	1205	14.62
Male, Group IX - 125 mg/kg/day - Day 93											
654914	OK	8.19	15.9	49.1	59.9	19.4	32.3	12.2	158.10	1190	16.26
654921	OK	8.09	15.6	46.7	57.7	19.2	33.3	12.7	180.70	1406	12.94
654951	OK	8.08	15.4	46.9	58.1	19.0	32.8	12.8	187.00	1178	14.26
654955	OK	6.96	14.1	42.0	60.4	20.2	33.5	18.2	324.30	1686	22.59
654965	OK	7.82	15.0	45.1	57.6	19.1	33.2	13.3	165.10	1454	13.10
654979	OK	7.07	13.9	42.5	60.1	19.7	32.8	12.6	253.40	1232	9.25
654983	OK	8.07	16.1	47.7	59.1	20.0	33.8	12.7	217.80	1003	13.11
654986	OK	7.53	15.1	47.7	63.3	20.0	31.6	13.7	278.20	1084	10.10
654996	OK	7.73	14.3	42.9	55.6	18.5	33.3	14.9	216.40	RNV	16.98
655003	OK	8.05	14.9	44.4	55.1	18.5	33.6	13.3	187.40	1239	10.26

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL	SPEC
Male, Group I - 0 mg/kg/day - Day 93							
654903	2.47	14.84	0.31	0.31	0.06	0.09	
654925	2.19	9.88	0.14	0.16	0.05	0.06	
654928	1.51	13.60	0.15	0.15	0.09	0.08	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654929	2.04	6.84	0.12	0.15	0.02	0.03	
654936	1.68	10.71	0.28	0.06	0.05	0.08	
654950	1.91	7.44	0.21	0.13	0.02	0.03	
654953	1.59	8.39	0.21	0.11	0.03	0.06	
654972	0.81	5.67	0.20	0.07	0.00	0.00	
654987	3.21	12.47	0.24	0.17	0.05	0.09	
654993	1.20	9.04	0.22	0.08	0.03	0.04	
Male, Group III - 1 mg/kg/day - Day 93							
654908	1.81	7.40	0.15	0.07	0.03	0.03	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654913	1.29	10.79	0.09	0.19	0.07	0.06	
654932	1.00	12.97	0.12	0.08	0.05	0.07	
654938	1.63	13.18	0.33	0.10	0.04	0.12	
654941	1.90	9.94	0.21	0.06	0.06	0.06	
654946	1.49	9.51	0.23	0.23	0.00	0.00	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654947	1.06	11.56	0.53	0.13	0.00	0.00	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654960	1.35	9.23	0.14	0.19	0.04	0.05	
654984	1.14	8.38	0.38	0.12	0.02	0.05	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654995	1.78	12.51	0.23	0.10	0.08	0.08	
Male, Group V - 5 mg/kg/day - Day 93							
654907	0.98	8.99	0.10	0.12	0.04	0.04	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654911	1.13	9.73	0.22	0.07	0.04	0.05	
654916	1.34	8.04	0.23	0.09	0.02	0.04	
654917	4.05	11.18	0.47	0.11	0.05	0.06	
654959	2.03	9.76	0.34	0.17	0.03	0.05	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654961	1.39	8.80	0.20	0.09	0.03	0.06	
654967	1.40	9.68	0.20	0.06	0.04	0.06	
654980	3.33	12.51	0.41	0.43	0.05	0.08	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654998	1.29	8.13	0.16	0.03	0.03	0.04	
655005	1.14	8.03	0.11	0.24	0.06	0.05	

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL	SPEC
Male, Group VII - 25 mg/kg/day - Day 93							
654922	1.53	7.40	0.14	0.06	0.03	0.04	
654923	4.05	12.45	0.38	0.34	0.05	0.09	
654930	1.85	8.26	0.19	0.11	0.04	0.04	
654940	2.09	6.71	0.17	0.10	0.03	0.03	
654952	1.44	7.07	0.15	0.14	0.03	0.04	
654958	4.65	11.19	0.38	0.16	0.05	0.05	
654975	1.58	12.58	0.35	0.48	0.05	0.08	
654989	2.73	14.66	0.24	0.11	0.05	0.12	
655001	3.13	10.70	0.39	0.08	0.03	0.07	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
655006	1.77	12.36	0.25	0.09	0.08	0.08	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
Male, Group IX - 125 mg/kg/day - Day 93							
654914	2.27	13.42	0.24	0.18	0.05	0.09	
654921	2.31	10.17	0.20	0.18	0.02	0.06	
654951	2.88	10.95	0.15	0.15	0.03	0.10	BLOOD VOLUME SIGNIFICANTLY MORE THAN SPECIFIED
654955	3.70	18.24	0.32	0.19	0.06	0.08	
654965	1.39	11.27	0.22	0.12	0.05	0.06	
654979	0.95	8.01	0.13	0.10	0.03	0.03	
654983	2.20	10.50	0.18	0.12	0.04	0.06	
654986	1.46	8.38	0.14	0.06	0.03	0.03	
654996	2.56	13.87	0.26	0.17	0.05	0.06	
655003	2.00	7.79	0.23	0.17	0.03	0.04	

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Male, Group I - 0 mg/kg/day - Day 183											
654909	OK	8.80	16.2	49.4	56.1	18.4	32.8	12.8	150.30	RNV	12.34
654910	OK	8.98	15.8	48.6	54.1	17.6	32.6	13.7	150.50	RNV	12.68
654915	OK	8.20	15.0	46.7	56.9	18.2	32.0	13.5	192.20	1100	17.42
654924	OK	9.50	16.0	49.8	52.5	16.9	32.2	13.8	175.80	RNV	18.99
654927	OK	8.82	15.0	46.9	53.2	17.0	32.0	14.4	186.90	1420	14.48
654943	OK	8.74	14.8	48.4	55.3	16.9	30.6	14.2	174.80	1265	15.79
654949	OK	7.95	14.8	44.7	56.3	18.7	33.2	13.6	236.20	1151	10.29
654956	OK	8.66	15.3	47.3	54.6	17.7	32.4	12.9	170.80	866	8.00
654992	OK	8.81	16.3	50.1	56.9	18.5	32.5	13.4	178.60	RNV	12.36
654994	OK	8.63	14.8	45.8	53.1	17.2	32.4	13.1	174.00	1065	12.30
Male, Group IX - 125 mg/kg/day - Day 183											
654942	OK	8.17	15.0	45.8	56.1	18.4	32.8	13.5	203.20	1063	15.54
654957	OK	7.74	14.6	44.0	56.8	18.9	33.2	14.1	225.90	1302	15.89
654973	OK	8.98	15.2	47.8	53.2	16.9	31.7	13.0	179.50	861	15.42
654974	OK	8.53	15.6	47.8	56.0	18.3	32.6	13.9	185.30	1092	16.17
654976	CLOT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654977	OK	9.00	15.4	48.8	54.2	17.1	31.6	13.0	153.50	967	12.25
654978	CLOT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654985	CLOT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654990	OK	8.28	15.2	46.2	55.8	18.4	33.0	12.6	195.70	957	10.57
654991	OK	8.04	15.0	45.9	57.0	18.6	32.7	12.8	175.70	1276	11.95

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL
Male, Group I - 0 mg/kg/day - Day 183						
654909	2.02	9.71	0.33	0.16	0.08	0.04
654910	3.08	9.09	0.31	0.11	0.04	0.05
654915	6.08	10.38	0.64	0.13	0.13	0.07
654924	2.60	15.52	0.34	0.26	0.19	0.08
654927	3.30	10.20	0.58	0.17	0.16	0.06
654943	3.38	11.55	0.48	0.18	0.14	0.06
654949	2.18	7.39	0.42	0.21	0.05	0.05
654956	1.64	5.75	0.42	0.09	0.06	0.04
654992	1.41	10.34	0.20	0.26	0.12	0.03
654994	1.76	9.94	0.24	0.14	0.17	0.06
Male, Group IX - 125 mg/kg/day - Day 183						
654942	2.43	12.26	0.51	0.16	0.12	0.07
654957	3.36	11.65	0.59	0.15	0.08	0.07
654973	2.80	11.78	0.37	0.14	0.25	0.08
654974	2.95	12.27	0.33	0.28	0.25	0.09
654976	NT	NT	NT	NT	NT	NT
654977	2.03	9.62	0.24	0.18	0.14	0.04
654978	NT	NT	NT	NT	NT	NT
654985	NT	NT	NT	NT	NT	NT
654990	1.92	7.90	0.44	0.19	0.06	0.07
654991	1.94	9.21	0.55	0.14	0.05	0.06

Individual Hematology Values

Animal Number	COND	RBC $x10^6/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET $x10^9/L$	PLT $x10^3/\mu L$	WBC $x10^3/\mu L$
Female, Group II - 0 mg/kg/day - Day 49											
655016	OK	8.75	16.4	52.0	59.5	18.8	31.6	11.6	348.0	RNV	11.06
655025	OK	8.21	15.5	48.0	58.5	18.9	32.4	11.4	259.0	1015	11.70
655031	OK	8.50	15.8	49.6	58.4	18.6	31.8	11.2	209.0	971	17.04
655032	OK	8.49	15.3	49.5	58.3	18.0	30.9	13.2	269.2	965	19.84
655036	OK	8.38	16.2	50.8	60.6	19.3	31.9	11.5	284.3	RNV	5.29
655079	OK	8.19	15.5	48.6	59.3	18.9	31.9	11.5	281.5	1043	13.14
655083	OK	7.79	14.7	46.3	59.4	18.8	31.7	11.8	257.2	908	15.98
655098	OK	7.98	15.2	47.2	59.2	19.0	32.1	11.6	195.2	978	14.70
655099	OK	8.04	15.5	48.8	60.6	19.3	31.8	11.9	250.9	933	11.73
655107	OK	8.51	15.6	49.4	58.0	18.3	31.5	11.1	211.4	RNV	9.76
Female, Group IV - 1 mg/kg/day - Day 49											
655013	OK	8.39	16.2	50.1	59.8	19.3	32.4	11.1	196.9	567	11.92
655033	OK	8.36	15.9	49.8	59.6	19.1	32.0	11.6	204.5	1024	14.85
655040	OK	8.07	15.0	46.3	57.4	18.6	32.4	11.5	194.7	945	9.99
655041	OK	7.89	15.0	46.9	59.5	19.0	32.0	12.2	257.4	910	14.33
655044	OK	8.36	15.6	49.0	58.6	18.6	31.8	11.6	206.4	957	8.16
655086	OK	8.32	16.0	49.2	59.2	19.2	32.5	11.2	225.8	630	13.69
655089	OK	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
655090	OK	7.58	14.6	45.1	59.5	19.3	32.5	11.8	264.6	811	13.78
655091	OK	7.81	15.3	48.0	61.5	19.6	31.9	11.9	226.7	RNV	11.93
655108	OK	8.03	15.2	48.2	60.1	19.0	31.6	11.3	251.6	RNV	7.85
Female, Group VI - 5 mg/kg/day - Day 49											
655020	OK	8.70	16.5	51.7	59.4	19.0	32.0	11.7	266.6	918	10.80
655029	OK	7.62	14.5	45.7	60.0	19.0	31.7	12.7	356.0	1512	8.46
655034	OK	8.02	14.9	47.0	58.7	18.6	31.7	11.2	222.4	1112	20.09
655038	OK	8.18	15.9	48.4	59.2	19.4	32.8	11.4	192.8	934	15.74
655039	OK	8.34	15.9	49.0	58.8	19.0	32.4	11.6	206.4	1021	11.33
655042	OK	7.83	15.2	47.9	61.2	19.4	31.7	12.3	261.7	1041	15.95
655054	OK	8.44	15.5	48.2	57.1	18.3	32.1	11.9	312.7	1118	11.50
655066	OK	7.95	15.5	49.5	62.3	19.6	31.4	11.6	232.0	RNV	14.85
655067	OK	8.53	15.7	48.9	57.4	18.4	32.1	12.1	226.3	1106	11.27
655087	OK	7.75	14.9	46.7	60.3	19.2	31.8	11.2	213.1	RNV	12.49

Individual Hematology Values

Animal Number	COND	RBC $x10^6/\mu L$	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET $x10^9/L$	PLT $x10^3/\mu L$	WBC $x10^3/\mu L$
Female, Group VIII - 25 mg/kg/day - Day 49											
655011	OK	7.64	14.6	46.1	60.4	19.2	31.8	11.9	248.1	889	10.07
655012	OK	7.95	14.8	46.4	58.4	18.6	31.8	11.1	205.1	1014	12.16
655047	OK	7.59	14.5	45.3	59.6	19.0	31.9	11.8	210.6	959	16.11
655055	OK	7.42	14.4	44.0	59.3	19.4	32.7	12.0	239.6	1259	13.50
655058	OK	8.06	15.0	46.6	57.8	18.7	32.3	11.5	193.9	RNV	14.86
655073	OK	7.84	14.2	44.2	56.4	18.2	32.2	11.7	198.1	RNV	9.32
655076	OK	8.41	15.4	47.7	56.7	18.4	32.4	11.3	208.3	1055	10.55
655078	OK	8.58	15.7	50.1	58.4	18.3	31.3	12.0	189.4	635	17.03
655085	OK	8.60	15.9	50.8	59.1	18.5	31.3	11.9	192.2	831	12.57
655105	OK	7.93	14.9	46.4	58.5	18.8	32.1	12.5	286.0	975	9.38
Female, Group X - 125 mg/kg/day - Day 49											
655007	OK	7.90	14.3	44.9	56.9	18.2	31.9	11.7	252.2	RNV	10.93
655023	OK	7.85	15.1	47.6	60.7	19.3	31.8	12.0	202.8	806	7.74
655026	OK	6.99	13.9	42.5	60.9	19.9	32.7	11.4	228.3	RNV	9.54
655052	OK	6.89	13.1	41.0	59.6	19.0	31.9	12.4	265.8	1059	9.40
655053	OK	7.40	14.6	44.9	60.7	19.8	32.6	12.5	239.9	RNV	11.07
655063	OK	7.53	13.8	43.1	57.3	18.4	32.1	11.6	252.4	1213	10.39
655092	OK	8.30	15.2	49.2	59.3	18.3	30.9	11.7	251.4	908	14.89
655095	OK	7.24	13.4	42.4	58.6	18.6	31.7	12.4	251.0	RNV	9.84
655097	OK	7.49	14.6	45.0	60.0	19.5	32.5	12.2	233.6	902	17.93
655103	OK	7.36	14.2	43.9	59.7	19.2	32.2	11.7	228.6	RNV	9.29

Individual Hematology Values

Animal Number	ANEU $x10^3/\mu L$	ALYM $x10^3/\mu L$	AMON $x10^3/\mu L$	AEOS $x10^3/\mu L$	ABAS $x10^3/\mu L$	ALUC $x10^3/\mu L$
Female, Group II - 0 mg/kg/day - Day 49						
655016	0.48	10.21	0.18	0.09	0.04	0.06
655025	1.76	9.53	0.24	0.09	0.03	0.05
655031	1.12	15.22	0.17	0.26	0.16	0.11
655032	2.16	16.77	0.57	0.15	0.11	0.10
655036	0.37	4.79	0.06	0.04	0.01	0.02
655079	2.06	10.58	0.21	0.09	0.15	0.05
655083	2.19	13.09	0.35	0.10	0.13	0.13
655098	1.26	12.97	0.13	0.13	0.12	0.10
655099	1.06	10.26	0.19	0.10	0.07	0.05
655107	1.10	8.35	0.08	0.07	0.09	0.07
Female, Group IV - 1 mg/kg/day - Day 49						
655013	0.74	10.78	0.25	0.06	0.05	0.05
655033	0.99	13.39	0.24	0.13	0.05	0.05
655040	0.91	8.77	0.13	0.08	0.05	0.05
655041	1.40	12.34	0.33	0.07	0.10	0.10
655044	0.65	7.20	0.16	0.05	0.06	0.03
655086	0.63	12.71	0.12	0.13	0.05	0.05
655089	NT	NT	NT	NT	NT	NT
655090	1.65	11.73	0.23	0.09	0.04	0.05
655091	0.72	10.83	0.14	0.12	0.05	0.06
655108	0.76	6.75	0.18	0.10	0.02	0.03
Female, Group VI - 5 mg/kg/day - Day 49						
655020	1.29	8.97	0.26	0.18	0.07	0.03
655029	1.42	6.71	0.11	0.11	0.06	0.05
655034	1.32	18.22	0.24	0.08	0.13	0.10
655038	1.65	13.36	0.31	0.17	0.15	0.11
655039	2.40	8.46	0.15	0.11	0.13	0.08
655042	2.04	13.30	0.38	0.08	0.07	0.08
655054	1.10	9.78	0.11	0.13	0.30	0.09
655066	2.19	12.07	0.39	0.09	0.05	0.07
655067	0.90	9.97	0.19	0.13	0.04	0.04
655087	0.70	11.43	0.18	0.08	0.03	0.05

Individual Hematology Values

Animal Number	ANEU $x10^3/\mu L$	ALYM $x10^3/\mu L$	AMON $x10^3/\mu L$	AEOS $x10^3/\mu L$	ABAS $x10^3/\mu L$	ALUC $x10^3/\mu L$
Female, Group VIII - 25 mg/kg/day - Day 49						
655011	1.33	8.35	0.20	0.09	0.03	0.06
655012	0.57	11.16	0.20	0.07	0.04	0.12
655047	0.88	14.66	0.19	0.12	0.16	0.11
655055	1.08	11.92	0.13	0.13	0.15	0.10
655058	1.11	13.28	0.15	0.09	0.13	0.10
655073	1.13	7.65	0.38	0.10	0.02	0.04
655076	0.66	9.58	0.12	0.05	0.09	0.05
655078	2.29	13.98	0.42	0.15	0.11	0.08
655085	3.14	8.58	0.48	0.23	0.08	0.06
655105	2.11	6.84	0.25	0.09	0.03	0.05
Female, Group X - 125 mg/kg/day - Day 49						
655007	1.64	8.82	0.29	0.11	0.04	0.04
655023	0.57	6.82	0.20	0.10	0.02	0.04
655026	0.75	8.38	0.16	0.12	0.05	0.08
655052	1.33	7.79	0.12	0.06	0.05	0.05
655053	1.07	9.55	0.31	0.07	0.02	0.05
655063	2.27	7.76	0.16	0.08	0.07	0.05
655092	1.20	13.18	0.24	0.07	0.09	0.12
655095	1.26	8.10	0.20	0.08	0.13	0.08
655097	2.16	14.90	0.38	0.22	0.13	0.15
655103	1.78	7.15	0.16	0.11	0.04	0.05

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Female, Group II - 0 mg/kg/day - Day 94											
655031	OK	8.10	15.5	45.8	56.6	19.2	33.9	10.8	104.40	1201	13.17
655016	OK	8.00	15.8	45.3	56.6	19.8	34.9	11.0	207.80	925	6.41
655025	OK	8.06	15.9	46.6	57.8	19.7	34.2	10.3	136.00	1197	8.01
655032	OK	8.59	16.2	48.2	56.1	18.9	33.7	11.7	173.20	928	19.52
655036	OK	8.33	16.7	48.7	58.5	20.0	34.2	11.2	161.50	1196	7.89
655079	OK	8.08	16.1	46.8	57.9	19.9	34.4	10.3	133.70	1248	11.65
655083	OK	8.60	16.7	48.2	56.1	19.4	34.6	11.0	137.70	942	13.05
655098	OK	8.48	16.7	49.2	58.1	19.7	34.0	11.3	120.70	976	9.80
655099	OK	8.34	16.3	48.0	57.5	19.6	34.0	11.4	128.50	1067	11.73
655107	OK	7.84	15.5	44.8	57.1	19.8	34.6	10.2	110.00	1153	7.16
Female, Group IV - 1 mg/kg/day - Day 94											
655013	OK	8.28	16.4	48.6	58.7	19.9	33.8	11.0	121.80	1138	8.61
655033	OK	8.47	16.7	49.0	57.8	19.7	34.1	11.0	132.00	1177	12.58
655040	OK	8.23	16.0	46.8	56.9	19.5	34.3	11.0	139.60	1040	5.94
655041	OK	8.17	16.1	46.2	56.5	19.7	34.9	11.2	115.40	899	12.09
655044	OK	8.32	16.5	47.8	57.4	19.9	34.7	10.8	135.00	1192	6.69
655086	OK	8.38	16.2	47.9	57.2	19.3	33.7	10.7	155.30	RNV	10.04
655089	OK	8.69	17.1	50.5	58.2	19.7	33.9	11.2	126.10	860	11.50
655090	OK	8.13	16.3	47.8	58.8	20.1	34.1	10.8	151.80	687	12.78
655091	OK	7.74	15.8	45.9	59.2	20.4	34.4	12.0	165.70	1164	8.70
655108	OK	8.39	16.7	48.0	57.3	19.9	34.7	10.4	147.10	1072	6.95
Female, Group VI - 5 mg/kg/day - Day 94											
655020	OK	8.42	16.9	49.2	58.5	20.1	34.3	10.7	180.60	1039	8.41
655029	OK	8.13	16.0	46.5	57.2	19.7	34.4	11.6	133.10	1274	8.69
655034	OK	8.90	17.1	52.0	58.5	19.2	32.9	11.3	194.80	RNV	14.43
655038	OK	8.31	16.5	47.8	57.5	19.8	34.5	10.9	143.40	RNV	12.22
655039	OK	8.58	17.1	49.5	57.7	19.9	34.5	10.6	147.70	1220	9.18
655042	OK	7.91	15.7	45.3	57.2	19.9	34.8	11.7	162.90	1177	13.19
655054	OK	8.53	16.4	48.4	56.7	19.3	34.0	10.9	163.20	1065	8.94
655066	OK	8.10	16.7	48.8	60.3	20.6	34.2	11.2	184.30	RNV	10.59
655067	OK	8.75	16.5	48.4	55.3	18.9	34.1	10.5	98.20	1112	7.10
655087	OK	8.19	16.4	47.5	58.0	20.0	34.5	10.8	143.10	1219	12.94

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Female, Group VIII - 25 mg/kg/day - Day 94											
655011	OK	7.30	14.6	42.3	57.9	20.0	34.4	11.1	170.40	1057	10.13
655012	OK	7.92	15.4	44.4	56.1	19.5	34.8	10.6	130.00	1321	10.27
655047	OK	7.78	15.5	44.7	57.4	19.9	34.7	10.5	120.70	811	12.05
655055	OK	7.56	15.1	43.3	57.3	19.9	34.7	10.8	139.70	RNV	7.43
655058	OK	8.49	16.5	48.6	57.2	19.4	34.0	10.4	133.30	1042	13.41
655073	OK	8.09	15.5	46.0	56.9	19.1	33.6	10.6	151.80	RNV	8.51
655076	OK	8.40	16.1	46.4	55.2	19.2	34.7	10.8	153.10	1204	8.30
655078	OK	8.49	15.9	48.1	56.6	18.7	33.1	11.4	164.20	824	8.77
655085	OK	8.74	16.8	49.7	56.9	19.2	33.8	11.3	137.80	923	13.87
655105	OK	7.90	15.9	44.2	56.0	20.2	36.0	10.8	105.30	RNV	5.81
Female, Group X - 125 mg/kg/day - Day 94											
655007	OK	8.11	15.3	45.9	56.5	18.8	33.3	11.2	145.40	1214	11.74
655023	OK	7.87	15.9	46.9	59.6	20.2	33.9	12.1	185.00	962	7.21
655026	OK	7.90	15.9	46.1	58.4	20.1	34.4	11.0	151.90	RNV	9.29
655052	OK	7.30	14.4	42.5	58.3	19.8	33.9	10.8	136.80	1186	9.71
655053	OK	7.56	15.6	46.2	61.1	20.7	33.9	11.4	148.00	1037	11.18
655063	OK	7.55	14.6	42.5	56.2	19.3	34.4	11.2	131.90	1112	10.25
655092	OK	8.14	15.8	46.6	57.2	19.4	34.0	12.0	240.90	1061	11.77
655095	OK	7.08	13.7	40.6	57.3	19.3	33.7	12.4	223.70	980	9.69
655097	OK	7.53	14.9	43.8	58.2	19.8	34.1	11.8	195.90	1060	11.15
655103	OK	7.56	15.3	45.2	59.8	20.3	33.9	11.6	206.80	997	10.59

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL
Female, Group II - 0 mg/kg/day - Day 94						
655031	1.29	11.28	0.19	0.29	0.05	0.06
655016	0.88	5.21	0.13	0.13	0.02	0.04
655025	1.21	6.42	0.14	0.15	0.04	0.04
655032	2.07	16.57	0.34	0.26	0.10	0.18
655036	0.52	7.02	0.15	0.11	0.04	0.04
655079	1.70	9.46	0.22	0.12	0.07	0.07
655083	1.20	11.36	0.17	0.23	0.05	0.04
655098	1.37	8.06	0.12	0.17	0.05	0.04
655099	1.75	9.36	0.25	0.22	0.08	0.08
655107	0.84	6.00	0.11	0.11	0.06	0.03
Female, Group IV - 1 mg/kg/day - Day 94						
655013	0.76	7.49	0.11	0.09	0.08	0.07
655033	1.47	10.50	0.29	0.18	0.07	0.08
655040	0.47	5.27	0.09	0.08	0.01	0.02
655041	3.09	8.40	0.33	0.13	0.07	0.07
655044	0.82	5.55	0.18	0.09	0.04	0.02
655086	1.08	8.41	0.15	0.16	0.14	0.11
655089	0.88	10.19	0.18	0.15	0.05	0.05
655090	1.43	10.85	0.25	0.16	0.05	0.04
655091	0.88	7.52	0.08	0.15	0.03	0.04
655108	2.29	4.35	0.11	0.12	0.06	0.02
Female, Group VI - 5 mg/kg/day - Day 94						
655020	1.38	6.65	0.06	0.24	0.05	0.03
655029	1.22	6.88	0.26	0.17	0.10	0.06
655034	1.15	12.70	0.29	0.29	0.00	0.00
655038	1.10	10.88	0.12	0.12	0.00	0.00
655039	2.34	6.60	0.09	0.07	0.03	0.04
655042	1.99	10.74	0.19	0.16	0.06	0.06
655054	1.20	7.28	0.10	0.13	0.16	0.07
655066	2.16	8.08	0.09	0.13	0.05	0.06
655067	1.02	5.74	0.10	0.19	0.02	0.03
655087	0.98	11.42	0.21	0.20	0.06	0.06

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL
Female, Group VIII - 25 mg/kg/day - Day 94						
655011	1.94	7.70	0.29	0.13	0.03	0.04
655012	0.47	9.32	0.14	0.21	0.06	0.06
655047	1.93	9.58	0.26	0.09	0.08	0.10
655055	1.08	5.98	0.18	0.11	0.04	0.04
655058	1.29	11.59	0.15	0.15	0.12	0.10
655073	2.21	6.13	0.08	0.09	0.00	0.00
655076	0.82	7.17	0.10	0.06	0.09	0.06
655078	1.68	6.71	0.13	0.15	0.06	0.04
655085	4.87	7.78	0.81	0.25	0.07	0.09
655105	1.29	4.14	0.14	0.21	0.02	0.01
Female, Group X - 125 mg/kg/day - Day 94						
655007	2.29	8.76	0.38	0.21	0.05	0.04
655023	1.01	5.81	0.20	0.13	0.03	0.03
655026	0.76	7.92	0.31	0.19	0.05	0.05
655052	1.69	7.45	0.31	0.10	0.10	0.06
655053	1.64	9.19	0.16	0.09	0.04	0.06
655063	1.51	8.44	0.10	0.09	0.05	0.05
655092	1.92	9.35	0.26	0.14	0.05	0.05
655095	1.90	7.36	0.22	0.09	0.06	0.05
655097	1.44	8.99	0.37	0.18	0.08	0.09
655103	3.21	6.87	0.28	0.12	0.06	0.05

Individual Hematology Values

Animal Number	COND	RBC x106/µL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x103/µL	PLT x103/µL	WBC x103/µL
Female, Group II - 0 mg/kg/day - Day 183											
655009	OK	8.46	16.0	47.7	56.3	18.9	33.6	11.2	111.60	956	11.29
655015	OK	7.47	13.8	41.6	55.7	18.4	33.1	11.8	144.80	RNV	6.67
655019	OK	7.32	14.7	43.7	59.7	20.1	33.6	12.4	158.50	RNV	8.98
655035	OK	7.90	15.1	44.7	56.6	19.1	33.8	12.5	216.50	1357	6.56
655062	OK	7.43	14.2	43.0	57.9	19.1	33.0	12.0	188.40	861	4.32
655068	OK	7.49	14.9	44.4	59.3	19.9	33.5	11.3	169.50	877	5.84
655072	OK	7.92	14.4	43.4	54.8	18.2	33.1	12.0	123.40	999	7.73
655101	OK	8.01	14.9	44.9	56.1	18.6	33.2	11.1	135.70	1283	7.24
655109	OK	7.81	14.3	42.8	54.8	18.3	33.4	11.7	132.90	1082	6.94
Female, Group X - 125 mg/kg/day - Day 183											
655010	OK	7.76	15.1	45.5	58.6	19.5	33.3	12.6	213.60	RNV	8.39
655030	OK	7.59	15.0	44.2	58.2	19.7	33.8	13.0	138.20	761	7.79
655037	OK	8.07	15.4	47.0	58.2	19.0	32.7	12.5	183.00	1026	7.54
655049	OK	7.93	15.2	45.4	57.3	19.2	33.5	11.2	183.40	1191	8.26
655061	OK	7.63	14.7	42.6	55.9	19.3	34.5	11.1	133.10	1250	7.11
655075	OK	7.57	14.8	45.3	59.8	19.5	32.7	12.7	162.00	RNV	9.99
655077	OK	8.22	15.4	47.4	57.7	18.8	32.6	11.6	179.10	RNV	6.18
655084	OK	7.84	15.6	45.8	58.5	19.9	34.0	11.4	150.60	786	9.13
655088	OK	7.78	15.4	46.0	59.1	19.7	33.4	11.9	128.30	726	11.63
655100	OK	7.12	13.9	41.4	58.2	19.6	33.6	13.1	172.70	RNV	5.92

Individual Hematology Values

Animal Number	ANEU x103/µL	ALYM x103/µL	AMON x103/µL	AEOS x103/µL	ABAS x103/µL	ALUC x103/µL
Female, Group II - 0 mg/kg/day - Day 183						
655009	2.23	8.45	0.40	0.11	0.06	0.04
655015	1.29	5.09	0.14	0.11	0.01	0.03
655019	1.35	7.21	0.22	0.14	0.04	0.03
655035	1.09	5.11	0.19	0.11	0.04	0.03
655062	0.79	3.26	0.19	0.04	0.03	0.02
655068	1.46	3.77	0.44	0.10	0.04	0.02
655072	0.63	6.75	0.11	0.07	0.13	0.03
655101	1.85	5.06	0.21	0.08	0.02	0.02
655109	1.24	5.28	0.31	0.05	0.03	0.03
Female, Group X - 125 mg/kg/day - Day 183						
655010	2.33	5.22	0.58	0.16	0.07	0.03
655030	1.53	5.81	0.19	0.15	0.07	0.03
655037	1.12	6.10	0.17	0.07	0.06	0.02
655049	2.14	5.84	0.17	0.06	0.04	0.02
655061	1.20	5.40	0.32	0.09	0.04	0.05
655075	1.61	7.74	0.42	0.09	0.08	0.04
655077	1.11	4.61	0.18	0.19	0.07	0.01
655084	1.11	7.61	0.23	0.07	0.06	0.04
655088	1.22	9.87	0.30	0.15	0.07	0.03
655100	0.96	4.48	0.35	0.07	0.04	0.02

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group I - 0 mg/kg/day - Day 48											
654903	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654925	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654928	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
654929	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
654936	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654950	NO	-	-	-	TRACE	-	-	-	-	-	-
654953	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654972	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
654987	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654993	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
Male, Group III - 1 mg/kg/day - Day 48											
654908	NO	-	-	-	TRACE	-	FEW	TRACE	-	-	-
654913	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654932	NO	-	-	-	TRACE	-	-	-	-	-	-
654938	NO	-	-	-	FEW	-	TRACE	FEW	-	-	-
654941	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
654946	NO	TRACE	TRACE	-	TRACE	-	-	FEW	-	-	-
654947	NO	-	-	-	TRACE	-	-	-	-	-	-
654960	NO	-	-	-	TRACE	-	-	-	-	-	-
654984	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654995	NO	-	-	-	TRACE	-	-	-	-	-	-
Male, Group V - 5 mg/kg/day - Day 48											
654907	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
654911	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
654916	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654917	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654959	NO	-	-	-	TRACE	-	-	-	-	-	-
654961	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654967	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654980	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
654998	NO	-	-	-	TRACE	-	-	-	-	-	-
655005	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group VII - 25 mg/kg/day - Day 48											
654922	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654923	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
654930	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
654940	NO	-	-	-	FEW	-	-	MODERATE	-	-	-
654952	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654958	NO	-	-	-	TRACE	-	FEW	Many	-	-	-
654975	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
654989	NO	-	-	-	TRACE	-	-	-	-	-	-
655001	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655006	NO	-	-	-	TRACE	-	-	-	-	-	-
Male, Group IX - 125 mg/kg/day - Day 48											
654914	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654921	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-
654951	NO	-	-	-	TRACE	-	-	FEW	-	-	-
654955	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
654965	NO	-	-	-	TRACE	-	TRACE	MODERATE	-	-	-
654979	NO	-	-	-	FEW	-	-	TRACE	-	-	-
654983	NO	-	-	-	TRACE	-	-	-	-	-	-
654986	NO	-	-	-	TRACE	-	-	-	-	-	-
654996	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
655003	NO	-	-	-	TRACE	-	-	MODERATE	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group I - 0 mg/kg/day - Day 93											
654903	NO	-	-	-	TRACE	-	MODERATE	-	-	-	-
654925	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654928	NO	-	-	-	TRACE	-	MANY	-	-	-	-
654929	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
654936	NO	-	-	-	TRACE	-	FEW	-	-	-	-
654950	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
654953	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654972	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
654987	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654993	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
Male, Group III - 1 mg/kg/day - Day 93											
654908	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654913	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654932	NO	-	-	-	TRACE	-	-	-	-	-	-
654938	NO	-	-	-	TRACE	-	MODERATE	-	-	-	-
654941	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
654946	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654947	NO	-	-	-	TRACE	-	FEW	-	-	-	-
654960	NO	-	-	-	TRACE	-	-	-	-	-	-
654984	NO	-	-	-	TRACE	-	MANY	FEW	-	-	-
654995	NO	-	-	-	TRACE	-	TRACE	-	-	-	TRACE
Male, Group V - 5 mg/kg/day - Day 93											
654907	NO	-	-	-	TRACE	-	FEW	-	-	-	-
654911	NO	-	-	-	TRACE	-	MODERATE	-	-	-	-
654916	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654917	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654959	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654961	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654967	NO	-	-	-	TRACE	-	MANY	FEW	-	-	-
654980	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654998	NO	-	-	-	TRACE	-	-	-	-	-	-
655005	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group VII - 25 mg/kg/day - Day 93											
654922	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654923	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654930	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654940	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654952	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654958	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654975	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654989	NO	-	-	-	TRACE	-	-	-	-	-	-
655001	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
655006	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
Male, Group IX - 125 mg/kg/day - Day 93											
654914	NO	-	-	-	TRACE	-	MANY	FEW	-	-	-
654921	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654951	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
654955	NO	FEW	FEW	-	TRACE	-	MANY	FEW	-	-	-
654965	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654979	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654983	NO	-	-	-	TRACE	-	MANY	-	-	-	-
654986	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-
654996	NO	FEW	FEW	-	TRACE	-	MODERATE	MODERATE	-	-	-
655003	NO	-	-	-	TRACE	-	MANY	TRACE	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group I - 0 mg/kg/day - Day 183											
654909	NO	-	-	-	TRACE	-	TRACE	MODERATE	-	-	-
654910	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	TRACE
654915	NO	-	-	-	TRACE	-	MANY	FEW	-	-	-
654924	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654927	NO	-	-	-	TRACE	-	MODERATE	MANY	-	-	-
654943	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654949	NO	-	-	-	FEW	-	MODERATE	MODERATE	-	-	-
654956	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
654992	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	-
654994	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	TRACE
Male, Group IX - 125 mg/kg/day - Day 183											
654942	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	-
654957	NO	-	-	-	TRACE	-	MODERATE	MANY	-	-	-
654973	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654974	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654976	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654977	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
654978	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654985	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
654990	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-
654991	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Female, Group II - 0 mg/kg/day - Day 49											
655016	NO	-	-	-	FEW	-	FEW	-	-	-	-
655025	NO	-	-	-	TRACE	-	-	-	-	-	-
655031	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
655032	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
655036	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-
655079	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655083	NO	-	-	-	TRACE	-	-	-	-	-	-
655098	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
655099	NO	-	-	-	TRACE	-	-	-	-	-	-
655107	NO	-	-	-	TRACE	-	-	-	-	-	-
Female, Group IV - 1 mg/kg/day - Day 49											
655013	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655033	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
655040	NO	-	-	-	TRACE	-	TRACE	MODERATE	-	-	-
655041	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655044	NO	-	-	-	TRACE	-	-	-	-	-	-
655086	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
655089	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655090	NO	-	-	-	FEW	-	-	FEW	-	-	-
655091	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655108	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
Female, Group VI - 5 mg/kg/day - Day 49											
655020	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
655029	NO	-	-	-	FEW	-	-	-	-	-	-
655034	NO	-	-	-	TRACE	-	-	-	-	-	-
655038	NO	-	-	-	TRACE	-	-	FEW	-	-	-
655039	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
655042	NO	TRACE	TRACE	-	TRACE	-	-	FEW	-	-	-
655054	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
655066	NO	-	-	-	TRACE	-	-	-	-	-	-
655067	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655087	NO	-	-	-	TRACE	-	-	-	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Female, Group VIII - 25 mg/kg/day - Day 49											
655011	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655012	NO	-	-	-	TRACE	-	-	-	-	-	-
655047	NO	-	-	-	TRACE	-	-	-	-	-	-
655055	NO	-	-	-	FEW	-	TRACE	MODERATE	-	-	-
655058	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655073	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-
655076	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
655078	NO	-	-	-	TRACE	-	-	-	-	-	-
655085	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
655105	NO	-	-	-	TRACE	-	-	FEW	-	-	-
Female, Group X - 125 mg/kg/day - Day 49											
655007	NO	TRACE	TRACE	-	TRACE	-	FEW	FEW	-	-	-
655023	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655026	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-
655052	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655053	NO	TRACE	TRACE	-	TRACE	-	-	FEW	-	-	-
655063	NO	-	-	-	TRACE	-	-	TRACE	-	-	-
655092	NO	-	-	-	TRACE	-	-	-	-	-	-
655095	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	-
655097	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655103	NO	-	-	-	TRACE	-	-	TRACE	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Female, Group II - 0 mg/kg/day - Day 94											
655016	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
655025	NO	-	-	-	FEW	-	FEW	-	-	-	-
655031	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
655032	NO	-	-	-	FEW	-	FEW	FEW	-	-	-
655036	NO	-	-	-	FEW	-	MANY	TRACE	-	-	-
655079	NO	-	-	-	FEW	-	FEW	TRACE	-	-	-
655083	NO	-	-	-	FEW	-	MODERATE	TRACE	-	-	-
655098	NO	-	-	-	FEW	-	MODERATE	TRACE	-	-	-
655099	NO	-	-	-	FEW	-	FEW	-	-	-	-
655107	NO	-	-	-	FEW	-	-	-	-	-	-
Female, Group IV - 1 mg/kg/day - Day 94											
655013	NO	-	-	-	FEW	-	MANY	TRACE	-	-	-
655033	NO	-	-	-	FEW	-	FEW	FEW	-	-	-
655040	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655041	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
655044	NO	-	-	-	FEW	-	FEW	-	-	-	-
655086	NO	-	-	-	FEW	-	FEW	-	-	-	-
655089	NO	-	-	-	FEW	-	FEW	-	-	-	-
655090	NO	-	-	-	FEW	-	MODERATE	FEW	-	-	-
655091	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655108	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
Female, Group VI - 5 mg/kg/day - Day 94											
655020	NO	-	-	-	FEW	-	-	-	-	-	-
655029	NO	-	-	-	FEW	-	FEW	-	-	-	-
655034	NO	-	-	-	FEW	-	-	-	-	-	-
655038	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
655039	NO	-	-	-	FEW	-	MANY	-	-	-	-
655042	NO	-	-	-	FEW	-	-	FEW	-	-	-
655054	NO	-	-	-	FEW	-	MANY	-	-	-	-
655066	NO	-	-	-	FEW	-	FEW	TRACE	-	-	-
655067	NO	-	-	-	FEW	-	MODERATE	FEW	-	-	-
655087	NO	-	-	-	FEW	-	-	-	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Female, Group VIII - 25 mg/kg/day - Day 94											
655011	NO	-	-	-	FEW	-	MANY	TRACE	-	-	-
655012	NO	-	-	-	FEW	-	FEW	FEW	-	-	-
655047	NO	-	-	-	FEW	-	FEW	-	-	-	-
655055	NO	-	-	-	FEW	-	MANY	TRACE	-	-	-
655058	NO	-	-	-	FEW	-	MODERATE	-	-	-	-
655073	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655076	NO	-	-	-	FEW	-	FEW	-	-	-	-
655078	NO	-	-	-	FEW	-	-	-	-	-	-
655085	NO	-	-	-	FEW	-	MODERATE	FEW	-	-	-
655105	NO	-	-	-	FEW	-	MODERATE	TRACE	-	-	-
Female, Group X - 125 mg/kg/day - Day 94											
655007	NO	-	-	-	FEW	-	MANY	-	-	-	-
655023	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655026	NO	-	-	-	FEW	-	MANY	-	-	-	-
655052	NO	-	-	-	FEW	-	FEW	-	-	-	-
655053	NO	-	-	-	FEW	-	MANY	TRACE	-	-	-
655063	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655092	NO	-	-	-	FEW	-	-	-	-	-	-
655095	NO	-	-	-	FEW	-	MANY	MODERATE	-	-	-
655097	NO	-	-	-	FEW	-	MANY	FEW	-	-	-
655103	NO	-	-	-	FEW	-	MANY	FEW	-	-	-

Individual Red Blood Cell Morphology Values

Animal Number	NORM	ANIS	MIC	MAC	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Female, Group II - 0 mg/kg/day - Day 183											
655009	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655015	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655019	NO	-	-	-	TRACE	-	TRACE	FEW	-	-	-
655035	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655062	YES	-	-	-	-	-	-	-	-	-	-
655068	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655072	NO	-	-	-	TRACE	-	FEW	FEW	-	-	-
655101	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655109	NO	-	-	-	TRACE	-	MODERATE	TRACE	-	-	-
Female, Group X - 125 mg/kg/day - Day 183											
655010	NO	-	-	-	TRACE	-	MANY	MANY	-	-	-
655030	NO	-	-	-	TRACE	-	FEW	TRACE	-	-	-
655037	NO	-	-	-	TRACE	-	FEW	MODERATE	-	-	-
655049	NO	-	-	-	TRACE	-	-	-	-	-	-
655061	NO	-	-	-	TRACE	-	-	-	-	-	-
655075	NO	-	-	-	TRACE	-	TRACE	TRACE	-	-	-
655077	NO	-	-	-	TRACE	-	MODERATE	FEW	-	-	-
655084	NO	-	-	-	TRACE	-	TRACE	-	-	-	-
655088	NO	-	-	-	TRACE	-	MODERATE	MODERATE	-	-	-
655100	NO	-	-	-	TRACE	-	MODERATE	MANY	-	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Male, Group I - 0 mg/kg/day - Day 48									
654903	YES	-	-	-	-	-	-	-	-
654925	YES	-	-	-	-	-	-	-	-
654928	YES	-	-	-	-	-	-	-	-
654929	YES	-	-	-	-	-	-	-	-
654936	NO	-	-	-	-	-	YES/ADEQ	-	-
654950	YES	-	-	-	-	-	-	-	-
654953	NO	-	-	-	-	-	YES/ADEQ	-	-
654972	NO	-	-	-	-	-	YES/DECR	-	-
654987	YES	-	-	-	-	-	-	-	-
654993	NO	-	-	-	-	-	YES/ADEQ	-	-
Male, Group III - 1 mg/kg/day - Day 48									
654908	NO	-	-	-	-	-	YES/ADEQ	-	-
654913	YES	-	-	-	-	-	-	-	-
654932	YES	-	-	-	-	-	-	-	-
654938	NO	-	-	-	-	-	YES/ADEQ	-	-
654941	NO	-	-	-	-	-	YES/ADEQ	-	-
654946	NO	-	-	-	-	-	YES/ADEQ	-	-
654947	NO	-	-	-	-	-	YES/UTD	-	-
654960	NO	-	-	-	-	-	YES/ADEQ	-	-
654984	YES	-	-	-	-	-	-	-	-
654995	YES	-	-	-	-	-	-	-	-
Male, Group V - 5 mg/kg/day - Day 48									
654907	YES	-	-	-	-	-	-	-	-
654911	NO	-	-	-	-	-	YES/ADEQ	-	-
654916	NO	-	-	-	-	-	YES/ADEQ	-	-
654917	YES	-	-	-	-	-	-	-	-
654959	NO	-	-	-	-	-	YES/UTD	-	-
654961	YES	-	-	-	-	-	-	-	-
654967	YES	-	-	-	-	-	-	-	-
654980	YES	-	-	-	-	-	-	-	-
654998	YES	-	-	-	-	-	-	-	-
655005	YES	-	-	-	-	-	-	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Male, Group VII - 25 mg/kg/day - Day 48									
654922	YES	-	-	-	-	-	-	-	-
654923	YES	-	-	-	-	-	-	-	-
654930	NO	-	-	-	-	-	YES/ADEQ	-	-
654940	NO	-	-	-	-	-	YES/ADEQ	-	-
654952	NO	-	-	-	-	-	YES/ADEQ	-	-
654958	NO	-	-	-	-	-	YES/DECR	-	-
654975	YES	-	-	-	-	-	-	-	-
654989	NO	-	-	-	-	-	YES/ADEQ	-	-
655001	YES	-	-	-	-	-	-	-	-
655006	YES	-	-	-	-	-	-	-	-
Male, Group IX - 125 mg/kg/day - Day 48									
654914	YES	-	-	-	-	-	-	-	-
654921	NO	-	-	-	-	-	YES/UTD	-	-
654951	NO	-	-	-	-	-	YES/DECR	-	-
654955	YES	-	-	-	-	-	-	-	-
654965	NO	-	-	-	-	-	YES/ADEQ	-	-
654979	NO	-	-	-	-	-	YES/ADEQ	-	-
654983	YES	-	-	-	-	-	-	-	-
654986	YES	-	-	-	-	-	-	-	-
654996	YES	-	-	-	-	-	-	-	-
655003	NO	-	-	-	-	-	YES/UTD	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Male, Group I - 0 mg/kg/day - Day 93									
654903	YES	-	-	-	-	-	-	-	-
654925	YES	-	-	-	-	-	-	-	-
654928	YES	-	-	-	-	-	-	-	-
654929	YES	-	-	-	-	-	-	-	-
654936	YES	-	-	-	-	-	-	-	-
654950	YES	-	-	-	-	-	-	-	-
654953	YES	-	-	-	-	-	-	-	-
654972	NO	-	-	-	-	-	YES/DECR	-	-
654987	YES	-	-	-	-	-	-	-	-
654993	YES	-	-	-	-	-	-	-	-
Male, Group III - 1 mg/kg/day - Day 93									
654908	YES	-	-	-	-	-	-	-	-
654913	YES	-	-	-	-	-	-	-	-
654932	YES	-	-	-	-	-	-	-	-
654938	YES	-	-	-	-	-	-	-	-
654941	YES	-	-	-	-	-	-	-	-
654946	NO	-	-	-	-	-	YES/DECR	-	-
654947	NO	-	-	-	-	-	YES/DECR	-	-
654960	YES	-	-	-	-	-	-	-	-
654984	NO	-	-	-	-	-	YES/ADEQ	-	-
654995	YES	-	-	-	-	-	-	-	-
Male, Group V - 5 mg/kg/day - Day 93									
654907	YES	-	-	-	-	-	-	-	-
654911	YES	-	-	-	-	-	-	-	-
654916	NO	-	-	-	-	-	YES/ADEQ	-	-
654917	YES	-	-	-	-	-	-	-	-
654959	YES	-	-	-	-	-	-	-	-
654961	YES	-	-	-	-	-	-	-	-
654967	YES	-	-	-	-	-	-	-	-
654980	YES	-	-	-	-	-	-	-	-
654998	YES	-	-	-	-	-	-	-	-
655005	NO	-	-	-	-	-	YES/ADEQ	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Male, Group VII - 25 mg/kg/day - Day 93									
654922	YES	-	-	-	-	-	-	-	-
654923	YES	-	-	-	-	-	-	-	-
654930	YES	-	-	-	-	-	-	-	-
654940	YES	-	-	-	-	-	-	-	-
654952	YES	-	-	-	-	-	-	-	-
654958	YES	-	-	-	-	-	-	-	-
654975	NO	-	-	-	-	-	YES/ADEQ	-	-
654989	NO	-	-	-	-	-	YES/DECR	-	-
655001	YES	-	-	-	-	-	-	-	-
655006	YES	-	-	-	-	-	-	-	-
Male, Group IX - 125 mg/kg/day - Day 93									
654914	YES	-	-	-	-	-	-	-	-
654921	YES	-	-	-	-	-	-	-	-
654951	YES	-	-	-	-	-	-	-	-
654955	YES	-	-	-	-	-	-	-	-
654965	YES	-	-	-	-	-	-	-	-
654979	YES	-	-	-	-	-	-	-	-
654983	YES	-	-	-	-	-	-	-	-
654986	YES	-	-	-	-	-	-	-	-
654996	NO	-	-	-	-	-	YES/ADEQ	-	-
655003	YES	-	-	-	-	-	-	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP	SPEC
Male, Group I - 0 mg/kg/day - Day 183										
654909	NO	-	-	-	-	-	YES/UTD	-	-	
654910	NO	-	-	-	-	-	YES/ADEQ	-	-	
654915	YES	-	-	-	-	-	-	-	-	
654924	NO	-	-	-	-	-	YES/UTD	-	-	
654927	YES	-	-	-	-	-	-	-	-	TRACE-SPHEROCYTE
654943	YES	-	-	-	-	-	-	-	-	
654949	YES	-	-	-	-	-	-	-	-	
654956	YES	-	-	-	-	-	-	-	-	
654992	NO	-	-	-	-	-	YES/UTD	-	-	
654994	YES	-	-	-	-	-	-	-	-	
Male, Group IX - 125 mg/kg/day - Day 183										
654942	YES	-	-	-	-	-	-	-	-	
654957	YES	-	-	-	-	-	-	-	-	
654973	YES	-	-	-	-	-	-	-	-	
654974	YES	-	-	-	-	-	-	-	-	
654976	NT	NT	NT	NT	NT	NT	NT	NT	NT	
654977	YES	-	-	-	-	-	-	-	-	
654978	NT	NT	NT	NT	NT	NT	NT	NT	NT	
654985	NT	NT	NT	NT	NT	NT	NT	NT	NT	
654990	YES	-	-	-	-	-	-	-	-	
654991	YES	-	-	-	-	-	-	-	-	

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Female, Group II - 0 mg/kg/day - Day 49									
655016	NO	-	-	-	-	-	YES/UTD	-	-
655025	YES	-	-	-	-	-	-	-	-
655031	YES	-	-	-	-	-	-	-	-
655032	YES	-	-	-	-	-	-	-	-
655036	NO	-	-	-	-	-	YES/ADEQ	-	-
655079	YES	-	-	-	-	-	-	-	-
655083	YES	-	-	-	-	-	-	-	-
655098	YES	-	-	-	-	-	-	-	-
655099	YES	-	-	-	-	-	-	-	-
655107	NO	-	-	-	-	-	YES/ADEQ	-	-
Female, Group IV - 1 mg/kg/day - Day 49									
655013	YES	-	-	-	-	-	-	-	-
655033	YES	-	-	-	-	-	-	-	-
655040	YES	-	-	-	-	-	-	-	-
655041	YES	-	-	-	-	-	-	-	-
655044	YES	-	-	-	-	-	-	-	-
655086	YES	-	-	-	-	-	-	-	-
655089	NO	-	-	-	-	-	YES/ADEQ	-	-
655090	YES	-	-	-	-	-	-	-	-
655091	NO	-	-	-	-	-	YES/ADEQ	-	-
655108	NO	-	-	-	-	-	YES/UTD	-	-
Female, Group VI - 5 mg/kg/day - Day 49									
655020	YES	-	-	-	-	-	-	-	-
655029	YES	-	-	-	-	-	-	-	-
655034	YES	-	-	-	-	-	-	-	-
655038	YES	-	-	-	-	-	-	-	-
655039	YES	-	-	-	-	-	-	-	-
655042	YES	-	-	-	-	-	-	-	-
655054	YES	-	-	-	-	-	-	-	-
655066	NO	-	-	-	-	-	YES/ADEQ	-	-
655067	YES	-	-	-	-	-	-	-	-
655087	NO	-	-	-	-	-	YES/UTD	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Female, Group VIII - 25 mg/kg/day - Day 49									
655011	YES	-	-	-	-	-	-	-	-
655012	YES	-	-	-	-	-	-	-	-
655047	YES	-	-	-	-	-	-	-	-
655055	YES	-	-	-	-	-	-	-	-
655058	NO	-	-	-	-	-	YES/ADEQ	-	-
655073	NO	-	-	-	-	-	YES/ADEQ	-	-
655076	YES	-	-	-	-	-	-	-	-
655078	YES	-	-	-	-	-	-	-	-
655085	YES	-	-	-	-	-	-	-	-
655105	YES	-	-	-	-	-	-	-	-
Female, Group X - 125 mg/kg/day - Day 49									
655007	NO	-	-	-	-	-	YES/ADEQ	-	-
655023	YES	-	-	-	-	-	-	-	-
655026	NO	-	-	-	-	-	YES/INCR	-	-
655052	YES	-	-	-	-	-	-	-	-
655053	NO	-	-	-	-	-	YES/UTD	-	-
655063	YES	-	-	-	-	-	-	-	-
655092	YES	-	-	-	-	-	-	-	-
655095	NO	-	-	-	-	-	YES/DECR	-	-
655097	YES	-	-	-	-	-	-	-	-
655103	NO	-	-	-	-	-	YES/DECR	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Female, Group II - 0 mg/kg/day - Day 94									
655016	YES	-	-	-	-	-	-	-	-
655025	YES	-	-	-	-	-	-	-	-
655031	YES	-	-	-	-	-	-	-	-
655032	YES	-	-	-	-	-	-	-	-
655036	YES	-	-	-	-	-	-	-	-
655079	YES	-	-	-	-	-	-	-	-
655083	YES	-	-	-	-	-	-	-	-
655098	YES	-	-	-	-	-	-	-	-
655099	YES	-	-	-	-	-	-	-	-
655107	YES	-	-	-	-	-	-	-	-
Female, Group IV - 1 mg/kg/day - Day 94									
655013	YES	-	-	-	-	-	-	-	-
655033	YES	-	-	-	-	-	-	-	-
655040	YES	-	-	-	-	-	-	-	-
655041	YES	-	-	-	-	-	-	-	-
655044	YES	-	-	-	-	-	-	-	-
655086	NO	-	-	-	-	-	YES/ADEQ	-	-
655089	YES	-	-	-	-	-	-	-	-
655090	YES	-	-	-	-	-	-	-	-
655091	YES	-	-	-	-	-	-	-	-
655108	YES	-	-	-	-	-	-	-	-
Female, Group VI - 5 mg/kg/day - Day 94									
655020	YES	-	-	-	-	-	-	-	-
655029	YES	-	-	-	-	-	-	-	-
655034	NO	-	-	-	-	-	YES/DECR	-	-
655038	NO	-	-	-	-	-	YES/DECR	-	-
655039	YES	-	-	-	-	-	-	-	-
655042	YES	-	-	-	-	-	-	-	-
655054	YES	-	-	-	-	-	-	-	-
655066	NO	-	-	-	-	-	YES/ADEQ	-	-
655067	YES	-	-	-	-	-	-	-	-
655087	YES	-	-	-	-	-	-	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Female, Group VIII - 25 mg/kg/day - Day 94									
655011	YES	-	-	-	-	-	-	-	-
655012	YES	-	-	-	-	-	-	-	-
655047	YES	-	-	-	-	-	-	-	-
655055	NO	-	-	-	-	-	YES/ADEQ	-	-
655058	YES	-	-	-	-	-	-	-	-
655073	NO	-	-	-	-	-	YES/DECR	-	-
655076	YES	-	-	-	-	-	-	-	-
655078	YES	-	-	-	-	-	-	-	-
655085	YES	-	-	-	-	-	-	-	-
655105	NO	-	-	-	-	-	YES/ADEQ	-	-
Female, Group X - 125 mg/kg/day - Day 94									
655007	YES	-	-	-	-	-	-	-	-
655023	YES	-	-	-	-	-	-	-	-
655026	NO	-	-	-	-	-	YES/ADEQ	-	-
655052	YES	-	-	-	-	-	-	-	-
655053	YES	-	-	-	-	-	-	-	-
655063	YES	-	-	-	-	-	-	-	-
655092	YES	-	-	-	-	-	-	-	-
655095	YES	-	-	-	-	-	-	-	-
655097	YES	-	-	-	-	-	-	-	-
655103	YES	-	-	-	-	-	-	-	-

Individual White Blood Cell / Platelet Morphology Values

Animal Number	NORM	SM	TOX	DB	VC	BC	PCE	GP	BP
Female, Group II - 0 mg/kg/day - Day 183									
655009	YES	-	-	-	-	-	-	-	-
655015	NO	-	-	-	-	-	YES/UTD	-	-
655019	NO	-	-	-	-	-	YES/UTD	-	-
655035	YES	-	-	-	-	-	-	-	-
655062	YES	-	-	-	-	-	-	-	-
655068	YES	-	-	-	-	-	-	-	-
655072	YES	-	-	-	-	-	-	-	-
655101	YES	-	-	-	-	-	-	-	-
655109	YES	-	-	-	-	-	-	-	-
Female, Group X - 125 mg/kg/day - Day 183									
655010	YES	-	-	-	-	-	-	-	-
655030	YES	-	-	-	-	-	-	-	-
655037	YES	-	-	-	-	-	-	-	-
655049	YES	-	-	-	-	-	-	-	-
655061	YES	-	-	-	-	-	-	-	-
655075	YES	-	-	-	-	-	-	-	-
655077	NO	-	-	-	-	-	YES/ADEQ	-	-
655084	YES	-	-	-	-	-	-	-	-
655088	YES	-	-	-	-	-	-	-	-
655100	NO	-	-	-	-	-	YES/ADEQ	-	-

Individual Coagulation Values

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Male, Group I - 0 mg/kg/day - Day 93					
654903	NONE	NONE	NONE	16.2	18.2
654925	NONE	NONE	NONE	15.5	19.9
654928	NONE	NONE	NONE	15.4	22.3
654929	NONE	NONE	NONE	16.8	15.2
654936	NONE	NONE	NONE	16.7	19.7
654950	NONE	NONE	NONE	16.6	16.9
654953	NONE	NONE	NONE	15.8	19.7
654972	NONE	NONE	NONE	15.9	17.0
654987	NONE	NONE	NONE	NT	NT
654993	NONE	NONE	NONE	14.4	14.7
Male, Group III - 1 mg/kg/day - Day 93					
654908	NONE	NONE	NONE	15.5	19.3
654913	NONE	NONE	NONE	16.2	24.2
654932	NONE	NONE	NONE	15.7	23.5
654938	NONE	NONE	NONE	15.9	19.8
654941	TRACE	NONE	NONE	15.6	17.7
654946	NONE	NONE	NONE	17.2	20.8
654947	NONE	NONE	NONE	16.0	18.0
654960	NONE	NONE	NONE	17.1	19.8
654984	NONE	NONE	NONE	15.5	19.3
654995	NONE	NONE	NONE	15.9	19.9
Male, Group V - 5 mg/kg/day - Day 93					
654907	NONE	NONE	NONE	15.1	18.0
654911	NONE	NONE	NONE	16.3	19.0
654916	NONE	NONE	NONE	18.6	20.8
654917	NONE	NONE	NONE	15.2	16.1
654959	NONE	NONE	NONE	15.7	19.1
654961	NONE	NONE	NONE	15.9	18.4
654967	NONE	NONE	NONE	15.6	19.4
654980	NONE	NONE	NONE	15.5	19.3
654998	NONE	NONE	NONE	15.1	21.8
655005	NONE	NONE	NONE	QNS	QNS

Individual Coagulation Values

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Male, Group VII - 25 mg/kg/day - Day 93					
654922	NONE	NONE	NONE	15.4	15.0
654923	NONE	NONE	NONE	15.5	19.1
654930	NONE	NONE	NONE	15.9	20.2
654940	NONE	NONE	NONE	15.1	17.4
654952	NONE	NONE	NONE	16.0	18.5
654958	NONE	NONE	NONE	15.0	16.2
654975	NONE	NONE	NONE	15.0	16.3
654989	NONE	NONE	NONE	15.7	19.7
655001	NONE	NONE	NONE	15.1	16.9
655006	NONE	NONE	NONE	16.7	17.8
Male, Group IX - 125 mg/kg/day - Day 93					
654914	NONE	NONE	NONE	20.2	22.4
654921	NONE	NONE	NONE	15.1	16.9
654951	NONE	NONE	NONE	16.2	22.0
654955	TRACE	NONE	NONE	15.7	19.8
654965	NSR	NT	NT	NT	NT
654979	NONE	NONE	NONE	15.3	19.9
654983	NONE	NONE	NONE	15.4	20.2
654986	NONE	NONE	NONE	14.3	17.1
654996	NONE	NONE	NONE	14.7	18.2
655003	NONE	NONE	NONE	15.8	17.4

Individual Coagulation Values

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Female, Group II - 0 mg/kg/day - Day 94					
655016	NONE	NONE	NONE	14.7	19.3
655025	NONE	NONE	NONE	14.9	12.9
655031	NONE	NONE	NONE	15.3	17.7
655032	NONE	NONE	NONE	16.0	15.0
655036	NONE	NONE	NONE	14.6	16.8
655079	NONE	NONE	NONE	15.0	15.4
655083	NONE	NONE	NONE	15.5	15.7
655098	NONE	NONE	NONE	16.0	15.6
655099	NONE	NONE	NONE	15.7	14.5
655107	NONE	NONE	NONE	15.1	14.9
Female, Group IV - 1 mg/kg/day - Day 94					
655013	NONE	NONE	NONE	15.5	18.1
655033	NONE	NONE	NONE	16.3	19.1
655040	NONE	NONE	NONE	14.3	15.2
655041	NONE	NONE	NONE	15.3	16.1
655044	NONE	NONE	NONE	14.5	13.2
655086	NONE	NONE	NONE	15.0	14.7
655089	TRACE	NONE	NONE	14.9	19.2
655090	NONE	NONE	NONE	14.6	15.0
655091	NONE	NONE	NONE	14.7	16.6
655108	NONE	NONE	NONE	14.2	15.0
Female, Group VI - 5 mg/kg/day - Day 94					
655020	NONE	NONE	NONE	15.1	18.6
655029	NONE	NONE	NONE	15.9	12.8
655034	NONE	NONE	NONE	14.8	14.2
655038	NONE	NONE	NONE	15.9	13.8
655039	NONE	NONE	NONE	15.5	13.8
655042	NONE	NONE	NONE	14.6	16.4
655054	NONE	NONE	NONE	15.0	16.0
655066	NONE	NONE	NONE	14.8	14.7
655067	NONE	NONE	NONE	14.8	15.0
655087	TRACE	TRACE	NONE	16.4	15.0

Individual Coagulation Values

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Female, Group VIII - 25 mg/kg/day - Day 94					
655011	NONE	NONE	NONE	14.6	15.0
655012	NONE	NONE	NONE	15.5	18.9
655047	NONE	NONE	NONE	15.9	15.1
655055	NONE	NONE	NONE	15.9	14.1
655058	NONE	NONE	NONE	15.7	13.0
655073	NONE	NONE	NONE	15.1	14.9
655076	NONE	NONE	NONE	15.5	13.7
655078	NONE	NONE	NONE	14.1	17.0
655085	NONE	NONE	NONE	14.9	16.5
655105	NONE	NONE	NONE	14.7	15.3
Female, Group X - 125 mg/kg/day - Day 94					
655007	NONE	NONE	NONE	13.1	10.6
655023	NONE	NONE	NONE	15.5	13.9
655026	NONE	NONE	NONE	16.3	13.7
655052	NONE	NONE	NONE	14.9	11.9
655053	NONE	NONE	NONE	14.4	14.3
655063	NONE	NONE	NONE	14.6	14.5
655092	NONE	NONE	NONE	15.9	17.9
655095	NONE	NONE	NONE	15.5	16.2
655097	NONE	NONE	NONE	13.8	13.3
655103	NONE	NONE	NONE	15.0	15.0

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group I - 0 mg/kg/day - Day 48											
654928	TRACE	NONE	NONE	83	39	21.6	131	0.13	15	0.27	84
654903	NONE	NONE	NONE	61	36	11.9	114	<0.10	14	0.22	66
654925	TRACE	NONE	NONE	65	32	9.3	96	0.13	19	0.39	74
654929	TRACE	NONE	NONE	68	33	14.3	145	0.11	12	0.18	61
654936	NONE	NONE	NONE	57	28	11.1	137	0.12	16	0.26	68
654950	TRACE	NONE	NONE	86	36	17.4	143	0.13	15	0.28	63
654953	TRACE	NONE	NONE	70	32	14.5	QNS	0.14	12	0.24	66
654972	NONE	NONE	NONE	56	28	14.5	120	0.10	16	0.21	52
654987	NONE	NONE	NONE	77	31	13.8	151	<0.10	11	0.21	66
654993	TRACE	NONE	NONE	66	30	12.3	138	0.15	14	0.28	56
Male, Group III - 1 mg/kg/day - Day 48											
654908	NONE	NONE	NONE	62	30	15.6	97	<0.10	14	0.23	55
654913	TRACE	NONE	NONE	70	35	13.9	127	<0.10	15	0.29	33
654932	NONE	NONE	NONE	71	26	10.5	112	<0.10	14	0.32	55
654938	TRACE	NONE	NONE	71	34	11.0	112	0.10	13	0.27	60
654941	NONE	NONE	NONE	73	40	17.5	75	0.10	12	0.22	45
654946	NONE	NONE	NONE	66	28	14.9	111	<0.10	12	0.24	50
654947	TRACE	NONE	NONE	79	44	14.2	127	0.10	14	0.29	57
654960	NONE	NONE	NONE	69	31	7.8	157	<0.10	15	0.29	43
654984	NONE	NONE	NONE	61	32	12.2	106	<0.10	14	0.33	70
654995	TRACE	NONE	NONE	71	34	14.1	119	0.11	15	0.26	61
Male, Group V - 5 mg/kg/day - Day 48											
654907	TRACE	NONE	NONE	59	23	11.0	142	0.10	11	0.25	77
654911	TRACE	NONE	NONE	77	29	11.5	124	0.13	13	0.25	49
654916	TRACE	NONE	NONE	78	33	13.7	137	<0.10	16	0.31	37
654917	NONE	NONE	NONE	77	36	16.5	147	0.15	15	0.31	71
654959	NONE	NONE	NONE	67	34	14.9	112	0.11	12	0.22	62
654961	NONE	NONE	NONE	63	28	8.2	QNS	0.11	10	0.23	61
654967	NONE	NONE	NONE	68	33	14.2	108	0.10	14	0.32	56
654980	TRACE	NONE	NONE	71	38	13.5	106	0.10	15	0.29	74
654998	NONE	NONE	NONE	71	27	10.9	113	<0.10	15	0.26	60
655005	TRACE	NONE	NONE	71	39	11.3	146	<0.10	17	0.34	70

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group VII - 25 mg/kg/day - Day 48											
654922	TRACE	NONE	NONE	69	32	10.4	169	0.13	16	0.29	42
654923	TRACE	NONE	NONE	69	36	11.5	112	0.18	15	0.22	76
654930	NONE	NONE	NONE	62	28	10.2	111	0.12	14	0.25	80
654940	TRACE	NONE	NONE	84	34	16.9	208	0.13	14	0.27	49
654952	NONE	NONE	NONE	88	34	14.3	101	<0.10	15	0.27	41
654958	TRACE	NONE	NONE	61	27	11.4	124	0.11	14	0.25	58
654975	TRACE	NONE	NONE	79	36	12.6	115	0.10	13	0.30	47
654989	TRACE	NONE	NONE	72	33	13.5	118	0.11	15	0.24	39
655001	TRACE	NONE	NONE	70	44	11.7	138	<0.10	15	0.27	43
655006	NONE	NONE	NONE	65	27	19.7	155	<0.10	13	0.25	47
Male, Group IX - 125 mg/kg/day - Day 48											
654914	NONE	NONE	NONE	67	28	12.7	243	<0.10	13	0.26	51
654921	SMALL	NONE	NONE	61	31	11.1	130	0.11	12	0.23	52
654951	NONE	NONE	NONE	82	48	22.1	191	<0.10	13	0.26	44
654955	TRACE	NONE	NONE	65	31	10.1	192	<0.10	14	0.21	51
654965	TRACE	NONE	NONE	70	28	13.3	135	<0.10	13	0.26	57
654979	NONE	NONE	NONE	69	37	10.0	165	<0.10	11	0.25	52
654983	TRACE	NONE	NONE	70	45	13.0	149	0.11	13	0.24	78
654986	NONE	NONE	NONE	72	32	11.7	167	<0.10	13	0.29	72
654996	NONE	NONE	NONE	62	34	13.8	101	0.10	12	0.22	51
655003	TRACE	NONE	NONE	75	30	15.1	172	0.12	16	0.34	61

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Male, Group I - 0 mg/kg/day - Day 48										
654928	78	115	6.4	4.2	2.2	11.5	9.0	147.5	6.08	97.9
654903	77	118	6.7	4.2	2.5	10.3	8.2	149.1	5.23	101.4
654925	58	122	6.7	4.1	2.6	10.5	8.0	148.5	5.91	101.8
654929	83	116	6.4	4.2	2.2	10.8	7.8	149.2	6.12	101.3
654936	111	117	7.1	4.4	2.7	11.1	9.2	149.3	5.47	102.3
654950	100	112	6.7	3.9	2.8	10.6	8.3	147.4	6.03	102.1
654953	132	134	6.5	4.0	2.5	11.1	8.7	146.7	6.36	102.7
654972	103	123	6.4	4.2	2.2	10.3	8.4	146.6	6.81	106.3
654987	78	123	6.1	4.0	2.1	10.4	7.1	150.7	5.10	104.1
654993	54	112	6.3	4.3	2.0	11.0	8.2	147.3	5.55	101.6
Male, Group III - 1 mg/kg/day - Day 48										
654908	27	126	6.7	4.2	2.5	10.5	7.5	148.0	6.04	103.8
654913	60	113	6.5	4.2	2.3	10.9	8.6	147.2	5.96	98.1
654932	51	127	7.4	4.6	2.8	10.8	7.7	162.6	5.98	112.4
654938	120	114	6.6	4.1	2.5	11.1	7.8	148.3	6.04	102.2
654941	80	107	6.5	4.0	2.5	10.6	7.8	148.2	5.07	104.8
654946	75	113	5.9	3.7	2.2	10.5	7.2	149.7	5.10	103.2
654947	92	105	6.8	4.4	2.4	11.2	8.5	146.2	6.42	100.8
654960	55	105	6.3	4.0	2.3	10.6	8.2	147.6	5.22	101.8
654984	102	125	6.9	4.3	2.6	10.9	7.1	148.2	5.33	101.5
654995	75	110	6.2	3.9	2.3	10.6	8.5	149.3	5.61	102.9
Male, Group V - 5 mg/kg/day - Day 48										
654907	91	108	6.0	4.1	1.9	10.3	7.8	147.0	5.75	100.9
654911	48	128	6.4	3.9	2.5	10.1	8.3	144.0	5.94	101.6
654916	18	145	6.7	4.1	2.6	10.6	9.6	147.0	7.27	104.5
654917	88	126	6.9	4.4	2.5	11.1	7.5	149.5	5.48	101.7
654959	142	116	7.4	4.6	2.8	11.4	8.2	147.0	6.09	102.2
654961	125	115	6.6	4.2	2.4	11.0	8.8	151.1	5.61	100.8
654967	57	120	6.4	4.2	2.2	10.3	7.2	150.0	5.19	103.6
654980	106	121	7.2	4.4	2.8	11.4	8.5	148.4	5.25	98.3
654998	80	124	6.4	4.0	2.4	10.7	8.9	151.6	5.14	103.8
655005	193	119	6.3	3.9	2.4	10.9	8.7	146.6	5.90	97.6

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Male, Group VII - 25 mg/kg/day - Day 48										
654922	34	109	6.5	4.3	2.2	10.6	8.6	147.2	5.62	99.7
654923	85	109	6.3	4.2	2.1	10.4	10.7	146.6	5.86	99.7
654930	173	126	6.9	4.3	2.6	10.7	7.7	148.8	5.53	102.6
654940	56	113	6.1	4.2	1.9	10.2	8.3	147.8	6.32	104.2
654952	51	117	6.7	4.1	2.6	10.2	7.5	150.1	4.80	101.3
654958	43	133	6.4	4.1	2.3	10.3	8.0	148.5	5.54	103.5
654975	77	112	6.9	4.4	2.5	11.3	8.7	148.6	5.38	99.4
654989	89	127	6.5	4.3	2.2	10.3	7.7	148.3	5.55	100.0
655001	129	110	6.1	3.8	2.3	11.2	9.0	147.2	5.66	97.7
655006	93	119	6.6	4.2	2.4	10.1	7.7	150.3	4.91	102.3
Male, Group IX - 125 mg/kg/day - Day 48										
654914	32	123	7.1	4.8	2.3	10.2	8.3	151.3	5.56	102.0
654921	38	138	6.9	4.6	2.3	11.0	10.4	146.3	6.37	102.8
654951	89	112	7.6	4.8	2.8	11.2	9.8	148.4	5.64	102.1
654955	42	111	6.2	4.4	1.8	10.3	9.4	147.1	5.49	100.7
654965	27	115	6.8	4.4	2.4	10.7	9.0	146.5	5.59	97.9
654979	23	94	6.5	4.5	2.0	10.6	8.5	148.6	5.50	100.9
654983	71	119	7.0	4.6	2.4	11.2	8.4	146.5	5.92	98.6
654986	47	122	7.0	5.0	2.0	10.8	9.1	146.0	5.36	104.1
654996	26	118	7.3	5.0	2.3	11.0	8.2	147.7	5.70	99.3
655003	38	170	7.2	4.9	2.3	11.3	10.8	148.4	6.24	102.2

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group I - 0 mg/kg/day - Day 93											
654903	NONE	NONE	NONE	69	31	18.3	111	<0.10	11	0.34	70
654925	TRACE	NONE	NONE	74	28	16.5	76	0.10	14	0.50	81
654928	SMALL	NONE	NONE	108	40	13.1	128	0.15	17	0.42	112
654929	TRACE	NONE	NONE	94	38	22.8	135	0.11	11	0.44	71
654936	NONE	NONE	NONE	84	37	18.8	107	0.12	13	0.37	94
654950	TRACE	NONE	NONE	93	34	17.6	120	<0.10	12	0.36	74
654953	SMALL	NONE	NONE	73	39	16.7	74	0.10	11	0.46	78
654972	SMALL	NONE	NONE	80	32	18.4	101	0.11	14	0.52	56
654987	NONE	NONE	NONE	86	46	23.2	150	0.12	12	0.36	93
654993	TRACE	NONE	NONE	84	38	21.7	85	0.11	14	0.47	74
Male, Group III - 1 mg/kg/day - Day 93											
654908	SMALL	NONE	NONE	93	39	17.6	84	<0.10	14	0.36	63
654913	SMALL	NONE	NONE	96	57	23.2	110	<0.10	14	0.43	40
654932	NONE	NONE	NONE	65	32	11.5	85	0.10	13	0.28	61
654938	TRACE	NONE	NONE	109	49	21.7	93	<0.10	17	0.47	65
654941	NONE	NONE	NONE	78	45	18.9	80	0.10	12	0.29	49
654946	MODERATE	NONE	NONE	NT-HEMOL	NT-HEMOL	7.1	NT-HEMOL	NT-HEMOL	12	0.44	49
654947	TRACE	NONE	NONE	95	41	20.4	111	<0.10	18	0.39	54
654960	TRACE	NONE	NONE	79	35	15.5	130	<0.10	13	0.44	56
654984	TRACE	NONE	NONE	83	34	15.5	79	<0.10	14	0.52	73
654995	TRACE	NONE	NONE	90	42	17.7	105	<0.10	15	0.29	57
Male, Group V - 5 mg/kg/day - Day 93											
654907	TRACE	NONE	NONE	163	35	10.4	123	0.11	12	0.37	81
654911	NONE	NONE	NONE	88	33	18.2	91	0.11	13	0.30	61
654916	SMALL	NONE	NONE	91	37	13.1	104	<0.10	14	0.37	36
654917	SMALL	NONE	NONE	293	173	63.0	115	0.17	14	0.37	100
654959	TRACE	NONE	NONE	111	47	12.3	80	<0.10	14	0.33	59
654961	TRACE	NONE	NONE	66	32	13.4	81	0.13	10	0.32	81
654967	NONE	NONE	NONE	73	31	11.5	76	0.11	12	0.37	67
654980	TRACE	NONE	NONE	79	32	14.3	68	0.11	15	0.41	96
654998	NONE	NONE	NONE	75	29	12.1	81	0.10	12	0.35	78
655005	SMALL	NONE	NONE	100	45	6.6	91	0.10	15	0.44	83

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group VII - 25 mg/kg/day - Day 93											
654922	SMALL	NONE	NONE	295	167	51.3	147	0.13	14	0.39	57
654923	NONE	NONE	NONE	495	213	116.8	107	0.20	17	0.42	104
654930	TRACE	NONE	NONE	62	28	11.8	88	<0.10	12	0.30	78
654940	SMALL	NONE	NONE	135	83	37.6	142	<0.10	15	0.36	60
654952	TRACE	NONE	NONE	94	33	14.4	72	<0.10	16	0.35	42
654958	TRACE	NONE	NONE	387	188	103.6	108	0.12	16	0.39	80
654975	SMALL	NONE	NONE	134	57	22.1	91	<0.10	15	0.47	63
654989	TRACE	NONE	NONE	92	42	14.9	87	<0.10	16	0.29	54
655001	SMALL	NONE	NONE	83	43	18.9	125	<0.10	16	0.32	58
655006	NONE	NONE	NONE	80	39	24.0	128	0.11	13	0.36	61
Male, Group IX - 125 mg/kg/day - Day 93											
654914	NONE	NONE	NONE	83	46	19.5	194	<0.10	12	0.39	58
654921	SMALL	NONE	NONE	64	27	11.8	96	0.11	11	0.35	63
654951	TRACE	NONE	NONE	93	60	22.6	176	0.10	14	0.37	51
654955	SMALL	NONE	NONE	72	42	13.7	171	0.10	16	0.37	91
654965	TRACE	NONE	NONE	87	34	18.0	101	0.10	14	0.40	55
654979	SMALL	NONE	NONE	119	78	33.7	142	0.11	13	0.37	56
654983	TRACE	NONE	NONE	75	42	20.4	138	<0.10	13	0.36	77
654986	TRACE	NONE	NONE	78	28	17.1	136	<0.10	15	0.45	86
654996	NONE	NONE	NONE	64	44	16.0	95	0.10	10	0.28	50
655003	SMALL	NONE	NONE	70	34	10.9	113	0.12	12	0.37	66

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Male, Group I - 0 mg/kg/day - Day 93											
654903	56	97	7.5	4.5	3.0	11.5	8.3	148.2	5.65	99.4	NONE
654925	51	92	7.5	4.5	3.0	11.1	7.9	148.8	6.09	99.3	NONE
654928	82	105	7.0	4.3	2.7	11.0	8.9	146.5	6.16	97.7	NONE
654929	40	94	6.9	4.5	2.4	11.1	8.3	148.1	6.89	103.0	NONE
654936	148	100	7.6	4.6	3.0	12.1	8.2	149.8	6.26	101.0	NONE
654950	95	101	6.9	3.9	3.0	11.1	8.8	148.7	7.03	103.0	NONE
654953	83	106	7.5	4.5	3.0	11.8	7.6	147.0	6.13	99.1	TRACE
654972	43	186	7.2	4.5	2.7	11.2	8.4	149.6	5.40	103.0	NONE
654987	80	115	7.0	4.4	2.6	11.4	7.5	150.6	5.71	100.1	TRACE
654993	89	89	6.5	4.3	2.2	10.9	6.8	147.1	6.17	101.0	NONE
Male, Group III - 1 mg/kg/day - Day 93											
654908	40	94	7.2	4.5	2.7	11.2	8.9	146.5	7.24	102.8	NONE
654913	49	95	6.6	4.2	2.4	10.4	8.5	148.4	5.85	98.4	NONE
654932	67	102	7.3	4.5	2.8	11.5	7.3	151.4	5.94	101.6	NONE
654938	89	165	7.3	4.4	2.9	11.8	9.6	147.9	6.20	102.4	NONE
654941	92	92	6.9	4.2	2.7	11.1	8.1	152.0	6.02	103.9	TRACE
654946	NT-HEMOL	149	NT-HEMOL	NT-HEMOL	NT-HEMOL	11.3	NT-HEMOL	147.2	NT-HEMOL	101.5	TRACE
654947	52	115	6.8	4.5	2.3	11.4	9.4	148.6	6.20	99.4	NONE
654960	36	96	6.8	4.2	2.6	11.2	8.0	148.1	5.51	103.3	TRACE
654984	88	170	7.2	4.4	2.8	12.6	12.1	153.1	6.28	101.4	NONE
654995	92	91	6.6	4.0	2.6	10.8	7.9	150.8	6.23	103.6	NONE
Male, Group V - 5 mg/kg/day - Day 93											
654907	74	96	6.6	4.2	2.4	10.1	7.5	147.1	6.22	102.9	NONE
654911	61	112	6.9	4.2	2.7	11.6	9.6	148.8	7.09	100.4	NONE
654916	18	178	6.7	4.1	2.6	11.1	10.0	145.4	6.45	101.4	NONE
654917	60	111	6.9	4.2	2.7	11.3	9.0	145.9	7.04	101.4	NONE
654959	102	122	7.0	4.3	2.7	11.0	9.6	146.3	6.41	101.7	NONE
654961	86	109	7.7	4.6	3.1	11.8	8.2	152.8	6.12	101.1	NONE
654967	67	103	6.8	4.4	2.4	11.4	8.6	152.3	6.18	103.7	NONE
654980	84	107	7.6	4.5	3.1	11.3	8.2	147.6	6.45	99.5	NONE
654998	95	98	7.6	4.5	3.1	12.1	8.2	151.6	5.71	100.2	NONE
655005	120	105	6.4	3.8	2.6	10.2	7.6	144.9	5.38	98.8	NONE

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Male, Group VII - 25 mg/kg/day - Day 93											
654922	35	88	7.1	4.7	2.4	11.1	9.0	149.7	6.17	100.9	NONE
654923	55	96	7.3	4.7	2.6	11.2	9.7	147.4	6.73	99.3	NONE
654930	91	117	7.2	4.4	2.8	11.2	8.1	152.7	6.45	103.5	NONE
654940	37	101	6.4	4.3	2.1	10.8	7.8	149.7	6.15	103.1	NONE
654952	62	106	6.8	4.1	2.7	11.0	9.6	148.3	6.50	100.8	NONE
654958	42	119	6.9	4.2	2.7	10.6	8.2	145.4	5.53	100.9	TRACE
654975	48	188	7.2	4.5	2.7	11.4	11.5	146.1	5.52	99.4	NONE
654989	113	96	6.9	4.5	2.4	11.3	10.3	145.7	7.89	102.6	NONE
655001	87	94	6.5	4.0	2.5	11.1	10.4	146.3	6.60	98.8	NONE
655006	74	99	7.6	4.7	2.9	11.3	7.8	151.5	5.64	102.4	NONE
Male, Group IX - 125 mg/kg/day - Day 93											
654914	23	103	7.6	5.0	2.6	11.4	10.1	150.3	7.20	101.3	NONE
654921	38	104	7.8	5.0	2.8	12.1	11.0	144.7	7.44	99.9	TRACE
654951	80	110	7.8	4.9	2.9	11.6	9.3	149.4	5.93	100.3	NONE
654955	50	99	7.5	5.0	2.5	11.8	10.6	150.8	6.41	99.2	NONE
654965	27	89	7.5	4.7	2.8	10.7	8.4	146.1	5.85	97.9	NONE
654979	26	89	7.4	4.9	2.5	11.3	9.3	150.2	5.99	100.3	NONE
654983	37	102	7.7	4.9	2.8	10.9	8.4	145.2	6.15	99.1	NONE
654986	34	164	7.6	5.3	2.3	11.5	11.0	148.0	5.83	101.9	NONE
654996	15	92	7.4	5.1	2.3	11.5	9.7	145.8	6.51	98.3	NONE
655003	35	102	7.6	5.1	2.5	11.3	7.6	150.3	5.75	102.4	NONE

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Male, Group I - 0 mg/kg/day - Day 93			
654903	NONE	NONE	0.1
654925	NONE	NONE	0.1
654928	NONE	NONE	0.2
654929	NONE	NONE	0.1
654936	NONE	NONE	0.1
654950	NONE	NONE	0.1
654953	NONE	NONE	0.1
654972	NONE	NONE	0.1
654987	NONE	NONE	0.1
654993	NONE	NONE	0.1
Male, Group III - 1 mg/kg/day - Day 93			
654908	NONE	NONE	0.1
654913	NONE	NONE	0.1
654932	NONE	NONE	0.1
654938	NONE	NONE	0.1
654941	NONE	NONE	0.1
654946	NONE	NONE	0.1
654947	NONE	NONE	0.1
654960	NONE	NONE	0.1
654984	NONE	NONE	0.1
654995	NONE	NONE	0.1
Male, Group V - 5 mg/kg/day - Day 93			
654907	NONE	NONE	0.1
654911	NONE	NONE	0.1
654916	NONE	NONE	0.1
654917	NONE	NONE	0.1
654959	NONE	NONE	0.1
654961	NONE	NONE	0.1
654967	NONE	NONE	0.1
654980	NONE	NONE	0.1
654998	NONE	NONE	0.1
655005	NONE	NONE	0.1

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Male, Group VII - 25 mg/kg/day - Day 93			
654922	NONE	NONE	0.1
654923	NONE	NONE	0.1
654930	NONE	NONE	0.1
654940	NONE	NONE	0.1
654952	NONE	NONE	0.1
654958	NONE	NONE	0.1
654975	NONE	NONE	0.1
654989	NONE	NONE	0.1
655001	NONE	NONE	0.2
655006	NONE	NONE	0.1
Male, Group IX - 125 mg/kg/day - Day 93			
654914	NONE	NONE	0.3
654921	NONE	NONE	0.4
654951	NONE	NONE	0.4
654955	NONE	NONE	0.4
654965	NONE	NONE	0.4
654979	NONE	NONE	0.4
654983	NONE	NONE	0.4
654986	NONE	NONE	0.4
654996	NONE	NONE	0.3
655003	NONE	NONE	0.4

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group I - 0 mg/kg/day - Day 183											
654909	TRACE	NONE	NONE	89	42	19.2	63	0.12	19	0.47	54
654910	NONE	NONE	NONE	81	30	11.0	76	0.12	18	0.41	78
654915	TRACE	NONE	NONE	523	332	74.0	129	0.26	17	0.44	148
654924	TRACE	NONE	NONE	89	41	18.7	82	0.10	18	0.44	54
654927	NONE	NONE	NONE	142	85	24.2	76	0.11	19	0.45	92
654943	TRACE	NONE	NONE	133	62	26.9	73	0.14	16	0.51	80
654949	TRACE	NONE	NONE	83	32	21.2	110	0.11	15	0.44	76
654956	TRACE	NONE	NONE	106	46	16.4	70	0.11	18	0.47	63
654992	TRACE	NONE	NONE	140	65	21.5	99	0.18	15	0.50	66
654994	TRACE	NONE	NONE	84	39	13.7	82	0.13	20	0.45	53
Male, Group IX - 125 mg/kg/day - Day 183											
654942	SMALL	NONE	NONE	146	89	18.2	134	0.14	16	0.38	87
654957	TRACE	NONE	NONE	235	78	33.1	109	0.11	12	0.38	89
654973	NONE	NONE	NONE	72	33	11.8	92	0.11	15	0.39	71
654974	TRACE	NONE	NONE	132	79	17.4	81	0.17	17	0.45	91
654976	SMALL	NONE	NONE	91	39	15.2	70	<0.10	15	0.38	75
654977	TRACE	NONE	NONE	157	95	20.8	72	0.15	16	0.37	55
654978	TRACE	NONE	NONE	88	38	22.0	77	<0.10	15	0.41	58
654985	TRACE	NONE	NONE	143	73	21.8	66	0.13	18	0.46	72
654990	TRACE	NONE	NONE	188	101	31.8	58	0.17	18	0.41	112
654991	NONE	NONE	NONE	92	41	17.6	97	0.13	14	0.46	77

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Male, Group I - 0 mg/kg/day - Day 183											
654909	48	156	6.6	4.3	2.3	11.2	8.8	147.0	6.47	102.7	NONE
654910	130	144	6.9	4.2	2.7	11.5	9.4	146.9	6.78	105.0	NONE
654915	97	102	6.7	3.7	3.0	11.9	9.6	149.9	6.28	102.0	NONE
654924	66	196	6.9	4.2	2.7	11.7	9.0	146.9	6.05	101.5	NONE
654927	55	92	7.3	4.4	2.9	11.7	8.8	148.1	6.87	103.5	NONE
654943	100	188	7.3	4.3	3.0	12.1	8.7	148.7	5.61	102.5	NONE
654949	132	104	7.0	4.2	2.8	10.6	7.3	147.0	5.60	98.8	NSR
654956	83	104	6.6	4.0	2.6	11.2	7.9	150.1	6.06	105.7	NONE
654992	38	119	7.0	4.2	2.8	11.3	8.3	146.1	6.29	101.5	NONE
654994	60	82	6.9	4.3	2.6	10.8	7.4	148.5	5.71	99.3	NONE
Male, Group IX - 125 mg/kg/day - Day 183											
654942	191	99	6.9	4.3	2.6	11.3	9.0	148.3	6.48	105.5	NONE
654957	48	152	6.8	4.1	2.7	11.5	10.3	147.3	5.95	105.2	NONE
654973	73	105	7.0	4.1	2.9	11.5	10.3	151.0	7.32	106.6	NONE
654974	104	163	6.9	4.2	2.7	11.7	8.7	145.7	5.68	102.9	NONE
654976	50	184	6.6	4.0	2.6	11.4	11.0	148.1	5.89	104.5	NONE
654977	50	122	6.7	4.1	2.6	11.6	8.4	150.0	6.09	106.5	NONE
654978	57	127	6.9	4.3	2.6	11.5	8.8	145.3	6.57	101.8	NONE
654985	45	128	6.9	4.3	2.6	11.6	9.0	149.6	6.56	100.9	NONE
654990	149	94	6.7	4.2	2.5	10.6	8.4	146.7	6.72	103.7	NONE
654991	186	91	7.0	4.3	2.7	11.9	7.8	152.0	5.59	103.5	NONE

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Male, Group I - 0 mg/kg/day - Day 183			
654909	NONE	NONE	0.1
654910	NONE	NONE	0.0
654915	NONE	NONE	0.0
654924	NONE	NONE	0.0
654927	NONE	NONE	0.0
654943	NONE	NONE	0.0
654949	NT	NT	NT
654956	NONE	NONE	0.0
654992	NONE	NONE	0.1
654994	NONE	NONE	0.4
Male, Group IX - 125 mg/kg/day - Day 183			
654942	NONE	NONE	0.1
654957	NONE	NONE	0.1
654973	NONE	NONE	0.0
654974	NONE	NONE	0.1
654976	NONE	NONE	0.1
654977	NONE	NONE	0.1
654978	NONE	NONE	0.1
654985	NONE	NONE	0.1
654990	NONE	NONE	0.1
654991	NONE	NONE	0.0

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Female, Group II - 0 mg/kg/day - Day 49											
655016	TRACE	NONE	NONE	75	36	13.9	109	0.13	15	0.34	98
655025	TRACE	NONE	NONE	58	33	7.3	89	0.16	17	0.34	64
655031	TRACE	NONE	NONE	76	36	11.4	83	0.12	17	0.38	101
655032	NONE	NONE	NONE	80	28	13.2	62	0.12	14	0.25	54
655036	TRACE	NONE	NONE	85	29	12.6	62	0.10	17	0.41	69
655079	NONE	NONE	NONE	62	22	10.5	79	0.13	16	0.36	99
655083	TRACE	NONE	NONE	70	44	8.6	79	0.13	15	0.32	50
655098	TRACE	NONE	NONE	55	32	6.0	70	0.18	14	0.29	90
655099	NONE	NONE	NONE	70	28	9.0	105	0.21	12	0.30	82
655107	TRACE	NONE	NONE	89	51	12.7	95	0.19	15	0.34	64
Female, Group IV - 1 mg/kg/day - Day 49											
655013	TRACE	NONE	NONE	83	28	6.9	105	0.13	16	0.32	98
655033	NONE	NONE	NONE	83	36	10.4	82	0.13	16	0.36	60
655040	NONE	NONE	NONE	80	49	11.4	59	0.15	17	0.34	65
655041	TRACE	NONE	NONE	72	34	9.5	75	0.17	13	0.27	78
655044	NONE	NONE	NONE	61	28	7.4	53	0.11	15	0.33	90
655086	TRACE	NONE	NONE	110	43	20.9	85	0.16	19	0.45	91
655089	TRACE	NONE	NONE	52	31	8.6	65	0.15	16	0.32	104
655090	TRACE	NONE	NONE	69	27	7.7	87	0.16	14	0.38	73
655091	TRACE	NONE	NONE	80	34	9.7	109	0.21	13	0.34	97
655108	TRACE	NONE	NONE	75	38	12.2	65	0.15	18	0.44	104
Female, Group VI - 5 mg/kg/day - Day 49											
655020	TRACE	NONE	NONE	68	30	7.8	85	0.13	18	0.28	67
655029	NONE	NONE	NONE	65	30	7.6	92	0.14	12	0.34	58
655034	TRACE	NONE	NONE	68	35	7.0	59	0.10	16	0.32	62
655038	TRACE	NONE	NONE	73	27	7.8	71	0.14	17	0.35	71
655039	NONE	NONE	NONE	66	32	7.7	66	0.16	16	0.41	92
655042	TRACE	NONE	NONE	70	25	7.9	62	0.11	15	0.40	70
655054	TRACE	NONE	NONE	68	31	9.5	139	0.12	19	0.41	87
655066	TRACE	NONE	NONE	60	30	7.3	78	0.14	15	0.25	90
655067	NONE	NONE	NONE	53	29	9.5	68	0.16	15	0.35	81
655087	TRACE	NONE	NONE	58	20	7.1	65	<0.10	16	0.29	53

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Female, Group VIII - 25 mg/kg/day - Day 49											
655011	NONE	NONE	NONE	50	26	7.9	62	0.18	14	0.29	123
655012	TRACE	NONE	NONE	96	48	14.0	50	0.13	17	0.36	102
655047	TRACE	NONE	NONE	66	34	8.9	92	0.13	18	0.35	102
655055	NONE	NONE	NONE	60	27	6.2	62	0.12	17	0.28	91
655058	SMALL	NONE	NONE	63	26	9.3	78	0.12	12	0.40	75
655073	NONE	NONE	NONE	52	30	7.0	42	0.10	18	0.32	101
655076	NONE	NONE	NONE	66	26	7.7	72	0.10	15	0.25	84
655078	TRACE	NONE	NONE	60	35	8.7	62	0.13	11	0.21	84
655085	TRACE	NONE	NONE	342	158	139.0	142	0.23	15	0.39	172
655105	NONE	NONE	NONE	57	33	9.7	66	0.13	17	0.42	114
Female, Group X - 125 mg/kg/day - Day 49											
655007	TRACE	NONE	NONE	56	33	8.0	54	0.19	13	0.30	120
655023	TRACE	NONE	NONE	74	33	12.7	104	0.12	18	0.31	94
655026	TRACE	NONE	NONE	53	27	8.8	70	0.16	20	0.39	96
655052	TRACE	NONE	NONE	53	33	8.1	79	0.18	16	0.31	92
655053	TRACE	NONE	NONE	73	30	10.4	67	0.14	15	0.30	102
655063	NONE	NONE	NONE	68	27	9.4	91	0.13	14	0.32	77
655092	TRACE	NONE	NONE	54	26	8.2	62	0.15	14	0.29	105
655095	TRACE	NONE	NONE	50	34	9.4	80	0.13	15	0.29	98
655097	TRACE	NONE	NONE	68	41	14.6	69	0.19	12	0.31	146
655103	TRACE	NONE	NONE	56	37	10.4	71	0.16	13	0.32	135

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Female, Group II - 0 mg/kg/day - Day 49										
655016	64	116	7.3	4.8	2.5	11.4	7.9	145.4	7.05	100.2
655025	38	114	7.3	5.1	2.2	11.4	9.1	143.4	5.15	100.1
655031	34	104	7.3	4.8	2.5	11.2	6.9	144.9	6.44	98.5
655032	29	106	6.9	4.5	2.4	11.0	7.1	147.3	5.76	103.9
655036	42	129	7.2	4.9	2.3	11.6	9.0	145.6	6.16	103.0
655079	27	126	7.6	5.1	2.5	11.3	6.0	145.1	5.16	100.2
655083	25	113	7.0	4.7	2.3	11.0	6.5	146.5	5.25	101.4
655098	89	123	7.0	4.8	2.2	10.9	5.9	143.1	5.37	102.1
655099	56	117	7.7	5.0	2.7	11.5	6.0	146.9	4.87	102.0
655107	31	100	7.6	5.3	2.3	11.4	5.7	143.8	6.20	100.7
Female, Group IV - 1 mg/kg/day - Day 49										
655013	35	101	7.5	4.9	2.6	11.2	6.9	146.1	5.17	100.0
655033	29	104	7.0	4.5	2.5	10.8	6.6	147.3	5.18	102.5
655040	36	107	7.0	4.8	2.2	10.9	6.2	143.4	5.75	102.5
655041	95	123	7.0	5.0	2.0	11.1	6.9	143.4	5.49	100.4
655044	56	116	7.5	4.9	2.6	11.3	6.4	146.6	5.34	101.5
655086	49	84	7.5	5.0	2.5	12.0	10.2	147.3	6.74	101.6
655089	74	122	7.5	5.0	2.5	11.5	7.0	142.5	5.55	102.8
655090	41	120	7.1	4.7	2.4	10.9	7.4	144.3	5.16	103.8
655091	46	116	7.5	5.1	2.4	11.7	7.8	144.6	5.89	100.7
655108	39	122	7.6	5.0	2.6	11.9	8.6	145.2	5.65	99.7
Female, Group VI - 5 mg/kg/day - Day 49										
655020	22	112	6.5	4.1	2.4	10.9	7.7	144.2	6.10	103.4
655029	44	108	6.9	4.2	2.7	10.8	6.2	145.2	5.61	103.0
655034	30	112	6.6	4.5	2.1	10.6	6.3	144.4	5.18	100.3
655038	44	103	6.7	4.4	2.3	10.9	7.4	142.2	5.31	99.8
655039	36	117	8.3	5.3	3.0	11.6	6.0	146.5	5.78	101.6
655042	34	119	6.9	4.4	2.5	10.8	6.8	146.9	4.98	102.7
655054	26	103	7.0	4.6	2.4	10.7	6.3	145.4	5.64	101.8
655066	64	121	6.9	4.5	2.4	11.4	6.8	147.8	5.02	102.3
655067	33	116	7.5	5.3	2.2	11.4	6.3	144.0	5.50	102.1
655087	39	147	7.1	4.4	2.7	11.1	8.1	144.1	5.91	101.9

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Female, Group VIII - 25 mg/kg/day - Day 49										
655011	50	121	7.7	5.1	2.6	11.8	6.8	146.8	5.01	101.8
655012	41	109	7.0	4.7	2.3	10.7	6.6	145.1	4.98	102.6
655047	33	110	7.5	5.0	2.5	11.7	7.3	141.6	5.09	104.0
655055	36	110	7.6	4.7	2.9	11.4	7.4	145.4	5.57	100.5
655058	32	115	6.7	4.6	2.1	10.7	7.3	143.5	5.63	100.2
655073	31	119	7.6	5.2	2.4	11.5	7.4	139.1	5.71	100.4
655076	30	107	7.2	4.7	2.5	11.1	6.0	144.6	5.44	100.5
655078	104	114	8.0	5.5	2.5	11.9	6.7	142.9	5.39	96.7
655085	40	118	8.1	5.0	3.1	11.7	6.9	147.1	5.59	100.8
655105	30	106	8.4	5.8	2.6	11.7	6.3	145.3	5.16	99.2
Female, Group X - 125 mg/kg/day - Day 49										
655007	51	109	8.1	5.7	2.4	11.6	7.1	144.5	5.27	101.1
655023	62	121	7.2	5.1	2.1	10.7	7.5	143.9	5.05	101.9
655026	34	111	7.4	5.2	2.2	11.5	8.7	144.3	5.66	101.6
655052	39	103	7.8	5.5	2.3	11.7	7.1	146.4	5.05	100.6
655053	30	112	7.7	5.2	2.5	11.2	9.7	144.6	6.06	101.7
655063	26	117	8.0	5.6	2.4	11.4	6.1	147.8	5.79	100.7
655092	43	109	7.4	5.1	2.3	11.0	8.2	145.7	5.32	101.5
655095	40	108	8.5	5.8	2.7	12.1	7.0	143.0	5.49	100.0
655097	183	116	8.3	5.8	2.5	12.4	7.3	141.2	6.11	98.5
655103	39	107	8.3	5.8	2.5	11.9	7.0	143.7	5.67	101.5

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Female, Group II - 0 mg/kg/day - Day 94											
655016	NONE	NONE	NONE	118	78	22.9	62	0.16	19	0.51	106
655025	NONE	NONE	NONE	66	35	13.4	41	0.14	17	0.45	89
655031	TRACE	NONE	NONE	89	32	21.3	56	0.14	20	0.50	108
655032	NONE	NONE	NONE	77	25	16.3	47	0.14	13	0.43	60
655036	TRACE	NONE	NONE	101	58	21.5	37	0.13	18	0.51	95
655079	NONE	NONE	NONE	66	23	11.0	45	0.14	18	0.50	99
655083	NONE	NONE	NONE	72	41	11.5	43	0.14	15	0.32	59
655098	NONE	NONE	NONE	73	29	12.7	42	0.17	18	0.48	94
655099	TRACE	NONE	NONE	92	32	17.3	64	0.14	16	0.55	77
655107	NONE	NONE	NONE	92	46	18.8	70	0.17	18	0.45	66
Female, Group IV - 1 mg/kg/day - Day 94											
655013	NONE	NONE	NONE	90	37	15.2	77	0.12	19	0.47	90
655033	NONE	NONE	NONE	126	72	20.5	55	0.18	17	0.47	70
655040	NONE	NONE	NONE	195	179	40.1	35	0.13	19	0.47	99
655041	NONE	NONE	NONE	221	100	28.3	43	0.21	13	0.46	112
655044	NONE	NONE	NONE	106	52	25.6	36	0.12	17	0.51	86
655086	NONE	NONE	NONE	108	43	22.9	55	0.15	16	0.54	102
655089	NONE	NONE	NONE	59	24	16.9	48	0.17	18	0.48	113
655090	NONE	NONE	NONE	94	39	13.6	58	0.12	19	0.47	84
655091	NONE	NONE	NONE	86	38	18.3	66	0.17	18	0.48	95
655108	NONE	NONE	NONE	100	54	13.4	43	0.15	17	0.56	116
Female, Group VI - 5 mg/kg/day - Day 94											
655020	TRACE	NONE	NONE	73	33	14.2	63	0.10	20	0.40	65
655029	NONE	NONE	NONE	83	40	15.6	55	0.15	18	0.45	83
655034	NONE	NONE	NONE	122	61	15.8	44	0.13	18	0.50	73
655038	TRACE	NONE	NONE	89	31	10.2	49	0.14	17	0.47	73
655039	TRACE	NONE	NONE	76	44	13.9	47	0.12	17	0.51	96
655042	NONE	NONE	NONE	77	35	13.1	32	0.12	18	0.32	72
655054	NONE	NONE	NONE	98	36	18.1	102	0.13	17	0.45	81
655066	TRACE	NONE	NONE	74	33	9.3	58	0.13	15	0.46	114
655067	NONE	NONE	NONE	70	28	14.3	39	0.13	16	0.44	88
655087	TRACE	NONE	NONE	58	26	11.1	49	<0.10	18	0.36	49

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Female, Group VIII - 25 mg/kg/day - Day 94											
655011	NONE	NONE	NONE	54	33	11.0	33	0.14	14	0.42	170
655012	NONE	NONE	NONE	73	32	13.1	43	0.15	20	0.50	121
655047	NONE	NONE	NONE	95	44	20.0	58	0.18	17	0.37	107
655055	NONE	NONE	NONE	140	53	24.9	42	0.14	20	0.42	93
655058	NONE	NONE	NONE	76	31	17.0	49	<0.10	15	0.45	80
655073	NONE	NONE	NONE	70	36	17.0	33	0.14	16	0.53	108
655076	NONE	NONE	NONE	71	31	17.3	57	0.14	15	0.40	100
655078	NONE	NONE	NONE	110	77	29.4	39	0.13	12	0.46	98
655085	NONE	NONE	NONE	984	374	283.2	99	0.20	17	0.57	228
655105	NONE	NONE	NONE	83	35	11.5	41	0.14	26	0.71	140
Female, Group X - 125 mg/kg/day - Day 94											
655007	TRACE	NONE	NONE	150	75	35.4	44	0.19	12	0.46	144
655023	NONE	NONE	NONE	65	32	17.3	72	0.18	17	0.43	95
655026	TRACE	NONE	NONE	61	31	10.7	54	0.22	18	0.50	125
655052	NONE	NONE	NONE	97	50	22.0	66	0.21	18	0.43	89
655053	NONE	NONE	NONE	92	39	18.3	52	0.13	17	0.46	105
655063	TRACE	NONE	NONE	79	35	12.9	55	0.13	15	0.43	105
655092	NONE	NONE	NONE	96	30	7.3	49	0.18	17	0.39	84
655095	NONE	NONE	NONE	55	38	12.7	47	0.11	18	0.44	106
655097	NONE	NONE	NONE	174	69	38.6	36	0.23	14	0.43	195
655103	NONE	NONE	NONE	64	47	14.5	58	0.16	21	0.60	184

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Female, Group II - 0 mg/kg/day - Day 94											
655016	64	105	8.1	5.5	2.6	11.6	6.0	142.3	5.03	100.2	NONE
655025	42	92	8.4	5.9	2.5	11.7	6.3	144.6	5.00	98.1	TRACE
655031	71	96	7.7	5.0	2.7	11.5	6.2	144.8	6.11	97.4	NONE
655032	34	90	7.6	4.8	2.8	11.7	7.3	146.7	5.73	102.5	NONE
655036	36	95	7.5	5.0	2.5	11.4	6.9	144.9	5.77	98.6	NONE
655079	24	105	7.7	5.1	2.6	11.5	6.3	146.1	5.66	99.0	NONE
655083	33	99	7.4	5.1	2.3	11.5	7.2	146.3	6.27	105.8	TRACE
655098	111	117	7.6	5.2	2.4	11.2	4.6	144.7	5.18	102.8	NONE
655099	44	114	8.3	5.2	3.1	12.8	11.1	150.3	7.19	105.3	NONE
655107	49	92	7.8	5.4	2.4	11.6	6.3	144.9	5.44	101.4	NONE
Female, Group IV - 1 mg/kg/day - Day 94											
655013	35	93	7.7	5.1	2.6	11.1	6.2	145.4	5.44	98.1	NONE
655033	33	92	7.6	5.0	2.6	11.6	7.0	145.0	5.39	101.7	NONE
655040	50	108	8.2	5.7	2.5	11.7	5.2	146.4	5.11	101.3	NONE
655041	85	108	7.9	5.4	2.5	11.2	4.6	144.1	5.26	101.1	NONE
655044	47	115	8.0	5.2	2.8	11.5	5.8	147.2	5.87	102.8	NONE
655086	61	89	7.8	5.2	2.6	11.5	5.5	146.8	5.51	100.3	NONE
655089	212	124	8.2	5.6	2.6	11.8	6.6	144.0	6.30	100.4	TRACE
655090	41	117	7.5	5.1	2.4	11.4	6.8	147.0	5.73	104.6	TRACE
655091	44	100	8.1	5.7	2.4	11.7	6.5	146.7	5.77	100.9	NONE
655108	55	97	8.5	5.8	2.7	11.6	5.0	143.9	5.02	99.3	NONE
Female, Group VI - 5 mg/kg/day - Day 94											
655020	24	97	6.9	4.5	2.4	11.0	7.2	145.7	6.39	102.3	TRACE
655029	35	107	7.9	5.1	2.8	11.5	6.8	146.5	5.55	104.2	NONE
655034	44	110	7.8	5.2	2.6	11.9	7.7	144.7	6.32	101.0	NONE
655038	41	94	7.2	4.7	2.5	11.2	7.0	144.8	5.57	102.4	NONE
655039	40	107	8.6	5.5	3.1	11.9	6.2	148.9	6.07	102.1	NONE
655042	32	108	7.3	4.9	2.4	11.2	7.9	145.9	6.01	104.5	NONE
655054	37	86	7.2	4.6	2.6	10.8	5.6	146.1	5.81	103.4	NONE
655066	54	115	7.9	5.0	2.9	11.7	7.1	147.9	6.25	103.3	NONE
655067	27	105	7.6	5.3	2.3	10.8	5.2	143.5	5.36	99.6	NONE
655087	57	113	7.7	4.7	3.0	11.4	7.2	145.1	6.23	101.3	TRACE

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Female, Group VIII - 25 mg/kg/day - Day 94											
655011	33	104	8.7	5.9	2.8	12.2	6.9	144.5	5.12	97.7	TRACE
655012	43	104	7.7	5.3	2.4	11.5	7.2	146.1	5.82	100.1	TRACE
655047	54	98	7.8	5.1	2.7	11.6	6.1	143.8	5.20	102.2	NONE
655055	28	91	7.9	5.2	2.7	11.4	6.7	144.5	5.37	103.2	NONE
655058	29	95	7.3	4.9	2.4	11.0	6.0	145.3	5.93	100.6	NONE
655073	27	147	8.0	5.6	2.4	11.9	8.6	146.0	5.05	102.0	NONE
655076	35	97	7.8	5.0	2.8	11.4	6.0	146.4	5.65	99.5	NONE
655078	64	116	9.0	6.3	2.7	12.0	6.0	144.2	5.39	97.9	NONE
655085	56	108	9.3	5.6	3.7	12.8	7.6	147.2	5.43	98.7	NONE
655105	43	101	9.0	6.2	2.8	12.3	6.0	147.1	5.08	103.0	NONE
Female, Group X - 125 mg/kg/day - Day 94											
655007	30	99	8.5	5.8	2.7	12.1	7.9	146.2	6.25	101.5	NONE
655023	20	102	7.9	5.6	2.3	11.7	7.9	146.6	5.80	100.9	TRACE
655026	23	101	9.1	6.2	2.9	12.6	7.5	148.0	5.94	100.5	NONE
655052	26	90	8.8	6.0	2.8	12.3	6.9	144.6	5.95	97.2	NONE
655053	37	102	8.7	5.7	3.0	12.4	7.3	150.8	5.31	100.6	TRACE
655063	19	108	8.4	5.8	2.6	12.2	7.4	146.0	5.94	99.9	NONE
655092	29	103	7.7	5.3	2.4	11.7	7.7	147.8	6.47	104.6	NONE
655095	31	98	8.4	5.4	3.0	11.9	6.5	142.8	6.16	100.8	NONE
655097	175	94	8.9	6.0	2.9	12.5	6.8	142.5	5.81	98.8	NONE
655103	34	98	9.6	6.4	3.2	13.0	6.9	147.2	5.84	100.6	NONE

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Female, Group II - 0 mg/kg/day - Day 94			
655016	NONE	NONE	0.1
655025	NONE	NONE	0.1
655031	NONE	NONE	0.2
655032	NONE	NONE	0.1
655036	NONE	NONE	0.1
655079	NONE	NONE	0.1
655083	NONE	NONE	0.1
655098	NONE	NONE	0.1
655099	NONE	NONE	0.2
655107	NONE	NONE	0.2
Female, Group IV - 1 mg/kg/day - Day 94			
655013	NONE	NONE	0.1
655033	NONE	NONE	0.1
655040	NONE	NONE	0.1
655041	NONE	NONE	0.1
655044	NONE	NONE	0.1
655086	NONE	NONE	0.3
655089	NONE	NONE	0.1
655090	NONE	NONE	0.1
655091	NONE	NONE	0.1
655108	NONE	NONE	0.1
Female, Group VI - 5 mg/kg/day - Day 94			
655020	NONE	NONE	0.1
655029	NONE	NONE	0.1
655034	NONE	NONE	0.1
655038	NONE	NONE	0.1
655039	NONE	NONE	0.1
655042	NONE	NONE	0.1
655054	NONE	NONE	0.2
655066	NONE	NONE	0.1
655067	NONE	NONE	0.1
655087	NONE	NONE	0.1

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Female, Group VIII - 25 mg/kg/day - Day 94			
655011	NONE	NONE	0.2
655012	NONE	NONE	0.2
655047	NONE	NONE	0.2
655055	NONE	NONE	0.2
655058	NONE	NONE	0.2
655073	NONE	NONE	0.1
655076	NONE	NONE	0.1
655078	NONE	NONE	0.2
655085	NONE	NONE	0.2
655105	NONE	NONE	0.2
Female, Group X - 125 mg/kg/day - Day 94			
655007	NONE	NONE	0.5
655023	NONE	NONE	0.6
655026	NONE	NONE	0.6
655052	NONE	NONE	0.6
655053	NONE	NONE	0.4
655063	NONE	NONE	0.5
655092	NONE	NONE	0.3
655095	NONE	NONE	0.3
655097	NONE	NONE	0.5
655103	NONE	NONE	0.3

Individual Clinical Chemistry Values

Animal Number	SHEM	SLIP	SICT	AST U/L	ALT U/L	SDH U/L	ALKP U/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Female, Group II - 0 mg/kg/day - Day 183											
655009	TRACE	NONE	NONE	626	323	98.0	47	0.34	13	0.52	126
655015	NONE	NONE	NONE	104	77	17.7	30	0.12	18	0.45	132
655019	TRACE	NONE	NONE	128	58	24.3	43	0.19	18	0.60	153
655035	NONE	NONE	NONE	114	61	24.0	40	0.16	17	0.49	109
655062	NONE	NONE	NONE	90	62	14.6	26	0.15	15	0.49	153
655068	TRACE	NONE	NONE	244	136	42.2	29	0.15	21	0.54	186
655072	NONE	NONE	NONE	85	36	11.0	28	0.14	18	0.57	121
655101	NONE	NONE	NONE	79	45	11.8	37	0.12	17	0.54	108
655109	NONE	NONE	NONE	119	65	19.2	24	0.13	19	0.50	118
Female, Group X - 125 mg/kg/day - Day 183											
655010	NONE	NONE	NONE	253	167	44.9	29	<0.10	18	0.48	255
655030	NONE	NONE	NONE	76	43	19.9	32	0.14	11	0.42	265
655037	TRACE	NONE	NONE	102	64	20.1	37	0.15	15	0.55	93
655049	TRACE	NONE	NONE	68	25	8.4	43	0.14	17	0.43	74
655061	TRACE	NONE	NONE	91	49	12.6	29	0.17	21	0.57	129
655075	TRACE	NONE	NONE	68	30	11.9	37	0.18	12	0.43	127
655077	NONE	NONE	NONE	79	32	12.4	39	0.13	15	0.53	86
655084	TRACE	NONE	NONE	105	46	11.0	60	0.20	19	0.50	113
655088	TRACE	NONE	NONE	91	64	18.7	47	0.16	13	0.39	151
655100	NONE	NONE	NONE	95	56	14.9	30	0.15	17	0.47	180

Individual Clinical Chemistry Values

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L	PHEM
Female, Group II - 0 mg/kg/day - Day 183											
655009	64	97	8.0	5.2	2.8	12.0	6.2	148.3	6.00	103.2	NONE
655015	83	99	8.5	5.7	2.8	12.1	6.5	149.6	4.94	104.7	NONE
655019	78	196	8.6	5.7	2.9	12.8	9.6	149.6	6.16	103.5	NONE
655035	75	95	8.9	5.9	3.0	12.3	5.9	148.9	5.37	100.9	NONE
655062	79	124	9.0	6.2	2.8	12.9	5.8	149.8	5.11	104.4	NONE
655068	101	129	8.4	5.7	2.7	12.5	8.3	146.0	5.92	102.9	NONE
655072	54	108	8.4	5.7	2.7	12.5	7.9	150.7	6.30	105.3	NONE
655101	93	133	8.1	5.6	2.5	12.3	7.2	146.8	6.56	105.7	NONE
655109	75	105	8.2	5.5	2.7	12.5	6.5	148.5	5.81	105.9	NONE
Female, Group X - 125 mg/kg/day - Day 183											
655010	100	99	8.6	5.0	3.6	12.2	8.0	147.1	5.67	101.2	NONE
655030	245	100	8.4	4.7	3.7	12.6	7.3	148.7	5.78	100.4	NONE
655037	52	107	7.9	5.3	2.6	11.8	6.1	149.2	5.57	103.8	NONE
655049	50	95	8.1	5.4	2.7	11.9	6.7	150.9	5.48	106.4	NONE
655061	50	111	9.0	6.2	2.8	12.7	7.5	151.6	5.32	106.2	NONE
655075	140	107	8.6	5.9	2.7	12.6	9.3	149.8	6.93	102.3	NONE
655077	41	110	7.9	5.3	2.6	11.9	6.5	150.8	6.69	107.2	NSR
655084	49	110	8.5	5.8	2.7	12.2	8.5	151.2	5.70	104.6	NONE
655088	81	102	8.1	5.4	2.7	12.3	7.9	147.9	6.22	102.5	NONE
655100	84	95	8.5	5.4	3.1	12.2	6.5	149.0	6.01	104.1	NONE

Individual Clinical Chemistry Values

Animal Number	PLIP	PICT	PFLU µg/mL
Female, Group II - 0 mg/kg/day - Day 183			
655009	NONE	NONE	0.0
655015	NONE	NONE	0.1
655019	NONE	NONE	0.1
655035	NONE	NONE	0.0
655062	NONE	NONE	0.1
655068	NONE	NONE	0.1
655072	NONE	NONE	0.1
655101	NONE	NONE	0.1
655109	NONE	NONE	0.1
Female, Group X - 125 mg/kg/day - Day 183			
655010	NONE	NONE	0.1
655030	NONE	NONE	0.1
655037	NONE	NONE	0.0
655049	NONE	NONE	0.1
655061	NONE	NONE	0.1
655075	NONE	NONE	0.1
655077	NT	NT	NT
655084	NONE	NONE	0.1
655088	NONE	NONE	0.1
655100	NONE	NONE	0.1

TRADE SECRET

Study Title

8-2 Telomer B Alcohol: Subchronic Toxicity
90-Day Oral Gavage Study in Rats

Volume 3 of 3

Laboratory Project ID: DuPont-9478

TEST GUIDELINES: U.S. EPA Health Effects Test Guidelines
OPPTS 870.3100 (1998)

AUTHOR: Gregory S. Ladics, Ph.D

STUDY COMPLETED ON: April 1, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER: 13690

SERVICE CODE NUMBER: 1022

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Male, Group I - 0 mg/kg/day - Day 48											
654928	MEDIUM	YELLOW	CLOUDY	4.2	1781	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654903	LIGHT	YELLOW	HAZY	9.0	856	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654925	MEDIUM	YELLOW	CLOUDY	10.8	840	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654929	LIGHT	YELLOW	HAZY	15.4	492	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654936	LIGHT	YELLOW	CLOUDY	11.0	822	8.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654950	LIGHT	YELLOW	HAZY	16.4	533	7.5	NEGATIVE	NEGATIVE	NEGATIVE	Moderate	0.2
654953	LIGHT	YELLOW	HAZY	19.4	593	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654972	MEDIUM	YELLOW	CLOUDY	5.0	1144	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654987	LIGHT	YELLOW	HAZY	41.0	233	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654993	LIGHT	YELLOW	CLOUDY	12.0	603	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Male, Group III - 1 mg/kg/day - Day 48											
654908	MEDIUM	YELLOW	HAZY	7.0	1203	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654913	LIGHT	YELLOW	CLOUDY	22.0	358	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654932	MEDIUM	YELLOW	CLOUDY	5.4	1431	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654938	MEDIUM	YELLOW	HAZY	10.8	949	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654941	LIGHT	YELLOW	HAZY	17.2	461	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654946	LIGHT	YELLOW	HAZY	6.2	925	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654947	LIGHT	YELLOW	CLOUDY	12.0	660	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654960	MEDIUM	YELLOW	HAZY	5.6	1056	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654984	LIGHT	YELLOW	HAZY	14.6	536	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654995	MEDIUM	YELLOW	HAZY	8.4	828	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
Male, Group V - 5 mg/kg/day - Day 48											
654907	LIGHT	YELLOW	CLOUDY	14.0	619	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654911	MEDIUM	YELLOW	HAZY	9.2	1027	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654916	MEDIUM	YELLOW	CLOUDY	5.2	1409	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654917	MEDIUM	YELLOW	HAZY	6.9	1300	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654959	MEDIUM	YELLOW	CLEAR	12.6	782	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654961	MEDIUM	YELLOW	HAZY	9.8	860	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654967	LIGHT	YELLOW	CLOUDY	27.0	351	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654980	MEDIUM	YELLOW	CLEAR	10.0	1036	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654998	LIGHT	YELLOW	CLOUDY	10.6	1004	7.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
655005	MEDIUM	YELLOW	CLEAR	11.2	742	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Male, Group VII - 25 mg/kg/day - Day 48											
654922	MEDIUM	YELLOW	CLOUDY	7.2	928	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654923	LIGHT	YELLOW	HAZY	29.0	378	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654930	LIGHT	YELLOW	CLOUDY	19.4	589	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654940	MEDIUM	YELLOW	CLEAR	5.6	1283	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654952	MEDIUM	YELLOW	HAZY	6.8	1301	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654958	MEDIUM	YELLOW	HAZY	11.6	627	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654975	MEDIUM	YELLOW	HAZY	10.4	839	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654989	LIGHT	YELLOW	HAZY	21.0	477	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655001	LIGHT	YELLOW	CLOUDY	14.4	610	7.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
655006	MEDIUM	YELLOW	HAZY	5.0	1364	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
Male, Group IX - 125 mg/kg/day - Day 48											
654914	LIGHT	YELLOW	CLOUDY	13.8	691	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654921	MEDIUM	YELLOW	CLOUDY	13.0	751	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654951	LIGHT	YELLOW	HAZY	10.4	695	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654955	MEDIUM	YELLOW	HAZY	11.0	896	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654965	LIGHT	YELLOW	CLOUDY	22.2	481	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654979	LIGHT	YELLOW	HAZY	27.0	355	8.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654983	LIGHT	YELLOW	HAZY	15.6	622	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654986	LIGHT	YELLOW	CLOUDY	23.0	530	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654996	LIGHT	YELLOW	HAZY	20.5	432	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
655003	LIGHT	YELLOW	HAZY	15.0	601	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	UMTP mg/dL
Male, Group I - 0 mg/kg/day - Day 48	
654928	118
654903	55
654925	27
654929	20
654936	54
654950	77
654953	24
654972	76
654987	10
654993	28
Male, Group III - 1 mg/kg/day - Day 48	
654908	62
654913	21
654932	91
654938	52
654941	24
654946	30
654947	77
654960	72
654984	19
654995	32
Male, Group V - 5 mg/kg/day - Day 48	
654907	21
654911	53
654916	78
654917	105
654959	41
654961	32
654967	13
654980	114
654998	60
655005	34

Individual Urinalysis Values

Animal Number	UMTP mg/dL
Male, Group VII - 25 mg/kg/day - Day 48	
654922	75
654923	13
654930	19
654940	99
654952	49
654958	25
654975	28
654989	24
655001	41
655006	101
Male, Group IX - 125 mg/kg/day - Day 48	
654914	42
654921	35
654951	39
654955	130
654965	64
654979	12
654983	27
654986	29
654996	19
655003	37

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Male, Group I - 0 mg/kg/day - Day 93											
654928	MEDIUM	YELLOW	HAZY	5.5	1475	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654903	LIGHT	YELLOW	CLEAR	5.0	1424	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654925	LIGHT	YELLOW	CLEAR	9.6	676	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654929	LIGHT	YELLOW	CLEAR	5.8	1415	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654936	LIGHT	YELLOW	HAZY	7.6	1177	8.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654950	LIGHT	YELLOW	CLEAR	8.2	879	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654953	LIGHT	YELLOW	CLEAR	8.0	1323	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654972	MEDIUM	YELLOW	HAZY	4.0	1648	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654987	LIGHT	YELLOW	HAZY	10.8	908	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654993	MEDIUM	YELLOW	HAZY	3.0	2283	7.0	NEGATIVE	5	NEGATIVE	TRACE	0.2
Male, Group III - 1 mg/kg/day - Day 93											
654908	MEDIUM	YELLOW	HAZY	5.0	1574	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654913	LIGHT	YELLOW	CLEAR	8.0	1033	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654932	LIGHT	YELLOW	HAZY	4.8	1516	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654938	LIGHT	YELLOW	CLOUDY	6.8	1645	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654941	LIGHT	YELLOW	CLEAR	5.4	1613	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654946	LIGHT	YELLOW	CLEAR	8.6	798	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654947	LIGHT	YELLOW	CLEAR	5.0	1125	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654960	LIGHT	YELLOW	CLEAR	3.6	1690	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654984	LIGHT	YELLOW	HAZY	6.8	1258	7.0	NEGATIVE	5	NEGATIVE	MODERATE	0.2
654995	LIGHT	YELLOW	CLEAR	8.8	989	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
Male, Group V - 5 mg/kg/day - Day 93											
654907	LIGHT	YELLOW	CLEAR	7.6	1117	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654911	LIGHT	YELLOW	CLEAR	16.8	536	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654916	LIGHT	YELLOW	HAZY	8.2	1248	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654917	MEDIUM	YELLOW	CLEAR	4.2	1886	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654959	LIGHT	YELLOW	CLEAR	10.4	947	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654961	LIGHT	YELLOW	CLEAR	7.4	1069	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654967	LIGHT	YELLOW	HAZY	7.2	590	7.0	NEGATIVE	NEGATIVE	NEGATIVE	TRACE	0.2
654980	MEDIUM	YELLOW	HAZY	9.0	1226	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654998	MEDIUM	YELLOW	HAZY	3.0	2013	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
655005	MEDIUM	YELLOW	CLEAR	1.8	2301	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Male, Group VII - 25 mg/kg/day - Day 93											
654922	MEDIUM	YELLOW	CLEAR	3.6	1813	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654923	LIGHT	YELLOW	CLEAR	19.6	484	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654930	LIGHT	YELLOW	HAZY	6.8	1285	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654940	LIGHT	YELLOW	CLEAR	5.8	1501	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654952	LIGHT	YELLOW	CLEAR	5.6	1454	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654958	MEDIUM	YELLOW	CLEAR	2.0	3643	7.0	NEGATIVE	5	SMALL	NEGATIVE	1.0
654975	MEDIUM	YELLOW	CLEAR	5.8	1618	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654989	LIGHT	YELLOW	HAZY	16.0	687	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
655001	LIGHT	YELLOW	HAZY	7.4	1242	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
655006	MEDIUM	YELLOW	HAZY	5.2	1766	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
Male, Group IX - 125 mg/kg/day - Day 93											
654914	LIGHT	YELLOW	HAZY	17.8	567	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654921	LIGHT	YELLOW	HAZY	29.0	400	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654951	LIGHT	YELLOW	HAZY	7.2	1487	7.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654955	MEDIUM	YELLOW	CLEAR	6.2	1480	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654965	LIGHT	YELLOW	HAZY	12.6	588	7.0	NEGATIVE	5	NEGATIVE	SMALL	0.2
654979	LIGHT	YELLOW	HAZY	31.5	350	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654983	LIGHT	YELLOW	CLEAR	10.8	922	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654986	LIGHT	YELLOW	CLEAR	41.0	284	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654996	LIGHT	YELLOW	CLEAR	41.0	324	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655003	LIGHT	YELLOW	HAZY	14.0	623	7.0	NEGATIVE	NEGATIVE	NEGATIVE	LARGE	0.2

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL
Male, Group I - 0 mg/kg/day - Day 93		
654928	4.4	74
654903	7.5	103
654925	8.7	22
654929	11.3	74
654936	20.5	95
654950	9.6	328
654953	12.5	71
654972	8.6	146
654987	14.3	27
654993	9.2	139
Male, Group III - 1 mg/kg/day - Day 93		
654908	12.7	100
654913	13.6	63
654932	14.1	129
654938	16.2	116
654941	14.9	112
654946	11.8	29
654947	9.5	171
654960	11.0	148
654984	13.0	77
654995	13.0	36
Male, Group V - 5 mg/kg/day - Day 93		
654907	39.3	37
654911	46.7	26
654916	38.9	68
654917	33.1	139
654959	36.6	46
654961	51.1	74
654967	21.6	27
654980	52.3	114
654998	29.3	163
655005	QNS	119

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL
Male, Group VII - 25 mg/kg/day - Day 93		
654922	282.4	158
654923	236.0	16
654930	131.5	69
654940	135.5	112
654952	126.1	67
654958	QNS	184
654975	242.3	75
654989	195.1	34
655001	231.7	60
655006	240.8	115
Male, Group IX - 125 mg/kg/day - Day 93		
654914	1203.7	36
654921	915.4	29
654951	895.7	90
654955	879.9	314
654965	716.7	68
654979	893.4	10
654983	958.5	47
654986	1158.1	9
654996	1557.8	14
655003	793.1	52

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Male, Group I - 0 mg/kg/day - Day 183											
654909	LIGHT	YELLOW	HAZY	5.8	913	6.5	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654910	MEDIUM	YELLOW	HAZY	3.6	2189	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654915	MEDIUM	YELLOW	HAZY	3.0	2545	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	1.0
654924	LIGHT	YELLOW	HAZY	22.0	457	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654927	LIGHT	YELLOW	CLOUDY	3.6	2552	8.0	NEGATIVE	15	NEGATIVE	NEGATIVE	1.0
654943	LIGHT	YELLOW	CLEAR	10.0	923	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654949	LIGHT	YELLOW	CLEAR	4.8	1095	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654956	LIGHT	YELLOW	CLEAR	5.8	1219	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654992	LIGHT	YELLOW	CLEAR	15.2	709	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654994	MEDIUM	YELLOW	HAZY	1.0	QNS	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Male, Group IX - 125 mg/kg/day - Day 183											
654942	MEDIUM	YELLOW	HAZY	4.8	1788	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654957	LIGHT	YELLOW	CLEAR	15.6	693	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654973	LIGHT	YELLOW	CLEAR	3.8	1387	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654974	MEDIUM	YELLOW	CLEAR	9.0	1375	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654976	LIGHT	YELLOW	CLEAR	13.2	671	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654977	LIGHT	YELLOW	CLEAR	8.6	752	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
654978	LIGHT	YELLOW	CLEAR	6.8	1012	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
654985	LIGHT	YELLOW	HAZY	6.0	1486	7.0	NEGATIVE	15	NEGATIVE	NEGATIVE	0.2
654990	MEDIUM	YELLOW	CLEAR	2.8	2594	6.0	NEGATIVE	5	NEGATIVE	NEGATIVE	1.0
654991	LIGHT	YELLOW	CLEAR	6.4	1461	6.5	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL
Male, Group I - 0 mg/kg/day - Day 183		
654909	6.8	52.0
654910	10.3	196.0
654915	7.5	600.0
654924	15.9	21.0
654927	11.7	110.0
654943	9.5	113.0
654949	6.4	143.0
654956	8.4	139.0
654992	13	52.0
654994	QNS	180.0
Male, Group IX - 125 mg/kg/day - Day 183		
654942	30.5	107.0
654957	26.2	22.0
654973	20.5	115.0
654974	36	71.0
654976	33.3	21.0
654977	26.4	23.0
654978	19.2	31.0
654985	27.4	100.0
654990	28.1	140.0
654991	28.1	320.0

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Female, Group II - 0 mg/kg/day - Day 49											
655016	MEDIUM	YELLOW	CLEAR	5.2	909	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655025	MEDIUM	YELLOW	CLEAR	8.8	599	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655031	MEDIUM	YELLOW	CLEAR	8.6	780	7.0	NEGATIVE	NEGATIVE	NEGATIVE	Moderate	0.2
655032	LIGHT	YELLOW	HAZY	15.0	497	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655036	MEDIUM	YELLOW	CLEAR	4.0	825	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655079	MEDIUM	YELLOW	CLEAR	3.6	1385	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655083	MEDIUM	YELLOW	CLEAR	5.2	1293	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655098	MEDIUM	YELLOW	CLEAR	6.0	879	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655099	MEDIUM	YELLOW	CLOUDY	7.4	970	7.5	NEGATIVE	NEGATIVE	NEGATIVE	Trace	0.2
655107	LIGHT	YELLOW	CLEAR	7.8	681	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group IV - 1 mg/kg/day - Day 49											
655013	LIGHT	YELLOW	CLOUDY	14.2	420	8.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655033	LIGHT	YELLOW	CLOUDY	18.8	432	8.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655040	MEDIUM	YELLOW	CLEAR	4.2	1037	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655041	MEDIUM	YELLOW	CLOUDY	4.6	1005	7.0	NEGATIVE	NEGATIVE	NEGATIVE	Trace	0.2
655044	MEDIUM	YELLOW	CLEAR	2.0	1537	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655086	MEDIUM	YELLOW	CLEAR	3.8	1182	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655089	MEDIUM	YELLOW	CLEAR	2.0	1835	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655090	MEDIUM	YELLOW	CLEAR	4.2	1336	7.0	NEGATIVE	5	NEGATIVE	NEGATIVE	0.2
655091	MEDIUM	YELLOW	HAZY	11.8	620	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655108	LIGHT	YELLOW	CLEAR	9.6	449	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group VI - 5 mg/kg/day - Day 49											
655020	MEDIUM	YELLOW	HAZY	3.2	1828	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655029	LIGHT	YELLOW	CLEAR	9.0	828	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655034	MEDIUM	YELLOW	CLEAR	3.6	1113	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655038	MEDIUM	YELLOW	CLEAR	5.2	1128	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655039	LIGHT	YELLOW	CLEAR	21.0	276	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655042	LIGHT	YELLOW	CLEAR	14.6	NT	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655054	MEDIUM	YELLOW	CLEAR	2.0	1706	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655066	MEDIUM	YELLOW	HAZY	6.6	968	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655067	LIGHT	YELLOW	CLOUDY	13.0	450	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655087	MEDIUM	YELLOW	CLEAR	3.8	1150	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Female, Group VIII - 25 mg/kg/day - Day 49											
655011	LIGHT	YELLOW	CLEAR	8.8	858	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655012	LIGHT	YELLOW	CLEAR	9.2	679	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655047	MEDIUM	YELLOW	CLEAR	8.0	870	7.0	NEGATIVE	NEGATIVE	NEGATIVE	Trace	0.2
655055	LIGHT	YELLOW	CLEAR	7.8	655	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655058	LIGHT	YELLOW	CLEAR	19.0	321	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655073	LIGHT	YELLOW	CLEAR	10.8	648	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655076	LIGHT	YELLOW	CLEAR	50.0	125	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655078	MEDIUM	YELLOW	CLEAR	8.4	744	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655085	MEDIUM	YELLOW	CLEAR	18.0	427	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655105	MEDIUM	YELLOW	CLEAR	4.2	906	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group X - 125 mg/kg/day - Day 49											
655007	MEDIUM	YELLOW	CLEAR	4.0	1156	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655023	LIGHT	YELLOW	CLOUDY	20.0	296	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655026	MEDIUM	YELLOW	CLEAR	7.0	849	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655052	MEDIUM	YELLOW	CLEAR	5.6	1223	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655053	MEDIUM	YELLOW	CLEAR	3.0	2185	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655063	LIGHT	YELLOW	CLEAR	11.0	324	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655092	LIGHT	YELLOW	HAZY	13.0	469	7.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655095	MEDIUM	YELLOW	CLEAR	4.6	1362	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655097	MEDIUM	YELLOW	CLEAR	8.4	758	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655103	MEDIUM	YELLOW	CLEAR	5.4	920	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	UMTP mg/dL	SPEC
Female, Group II - 0 mg/kg/day - Day 49		
655016	26	
655025	16	FECAL CONTAMINATION OBSERVED
655031	27	
655032	9	
655036	19	
655079	27	
655083	24	
655098	22	
655099	35	FECAL CONTAMINATION OBSERVED
655107	15	
Female, Group IV - 1 mg/kg/day - Day 49		
655013	16	
655033	10	
655040	25	
655041	40	FECAL CONTAMINATION OBSERVED
655044	52	
655086	33	
655089	69	
655090	74	
655091	15	
655108	8	
Female, Group VI - 5 mg/kg/day - Day 49		
655020	57	
655029	57	
655034	21	
655038	21	
655039	5	
655042	12	FECAL CONTAMINATION OBSERVED
655054	37	
655066	17	
655067	13	
655087	21	

Individual Urinalysis Values

Animal Number	UMTP mg/dL
Female, Group VIII - 25 mg/kg/day - Day 49	
655011	18
655012	11
655047	18
655055	13
655058	6
655073	13
655076	2
655078	18
655085	11
655105	18
Female, Group X - 125 mg/kg/day - Day 49	
655007	95
655023	12
655026	17
655052	28
655053	74
655063	21
655092	12
655095	104
655097	59
655103	33

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Female, Group II - 0 mg/kg/day - Day 94											
655016	MEDIUM	YELLOW	CLEAR	1.8	2486	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655025	LIGHT	YELLOW	HAZY	3.6	864	6.0	NEGATIVE	NEGATIVE	NEGATIVE	TRACE	0.2
655031	LIGHT	YELLOW	CLEAR	4.8	1088	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655032	LIGHT	YELLOW	HAZY	6.4	1075	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655036	LIGHT	YELLOW	CLEAR	2.0	2137	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655079	LIGHT	YELLOW	CLEAR	3.0	1078	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655083	LIGHT	YELLOW	CLEAR	5.8	1217	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655098	LIGHT	YELLOW	CLEAR	3.2	1344	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655099	LIGHT	YELLOW	CLEAR	17.0	393	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655107	LIGHT	YELLOW	CLEAR	2.6	1678	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group IV - 1 mg/kg/day - Day 94											
655013	LIGHT	YELLOW	CLEAR	3.0	1176	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655033	LIGHT	YELLOW	CLEAR	3.4	1181	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655040	LIGHT	YELLOW	CLEAR	1.8	2122	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655041	LIGHT	YELLOW	CLEAR	1.0	QNS	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655044	LIGHT	YELLOW	CLEAR	2.8	1548	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655086	LIGHT	YELLOW	CLEAR	2.6	1044	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655089	NT	NT	NT	QNS	NT	NT	NT	NT	NT	NT	NT
655090	LIGHT	YELLOW	CLEAR	2.6	1800	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655091	LIGHT	YELLOW	CLEAR	7.2	755	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655108	MEDIUM	YELLOW	CLEAR	1.0	2528	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group VI - 5 mg/kg/day - Day 94											
655020	LIGHT	YELLOW	CLEAR	4.4	1464	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655029	LIGHT	YELLOW	CLEAR	10.0	460	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655034	LIGHT	YELLOW	HAZY	2.0	2243	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655038	LIGHT	YELLOW	CLEAR	6.8	768	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655039	LIGHT	YELLOW	HAZY	3.4	940	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655042	LIGHT	YELLOW	CLEAR	4.0	1394	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655054	LIGHT	YELLOW	CLEAR	3.0	1136	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655066	LIGHT	YELLOW	CLEAR	2.8	1941	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655067	LIGHT	YELLOW	CLEAR	1.8	1374	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655087	LIGHT	YELLOW	HAZY	4.0	1452	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Female, Group VIII - 25 mg/kg/day - Day 94											
655011	MEDIUM	YELLOW	HAZY	2.8	2013	6.0	NEGATIVE	NEGATIVE	SMALL	NEGATIVE	0.2
655012	LIGHT	YELLOW	HAZY	3.4	1690	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655047	LIGHT	YELLOW	HAZY	10.8	686	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655055	LIGHT	YELLOW	HAZY	8.6	578	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655058	LIGHT	YELLOW	CLEAR	2.6	1272	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655073	LIGHT	YELLOW	CLOUDY	4.6	1004	7.0	NEGATIVE	NEGATIVE	NEGATIVE	MODERATE	0.2
655076	LIGHT	YELLOW	HAZY	2.0	1639	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655078	LIGHT	YELLOW	CLEAR	2.0	1655	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655085	LIGHT	YELLOW	CLEAR	7.4	833	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655105	LIGHT	YELLOW	CLEAR	3.4	939	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group X - 125 mg/kg/day - Day 94											
655007	LIGHT	YELLOW	HAZY	14.2	345	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655023	LIGHT	YELLOW	HAZY	9.0	625	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655026	LIGHT	YELLOW	CLEAR	4.4	1367	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655052	LIGHT	YELLOW	HAZY	8.8	718	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655053	LIGHT	YELLOW	HAZY	4.6	1244	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655063	MEDIUM	YELLOW	CLEAR	1.6	2593	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655092	LIGHT	YELLOW	HAZY	13.0	542	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655095	LIGHT	YELLOW	CLEAR	2.4	1848	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655097	LIGHT	YELLOW	HAZY	11.0	557	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655103	LIGHT	YELLOW	CLEAR	8.0	674	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL	SPEC
Female, Group II - 0 mg/kg/day - Day 94			
655016	QNS	85	
655025	4.1	30	FECAL CONTAMINATION OBSERVED
655031	5.3	20	
655032	8.7	20	FECAL CONTAMINATION OBSERVED
655036	QNS	59	
655079	3.7	24	
655083	7.6	27	
655098	4.4	24	
655099	9.7	8	
655107	4.4	29	
Female, Group IV - 1 mg/kg/day - Day 94			
655013	4.9	30	
655033	6.3	19	
655040	QNS	44	
655041	QNS	45	
655044	6.4	36	
655086	3.4	22	
655089	NT	NT	
655090	5.8	112	
655091	7.6	16	
655108	QNS	111	
Female, Group VI - 5 mg/kg/day - Day 94			
655020	12.4	27	
655029	15.7	12	
655034	QNS	54	
655038	16.7	12	
655039	9.0	16	
655042	17.3	32	
655054	10.3	25	
655066	14.1	31	
655067	QNS	56	
655087	17.5	34	

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL	SPEC
Female, Group VIII - 25 mg/kg/day - Day 94			
655011	144.9	496	
655012	61.6	34	FECAL CONTAMINATION OBSERVED
655047	71.0	15	FECAL CONTAMINATION OBSERVED
655055	70.6	11	
655058	83.8	22	
655073	78.6	58	FECAL CONTAMINATION OBSERVED
655076	QNS	51	
655078	QNS	115	
655085	119.9	50	
655105	73.2	24	
Female, Group X - 125 mg/kg/day - Day 94			
655007	873.5	128	
655023	766.5	21	
655026	436.4	33	
655052	883.7	40	
655053	1096.9	46	
655063	QNS	840	
655092	514.7	11	
655095	346.3	756	
655097	888.0	310	
655103	517.0	111	

Individual Urinalysis Values

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	pH	UGLU mg/dL	KET mg/dL	UBIL	BLD	URO EU/dL
Female, Group II - 0 mg/kg/day - Day 183											
655009	NT	NT	NT	QNS	NT	NT	NT	NT	NT	NT	NT
655015	NT	NT	NT	QNS	NT	NT	NT	NT	NT	NT	NT
655019	MEDIUM	YELLOW	CLEAR	1.0	3391	6.0	NEGATIVE	NEGATIVE	SMALL	NEGATIVE	0.2
655035	LIGHT	YELLOW	CLEAR	3.6	1540	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655062	LIGHT	YELLOW	CLEAR	3.6	1616	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655068	LIGHT	YELLOW	HAZY	4.0	269	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655072	LIGHT	YELLOW	CLEAR	1.4	2072	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655101	LIGHT	YELLOW	CLEAR	4.0	1306	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655109	LIGHT	YELLOW	HAZY	40.0	142	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
Female, Group X - 125 mg/kg/day - Day 183											
655010	MEDIUM	YELLOW	CLEAR	2.4	1753	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655030	LIGHT	YELLOW	CLEAR	11.8	502	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655037	LIGHT	YELLOW	HAZY	2.2	2187	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655049	LIGHT	YELLOW	CLEAR	2.8	1447	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655061	MEDIUM	YELLOW	HAZY	1.0	3195	6.5	NEGATIVE	NEGATIVE	SMALL	TRACE	1.0
655075	MEDIUM	YELLOW	CLEAR	5.8	1151	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655077	LIGHT	YELLOW	CLEAR	4.4	1053	7.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655084	LIGHT	YELLOW	HAZY	13.8	261	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655088	LIGHT	YELLOW	CLEAR	1.0	1972	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2
655100	LIGHT	YELLOW	HAZY	4.2	925	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE	0.2

Individual Urinalysis Values

Animal Number	UFLU µg	UMTP mg/dL
Female, Group II - 0 mg/kg/day - Day 183		
655009	QNS	QNS
655015	QNS	QNS
655019	QNS	780
655035	5.6	31
655062	7.3	220.0
655068	5.4	85
655072	QNS	47.0
655101	7	37.0
655109	34	2.0
Female, Group X - 125 mg/kg/day - Day 183		
655010	13.7	3380
655030	18.8	990.0
655037	QNS	62
655049	11.4	22.0
655061	QNS	135.0
655075	18.7	181.0
655077	16.4	156.0
655084	18.3	21.0
655088	QNS	230
655100	12.3	700.0

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER
Male, Group I - 0 mg/kg/day - Day 48						
654903	1	0	0	1	3	2
654925	1	0	0	3	3	2
654928	1	0	0	1	2	2
654929	1	0	0	1	3	1
654936	1	0	0	2	3	1
654950	1	0	0	1	3	2
654953	1	0	0	2	3	1
654972	1	0	0	2	3	2
654987	1	0	0	1	3	3
654993	1	0	0	1	3	1
Male, Group III - 1 mg/kg/day - Day 48						
654908	1	0	0	1	2	1
654913	1	0	0	0	3	2
654932	1	0	0	2	3	1
654938	1	0	0	1	2	2
654941	1	0	0	1	3	3
654946	1	0	0	1	3	3
654947	1	0	0	1	2	1
654960	1	0	0	2	3	2
654984	1	0	0	1	3	3
654995	1	0	0	1	3	2
Male, Group V - 5 mg/kg/day - Day 48						
654907	1	0	0	1	3	1
654911	1	0	0	1	3	1
654916	1	0	0	2	2	3
654917	1	0	0	1	3	2
654959	1	0	0	1	2	1
654961	1	0	0	2	2	1
654967	1	0	0	1	3	1
654980	1	0	0	2	2	3
654998	1	0	0	2	3	3
655005	1	0	0	1	3	3

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER
Male, Group VII - 25 mg/kg/day - Day 48						
654922	1	0	0	2	3	1
654923	1	0	0	1	3	1
654930	1	0	0	1	3	3
654940	1	0	0	1	2	1
654952	1	0	0	1	2	1
654958	1	0	0	1	2	2
654975	1	0	0	1	2	2
654989	1	0	0	1	3	2
655001	1	0	0	2	3	3
655006	1	0	0	1	3	3
Male, Group IX - 125 mg/kg/day - Day 48						
654914	1	0	0	2	3	3
654921	1	0	0	1	3	3
654951	1	0	0	1	3	2
654955	1	1	0	1	2	2
654965	1	0	0	2	3	3
654979	1	0	0	1	2	3
654983	1	0	0	1	3	0
654986	1	0	0	1	3	3
654996	1	0	0	1	2	3
655003	1	0	0	1	2	2

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Male, Group I - 0 mg/kg/day - Day 93							
654903	1	0	0	1	1	1	BELOW RECOMMENDED VOLUME
654925	1	0	0	1	1	1	1-MUCUS STRANDS
654928	1	0	0	1	1	3	1-MUCUS STRANDS
654929	0	0	0	1	1	2	1-MUCUS STRANDS
654936	1	0	0	1	1	0	1-MUCUS STRANDS
654950	1	0	0	1	1	0	1-MUCUS STRANDS
654953	1	0	0	1	1	1	1-MUCUS STRANDS
654972	0	0	0	1	1	2	1-MUCUS STRANDS; BELOW RECOMMENDED VOLUME
654987	1	0	0	1	1	3	1-MUCUS STRANDS
654993	QNS	QNS	QNS	QNS	QNS	QNS	
Male, Group III - 1 mg/kg/day - Day 93							
654908	1	0	0	1	1	2	
654913	1	0	0	1	1	3	
654932	1	0	0	1	1	3	BELOW RECOMMENDED VOLUME
654938	0	0	0	1	2	1	
654941	1	0	0	1	1	3	
654946	0	0	0	1	1	2	
654947	1	0	0	1	1	1	
654960	0	0	0	1	1	3	BELOW RECOMMENDED VOLUME
654984	1	0	2	1	1	2	1-MUCUS STRANDS
654995	0	0	0	1	1	2	
Male, Group V - 5 mg/kg/day - Day 93							
654907	1	0	0	1	1	1	1-MUCUS STRANDS
654911	0	0	0	1	1	2	
654916	0	0	0	1	1	3	
654917	0	0	1	1	1	2	
654959	0	0	0	1	1	1	1-MUCUS STRANDS
654961	0	0	0	1	1	3	
654967	1	0	0	2	1	1	1-MUCUS STRANDS
654980	0	0	0	1	1	3	1-MUCUS STRANDS
654998	QNS	QNS	QNS	QNS	QNS	QNS	
655005	QNS	QNS	QNS	QNS	QNS	QNS	

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Male, Group VII - 25 mg/kg/day - Day 93							
654922	1	0	0	1	1	2	BELOW RECOMMENDED VOLUME
654923	1	0	0	1	1	2	
654930	0	0	0	1	1	3	
654940	0	0	0	1	1	2	1-MUCUS STRANDS
654952	1	0	0	1	1	2	1-MUCUS STRANDS
654958	QNS	QNS	QNS	QNS	QNS	QNS	
654975	0	0	0	1	1	2	
654989	1	0	0	1	2	1	
655001	0	0	0	1	1	3	
655006	0	0	0	1	1	3	BELOW RECOMMENDED VOLUME
Male, Group IX - 125 mg/kg/day - Day 93							
654914	0	0	0	1	3	3	
654921	0	0	0	0	2	3	
654951	1	0	0	2	1	3	
654955	1	0	0	1	1	1	
654965	0	0	0	1	1	3	
654979	0	0	0	1	2	3	
654983	0	0	0	1	1	1	
654986	0	0	0	1	1	1	
654996	1	0	0	1	2	2	
655003	1	0	2	1	1	1	1-MUCUS STRANDS

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Female, Group II - 0 mg/kg/day - Day 49							
655016	1	0	0	1	2	0	
655025	1	0	0	1	2	0	
655031	1	0	1	1	3	0	
655032	1	0	0	2	3	0	
655036	0	0	0	0	3	0	
655079	1	0	0	0	1	0	
655083	1	0	0	1	1	0	
655098	1	1	0	1	2	0	
655099	1	1	0	1	3	0	
655107	1	0	0	1	3	0	
Female, Group IV - 1 mg/kg/day - Day 49							
655013	0	0	0	1	3	0	
655033	1	0	0	1	3	0	
655040	1	1	0	0	3	0	
655041	1	0	0	2	3	0	
655044	1	1	0	0	2	0	BELOW RECOMMENDED VOLUME
655086	1	0	0	0	2	0	
655089	1	0	0	0	3	0	BELOW RECOMMENDED VOLUME
655090	1	0	0	1	2	0	
655091	1	0	0	1	3	0	
655108	1	0	0	0	2	0	
Female, Group VI - 5 mg/kg/day - Day 49							
655020	1	1	0	0	3	0	BELOW RECOMMENDED VOLUME
655029	0	0	0	0	2	0	
655034	1	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655038	1	0	0	0	1	0	
655039	1	0	0	0	3	0	
655042	0	0	0	3	3	0	
655054	1	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655066	1	0	0	2	3	0	
655067	1	0	0	1	3	0	
655087	1	0	0	0	1	0	

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Female, Group VIII - 25 mg/kg/day - Day 49							
655011	1	0	0	2	3	0	
655012	1	0	0	0	2	0	
655047	1	0	0	0	2	0	
655055	1	1	0	0	3	0	
655058	0	0	0	0	2	0	
655073	0	0	0	1	3	0	
655076	1	0	0	0	3	0	
655078	1	0	0	1	2	0	
655085	1	0	0	2	2	0	
655105	1	0	0	1	2	0	
Female, Group X - 125 mg/kg/day - Day 49							
655007	1	0	0	2	3	0	
655023	1	0	0	1	3	0	EPITHELIAL CELLS APPEAR DEGENERATED
655026	1	0	0	0	1	0	EPITHELIAL CELLS APPEAR DEGENERATED
655052	1	0	0	0	3	0	1-MUCUS STRANDS
655053	1	0	0	0	2	0	BELOW RECOMMENDED VOLUME
655063	1	0	0	0	1	0	
655092	1	0	0	2	3	0	
655095	1	0	0	0	2	0	1-MUCUS STRANDS
655097	1	0	0	0	3	0	
655103	1	0	0	1	2	0	

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Female, Group II - 0 mg/kg/day - Day 94							
655031	0	0	0	1	1	0	1-MUCUS STANDS; BELOW RECOMMENDED VOLUME
655016	QNS	QNS	QNS	QNS	QNS	QNS	
655025	QNS	QNS	QNS	QNS	QNS	QNS	
655032	1	0	0	1	1	0	
655036	QNS	QNS	QNS	QNS	QNS	QNS	
655079	QNS	QNS	QNS	QNS	QNS	QNS	
655083	1	0	0	0	1	0	
655098	QNS	QNS	QNS	QNS	QNS	QNS	
655099	0	0	0	0	1	0	
655107	QNS	QNS	QNS	QNS	QNS	QNS	
Female, Group IV - 1 mg/kg/day - Day 94							
655013	QNS	QNS	QNS	QNS	QNS	QNS	
655033	0	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655040	QNS	QNS	QNS	QNS	QNS	QNS	
655041	QNS	QNS	QNS	QNS	QNS	QNS	
655044	QNS	QNS	QNS	QNS	QNS	QNS	
655086	QNS	QNS	QNS	QNS	QNS	QNS	
655089	QNS	QNS	QNS	QNS	QNS	QNS	
655090	QNS	QNS	QNS	QNS	QNS	QNS	
655091	1	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655108	QNS	QNS	QNS	QNS	QNS	QNS	
Female, Group VI - 5 mg/kg/day - Day 94							
655020	0	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655029	0	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655034	QNS	QNS	QNS	QNS	QNS	QNS	
655038	1	0	0	1	1	0	
655039	QNS	QNS	QNS	QNS	QNS	QNS	
655042	1	0	0	1	1	0	BELOW RECOMMENDED VOLUME
655054	QNS	QNS	QNS	QNS	QNS	QNS	
655066	QNS	QNS	QNS	QNS	QNS	QNS	
655067	QNS	QNS	QNS	QNS	QNS	QNS	
655087	1	0	0	1	1	0	BELOW RECOMMENDED VOLUME

Individual Urine Microscopic Values

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPER	SPEC
Female, Group VIII - 25 mg/kg/day - Day 94							
655011	QNS	QNS	QNS	QNS	QNS	QNS	
655012	QNS	QNS	QNS	QNS	QNS	QNS	
655047	1	0	0	1	1	0	
655055	1	0	0	1	1	0	
655058	QNS	QNS	QNS	QNS	QNS	QNS	
655073	0	0	0	1	2	0	BELOW RECOMMENDED VOLUME
655076	QNS	QNS	QNS	QNS	QNS	QNS	
655078	QNS	QNS	QNS	QNS	QNS	QNS	
655085	0	0	0	0	1	0	
655105	QNS	QNS	QNS	QNS	QNS	QNS	
Female, Group X - 125 mg/kg/day - Day 94							
655007	0	0	0	0	1	0	
655023	0	0	0	1	1	0	
655026	1	0	0	1	1	0	BELOW RECOMMENDED VOLUME
655052	0	0	1	1	1	0	
655053	1	0	0	0	1	0	BELOW RECOMMENDED VOLUME
655063	QNS	QNS	QNS	QNS	QNS	QNS	
655092	0	0	0	1	1	0	
655095	QNS	QNS	QNS	QNS	QNS	QNS	
655097	0	0	0	1	1	0	1-MUCUS STRANDS
655103	0	0	0	1	1	0	

APPENDIX L

INDIVIDUAL ANIMAL BIOCHEMICAL DATA

INDIVIDUAL ANIMAL BIOCHEMICAL DATA IN MALE RATS
AT THE 10-DAY TIME POINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
I	655115	13.71
	655119	14.73
	655124	16.45
	655135	14.21
	655137	14.97
III	655144	11.31
	655118	13.43
	655120	15.37
	655132	15.52
	655139	14.59
V	655121	18.35
	655126	17.77
	655127	13.89
	655131	15.53
	655138	14.12
VII	655112	16.17
	655116	14.27
	655125	14.32
	655129	13.34
	655133	15.19
IX	655113	26.88
	655122	25.23
	655123	26.16
	655128	17.65
	655130	24.61

INDIVIDUAL ANIMAL BIOCHEMICAL DATA IN MALE RATS
AT THE 90-DAY TIME POINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
I	654928	12.52
	654929	13.02
	654950	11.22
	654972	11.35
	654993	14.00
III	654913	15.49
	654938	12.41
	654941	11.97
	654947	14.65
	654995	13.25
V	655005	13.02
	654907	11.62
	654959	11.01
	654961	13.92
	654980	18.59
VII	654922	12.69
	654930	14.15
	654940	15.82
	654975	10.15
	655001	14.04
IX	654965	22.46
	654979	17.74
	654983	23.81
	654986	17.57
	655003	21.58

INDIVIDUAL ANIMAL BIOCHEMICAL DATA IN MALE RATS
AT THE 3-MONTH RECOVERY TIMEPOINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
I	654994	11.86
	654992	8.05
	654909	11.90
	654924	12.53
	654943	11.59
IX	654978	12.48
	654974	15.32
	654985	16.42
	654990	17.03
	654976	13.27

INDIVIDUAL ANIMAL DATA IN FEMALE RATS
AT THE 10-DAY TIME POINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
II	655141	24.98
	655149	21.43
	655152	19.38
	655155	24.16
	655159	22.38
IV	655142	22.73
	655160	23.21
	655162	23.58
	655164	21.46
	655165	19.99
VI	655140	26.61
	655145	19.16
	655154	29.66
	655158	19.81
	655167	24.01
VIII	655144	22.45
	655148	23.27
	655161	21.53
	655163	21.82
	655166	27.02
X	655143	22.76
	655146	28.39
	655147	34.45
	655150	30.13
	655151	31.75

INDIVIDUAL ANIMAL DATA IN FEMALE RATS
AT THE 90-DAY TIME POINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
II	655016	25.67
	655031	29.04
	655079	24.65
	655098	20.73
	655107	28.10
IV	655040	25.00
	655041	25.98
	655044	24.60
	655086	24.00
	655108	27.46
VI	655029	30.69
	655034	25.64
	655038	25.24
	655039	27.33
	655054	27.36
VIII	655047	28.24
	655055	33.60
	655058	32.41
	655076	28.80
	655105	25.35
X	655026	35.00
	655052	42.79
	655063	33.28
	655097	43.57
	655103	40.78

INDIVIDUAL ANIMAL DATA IN FEMALE RATS
AT THE 3-MONTH RECOVERY TIMEPOINT

Group	Animal Number	Beta-Oxidation Rate (nmol/min/mg protein)
II	655035	23.78
	655015	21.61
	655009	25.06
	655068	23.75
	655062	24.62
VIII	655088	25.91
	655077	25.38
	655010	32.42
	655030	18.98
	655049	32.17

APPENDIX M

INDIVIDUAL ANIMAL BODY AND ORGAN WEIGHTS

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654903	578.50	2.187	0.3780	0.057	0.0099	2.6063	1.634	0.2825	74.714	1.885	0.3258	86.191	4.177	0.7220	190.99
654925	575.80	2.190	0.3803	0.065	0.0113	2.9680	1.735	0.3013	79.224	1.652	0.2869	75.434	3.551	0.6167	162.15
654928	566.30	2.123	0.3749	0.061	0.0108	2.8733	1.651	0.2915	77.767	1.785	0.3152	84.079	3.885	0.6860	183.00
654929	506.10	2.184	0.4315	0.063	0.0124	2.8846	1.783	0.3523	81.639	1.847	0.3649	84.570	3.745	0.7400	171.47
654936	583.70	2.137	0.3661	0.048	0.0082	2.2461	0.791	0.1355	37.015	1.555	0.2664	72.766	3.497	0.5991	163.64
654950	520.70	2.139	0.4108	0.058	0.0111	2.7115	1.609	0.3090	75.222	1.901	0.3651	88.873	4.513	0.8667	210.99
654953	646.30	2.175	0.3365	0.072	0.0111	3.3103	1.555	0.2406	71.494	1.921	0.2972	88.322	4.361	0.6748	200.51
654972	498.80	2.341	0.4693	0.063	0.0126	2.6912	1.655	0.3318	70.696	1.678	0.3364	71.679	4.197	0.8414	179.28
654987	566.40	2.316	0.4089	0.077	0.0136	3.3247	1.561	0.2756	67.401	1.981	0.3498	85.535	4.268	0.7535	184.28
654993	486.80	2.066	0.4244	0.048	0.0099	2.3233	1.308	0.2687	63.311	1.405	0.2886	68.006	3.041	0.6247	147.19
Mean	552.94	2.186	0.3981	0.061	0.0111	2.7939	1.528	0.2789	69.848	1.761	0.3196	80.545	3.924	0.7125	179.35
S.D.	49.145	0.084	0.0383	0.009	0.0016	0.3601	0.289	0.0595	12.791	0.184	0.0345	7.7301	0.463	0.0912	19.034

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654908	516.10	2.313	0.4482	0.031	0.0060	1.3403	1.372	0.2658	59.317	1.736	0.3364	75.054	3.872	0.7502	167.40
654913	534.10	2.149	0.4024	0.035	0.0066	1.6287	1.605	0.3005	74.686	1.820	0.3408	84.691	3.455	0.6469	160.77
654932	566.10	2.082	0.3678	0.035	0.0062	1.6811	1.573	0.2779	75.552	1.856	0.3279	89.145	4.174	0.7373	200.48
654938	579.40	2.213	0.3819	0.038	0.0066	1.7171	1.536	0.2651	69.408	2.031	0.3505	91.776	3.756	0.6483	169.72
654941	515.80	2.229	0.4321	0.045	0.0087	2.0188	1.650	0.3199	74.024	1.766	0.3424	79.228	4.177	0.8098	187.39
654946	577.70	2.175	0.3765	0.065	0.0113	2.9885	1.775	0.3073	81.609	1.856	0.3213	85.333	3.673	0.6358	168.87
654947	489.60	1.999	0.4083	0.051	0.0104	2.5513	1.355	0.2768	67.784	1.688	0.3448	84.442	3.737	0.7633	186.94
654960	513.20	2.030	0.3956	0.053	0.0103	2.6108	1.458	0.2841	71.823	1.889	0.3681	93.054	3.658	0.7128	180.20

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654984	601.80	2.184	0.3629	0.066	0.0110	3.0220	1.498	0.2489	68.590	1.879	0.3122	86.035	3.475	0.5774	159.11
654995	514.10	2.295	0.4464	0.063	0.0123	2.7451	1.669	0.3246	72.723	1.800	0.3501	78.431	4.065	0.7907	177.12
Mean	540.79	2.167	0.4022	0.048	0.0089	2.2304	1.549	0.2871	71.552	1.832	0.3394	84.719	3.804	0.7073	175.80
S.D.	37.400	0.105	0.0313	0.013	0.0024	0.6217	0.133	0.0251	5.8859	0.095	0.0160	5.8132	0.263	0.0764	13.117

Group : V 5 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654907	532.90	2.138	0.4012	0.055	0.0103	2.5725	1.368	0.2567	63.985	1.555	0.2918	72.732	3.747	0.7031	175.26
654911	619.90	2.419	0.3902	0.061	0.0098	2.5217	1.706	0.2752	70.525	1.981	0.3196	81.893	4.815	0.7767	199.05
654916	526.30	2.329	0.4425	0.066	0.0125	2.8338	1.674	0.3181	71.876	1.703	0.3236	73.122	4.286	0.8144	184.03
654917	587.80	2.187	0.3721	0.071	0.0121	3.2465	1.846	0.3141	84.408	1.816	0.3089	83.036	4.109	0.6990	187.88
654959	621.10	2.271	0.3656	0.067	0.0108	2.9502	1.747	0.2813	76.926	1.763	0.2839	77.631	4.601	0.7408	202.60
654961	643.30	2.228	0.3463	0.062	0.0096	2.7828	1.570	0.2441	70.467	1.943	0.3020	87.208	4.430	0.6886	198.83
654967	513.30	2.171	0.4229	0.059	0.0115	2.7176	1.545	0.3010	71.165	1.549	0.3018	71.350	3.372	0.6569	155.32
654980	626.50	2.248	0.3588	0.091	0.0145	4.0480	1.530	0.2442	68.061	1.981	0.3162	88.123	3.928	0.6270	174.73
654998	587.60	2.214	0.3768	0.061	0.0104	2.7552	1.434	0.2440	64.770	2.055	0.3497	92.818	4.282	0.7287	193.41
655005	567.80	2.134	0.3758	0.055	0.0097	2.5773	1.814	0.3195	85.005	1.627	0.2865	76.242	3.304	0.5819	154.83
Mean	582.65	2.234	0.3852	0.065	0.0111	2.9006	1.623	0.2798	72.719	1.797	0.3084	80.415	4.087	0.7017	182.59
S.D.	46.186	0.089	0.0296	0.011	0.0016	0.4555	0.160	0.0317	7.2988	0.187	0.0199	7.3639	0.501	0.0689	17.359

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : VII 25 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654922	555.60	2.183	0.3929	0.049	0.0088	2.2446	1.487	0.2676	68.117	1.764	0.3175	80.806	4.301	0.7741	197.02
654923	539.30	2.242	0.4157	0.059	0.0109	2.6316	1.728	0.3204	77.074	1.821	0.3377	81.222	4.319	0.8009	192.64
654930	596.10	2.234	0.3748	0.035	0.0059	1.5667	1.663	0.2790	74.440	2.048	0.3436	91.674	4.331	0.7266	193.87
654940	534.80	2.330	0.4357	0.066	0.0123	2.8326	1.760	0.3291	75.536	1.709	0.3196	73.348	4.014	0.7506	172.27
654952	598.40	2.126	0.3553	0.076	0.0127	3.5748	1.446	0.2416	68.015	1.978	0.3305	93.039	4.656	0.7781	219.00
654958	483.10	1.979	0.4096	0.055	0.0114	2.7792	1.325	0.2743	66.953	1.630	0.3374	82.365	3.399	0.7036	171.75
654975	554.90	2.120	0.3821	0.048	0.0087	2.2642	1.336	0.2408	63.019	1.877	0.3383	88.538	4.435	0.7992	209.20
654989	580.50	2.181	0.3757	0.057	0.0098	2.6135	1.888	0.3252	86.566	1.915	0.3299	87.804	4.571	0.7874	209.58
655001	641.70	2.139	0.3333	0.057	0.0089	2.6648	1.896	0.2955	88.640	1.971	0.3072	92.146	4.952	0.7717	231.51
655006	557.00	2.214	0.3975	0.072	0.0129	3.2520	1.830	0.3285	82.656	1.947	0.3496	87.940	4.528	0.8129	204.52
Mean	564.14	2.175	0.3873	0.057	0.0102	2.6424	1.636	0.2902	75.102	1.866	0.3311	85.888	4.351	0.7705	200.14
S.D.	43.119	0.094	0.0299	0.012	0.0022	0.5534	0.221	0.0347	8.7412	0.133	0.0130	6.2888	0.417	0.0345	18.909

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654914	563.50	2.298	0.4078	0.096	0.0170	4.1775	1.610	0.2857	70.061	1.869	0.3317	81.332	4.636	0.8227	201.74
654921	553.20	2.064	0.3731	0.054	0.0098	2.6163	1.421	0.2569	68.847	1.819	0.3288	88.130	4.372	0.7903	211.82
654951	555.00	2.159	0.3890	0.056	0.0101	2.5938	1.549	0.2791	71.746	1.870	0.3369	86.614	4.618	0.8321	213.90
654955	542.50	2.226	0.4103	0.066	0.0122	2.9650	1.543	0.2844	69.317	2.121	0.3910	95.283	4.895	0.9023	219.90
654965	483.60	2.132	0.4409	0.070	0.0145	3.2833	1.507	0.3116	70.685	1.480	0.3060	69.418	4.681	0.9679	219.56
654979	512.40	2.185	0.4264	0.052	0.0101	2.3799	1.446	0.2822	66.178	2.590	0.5055	118.54	4.605	0.8987	210.76
654983	569.90	2.139	0.3753	0.061	0.0107	2.8518	0.807	0.1416	37.728	1.841	0.3230	86.068	4.557	0.7996	213.04
654986	575.00	2.130	0.3704	0.050	0.0087	2.3474	1.364	0.2372	64.038	2.012	0.3499	94.460	4.308	0.7492	202.25
654996	508.60	2.156	0.4239	0.067	0.0132	3.1076	1.670	0.3284	77.458	1.968	0.3869	91.280	5.452	1.0720	252.88

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655003	506.10	2.257	0.4460	0.049	0.0097	2.1710	1.643	0.3246	72.796	1.586	0.3134	70.270	4.240	0.8378	187.86
Mean	536.98	2.175	0.4063	0.062	0.0116	2.8494	1.456	0.2732	66.885	1.916	0.3573	88.139	4.636	0.8673	213.37
S.D.	31.734	0.069	0.0282	0.014	0.0026	0.5854	0.248	0.0542	10.870	0.303	0.0593	13.934	0.346	0.0959	16.868

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654903	16.824	2.9082	769.27	1.074	0.1857	49.108	3.893	0.6729	178.01	0.359	0.0621	16.415	0.024	0.0041	1.0974
654925	13.693	2.3781	625.25	0.885	0.1537	40.411	3.365	0.5844	153.65	0.496	0.0861	22.648	0.017	0.0030	0.7763
654928	15.743	2.7800	741.54	0.960	0.1695	45.219	3.759	0.6638	177.06	0.274	0.0484	12.906	0.021	0.0037	0.9892
654929	13.187	2.6056	603.80	0.853	0.1685	39.057	3.669	0.7250	167.99	0.387	0.0765	17.720	0.024	0.0047	1.0989
654936	15.095	2.5861	706.36	0.811	0.1389	37.950	3.715	0.6365	173.84	0.541	0.0927	25.316	0.024	0.0041	1.1231
654950	15.783	3.0311	737.87	0.942	0.1809	44.039	3.490	0.6703	163.16	0.498	0.0956	23.282	0.028	0.0054	1.3090
654953	17.121	2.6491	787.17	0.952	0.1473	43.770	3.691	0.5711	169.70	0.621	0.0961	28.552	0.027	0.0042	1.2414
654972	14.283	2.8635	610.12	0.822	0.1648	35.113	3.512	0.7041	150.02	0.387	0.0776	16.531	0.024	0.0048	1.0252
654987	15.690	2.7701	677.46	1.156	0.2041	49.914	3.681	0.6499	158.94	0.655	0.1156	28.282	0.030	0.0053	1.2953
654993	11.344	2.3303	549.08	0.677	0.1391	32.769	3.101	0.6370	150.10	0.278	0.0571	13.456	0.020	0.0041	0.9681
Mean	14.876	2.6902	680.79	0.913	0.1653	41.735	3.588	0.6515	164.25	0.450	0.0808	20.511	0.024	0.0043	1.0924
S.D.	1.770	0.2248	80.356	0.137	0.0212	5.6798	0.228	0.0478	10.716	0.134	0.0206	5.8536	0.004	0.0007	0.1639

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654908	13.521	2.6198	584.57	0.793	0.1537	34.284	2.930	0.5677	126.68	0.309	0.0599	13.359	0.025	0.0048	1.0808
654913	13.493	2.5263	627.87	0.845	0.1582	39.321	3.529	0.6607	164.22	0.312	0.0584	14.518	0.020	0.0037	0.9307
654932	15.900	2.8087	763.69	0.761	0.1344	36.551	3.830	0.6766	183.96	0.364	0.0643	17.483	0.029	0.0051	1.3929
654938	16.451	2.8393	743.38	1.094	0.1888	49.435	3.529	0.6091	159.47	0.518	0.0894	23.407	0.024	0.0041	1.0845
654941	13.863	2.6877	621.94	0.989	0.1917	44.370	3.384	0.6561	151.82	0.354	0.0686	15.882	0.022	0.0043	0.9870
654946	14.040	2.4303	645.52	0.844	0.1461	38.805	3.450	0.5972	158.62	0.423	0.0732	19.448	0.027	0.0047	1.2414
654947	13.017	2.6587	651.18	0.637	0.1301	31.866	3.359	0.6861	168.03	0.266	0.0543	13.307	0.019	0.0039	0.9505
654960	13.151	2.5625	647.83	0.857	0.1670	42.217	3.652	0.7116	179.90	0.385	0.0750	18.966	0.020	0.0039	0.9852

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654984	14.923	2.4797	683.29	0.764	0.1270	34.982	3.533	0.5871	161.77	0.424	0.0705	19.414	0.018	0.0030	0.8242
654995	12.728	2.4758	554.60	0.834	0.1622	36.340	3.799	0.7390	165.53	0.394	0.0766	17.168	0.027	0.0053	1.1765
Mean	14.109	2.6089	652.39	0.842	0.1559	38.817	3.500	0.6491	162.00	0.375	0.0690	17.295	0.023	0.0043	1.0654
S.D.	1.254	0.1403	64.449	0.126	0.0226	5.2729	0.255	0.0568	15.726	0.072	0.0103	3.1698	0.004	0.0007	0.1678

Group : V 5 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654907	13.279	2.4918	621.09	0.621	0.1165	29.046	3.202	0.6009	149.77	0.529	0.0993	24.743	0.027	0.0051	1.2629
654911	15.581	2.5135	644.11	0.893	0.1441	36.916	3.803	0.6135	157.21	0.457	0.0737	18.892	0.028	0.0045	1.1575
654916	14.164	2.6912	608.16	0.786	0.1493	33.748	3.555	0.6755	152.64	0.420	0.0798	18.033	0.031	0.0059	1.3310
654917	16.489	2.8052	753.96	1.014	0.1725	46.365	3.729	0.6344	170.51	0.646	0.1099	29.538	0.026	0.0044	1.1888
654959	17.731	2.8548	780.76	1.120	0.1803	49.317	3.871	0.6232	170.45	0.602	0.0969	26.508	0.028	0.0045	1.2329
654961	17.017	2.6453	763.78	0.941	0.1463	42.235	3.879	0.6030	174.10	0.519	0.0807	23.294	0.025	0.0039	1.1221
654967	12.452	2.4259	573.56	0.753	0.1467	34.684	3.281	0.6392	151.13	0.355	0.0692	16.352	0.023	0.0045	1.0594
654980	16.952	2.7058	754.09	1.112	0.1775	49.466	4.728	0.7547	210.32	0.601	0.0959	26.735	0.022	0.0035	0.9786
654998	16.528	2.8128	746.52	0.796	0.1355	35.953	3.268	0.5562	147.61	0.313	0.0533	14.137	0.025	0.0043	1.1292
655005	15.559	2.7402	729.10	0.702	0.1236	32.896	3.682	0.6485	172.54	0.357	0.0629	16.729	0.025	0.0044	1.1715
Mean	15.575	2.6687	697.51	0.874	0.1492	39.063	3.700	0.6349	165.63	0.480	0.0822	21.496	0.026	0.0045	1.1634
S.D.	1.744	0.1475	76.846	0.171	0.0218	7.2788	0.442	0.0529	18.827	0.117	0.0180	5.3033	0.003	0.0006	0.1008

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : VII 25 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654922	16.414	2.9543	751.90	0.760	0.1368	34.814	3.552	0.6393	162.71	0.269	0.0484	12.322	0.023	0.0041	1.0536
654923	16.965	3.1457	756.69	0.822	0.1524	36.664	3.816	0.7076	170.21	0.370	0.0686	16.503	0.027	0.0050	1.2043
654930	18.546	3.1112	830.17	1.134	0.1902	50.761	4.003	0.6715	179.19	0.523	0.0877	23.411	0.031	0.0052	1.3876
654940	15.957	2.9837	684.85	0.970	0.1814	41.631	3.522	0.6586	151.16	0.366	0.0684	15.708	0.026	0.0049	1.1159
654952	17.594	2.9402	827.56	0.888	0.1484	41.769	3.328	0.5561	156.54	0.339	0.0567	15.945	0.031	0.0052	1.4581
654958	14.340	2.9683	724.61	0.895	0.1853	45.225	3.312	0.6856	167.36	0.437	0.0905	22.082	0.027	0.0056	1.3643
654975	17.187	3.0973	810.71	0.968	0.1744	45.660	3.706	0.6679	174.81	0.486	0.0876	22.925	0.022	0.0040	1.0377
654989	16.625	2.8639	762.27	0.980	0.1688	44.934	3.395	0.5848	155.66	0.673	0.1159	30.857	0.023	0.0040	1.0546
655001	20.773	3.2372	971.15	0.877	0.1367	41.000	4.203	0.6550	196.49	0.647	0.1008	30.248	0.022	0.0034	1.0285
655006	17.787	3.1934	803.39	0.898	0.1612	40.560	4.131	0.7417	186.59	0.462	0.0829	20.867	0.026	0.0047	1.1743
Mean	17.219	3.0495	792.33	0.919	0.1636	42.302	3.697	0.6568	170.07	0.457	0.0808	21.087	0.026	0.0046	1.1879
S.D.	1.693	0.1237	78.215	0.102	0.0196	4.6142	0.330	0.0543	14.477	0.131	0.0204	6.1679	0.003	0.0007	0.1611

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654914	22.509	3.9945	979.50	0.921	0.1634	40.078	3.548	0.6296	154.40	0.618	0.1097	26.893	0.026	0.0046	1.1314
654921	21.736	3.9291	1053.1	0.949	0.1715	45.979	3.541	0.6401	171.56	0.289	0.0522	14.002	0.023	0.0042	1.1143
654951	22.546	4.0623	1044.3	0.862	0.1553	39.926	4.169	0.7512	193.10	0.443	0.0798	20.519	0.023	0.0041	1.0653
654955	23.398	4.3130	1051.1	1.449	0.2671	65.094	3.883	0.7158	174.44	0.725	0.1336	32.570	0.027	0.0050	1.2129
654965	19.727	4.0792	925.28	0.959	0.1983	44.981	3.651	0.7550	171.25	0.378	0.0782	17.730	0.019	0.0039	0.8912
654979	21.382	4.1729	978.58	1.000	0.1952	45.767	3.302	0.6444	151.12	0.265	0.0517	12.128	0.023	0.0045	1.0526
654983	20.456	3.5894	956.33	0.732	0.1284	34.222	2.192	0.3846	102.48	0.474	0.0832	22.160	0.020	0.0035	0.9350
654986	22.395	3.8948	1051.4	0.928	0.1614	43.568	3.976	0.6915	186.67	0.431	0.0750	20.235	0.022	0.0038	1.0329
654996	26.082	5.1282	1209.7	0.943	0.1854	43.738	3.890	0.7648	180.43	0.451	0.0887	20.918	0.028	0.0055	1.2987

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Subchronic Toxicity

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655003	19.526	3.8581	865.13	0.891	0.1761	39.477	3.371	0.6661	149.36	0.477	0.0943	21.134	0.022	0.0043	0.9747
Mean	21.976	4.1022	1011.4	0.963	0.1802	44.283	3.552	0.6643	163.48	0.455	0.0846	20.829	0.023	0.0043	1.0709
S.D.	1.928	0.4098	93.853	0.186	0.0367	8.1682	0.552	0.1104	26.042	0.138	0.0246	5.8581	0.003	0.0006	0.1245

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Recovery

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654909	578.30	2.124	0.3673	0.041	0.0071	1.9303	1.533	0.2651	72.175	1.733	0.2997	81.591	3.825	0.6614	180.08
654910	691.50	2.184	0.3158	0.055	0.0080	2.5183	1.706	0.2467	78.114	1.907	0.2758	87.317	4.529	0.6550	207.37
654915	725.90	2.295	0.3162	0.062	0.0085	2.7015	1.611	0.2219	70.196	1.857	0.2558	80.915	4.260	0.5869	185.62
654924	631.40	2.074	0.3285	0.041	0.0065	1.9769	1.479	0.2342	71.311	1.728	0.2737	83.317	4.031	0.6384	194.36
654927	674.60	2.356	0.3492	0.060	0.0089	2.5467	1.496	0.2218	63.497	2.037	0.3020	86.460	4.138	0.6134	175.64
654943	605.80	2.106	0.3476	0.060	0.0099	2.8490	1.398	0.2308	66.382	1.615	0.2666	76.686	3.879	0.6403	184.19
654956	551.90	2.124	0.3849	0.068	0.0123	3.2015	1.717	0.3111	80.838	1.854	0.3359	87.288	3.232	0.5856	152.17
654992	656.30	2.123	0.3235	0.050	0.0076	2.3552	1.329	0.2025	62.600	1.931	0.2942	90.956	4.033	0.6145	189.97
654994	521.10	2.065	0.3963	0.060	0.0115	2.9056	1.344	0.2579	65.085	1.530	0.2936	74.092	3.269	0.6273	158.31
Mean	626.31	2.161	0.3477	0.055	0.0089	2.5539	1.513	0.2436	70.022	1.799	0.2886	83.180	3.911	0.6248	180.86
S.D.	67.783	0.100	0.0298	0.009	0.0020	0.4205	0.144	0.0319	6.3647	0.161	0.0238	5.4505	0.428	0.0271	17.182

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654942	620.80	2.113	0.3404	0.041	0.0066	1.9404	1.548	0.2494	73.261	1.788	0.2880	84.619	4.126	0.6646	195.27
654957	616.90	2.080	0.3372	0.039	0.0063	1.8750	1.451	0.2352	69.760	1.864	0.3022	89.615	4.567	0.7403	219.57
654973	642.70	2.202	0.3426	0.064	0.0100	2.9064	1.582	0.2461	71.844	1.847	0.2874	83.878	4.389	0.6829	199.32
654974	673.00	2.081	0.3092	0.062	0.0092	2.9793	1.503	0.2233	72.225	2.076	0.3085	99.760	4.187	0.6221	201.20
654976	597.10	2.192	0.3671	0.051	0.0085	2.3266	1.481	0.2480	67.564	1.742	0.2917	79.471	3.784	0.6337	172.63
654977	492.60	2.180	0.4425	0.042	0.0085	1.9266	1.530	0.3106	70.183	1.453	0.2950	66.651	3.039	0.6169	139.40
654978	552.60	2.091	0.3784	0.033	0.0060	1.5782	1.218	0.2204	58.250	1.617	0.2926	77.331	3.551	0.6426	169.82
654985	475.30	1.995	0.4197	0.048	0.0101	2.4060	1.603	0.3373	80.351	1.553	0.3267	77.845	3.212	0.6758	161.00
654990	667.90	2.044	0.3060	0.050	0.0075	2.4462	1.516	0.2270	74.168	2.136	0.3198	104.50	4.213	0.6308	206.12

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Recovery

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			EPIDIDYMIDES			HEART			KIDNEYS		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654991	759.70	2.131	0.2805	0.057	0.0075	2.6748	1.366	0.1798	64.101	2.337	0.3076	109.67	4.333	0.5704	203.33
Mean	609.86	2.111	0.3524	0.049	0.0080	2.3060	1.480	0.2477	70.171	1.841	0.3020	87.334	3.940	0.6480	186.77
S.D.	85.864	0.067	0.0508	0.010	0.0015	0.4682	0.114	0.0454	5.9824	0.276	0.0136	13.549	0.520	0.0459	24.848

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Recovery

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654909	13.874	2.3991	653.20	0.788	0.1363	37.100	3.814	0.6595	179.57	0.159	0.0275	7.4859	0.021	0.0036	0.9887
654910	19.106	2.7630	874.82	1.040	0.1504	47.619	4.242	0.6134	194.23	0.374	0.0541	17.125	0.026	0.0038	1.1905
654915	19.298	2.6585	840.87	1.028	0.1416	44.793	3.522	0.4852	153.46	0.139	0.0191	6.0566	0.031	0.0043	1.3508
654924	16.367	2.5922	789.15	0.748	0.1185	36.066	3.659	0.5795	176.42	0.296	0.0469	14.272	0.037	0.0059	1.7840
654927	17.544	2.6007	744.65	0.916	0.1358	38.879	3.520	0.5218	149.41	0.149	0.0221	6.3243	0.031	0.0046	1.3158
654943	15.294	2.5246	726.21	0.723	0.1193	34.330	3.819	0.6304	181.34	0.170	0.0281	8.0722	0.031	0.0051	1.4720
654956	13.066	2.3675	615.16	0.866	0.1569	40.772	3.512	0.6363	165.35	0.155	0.0281	7.2976	0.030	0.0054	1.4124
654992	14.895	2.2695	701.60	0.783	0.1193	36.882	3.423	0.5216	161.23	0.234	0.0357	11.022	0.039	0.0059	1.8370
654994	12.566	2.4114	608.52	0.872	0.1673	42.228	3.382	0.6490	163.78	0.322	0.0618	15.593	0.031	0.0059	1.5012
Mean	15.779	2.5096	728.24	0.863	0.1384	39.852	3.655	0.5885	169.42	0.222	0.0359	10.361	0.031	0.0050	1.4280
S.D.	2.481	0.1587	94.614	0.115	0.0176	4.3789	0.270	0.0643	14.492	0.088	0.0149	4.2803	0.005	0.0009	0.2668

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654942	16.631	2.6790	787.08	0.872	0.1405	41.268	3.560	0.5735	168.48	0.414	0.0667	19.593	0.029	0.0047	1.3725
654957	14.671	2.3782	705.34	0.916	0.1485	44.038	3.385	0.5487	162.74	0.317	0.0514	15.240	0.033	0.0053	1.5865
654973	14.447	2.2479	656.09	0.904	0.1407	41.054	3.715	0.5780	168.71	0.388	0.0604	17.620	0.025	0.0039	1.1353
654974	17.388	2.5837	835.56	0.940	0.1397	45.171	3.480	0.5171	167.23	0.414	0.0615	19.894	0.034	0.0051	1.6338
654976	13.934	2.3336	635.68	0.773	0.1295	35.265	3.458	0.5791	157.76	0.288	0.0482	13.139	0.026	0.0044	1.1861
654977	10.701	2.1724	490.87	0.635	0.1289	29.128	3.436	0.6975	157.61	0.251	0.0510	11.514	0.025	0.0051	1.1468
654978	13.068	2.3648	624.96	0.694	0.1256	33.190	3.542	0.6410	169.39	0.345	0.0624	16.499	0.040	0.0072	1.9130
654985	12.493	2.6284	626.22	0.823	0.1732	41.253	3.260	0.6859	163.41	0.291	0.0612	14.586	0.023	0.0048	1.1529
654990	17.770	2.6606	869.37	0.924	0.1383	45.205	3.364	0.5037	164.58	0.314	0.0470	15.362	0.026	0.0039	1.2720

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Recovery

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	LIVER			SPLEEN			TESTES			THYMUS			THYROID GLAND		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
654991	19.568	2.5758	918.25	0.916	0.1206	42.985	3.398	0.4473	159.46	0.362	0.0477	16.987	0.028	0.0037	1.3139
Mean	15.067	2.4624	714.94	0.840	0.1385	39.856	3.460	0.5772	163.94	0.338	0.0557	16.044	0.029	0.0048	1.3713
S.D.	2.727	0.1840	133.73	0.106	0.0148	5.4785	0.125	0.0796	4.5266	0.056	0.0074	2.6500	0.005	0.0010	0.2603

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (10-Day Sacrifice)

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655115	254.1	11.566	4.552
655119	241.7	9.945	4.115
655124	266.0	11.053	4.155
655135	222.4	9.158	4.118
655137	257.7	10.375	4.026
Mean	248.38	10.419	4.193
S.D.	16.953	0.940	0.206

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655114	247.2	9.848	3.984
655118	247.9	10.209	4.118
655120	226.2	9.572	4.232
655132	242.8	9.991	4.115
655139	259.2	11.460	4.421
Mean	244.66	10.216	4.174
S.D.	11.964	0.733	0.164

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (10-Day Sacrifice)

Group : V 5 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655121	271.9	12.100	4.450
655126	209.0	8.676	4.151
655127	249.7	9.924	3.974
655131	253.9	11.717	4.615
655138	243.8	9.680	3.970
Mean	245.66	10.419	4.232
S.D.	23.023	1.444	0.290

Group : VII 25 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655112	212.9	9.320	4.378
655116	254.1	10.352	4.074
655125	238.0	10.490	4.408
655129	251.9	11.846	4.703
655133	249.9	11.508	4.605
Mean	241.36	10.703	4.433
S.D.	17.085	1.004	0.242

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (10-Day Sacrifice)

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655113	238.1	12.784	5.369
655122	276.2	16.404	5.939
655123	245.5	12.838	5.229
655128	237.4	13.321	5.611
655130	267.5	15.563	5.818
Mean	252.94	14.182	5.593
S.D.	17.819	1.684	0.297

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (Final Sacrifice)

Group : I 0 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
654919	551.10	19.363	3.5135
654939	743.60	24.134	3.2456
654966	489.70	12.940	2.6424
654971	575.70	18.670	3.2430
654997	655.10	23.031	3.5156
Mean	603.04	19.628	3.2320
S.D.	98.436	4.405	0.3562

Group : III 1 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
654904	616.70	18.945	3.0720
654945	572.60	17.032	2.9745
654948	738.30	24.199	3.2777
654954	690.90	24.931	3.6085
654988	613.20	17.496	2.8532
Mean	646.34	20.521	3.1572
S.D.	66.814	3.768	0.2963

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (Final Sacrifice)

Group : V 5 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
654918	726.80	23.418	3.2221
654926	722.10	24.295	3.3645
654969	582.00	19.389	3.3314
654970	542.40	15.430	2.8448
654981	589.10	17.283	2.9338
Mean	632.48	19.963	3.1393
S.D.	85.838	3.833	0.2364

Group : VII 25 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
654912	622.50	19.039	3.0585
654920	688.00	21.986	3.1956
654933	816.80	28.040	3.4329
654934	618.70	18.824	3.0425
654964	723.20	25.118	3.4732
Mean	693.84	22.601	3.2405
S.D.	81.778	3.976	0.2034

FBW - Final Body Weight

Organ Weight Listing
Male Rats Designated for Satellite Evaluation (Final Sacrifice)

Group : IX 125 mg/kg/day Sex :MALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
654906	801.50	28.596	3.5678
654931	692.30	21.588	3.1183
654937	704.70	20.829	2.9557
654962	623.30	18.843	3.0231
654982	667.90	22.940	3.4346
Mean	697.94	22.559	3.2199
S.D.	65.719	3.686	0.2674

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655016	286.50	1.957	0.6831	0.074	0.0258	3.7813	1.971	0.6880	100.72	2.378	0.8300	121.51	8.877	3.0984	453.60
655025	301.70	2.094	0.6941	0.072	0.0239	3.4384	1.286	0.4263	61.414	2.252	0.7464	107.55	8.737	2.8959	417.24
655031	292.60	1.964	0.6712	0.060	0.0205	3.0550	1.141	0.3900	58.096	2.174	0.7430	110.69	7.403	2.5301	376.93
655032	302.90	2.002	0.6609	0.098	0.0324	4.8951	1.277	0.4216	63.786	2.246	0.7415	112.19	8.256	2.7257	412.39
655036	322.50	2.043	0.6335	0.086	0.0267	4.2095	1.243	0.3854	60.842	2.521	0.7817	123.40	8.859	2.7470	433.63
655079	266.80	1.982	0.7429	0.080	0.0300	4.0363	1.046	0.3921	52.775	2.201	0.8250	111.05	7.413	2.7785	374.02
655083	310.80	1.948	0.6268	0.081	0.0261	4.1581	1.230	0.3958	63.142	2.459	0.7912	126.23	8.359	2.6895	429.11
655098	261.10	1.879	0.7196	0.059	0.0226	3.1400	1.042	0.3991	55.455	2.220	0.8502	118.15	7.334	2.8089	390.31
655099	284.90	1.925	0.6757	0.074	0.0260	3.8442	1.135	0.3984	58.961	2.068	0.7259	107.43	7.526	2.6416	390.96
655107	238.50	1.873	0.7853	0.076	0.0319	4.0577	0.859	0.3602	45.862	1.869	0.7836	99.786	6.280	2.6331	335.29
Mean	286.83	1.967	0.6893	0.076	0.0266	3.8616	1.223	0.4257	62.105	2.239	0.7819	113.80	7.904	2.7549	401.35
S.D.	25.304	0.068	0.0488	0.012	0.0039	0.5481	0.294	0.0940	14.598	0.188	0.0428	8.3064	0.849	0.1580	34.727

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655013	299.40	2.040	0.6814	0.079	0.0264	3.8725	1.073	0.3584	52.598	2.252	0.7522	110.39	8.222	2.7462	403.04
655033	303.60	2.052	0.6759	0.094	0.0310	4.5809	1.136	0.3742	55.361	2.012	0.6627	98.051	8.763	2.8864	427.05
655040	293.10	1.842	0.6285	0.040	0.0136	2.1716	1.207	0.4118	65.527	2.253	0.7687	122.31	8.498	2.8994	461.35
655041	276.10	2.028	0.7345	0.067	0.0243	3.3037	1.092	0.3955	53.846	2.557	0.9261	126.08	8.085	2.9283	398.67
655044	317.20	2.059	0.6491	0.032	0.0101	1.5542	1.073	0.3383	52.113	1.928	0.6078	93.638	7.659	2.4146	371.98
655086	243.30	1.977	0.8126	0.071	0.0292	3.5913	1.023	0.4205	51.745	1.766	0.7259	89.327	6.383	2.6235	322.86
655089	317.90	1.872	0.5889	0.074	0.0233	3.9530	1.053	0.3312	56.250	2.346	0.7380	125.32	10.197	3.2076	544.71
655090	323.50	2.027	0.6266	0.055	0.0170	2.7134	1.137	0.3515	56.093	2.088	0.6454	103.01	8.578	2.6516	423.19

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655091	302.60	1.933	0.6388	0.066	0.0218	3.4144	1.228	0.4058	63.528	2.318	0.7660	119.92	8.370	2.7660	433.01
655108	269.30	1.946	0.7226	0.053	0.0197	2.7235	1.062	0.3944	54.573	1.951	0.7245	100.26	7.484	2.7791	384.58
Mean	294.60	1.978	0.6759	0.063	0.0216	3.1878	1.108	0.3781	56.163	2.147	0.7317	108.83	8.224	2.7903	417.04
S.D.	25.107	0.077	0.0656	0.019	0.0067	0.9046	0.067	0.0319	4.7035	0.239	0.0872	13.790	0.982	0.2122	58.824

Group : VI 5 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655020	301.60	1.931	0.6403	0.063	0.0209	3.2626	0.987	0.3273	51.113	2.149	0.7125	111.29	8.880	2.9443	459.87
655029	279.90	1.831	0.6542	0.068	0.0243	3.7138	1.078	0.3851	58.875	2.021	0.7220	110.38	7.202	2.5731	393.34
655034	259.10	1.758	0.6785	0.056	0.0216	3.1854	0.941	0.3632	53.527	1.845	0.7121	104.95	6.924	2.6723	393.86
655038	292.70	2.025	0.6918	0.082	0.0280	4.0494	1.111	0.3796	54.864	2.116	0.7229	104.49	8.505	2.9057	420.00
655039	301.30	1.989	0.6601	0.060	0.0199	3.0166	1.101	0.3654	55.354	2.170	0.7202	109.10	7.750	2.5722	389.64
655042	339.80	1.950	0.5739	0.087	0.0256	4.4615	1.206	0.3549	61.846	2.339	0.6883	119.95	9.454	2.7822	484.82
655054	252.30	1.948	0.7721	0.064	0.0254	3.2854	1.094	0.4336	56.160	2.090	0.8284	107.29	7.625	3.0222	391.43
655066	308.10	1.959	0.6358	0.070	0.0227	3.5733	1.312	0.4258	66.973	2.186	0.7095	111.59	8.270	2.6842	422.15
655067	291.40	1.890	0.6486	0.075	0.0257	3.9683	1.177	0.4039	62.275	2.139	0.7340	113.17	7.990	2.7419	422.75
655087	314.70	2.030	0.6451	0.077	0.0245	3.7931	1.292	0.4105	63.645	2.491	0.7915	122.71	9.248	2.9387	455.57
Mean	294.09	1.931	0.6600	0.070	0.0239	3.6309	1.130	0.3849	58.463	2.155	0.7342	111.49	8.185	2.7837	423.34
S.D.	25.820	0.085	0.0502	0.010	0.0025	0.4529	0.120	0.0336	5.0742	0.173	0.0426	5.9315	0.845	0.1615	33.481

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : VIII 25 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655011	306.70	1.958	0.6384	0.073	0.0238	3.7283	1.060	0.3456	54.137	2.627	0.8565	134.17	10.728	3.4979	547.91
655012	305.60	1.998	0.6538	0.056	0.0183	2.8028	1.293	0.4231	64.715	2.347	0.7680	117.47	9.551	3.1253	478.03
655047	264.90	1.895	0.7154	0.056	0.0211	2.9551	1.012	0.3820	53.404	2.134	0.8056	112.61	7.515	2.8369	396.57
655055	279.50	2.107	0.7538	0.067	0.0240	3.1799	1.069	0.3825	50.736	2.234	0.7993	106.03	8.585	3.0716	407.45
655058	278.20	2.042	0.7340	0.063	0.0226	3.0852	1.090	0.3918	53.379	2.301	0.8271	112.68	8.310	2.9871	406.95
655073	305.30	1.974	0.6466	0.064	0.0210	3.2421	1.159	0.3796	58.713	2.353	0.7707	119.20	9.671	3.1677	489.92
655076	297.00	2.108	0.7098	0.075	0.0253	3.5579	1.173	0.3949	55.645	2.864	0.9643	135.86	8.930	3.0067	423.62
655078	351.30	2.069	0.5890	0.067	0.0191	3.2383	1.399	0.3982	67.617	2.897	0.8247	140.02	10.928	3.1107	528.18
655085	317.90	1.855	0.5835	0.062	0.0195	3.3423	1.275	0.4011	68.733	2.529	0.7955	136.33	9.605	3.0214	517.79
655105	268.80	2.019	0.7511	0.070	0.0260	3.4671	1.076	0.4003	53.294	2.243	0.8344	111.09	8.475	3.1529	419.76
Mean	297.52	2.003	0.6775	0.065	0.0221	3.2599	1.161	0.3899	58.037	2.453	0.8246	122.55	9.230	3.0978	461.62
S.D.	26.045	0.085	0.0638	0.006	0.0027	0.2784	0.125	0.0200	6.5924	0.267	0.0564	12.670	1.076	0.1713	57.204

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655007	283.00	1.923	0.6795	0.070	0.0247	3.6401	1.232	0.4353	64.067	2.522	0.8912	131.15	11.585	4.0936	602.44
655023	282.70	1.860	0.6579	0.050	0.0177	2.6882	1.064	0.3764	57.204	2.159	0.7637	116.08	10.675	3.7761	573.92
655026	283.10	2.001	0.7068	0.077	0.0272	3.8481	1.172	0.4140	58.571	2.496	0.8817	124.74	10.693	3.7771	534.38
655052	277.80	2.076	0.7473	0.063	0.0227	3.0347	1.094	0.3938	52.697	2.563	0.9226	123.46	12.457	4.4842	600.05
655053	305.90	2.126	0.6950	0.097	0.0317	4.5626	1.235	0.4037	58.090	2.435	0.7960	114.53	12.127	3.9644	570.41
655063	251.50	1.912	0.7602	0.066	0.0262	3.4519	1.002	0.3984	52.406	2.079	0.8266	108.73	10.581	4.2072	553.40
655092	299.40	2.031	0.6784	0.080	0.0267	3.9389	1.143	0.3818	56.278	2.464	0.8230	121.32	10.646	3.5558	524.18
655095	317.10	2.249	0.7092	0.083	0.0262	3.6905	1.191	0.3756	52.957	3.048	0.9612	135.53	13.348	4.2094	593.51
655097	294.80	1.850	0.6275	0.062	0.0210	3.3514	1.186	0.4023	64.108	2.306	0.7822	124.65	12.171	4.1286	657.89

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655103	294.30	2.063	0.7010	0.081	0.0275	3.9263	1.184	0.4023	57.392	2.551	0.8668	123.65	10.851	3.6871	525.98
Mean	288.96	2.009	0.6963	0.073	0.0252	3.6133	1.150	0.3984	57.377	2.462	0.8515	122.38	11.513	3.9883	573.62
S.D.	17.911	0.126	0.0391	0.013	0.0039	0.5220	0.075	0.0182	4.2082	0.265	0.0640	7.8306	0.972	0.2870	41.766

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655016	0.131	0.0457	6.6939	0.634	0.2213	32.397	0.290	0.1012	14.819	0.022	0.0077	1.1242	0.818	0.2855	41.799
655025	0.116	0.0384	5.5396	0.614	0.2035	29.322	0.242	0.0802	11.557	0.018	0.0060	0.8596	0.708	0.2347	33.811
655031	0.143	0.0489	7.2811	0.583	0.1992	29.684	0.372	0.1271	18.941	0.022	0.0075	1.1202	0.937	0.3202	47.709
655032	0.167	0.0551	8.3417	0.715	0.2361	35.714	0.395	0.1304	19.730	0.021	0.0069	1.0490	0.944	0.3117	47.153
655036	0.163	0.0505	7.9785	0.650	0.2016	31.816	0.513	0.1591	25.110	0.018	0.0056	0.8811	0.542	0.1681	26.530
655079	0.144	0.0540	7.2654	0.618	0.2316	31.181	0.312	0.1169	15.742	0.020	0.0075	1.0091	0.525	0.1968	26.488
655083	0.159	0.0512	8.1622	0.598	0.1924	30.698	0.373	0.1200	19.148	0.020	0.0064	1.0267	0.589	0.1895	30.236
655098	0.134	0.0513	7.1315	0.466	0.1785	24.800	0.377	0.1444	20.064	0.018	0.0069	0.9580	0.549	0.2103	29.218
655099	0.135	0.0474	7.0130	0.461	0.1618	23.948	0.327	0.1148	16.987	0.026	0.0091	1.3506	0.588	0.2064	30.545
655107	0.119	0.0499	6.3534	0.449	0.1883	23.972	0.311	0.1304	16.604	0.015	0.0063	0.8009	0.841	0.3526	44.901
Mean	0.141	0.0492	7.1760	0.579	0.2014	29.353	0.351	0.1225	17.870	0.020	0.0070	1.0179	0.704	0.2476	35.839
S.D.	0.018	0.0047	0.8570	0.090	0.0233	3.9433	0.074	0.0219	3.6447	0.003	0.0010	0.1592	0.168	0.0645	8.6153

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655013	0.153	0.0511	7.5000	0.590	0.1971	28.922	0.326	0.1089	15.980	0.014	0.0047	0.6863	0.720	0.2405	35.294
655033	0.169	0.0557	8.2359	0.728	0.2398	35.478	0.360	0.1186	17.544	0.024	0.0079	1.1696	1.051	0.3462	51.218
655040	0.107	0.0365	5.8089	0.462	0.1576	25.081	0.180	0.0614	9.7720	0.024	0.0082	1.3029	0.788	0.2689	42.780
655041	0.095	0.0344	4.6844	0.523	0.1894	25.789	0.242	0.0876	11.933	0.022	0.0080	1.0848	0.816	0.2955	40.237
655044	0.133	0.0419	6.4594	0.523	0.1649	25.401	0.161	0.0508	7.8193	0.020	0.0063	0.9713	0.662	0.2087	32.152
655086	0.158	0.0649	7.9919	0.465	0.1911	23.520	0.256	0.1052	12.949	0.017	0.0070	0.8599	1.086	0.4464	54.932
655089	0.140	0.0440	7.4786	0.599	0.1884	31.998	0.305	0.0959	16.293	0.016	0.0050	0.8547	0.728	0.2290	38.889
655090	0.139	0.0430	6.8574	0.621	0.1920	30.636	0.350	0.1082	17.267	0.017	0.0053	0.8387	0.542	0.1675	26.739

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655091	0.123	0.0406	6.3632	0.584	0.1930	30.212	0.230	0.0760	11.899	0.015	0.0050	0.7760	0.679	0.2244	35.127
655108	0.104	0.0386	5.3443	0.400	0.1485	20.555	0.257	0.0954	13.207	0.032	0.0119	1.6444	0.721	0.2677	37.050
Mean	0.132	0.0451	6.6724	0.550	0.1862	27.759	0.267	0.0908	13.466	0.020	0.0069	1.0189	0.779	0.2695	39.442
S.D.	0.025	0.0095	1.1622	0.095	0.0254	4.4680	0.068	0.0220	3.2670	0.006	0.0022	0.2898	0.170	0.0792	8.4771

Group : VI 5 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655020	0.144	0.0477	7.4573	0.703	0.2331	36.406	0.302	0.1001	15.640	0.024	0.0080	1.2429	0.560	0.1857	29.001
655029	0.127	0.0454	6.9361	0.510	0.1822	27.854	0.321	0.1147	17.531	0.014	0.0050	0.7646	0.539	0.1926	29.437
655034	0.127	0.0490	7.2241	0.643	0.2482	36.576	0.324	0.1250	18.430	0.019	0.0073	1.0808	0.438	0.1690	24.915
655038	0.164	0.0560	8.0988	0.555	0.1896	27.407	0.337	0.1151	16.642	0.020	0.0068	0.9877	0.754	0.2576	37.235
655039	0.104	0.0345	5.2288	0.580	0.1925	29.160	0.193	0.0641	9.7034	0.024	0.0080	1.2066	1.067	0.3541	53.645
655042	0.163	0.0480	8.3590	0.821	0.2416	42.103	0.520	0.1530	26.667	0.023	0.0068	1.1795	0.754	0.2219	38.667
655054	0.170	0.0674	8.7269	0.593	0.2350	30.441	0.347	0.1375	17.813	0.019	0.0075	0.9754	1.435	0.5688	73.665
655066	0.161	0.0523	8.2185	0.548	0.1779	27.973	0.322	0.1045	16.437	0.021	0.0068	1.0720	0.656	0.2129	33.486
655067	0.074	0.0254	3.9153	0.521	0.1788	27.566	0.310	0.1064	16.402	0.019	0.0065	1.0053	0.615	0.2111	32.540
655087	0.174	0.0553	8.5714	0.750	0.2383	36.946	0.263	0.0836	12.956	0.019	0.0060	0.9360	0.557	0.1770	27.438
Mean	0.141	0.0481	7.2736	0.622	0.2117	32.243	0.324	0.1104	16.822	0.020	0.0069	1.0451	0.738	0.2551	38.003
S.D.	0.033	0.0116	1.5691	0.105	0.0296	5.2803	0.082	0.0255	4.3252	0.003	0.0009	0.1436	0.300	0.1226	14.926

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : VIII 25 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655011	0.120	0.0391	6.1287	0.660	0.2152	33.708	0.364	0.1187	18.590	0.019	0.0062	0.9704	0.801	0.2612	40.909
655012	0.165	0.0540	8.2583	0.666	0.2179	33.333	0.283	0.0926	14.164	0.031	0.0101	1.5516	0.560	0.1832	28.028
655047	0.112	0.0423	5.9103	0.580	0.2190	30.607	0.427	0.1612	22.533	0.019	0.0072	1.0026	0.847	0.3197	44.697
655055	0.156	0.0558	7.4039	0.535	0.1914	25.392	0.298	0.1066	14.143	0.016	0.0057	0.7594	0.525	0.1878	24.917
655058	0.124	0.0446	6.0725	0.617	0.2218	30.215	0.249	0.0895	12.194	0.017	0.0061	0.8325	0.613	0.2203	30.020
655073	0.166	0.0544	8.4093	0.527	0.1726	26.697	0.301	0.0986	15.248	0.022	0.0072	1.1145	0.972	0.3184	49.240
655076	0.156	0.0525	7.4004	0.655	0.2205	31.072	0.275	0.0926	13.046	0.022	0.0074	1.0436	0.827	0.2785	39.231
655078	0.116	0.0330	5.6066	0.530	0.1509	25.616	0.331	0.0942	15.998	0.023	0.0065	1.1116	0.962	0.2738	46.496
655085	0.112	0.0352	6.0377	0.506	0.1592	27.278	0.422	0.1327	22.749	0.025	0.0079	1.3477	0.948	0.2982	51.105
655105	0.108	0.0402	5.3492	0.460	0.1711	22.784	0.334	0.1243	16.543	0.019	0.0071	0.9411	0.743	0.2764	36.800
Mean	0.134	0.0451	6.6577	0.574	0.1940	28.670	0.328	0.1111	16.521	0.021	0.0071	1.0675	0.780	0.2618	39.144
S.D.	0.024	0.0085	1.1116	0.073	0.0282	3.6453	0.060	0.0231	3.6987	0.004	0.0012	0.2351	0.166	0.0493	9.1149

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655007	0.111	0.0392	5.7722	0.561	0.1982	29.173	0.310	0.1095	16.121	0.028	0.0099	1.4561	0.468	0.1654	24.337
655023	0.157	0.0555	8.4409	0.576	0.2037	30.968	0.273	0.0966	14.677	0.020	0.0071	1.0753	0.570	0.2016	30.645
655026	0.169	0.0597	8.4458	0.753	0.2660	37.631	0.222	0.0784	11.094	0.022	0.0078	1.0995	0.530	0.1872	26.487
655052	0.152	0.0547	7.3218	0.624	0.2246	30.058	0.414	0.1490	19.942	0.028	0.0101	1.3487	0.821	0.2955	39.547
655053	0.151	0.0494	7.1025	0.594	0.1942	27.940	0.266	0.0870	12.512	0.023	0.0075	1.0818	0.548	0.1791	25.776
655063	0.141	0.0561	7.3745	0.624	0.2481	32.636	0.361	0.1435	18.881	0.016	0.0064	0.8368	0.503	0.2000	26.308
655092	0.178	0.0595	8.7642	0.618	0.2064	30.428	0.388	0.1296	19.104	0.023	0.0077	1.1324	1.484	0.4957	73.067
655095	0.121	0.0382	5.3802	0.646	0.2037	28.724	0.430	0.1356	19.120	0.018	0.0057	0.8004	1.262	0.3980	56.114
655097	0.103	0.0349	5.5676	0.594	0.2015	32.108	0.237	0.0804	12.811	0.016	0.0054	0.8649	0.850	0.2883	45.946

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Subchronic Toxicity

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655103	0.119	0.0404	5.7683	0.504	0.1713	24.430	0.326	0.1108	15.802	0.023	0.0078	1.1149	1.043	0.3544	50.557
Mean	0.140	0.0488	6.9938	0.609	0.2118	30.410	0.323	0.1120	16.006	0.022	0.0075	1.0811	0.808	0.2765	39.878
S.D.	0.025	0.0096	1.3010	0.065	0.0275	3.4424	0.074	0.0263	3.1870	0.004	0.0016	0.2112	0.354	0.1109	16.348

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Recovery

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655009	317.10	1.939	0.6115	0.090	0.0284	4.6416	1.165	0.3674	60.083	2.266	0.7146	116.86	8.669	2.7338	447.09
655015	288.40	1.944	0.6741	0.087	0.0302	4.4753	1.208	0.4189	62.140	2.580	0.8946	132.72	9.943	3.4476	511.47
655019	347.70	2.218	0.6379	0.128	0.0368	5.7710	1.506	0.4331	67.899	2.890	0.8312	130.30	11.718	3.3701	528.31
655035	322.80	2.005	0.6211	0.060	0.0186	2.9925	1.503	0.4656	74.963	2.396	0.7423	119.50	9.806	3.0378	489.08
655062	344.40	2.091	0.6071	0.092	0.0267	4.3998	1.433	0.4161	68.532	3.128	0.9082	149.59	11.122	3.2294	531.90
655068	329.80	1.950	0.5913	0.075	0.0227	3.8462	1.346	0.4081	69.026	2.501	0.7583	128.26	9.951	3.0173	510.31
655072	340.90	2.148	0.6301	0.090	0.0264	4.1899	1.343	0.3940	62.523	2.620	0.7686	121.97	11.076	3.2490	515.64
655101	405.90	2.063	0.5083	0.062	0.0153	3.0053	1.428	0.3518	69.220	2.730	0.6726	132.33	11.298	2.7834	547.65
655109	309.30	2.138	0.6912	0.080	0.0259	3.7418	1.053	0.3404	49.252	2.338	0.7559	109.35	9.201	2.9748	430.36
Mean	334.03	2.055	0.6192	0.085	0.0257	4.1182	1.332	0.3995	64.848	2.605	0.7829	126.77	10.309	3.0937	501.31
S.D.	32.847	0.102	0.0524	0.020	0.0063	0.8616	0.158	0.0404	7.4199	0.277	0.0795	11.614	1.040	0.2483	39.253

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW	BRAIN		ADRENAL GLANDS			HEART			KIDNEYS			LIVER		
	(Gms)	(Gms)	%FBW	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655010	306.30	1.816	0.5929	0.074	0.0242	4.0749	1.192	0.3892	65.639	3.426	1.1185	188.66	11.589	3.7835	638.16
655030	455.30	2.008	0.4410	0.071	0.0156	3.5359	1.472	0.3233	73.307	3.615	0.7940	180.03	13.781	3.0268	686.30
655037	394.40	1.968	0.4990	0.092	0.0233	4.6748	1.245	0.3157	63.262	2.503	0.6346	127.18	10.562	2.6780	536.69
655049	249.70	1.863	0.7461	0.062	0.0248	3.3280	0.977	0.3913	52.442	2.027	0.8118	108.80	7.045	2.8214	378.15
655061	289.30	1.786	0.6174	0.076	0.0263	4.2553	1.022	0.3533	57.223	2.218	0.7667	124.19	8.489	2.9343	475.31
655075	432.20	1.968	0.4553	0.089	0.0206	4.5224	1.491	0.3450	75.762	2.920	0.6756	148.37	11.180	2.5868	568.09
655077	326.60	2.010	0.6154	0.081	0.0248	4.0299	1.181	0.3616	58.756	2.312	0.7079	115.02	9.701	2.9703	482.64
655084	302.10	2.012	0.6660	0.075	0.0248	3.7276	1.162	0.3846	57.753	2.425	0.8027	120.53	8.440	2.7938	419.48
655088	374.80	2.010	0.5363	0.047	0.0125	2.3383	1.188	0.3170	59.104	2.705	0.7217	134.58	10.908	2.9104	542.69

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Recovery

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	BRAIN (Gms)	BRAIN %FBW	ADRENAL GLANDS (Gms)	ADRENAL GLANDS %FBW	ADRENAL GLANDS %BRAIN	HEART (Gms)	HEART %FBW	HEART %BRAIN	KIDNEYS (Gms)	KIDNEYS %FBW	KIDNEYS %BRAIN	LIVER (Gms)	LIVER %FBW	LIVER %BRAIN
655100	358.50	1.917	0.5347	0.083	0.0232	4.3297	1.409	0.3930	73.500	3.231	0.9013	168.54	11.691	3.2611	609.86
Mean	348.92	1.936	0.5704	0.075	0.0220	3.8817	1.234	0.3574	63.675	2.738	0.7935	141.59	10.339	2.9766	533.74
S.D.	65.818	0.086	0.0956	0.013	0.0045	0.6889	0.175	0.0314	8.0787	0.541	0.1374	28.381	1.961	0.3399	96.914

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Recovery

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655009	0.142	0.0448	7.3234	0.622	0.1962	32.078	0.164	0.0517	8.4580	0.027	0.0085	1.3925	0.721	0.2274	37.184
655015	0.099	0.0343	5.0926	0.646	0.2240	33.230	0.204	0.0707	10.494	0.013	0.0045	0.6687	0.910	0.3155	46.811
655019	0.164	0.0472	7.3940	0.819	0.2355	36.925	0.359	0.1032	16.186	0.037	0.0106	1.6682	1.811	0.5209	81.650
655035	0.100	0.0310	4.9875	0.648	0.2007	32.319	0.221	0.0685	11.022	0.025	0.0077	1.2469	0.725	0.2246	36.160
655062	0.079	0.0229	3.7781	0.601	0.1745	28.742	0.165	0.0479	7.8910	0.027	0.0078	1.2912	0.784	0.2276	37.494
655068	0.100	0.0303	5.1282	0.503	0.1525	25.795	0.261	0.0791	13.385	0.029	0.0088	1.4872	0.904	0.2741	46.359
655072	0.196	0.0575	9.1248	0.749	0.2197	34.870	0.247	0.0725	11.499	0.020	0.0059	0.9311	0.782	0.2294	36.406
655101	0.175	0.0431	8.4828	0.631	0.1555	30.587	0.183	0.0451	8.8706	0.028	0.0069	1.3572	0.536	0.1321	25.982
655109	0.121	0.0391	5.6595	0.512	0.1655	23.948	0.345	0.1115	16.137	0.028	0.0091	1.3096	0.798	0.2580	37.325
Mean	0.131	0.0389	6.3301	0.637	0.1916	30.944	0.239	0.0723	11.549	0.026	0.0078	1.2614	0.886	0.2677	42.819
S.D.	0.040	0.0105	1.8133	0.101	0.0310	4.1837	0.072	0.0232	3.1108	0.007	0.0018	0.2972	0.364	0.1069	15.794

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655010	0.111	0.0362	6.1123	0.623	0.2034	34.306	0.249	0.0813	13.711	0.026	0.0085	1.4317	1.109	0.3621	61.068
655030	0.085	0.0187	4.2331	0.591	0.1298	29.432	0.439	0.0964	21.863	0.025	0.0055	1.2450	0.776	0.1704	38.645
655037	0.134	0.0340	6.8089	0.702	0.1780	35.671	0.336	0.0852	17.073	0.024	0.0061	1.2195	0.711	0.1803	36.128
655049	0.114	0.0457	6.1192	0.585	0.2343	31.401	0.210	0.0841	11.272	0.026	0.0104	1.3956	1.329	0.5322	71.337
655061	0.103	0.0356	5.7671	0.471	0.1628	26.372	0.157	0.0543	8.7906	0.027	0.0093	1.5118	0.760	0.2627	42.553
655075	0.092	0.0213	4.6748	0.511	0.1182	25.965	0.405	0.0937	20.579	0.030	0.0069	1.5244	0.816	0.1888	41.463
655077	0.195	0.0597	9.7015	0.595	0.1822	29.602	0.232	0.0710	11.542	0.021	0.0064	1.0448	1.376	0.4213	68.458
655084	0.168	0.0556	8.3499	0.516	0.1708	25.646	0.171	0.0566	8.4990	0.026	0.0086	1.2922	0.706	0.2337	35.089
655088	0.132	0.0352	6.5672	0.560	0.1494	27.861	0.331	0.0883	16.468	0.035	0.0093	1.7413	0.433	0.1155	21.542

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Recovery

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	OVARIES			SPLEEN			THYMUS			THYROID GLAND			UTERUS		
	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN	(Gms)	%FBW	%BRAIN
655100	0.100	0.0279	5.2165	0.770	0.2148	40.167	0.164	0.0457	8.5550	0.020	0.0056	1.0433	1.126	0.3141	58.738
Mean	0.123	0.0370	6.3550	0.592	0.1744	30.642	0.269	0.0757	13.835	0.026	0.0077	1.3450	0.914	0.2781	47.502
S.D.	0.035	0.0134	1.6503	0.090	0.0366	4.7768	0.102	0.0178	4.9551	0.004	0.0018	0.2203	0.305	0.1296	16.378

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (10-Day Sacrifice)

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655141	148.6	6.422	4.322
655149	184.2	7.580	4.115
655152	192.1	8.276	4.308
655155	168.9	7.192	4.258
655159	158.9	6.454	4.062
Mean	170.54	7.185	4.213
S.D.	17.825	0.785	0.118

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655142	163.8	7.398	4.516
655160	135.6	6.456	4.761
655162	159.1	6.247	3.926
655164	178.8	8.583	4.800
655165	164.9	7.188	4.359
Mean	160.44	7.174	4.473
S.D.	15.709	0.923	0.355

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (10-Day Sacrifice)

Group : VI 5 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655140	146.6	6.848	4.671
655145	167.3	8.360	4.997
655154	170.8	7.907	4.629
655158	190.3	8.156	4.286
655167	178.7	7.798	4.364
Mean	170.74	7.814	4.589
S.D.	16.129	0.582	0.282

Group : VIII 25 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655144	177.0	8.157	4.608
655148	179.5	9.610	5.354
655161	152.3	6.735	4.422
655163	177.5	7.720	4.349
655166	191.6	9.596	5.008
Mean	175.58	8.364	4.748
S.D.	14.315	1.243	0.424

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (10-Day Sacrifice)

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655143	190.1	9.516	5.006
655146	170.2	9.894	5.813
655147	206.8	12.044	5.824
655150	185.3	10.084	5.442
655151	160.2	9.130	5.699
Mean	182.52	10.134	5.557
S.D.	18.06	1.129	0.344

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (Final Sacrifice)

Group : II 0 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655022	316.90	10.043	3.1691
655045	336.30	13.912	4.1368
655065	378.00	15.652	4.1407
655074	345.80	13.889	4.0165
655093	252.50	8.723	3.4547
Mean	325.90	12.444	3.7836
S.D.	46.602	2.922	0.4451

Group : IV 1 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655018	364.30	14.077	3.8641
655028	332.90	11.003	3.3052
655051	322.30	9.970	3.0934
655057	296.20	11.429	3.8585
655096	365.10	13.007	3.5626
Mean	336.16	11.897	3.5368
S.D.	29.278	1.637	0.3397

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (Final Sacrifice)

Group : VI 5 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655017	334.50	11.964	3.5767
655021	321.60	13.230	4.1138
655050	328.50	13.097	3.9869
655059	286.60	12.290	4.2882
655064	408.40	12.973	3.1765
Mean	335.92	12.711	3.8284
S.D.	44.576	0.553	0.4490

Group : VIII 25 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655043	305.60	10.699	3.5010
655056	311.80	9.860	3.1623
655060	393.70	13.407	3.4054
655081	417.30	16.478	3.9487
655082	405.80	17.192	4.2366
Mean	366.84	13.527	3.6508
S.D.	53.771	3.301	0.4339

FBW - Final Body Weight

Organ Weight Listing
Female Rats Designated for Satellite Evaluations (Final Sacrifice)

Group : X 125 mg/kg/day Sex :FEMALES

ANIMAL	FBW (Gms)	LIVER (Gms)	LIVER %FBW
655024	364.00	12.552	3.4484
655027	346.20	10.958	3.1652
655046	418.30	14.617	3.4944
655104	372.10	12.954	3.4813
655106	296.00	12.562	4.2439
Mean	359.32	12.729	3.5666
S.D.	44.287	1.305	0.4020

FBW - Final Body Weight

APPENDIX N

INDIVIDUAL ANIMAL GROSS AND MICROSCOPIC OBSERVATIONS

INDIVIDUAL ANIMAL GROSS AND MICROSCOPIC OBSERVATIONS

EXPLANTORY NOTES

Accidently killed (includes animals presented dead or moribund that have injured themselves or were inadvertently injured when being handled. In-life and necropsy findings may be used to make this determination.)

Lesion Grading

Histopathological changes are described according to their morphologic character, distribution and severity. The distribution (extent of tissue involvement) is indicated, where appropriate, by modifiers such as focal, multifocal, diffuse, unilateral, bilateral, etc.; A severity score, if appropriate, is also assigned as follows:

- Minimal: the amount of change present barely exceeds that which is considered to be within normal limits.
- Mild: in general, the lesion is easily identified but of limited severity. The lesion probably does not produce any functional impairment.
- Moderate: the lesion is prominent but there is significant potential for increased severity. Limited tissue or organ dysfunction is possible.
- Severe: the degree of change is either as complete as considered possible or great enough in intensity or extent to expect significant tissue or organ dysfunction.

Comment: grades minimal through severe represent progressive involvement/severity along a continuum with minimal lesions being the least severe and severe lesions being the most severe. While the grades refer to the morphological characteristics of lesions, they also indicate their relative biological significance.

Gross observations listing multiple masses for a tissue are distinguished with letters (i.e., a, b, c, d, etc.)

Neoplasm Designations

*B: Benign neoplasm, primary site
*M: Malignant neoplasm, primary site

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654903	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654909	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
NECROSIS, FOCAL, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654910	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
THYROID GLAND :
ALTERATION, COLLOID, mild.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654915	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, mild.
NECROSIS, FOCAL, mild.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654919	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654924	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654924 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654924	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
THYMUS, THYROID GLAND, NOSE

654925 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654925 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654925	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
PITUITARY GLAND :
NOT PRESENT.
EYE(S) WITH OPTIC NERVE :
OPTIC NERVE NOT PRESENT.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654927	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, moderate.

No Microscopic Abnormality Observed :
THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654928	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.
PANCREAS :
ATROPHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
EYE(S) WITH OPTIC NERVE :
OPTIC NERVE NOT PRESENT.

654928 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654928	Continued from previous page

Histopathology :

PROSTATE :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654929 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654929 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654929	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654936	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

TESTES :
DISCOLORATION, OPAQUE.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.
TESTES :
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL, severe.
EPIDIDYMIDES :
OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, severe.

654936 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654936	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654939 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654943	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654949	Accidentally Killed Duration of dosing-days: 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
THYMUS, THYROID GLAND, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654950	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.
PARATHYROID GLANDS :
NOT PRESENT.
EYE(S) WITH OPTIC NERVE :
FOLD/ROSETTE, RETINAL, minimal.
TESTES :
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL, minimal.

654950 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654950	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654953 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654953 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654953	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
LUNGS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.
PANCREAS :
ATROPHY, minimal.
PITUITARY GLAND :
CYST, minimal.
EYE(S) WITH OPTIC NERVE :
OPTIC NERVE NOT PRESENT.
PROSTATE :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654956	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654966	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654971	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654971 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654971	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654972 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

654972 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654972	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
EYE(S) WITH OPTIC NERVE :
ADHESION, RETINAL, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654987 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654987 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654987	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654992	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
THYMUS, THYROID GLAND, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654993	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
PROSTATE :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS,

654993 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654993	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
TRACHEA, ESOPHAGUS, PHARYNX/LARYNX,
EYE(S) WITH OPTIC NERVE, SKIN, SEMINAL VESICLES, URINARY
BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM,
BONE MARROW, NOSE

654994 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN,
AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM,
ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH
NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS,
ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS,
PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
654994 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : I 0 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654994	Continued from previous page

Histopathology :

THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

654997 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654904	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654908	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

SKIN :
ALOPECIA, RIGHT, SIDE.

654908 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654908	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
SKIN, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654913	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654932	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654938	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654941	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, mild.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654945	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654946	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654946 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654946	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654947 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654947 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654947	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654948 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654948 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654948	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654954 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654960	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYROID GLAND, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654984	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
THYROID GLAND, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654988	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654995	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654995 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : III 1 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654995	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654907	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654911	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654916	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
THYROID GLAND, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654917	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654918	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654926	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654926 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654926	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654959 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
654959 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654959	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654961 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654961 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654961	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654967 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654967 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654967	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

654969 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654970	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654980	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

TESTES :
SMALL, UNILATERAL.

654980 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654980	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
TESTES :
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL, mild.
DILATATION, SEMINIFEROUS TUBULES, UNILATERAL, moderate.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654981	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654998	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

URINARY BLADDER :
DILATATION, moderate.

654998 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654998	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
URINARY BLADDER, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : V 5 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
655005	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654912	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654920	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654920 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654920	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654922 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
NECROSIS, FOCAL, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

654922 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654922	Continued from previous page

Histopathology :

THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, NOSE

654923 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.

654923 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654923	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654930 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654930 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654930	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654933 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654934	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654940	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654940 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654940	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654952 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654952 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654952	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654958 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654958 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654958	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
NECROSIS, FOCAL, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654964	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654975	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654975 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654975	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
NECROSIS, FOCAL, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

654989 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654989 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654989	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

655001 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655001 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
655001	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

655006 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655006 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : VII 25 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
655006	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CYST, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654906	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654914	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654914 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654914	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERTROPHY, HEPATOCELLULAR, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
JEJUNUM :
NOT PRESENT.
ILEUM :
NOT PRESENT.
CECUM :
NOT PRESENT.
RECTUM :
NOT PRESENT.
MESENTERIC LYMPH NODE :
NOT PRESENT.
THYROID GLAND :
ALTERATION, COLLOID, mild.

654914 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654914	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, PANCREAS, COLON, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654921 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654921 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654921	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, mild.
NECROSIS, FOCAL, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
PANCREAS :
ATROPHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, severe.
NOSE :
DEGENERATION, AMELOBLASTS, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654931	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654937	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654937 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654937	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654942 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERPLASIA, BILE DUCT, minimal.
NECROSIS, FOCAL, minimal.

654942 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654942	Continued from previous page

Histopathology :

THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

654951 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

654951 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654951	Continued from previous page

Histopathology :

LIVER :
HYPERTROPHY, HEPATOCELLULAR, mild.
NECROSIS, FOCAL, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.
PANCREAS :
ATROPHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, severe.
NOSE :
DEGENERATION, AMELOBLASTS, minimal.

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654955	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

KIDNEYS :
DILATATION, RIGHT, severe.

No Macroscopic Abnormality Observed :
LIVER, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYDRONEPHROSIS, UNILATERAL, minimal.
HYPERTROPHY, TUBULAR, minimal.
HEART :
CARDIOMYOPATHY, minimal.

654955 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654955	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654957 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654957 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654957	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, mild.

No Microscopic Abnormality Observed :
THYMUS, NOSE

654962 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654965	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

EYE(S) WITH OPTIC NERVE :
MISSING, RIGHT.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, mild.
NECROSIS, FOCAL, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, moderate.

654965 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654965	Continued from previous page

Histopathology :

EYE(S) WITH OPTIC NERVE :
OPTIC NERVE NOT PRESENT.
NOSE :
DEGENERATION, AMELOBLASTS, mild.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW

654973 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654973 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654973	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.
NECROSIS, FOCAL, minimal.
THYROID GLAND :
ALTERATION, COLLOID, moderate.
NOSE :
DEGENERATION, AMELOBLASTS, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654974	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYDRONEPHROSIS, BILATERAL, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
THYMUS, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654976	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
NOSE :
DEGENERATION, AMELOBLASTS, minimal.

No Microscopic Abnormality Observed :
THYMUS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654977	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

KIDNEYS :
CALCULUS\CALCULI, RIGHT.

No Macroscopic Abnormality Observed :
LIVER, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
HYPERPLASIA, TRANSITIONAL CELL, minimal.
HYDRONEPHROSIS, UNILATERAL, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

654977 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654977	Continued from previous page
	Histopathology :
	No Microscopic Abnormality Observed : THYMUS, NOSE
654978	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy
	Gross Pathology :
	No Macroscopic Abnormality Observed : LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE
	Histopathology :
	LIVER : INFLAMMATION, SUBACUTE/CHRONIC, minimal. HYPERPLASIA, BILE DUCT, minimal. THYROID GLAND : ALTERATION, COLLOID, minimal.

654978 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654978	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS, THYMUS, NOSE

654979 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, minimal.
KIDNEYS :
PIGMENT, TUBULAR, minimal.
HYPERTROPHY, TUBULAR, minimal.

654979 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654979	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

654982 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

654982 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654982	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654983 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

TESTES :
SMALL, UNILATERAL.
EPIDIDYMIDES :
SMALL, UNILATERAL.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

654983 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654983	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.
LUNGS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
TESTES :
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL, moderate.
EPIDIDYMIDES :
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL, severe.

No Microscopic Abnormality Observed :
SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654985	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CYST, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
NOSE :
ODONTODYSPLASIA, moderate.
INFLAMMATION, SUBACUTE/CHRONIC, mild.

No Microscopic Abnormality Observed :
THYMUS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654986	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERTROPHY, HEPATOCELLULAR, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
THYROID GLAND :
ALTERATION, COLLOID, mild.
NOSE :
DEGENERATION, AMELOBLASTS, mild.

654986 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654986	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW

654990 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654990 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654990	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
NECROSIS, FOCAL, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, moderate.

No Microscopic Abnormality Observed :
THYMUS, NOSE

654991 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654991 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654991	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, mild.

No Microscopic Abnormality Observed :
THYMUS, NOSE

654996 Terminal Sacrifice
Killed on Day : 93
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

654996 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
654996	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HYPERTROPHY, TUBULAR, minimal.
HEART :
CARDIOMYOPATHY, minimal.
THYROID GLAND :
ALTERATION, COLLOID, minimal.
PARATHYROID GLANDS :
NOT PRESENT.
NOSE :
DEGENERATION, AMELOBLASTS, mild.

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, BONE MARROW

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
655003	Terminal Sacrifice Killed on Day : 93 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, CENTRILOBULAR, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERTROPHY, HEPATOCELLULAR, minimal.
KIDNEYS :
HYPERTROPHY, TUBULAR, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS,

655003 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/male
Dose Group : IX 125 mg/kg/day Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
655003	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
TRACHEA, ESOPHAGUS, PHARYNX/LARYNX,
EYE(S) WITH OPTIC NERVE, SKIN, PROSTATE, SEMINAL VESICLES,
URINARY BLADDER, TESTES, EPIDIDYMIDES, FEMUR/KNEE JOINT,
STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655009	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
NECROSIS, FOCAL, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655015	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655016	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

HEART :
LARGE.

655016 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655016	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655019	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

UTERUS :
DILATATION.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
UTERUS :
DILATATION, mild.

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655022	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655025	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655025 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655025	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.
HEART :
CARDIOMYOPATHY, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655031	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
HYDRONEPHROSIS, BILATERAL, minimal.
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.

655031 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655031	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655032 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655032 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655032	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655035 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655035 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655035	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
LIVER, KIDNEYS

655036 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655036 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655036	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
PARATHYROID GLANDS :
NOT PRESENT.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655045 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655045 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655045	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655062 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

PITUITARY GLAND :
LARGE.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655062 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655062	Continued from previous page

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
PITUITARY GLAND

655065 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655068	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
LIVER

655071	Accidentally Killed Duration of dosing-days: 19 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

STOMACH :
FLUID, RED.

655071 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655071	Continued from previous page

Gross Pathology :

ESOPHAGUS :
PERFORATION, LARGE CLOTTING IN AREA OF PUNCTURE.
SKIN :
STAIN, RED, NOSE.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
ESOPHAGUS :
INFLAMMATION, SUBACUTE/CHRONIC, severe.
LACERATION.
BONE MARROW :
HYPERPLASIA, GRANULOCYTIC, mild.

655071 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655071	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655072 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655072 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655072	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS

655074 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655079	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.
HEART :
CARDIOMYOPATHY, minimal.
PARATHYROID GLANDS :
NOT PRESENT.

655079 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655079	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655083 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655083 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655083	Continued from previous page

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655093 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655093 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655093	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655098 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
655098 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655098	Continued from previous page

Histopathology :

HEART :
CARDIOMYOPATHY, minimal.
URINARY BLADDER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
LIVER, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655099 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655099 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655099	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655101	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
LIVER

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655107	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : II 0 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655109	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERPLASIA, BILE DUCT, minimal.

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655013	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655018	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655018 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655018	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655028 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655033	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655040	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655040 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655040	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655041 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655041 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655041	Continued from previous page
	Histopathology :
	No Microscopic Abnormality Observed : KIDNEYS
655044	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy
	Gross Pathology :
	No Macroscopic Abnormality Observed : LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE
	Histopathology :
	No Microscopic Abnormality Observed : KIDNEYS

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655051	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655057	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655057 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655057	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655086 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655089	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655090	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655090 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655090	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655091 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655091 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655091	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

655096 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : IV 1 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655108	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655017	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Animal Ref	Microscopic & Macroscopic Findings
655020	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655020 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655020	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655021 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655029	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655034	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655034 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655034	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655038 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655038 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655038	Continued from previous page
	Histopathology :
	No Microscopic Abnormality Observed : KIDNEYS
655039	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy
	Gross Pathology :
	No Macroscopic Abnormality Observed : LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE
	Histopathology :
	No Microscopic Abnormality Observed : KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655042	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655050	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655050 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655050	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655054 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655059	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Animal Ref	Microscopic & Macroscopic Findings
655064	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655064 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655064	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655066 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655067	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy
	Gross Pathology :
	No Macroscopic Abnormality Observed : LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE
	Histopathology :
	No Microscopic Abnormality Observed : KIDNEYS
655087	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy
	Gross Pathology :
	No Macroscopic Abnormality Observed : LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655087 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VI 5 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655087	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655011	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

Animal Ref	Microscopic & Macroscopic Findings
655012	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655012 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655012	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655043 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655047	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655055	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655055 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655055	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655056 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655058	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655060	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655060 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655060	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655073 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655076	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655078	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655078 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655078	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655081 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655082	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Animal Ref	Microscopic & Macroscopic Findings
655085	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655085 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655085	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

655105 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655105 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : VIII 25 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655105	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655007	Terminal Sacrifice
	Killed on Day : 94
	Exposure Group : 90DAY
	Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERPLASIA, BILE DUCT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
HEART :
CARDIOMYOPATHY, minimal.

655007 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655007	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655010 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655010 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655010	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, mild.

No Microscopic Abnormality Observed :
LIVER

655023 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

655023 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655023	Continued from previous page

Histopathology :

KIDNEYS :
HYDRONEPHROSIS, UNILATERAL, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655024 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655024 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655024	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655026 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.

655026 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655026	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655027 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655027 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655027	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655030 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
ANGIECTASIS, minimal.

655030 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655030	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, mild.
HYDRONEPHROSIS, BILATERAL, minimal.

655037 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :
KIDNEYS

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655046	Terminal Sacrifice Killed on Day : 175 Exposure Group : SATEL Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655049	Terminal Sacrifice Killed on Day : 183 Exposure Group : RECOV Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655049 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655049	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA, BILE DUCT, minimal.

No Microscopic Abnormality Observed :
KIDNEYS

655052 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655052 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655052	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
ADRENAL GLANDS :
MINERALIZATION, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655053	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HEART :
CARDIOMYOPATHY, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, LUNGS, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND,

655053 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655053	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655061 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
655061 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655061	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655063 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
SKELETAL MUSCLE :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
655063 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655063	Continued from previous page

Histopathology :

EYE(S) WITH OPTIC NERVE :
OPTIC NERVE NOT PRESENT.
FOLD/ROSETTE, RETINAL, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655075 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655075 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655075	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655077 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655077 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655077	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
ANGIECTASIS, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655084 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655084 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655084	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, mild.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655088 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655088 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655088	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

655092 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655092 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655092	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
PANCREAS :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
MAMMARY GLAND (FEMALE) :
NOT PRESENT.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655095	Terminal Sacrifice Killed on Day : 94 Exposure Group : 90DAY Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
FATTY CHANGE, MEDIAN CLEFT, minimal.
KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS,

655095 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655095	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
TRACHEA, ESOPHAGUS, PHARYNX/LARYNX,
EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE),
OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT,
STERNUM, BONE MARROW, NOSE

655097 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN,
AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM,
ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH
NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS,
ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS,
PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY
GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER,
FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
655097 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655097	Continued from previous page

Histopathology :

No Microscopic Abnormality Observed :
LIVER, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655100 Terminal Sacrifice
Killed on Day : 183
Exposure Group : RECOV
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655100 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655100	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, mild.

No Microscopic Abnormality Observed :
LIVER

655103 Terminal Sacrifice
Killed on Day : 94
Exposure Group : 90DAY
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

Histopathology :

LIVER :
HYPERPLASIA, BILE DUCT, minimal.

655103 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals
STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655103	Continued from previous page

Histopathology :

KIDNEYS :
CHRONIC PROGRESSIVE NEPHROPATHY, minimal.
PARATHYROID GLANDS :
NOT PRESENT.
MAMMARY GLAND (FEMALE) :
NOT PRESENT.

No Microscopic Abnormality Observed :
LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, OVARIES, UTERUS, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, BONE MARROW, NOSE

655104 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND,

655104 Continued on the next page ....

Individual Animal Listing
Showing animal data for individual animals

STUDY : 13690/24691/fem
Dose Group : X 125 mg/kg/day Sex: Females

Animal Ref	Microscopic & Macroscopic Findings
655104	Continued from previous page

Gross Pathology :

No Macroscopic Abnormality Observed :
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

655106 Terminal Sacrifice
Killed on Day : 175
Exposure Group : SATEL
Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SKELETAL MUSCLE, SPLEEN, AORTA, BRAIN, SPINAL CORD, STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC LYMPH NODE, SALIVARY GLANDS, MANDIBULAR LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, PITUITARY GLAND, THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX, EYE(S) WITH OPTIC NERVE, SKIN, MAMMARY GLAND (FEMALE), OVARIES, UTERUS, VAGINA, URINARY BLADDER, FEMUR/KNEE JOINT, STERNUM, NOSE

APPENDIX O

INDIVIDUAL ANIMAL MICROSCOPIC OBSERVATIONS LISTING INDIVIDUAL ANIMALS AFFECTED

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
LIVER		(20)	(10)	(10)	(10)	(20)
NECROSIS, FOCAL.		654909		654917	654922	654921
		654915			654923	654942
		654927			654940	654951
					654958	654957
					654975	654965
						654973
						654974
						654976
						654977
						654990
INFLAMMATION, SUBACUTE/CHRONIC.		654903	654908	654907	654922	654921
		654909	654913	654911	654923	654951
		654910	654932	654916	654930	654955
		654915	654938	654917	654940	654957
		654924	654941	654959	654952	654965
		654925	654946	654961	654958	654973
		654927	654947	654967	654989	654974
		654928	654960	654980	655001	654976
		654929	654995	654998	655006	654977
		654936		655005		654978
		654949				654979
		654950				654983

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	LESION INCIDENCE (NUMERIC) Males				
	TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
LIVER		(20)	(10)	(10)	(10)	(20)
INFLAMMATION, SUBACUTE/CHRONIC.		654953				654985
		654956				654990
		654972				654991
		654987				654996
		654992				655003
		654993				
		654994				
HYPERTROPHY, HEPATOCELLULAR.						654914
						654921
						654951
						654955
						654965
						654979
						654983
						654986
						654996
						655003
HYPERPLASIA, BILE DUCT.		654915				654942
		654927				654973
		654943				654974
		654949				654977
		654992				654978
						654990

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
LIVER		(20)	(10)	(10)	(10)	(20)
FATTY CHANGE, MEDIAN CLEFT.		654909 654910 654929 654972	654984 654995	654907 654911	654958	654951
FATTY CHANGE, CENTRILOBULAR.						655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
PANCREAS		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654955
		654929				654965
		654936				654979
		654950				654983
		654972				654986
		654987				654996
		654993				655003
ATROPHY.		654928				654921
		654953				654951

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
ESOPHAGUS		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
STOMACH		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
DUODENUM		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
JEJUNUM		(10)				(9)
NO ABNORMALITY DETECTED		654903				654921
		654925				654951
		654928				654955
		654929				654965
		654936				654979
		654950				654983
		654953				654986
		654972				654996
		654987				655003
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
ILEUM		(10)				(9)
NO ABNORMALITY DETECTED		654903				654921
		654925				654951
		654928				654955
		654929				654965
		654936				654979
		654950				654983
		654953				654986
		654972				654996
		654987				655003
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
CECUM		(10)				(9)
NO ABNORMALITY DETECTED		654903				654921
		654925				654951
		654928				654955
		654929				654965
		654936				654979
		654950				654983
		654953				654986
		654972				654996
		654987				655003
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
COLON		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
RECTUM		(10)				(9)
NO ABNORMALITY DETECTED		654903				654921
		654925				654951
		654928				654955
		654929				654965
		654936				654979
		654950				654983
		654953				654986
		654972				654996
		654987				655003
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
DIGESTIVE SYSTEM						
SALIVARY GLANDS		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
URINARY SYSTEM					
KIDNEYS	(20)	(10)	(10)	(10)	(20)
NO ABNORMALITY DETECTED	654903	654932	654907	654922	654942
	654909	654938	654967		654973
	654910	654941	655005		654978
	654925	654960			
	654929				
	654936				
	654956				
	654987				
	654994				
CHRONIC PROGRESSIVE NEPHROPATHY.	654915	654908	654911	654923	654914
	654924	654913	654916	654930	654921
	654927	654946	654917	654958	654951
	654928	654947	654959	654989	654955
	654943	654984	654961		654957
	654949	654995	654980		654965
	654950		654998		654974
	654953				654976
	654972				654979
	654992				654986
	654993				654990
					654991
					654996

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
URINARY SYSTEM						
KIDNEYS		(20)	(10)	(10)	(10)	(20)
PIGMENT, TUBULAR.						654979
HYPERTROPHY, TUBULAR.					654923	654914
					654930	654921
					654940	654951
					654952	654955
					654958	654965
					654975	654979
					654989	654983
					655001	654986
					655006	654996
						655003
HYPERPLASIA, TRANSITIONAL CELL.						654977
HYDRONEPHROSIS, UNILATERAL.						654955
						654977
HYDRONEPHROSIS, BILATERAL.						654974
CYST.					655006	654985

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
URINARY SYSTEM						
URINARY BLADDER		(10)		(1)		(10)
NO ABNORMALITY DETECTED		654903		654998		654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM						
LUNGS		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654972				654986
		654987				654996
		654993				655003
INFLAMMATION, SUBACUTE/CHRONIC.		654953				654983

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM						
TRACHEA		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM						
PHARYNX/LARYNX		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM						
NOSE		(20)	(10)	(10)	(10)	(20)
NO ABNORMALITY DETECTED		654903	654908	654907	654922	654914
		654909	654913	654911	654923	654942
		654910	654932	654916	654930	654955
		654915	654938	654917	654940	654957
		654924	654941	654959	654952	654974
		654925	654946	654961	654958	654977
		654927	654947	654967	654975	654978
		654928	654960	654980	654989	654979
		654929	654984	654998	655001	654983
		654936	654995	655005	655006	654990
		654943				654991
		654949				655003
		654950				
		654953				
		654956				
		654972				
		654987				
		654992				
		654993				
		654994				
ODONTODYSPLASIA.						654985
INFLAMMATION, SUBACUTE/CHRONIC.						654985

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
RESPIRATORY SYSTEM						
NOSE		(20)	(10)	(10)	(10)	(20)
DEGENERATION, AMELOBLASTS.						654921
						654951
						654965
						654973
						654976
						654986
						654996

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CARDIOVASCULAR SYSTEM						
HEART		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654929				654965
		654972				654986
		654993				655003
CARDIOMYOPATHY.		654928				654951
		654936				654955
		654950				654979
		654953				654983
		654987				654996

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CARDIOVASCULAR SYSTEM						
AORTA		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM						
SPLEEN		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
THYMUS	(20)				(20)
NO ABNORMALITY DETECTED	654903				654914
	654909				654921
	654910				654942
	654915				654951
	654924				654955
	654925				654957
	654927				654965
	654928				654973
	654929				654974
	654936				654976
	654943				654977
	654949				654978
	654950				654979
	654953				654983
	654956				654985
	654972				654986
	654987				654990
	654992				654991
	654993				654996
	654994				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM						
MANDIBULAR LYMPH NODE		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM						
MESENTERIC LYMPH NODE		(10)				(9)
NO ABNORMALITY DETECTED		654903				654921
		654925				654951
		654928				654955
		654929				654965
		654936				654979
		654950				654983
		654953				654986
		654972				654996
		654987				655003
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
LYMPHATIC AND HEMATOPOIETIC SYSTEM						
BONE MARROW		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM						
PITUITARY GLAND		(9)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654928				654921
		654929				654951
		654936				654955
		654950				654965
		654972				654979
		654987				654983
		654993				654986
						654996
						655003
CYST.		654953				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM						
THYROID GLAND		(20)	(10)	(10)	(10)	(20)
NO ABNORMALITY DETECTED		654903	654960	654916		654955
		654924	654984			655003
		654925				
		654936				
		654949				
		654950				
		654953				
		654972				
		654992				
		654993				
ALTERATION, COLLOID.		654909	654908	654907	654922	654914
		654910	654913	654911	654923	654921
		654915	654932	654917	654930	654942
		654927	654938	654959	654940	654951
		654928	654941	654961	654952	654957
		654929	654946	654967	654958	654965
		654943	654947	654980	654975	654973
		654956	654995	654998	654989	654974
		654987		655005	655001	654976
		654994			655006	654977
						654978
						654979

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM						
THYROID GLAND		(20)	(10)	(10)	(10)	(20)
ALTERATION, COLLOID.						654983
						654985
						654986
						654990
						654991
						654996

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM						
PARATHYROID GLANDS		(9)				(9)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654953				654979
		654972				654983
		654987				654986
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
ENDOCRINE SYSTEM						
ADRENAL GLANDS		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
NERVOUS SYSTEM						
BRAIN		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
NERVOUS SYSTEM						
SPINAL CORD		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
NERVOUS SYSTEM						
SCIATIC NERVE		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
MUSCULAR AND SKELETAL SYSTEM						
SKELETAL MUSCLE		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
MUSCULAR AND SKELETAL SYSTEM						
FEMUR/KNEE JOINT		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
MUSCULAR AND SKELETAL SYSTEM						
STERNUM		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (NUMERIC)				
	Males				
LESIONS / TREATMENT	0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM					
TESTES	(10)		(1)		(10)
NO ABNORMALITY DETECTED	654903				654914
	654925				654921
	654928				654951
	654929				654955
	654953				654965
	654972				654979
	654987				654986
	654993				654996
					655003
DILATATION, SEMINIFEROUS TUBULES, UNILATERAL.			654980		
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL.			654980		654983
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL.	654936				
	654950				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM						
EPIDIDYMIDES		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654950				654965
		654953				654979
		654972				654986
		654987				654996
		654993				655003
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL.						654983
OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL.		654936				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM						
PROSTATE		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654929				654951
		654936				654955
		654950				654965
		654972				654979
		654987				654983
						654986
						654996
						655003
INFLAMMATION, SUBACUTE/CHRONIC.		654928				
		654953				
		654993				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
REPRODUCTIVE SYSTEM						
SEMINAL VESICLES		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
CUTANEOUS SYSTEM						
SKIN		(10)	(1)			(10)
NO ABNORMALITY DETECTED		654903	654908			654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654950				654979
		654953				654983
		654972				654986
		654987				654996
		654993				655003

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Male Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males				
		0 mg/kg I	1 mg/kg III	5 mg/kg V	25 mg/kg VII	125 mg/kg IX
SPECIAL SENSES SYSTEM						
EYE(S) WITH OPTIC NERVE		(10)				(10)
NO ABNORMALITY DETECTED		654903				654914
		654925				654921
		654928				654951
		654929				654955
		654936				654965
		654953				654979
		654987				654983
		654993				654986
						654996
						655003
OPTIC NERVE NOT PRESENT.		654925				654965
		654928				
		654953				
FOLD/ROSETTE, RETINAL.		654950				
ADHESION, RETINAL.		654972				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	LESION INCIDENCE (Animal #) Females				
	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LIVER		(20)				(20)
NO ABNORMALITY DETECTED		655035				655010
		655068				655097
		655098				655100
		655101				
NECROSIS, FOCAL.		655009				
INFLAMMATION, SUBACUTE/CHRONIC.		655009				655023
		655016				655026
		655019				655037
		655025				655049
		655031				655052
		655032				655053
		655036				655061
		655071				655063
		655072				655075
		655079				655077
		655083				655088
		655099				655092
		655107				
HYPERPLASIA, BILE DUCT.		655031				655007
		655079				655026
		655109				655049
						655103
FATTY CHANGE, MEDIAN CLEFT.		655015				655084
		655016				655095
		655025				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LIVER	(20)				(20)
FATTY CHANGE, MEDIAN CLEFT.	655062				
ANGIECTASIS.					655030
					655077

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	LESION INCIDENCE (Animal #) — Females				
	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
KIDNEYS		(20)	(10)	(10)	(10)	(20)
NO ABNORMALITY DETECTED		655009	655013	655020	655012	655037
		655016	655040	655034	655047	655049
		655025	655041	655038	655055	655053
		655032	655044	655039	655058	
		655035	655086	655042	655073	
		655036	655089	655066	655085	
		655071	655090	655067	655105	
		655072	655108			
		655079				
		655107				
		655109				
CHRONIC PROGRESSIVE NEPHROPATHY.		655015	655033	655029	655011	655007
		655019	655091	655054	655076	655010
		655031		655087	655078	655026
		655062				655030
		655068				655052
		655099				655061
		655101				655063
						655075
						655077
						655084
						655088
						655095
						655097
						655100

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
KIDNEYS	(20)	(10)	(10)	(10)	(20)
CHRONIC PROGRESSIVE NEPHROPATHY.					655103
INFLAMMATION, SUBACUTE/CHRONIC.	655083 655098	655091			655092
HYDRONEPHROSIS, UNILATERAL.					655023
HYDRONEPHROSIS, BILATERAL.	655031				655030

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
LUNGS	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
HEART		(11)				(10)
NO ABNORMALITY DETECTED		655016				655023
		655036				655026
		655071				655052
		655083				655063
		655099				655092
		655107				655095
						655097
						655103
CARDIOMYOPATHY.		655025				655007
		655031				655053
		655032				
		655079				
		655098				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SKELETAL MUSCLE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655092
		655079				655095
		655083				655097
		655098				655103
		655099				
		655107				
INFLAMMATION, SUBACUTE/CHRONIC.						655063

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SPLEEN	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
AORTA		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
BRAIN	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SPINAL CORD	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
STOMACH		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
DUODENUM	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
JEJUNUM		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ILEUM	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

		LESION INCIDENCE (Animal #)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
PANCREAS		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655095
		655083				655097
		655098				655103
		655099				
		655107				
INFLAMMATION, SUBACUTE/CHRONIC.						655092

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
CECUM	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

		LESION INCIDENCE (Animal #)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
COLON		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
RECTUM		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
MESENTERIC LYMPH NODE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

		LESION INCIDENCE (Animal #)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SALIVARY GLANDS		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
MANDIBULAR LYMPH NODE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

		LESION INCIDENCE (Animal #)				
		Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
THYMUS		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ADRENAL GLANDS		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655053
		655036				655063
		655071				655092
		655079				655095
		655083				655097
		655098				655103
		655099				
		655107				
MINERALIZATION.						655052

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SCIATIC NERVE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
PITUITARY GLAND	(12)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655062				655063
	655071				655092
	655079				655095
	655083				655097
	655098				655103
	655099				
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
THYROID GLAND		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	LESION INCIDENCE (Animal #)				
	Females				
	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
PARATHYROID GLANDS	(9)				(9)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655071				655053
	655083				655063
	655098				655092
	655099				655095
	655107				655097

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
TRACHEA		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
ESOPHAGUS	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655079				655063
	655083				655092
	655098				655095
	655099				655097
	655107				655103
INFLAMMATION, SUBACUTE/CHRONIC.	655071				
LACERATION.	655071				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
PHARYNX/LARYNX		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS	TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
EYE(S) WITH OPTIC NERVE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655092
		655079				655095
		655083				655097
		655098				655103
		655099				
		655107				
OPTIC NERVE NOT PRESENT.						655063
FOLD/ROSETTE, RETINAL.						655063

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
SKIN		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
MAMMARY GLAND (FEMALE)		(11)				(8)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655095
		655083				655097
		655098				
		655099				
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
OVARIES	(11)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

	LESION INCIDENCE (Animal #)				
	Females				
LESIONS / TREATMENT	0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
UTERUS	(12)				(10)
NO ABNORMALITY DETECTED	655016				655007
	655025				655023
	655031				655026
	655032				655052
	655036				655053
	655071				655063
	655079				655092
	655083				655095
	655098				655097
	655099				655103
	655107				
DILATATION.	655019				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
URINARY BLADDER		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655099				655097
		655107				655103
INFLAMMATION, SUBACUTE/CHRONIC.		655098				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
FEMUR/KNEE JOINT		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
STERNUM		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
BONE MARROW		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655079				655063
		655083				655092
		655098				655095
		655099				655097
		655107				655103
HYPERPLASIA, GRANULOCYTIC.		655071				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Microscopic Observations in Female Rats Listing Individual Animals Affected
Neoplastic and Non-Neoplastic Lesions

LESIONS	TREATMENT	LESION INCIDENCE (Animal #) Females				
		0 mg/kg II	1 mg/kg IV	5 mg/kg VI	25 mg/kg VIII	125 mg/kg X
NOSE		(11)				(10)
NO ABNORMALITY DETECTED		655016				655007
		655025				655023
		655031				655026
		655032				655052
		655036				655053
		655071				655063
		655079				655092
		655083				655095
		655098				655097
		655099				655103
		655107				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified